{"topoisomerase-i-payloads":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/adc-chemistry.ts"},"tubulin-inhibitor-payloads":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/adc-chemistry.ts"},"pbd-dimer-payloads":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/adc-chemistry.ts"},"dna-cleaver-payloads":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/adc-chemistry.ts"},"dna-alkylator-payloads":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/adc-chemistry.ts"},"pdl1-22c3":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"pdl1-sp142":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"pdl1-sp263":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"pdl1-28-8":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"her2-herceptest":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"her2-pathway-4b5":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"her2-ish":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"egfr-cobas-v2":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"egfr-therascreen":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"kras-therascreen":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"braf-cobas":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"braf-thxid":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"braf-therascreen":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"alk-vysis-fish":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"alk-d5f3":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"foundationone-cdx-panel":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"foundationone-liquid-cdx":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"guardant360-cdx":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"oncomine-dx":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"resolution-ctdx-first":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"fgfr-therascreen":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"pik3ca-therascreen":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"idh1-abbott":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"idh2-abbott":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"flt3-leukostrat":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"bracanalysis-cdx":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"mychoice-cdx":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"foundationfocus-brca":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"mmr-ventana":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"msi-pcr":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"folr1-ventana":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"cldn18-ventana":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"egfr-pharmdx":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"psma-pet-selection":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"oncotype-dx":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"signatera-mrd":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"ki67-mib1":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"tmb-panel":{"commit":"aa9295eb27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch C: scientist tools","file":"src/data/assays.ts"},"us-part-d-cap":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-extra-help":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-340b":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-manufacturer-pap":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-paf-copay":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-cancercare":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-healthwell":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-lls-copay":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-acs-road":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"us-acs-hope-lodge":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-medex":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-macmillan-grants":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-pip":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-attendance":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-cdf":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"uk-maggies":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"eu-cross-border":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"au-pbs-safety-net":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"au-medicare-safety-net":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"au-cancer-council":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"jp-kougaku":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"cn-nrdl":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"ca-provincial":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/assistance-schemes.ts"},"ca-ccs":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/assistance-schemes.ts"},"in-pmjay":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/assistance-schemes.ts"},"in-tata-memorial-charity":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/assistance-schemes.ts"},"non-muscle-invasive-bladder-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/bladder-subtypes.ts"},"muscle-invasive-bladder-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/bladder-subtypes.ts"},"aml-flt3":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"aml-idh":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"aml-npm1-kmt2a":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"aml-secondary":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"apl":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"aml-older-unfit":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"smouldering-myeloma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"myeloma-transplant-eligible":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"myeloma-transplant-ineligible":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"myeloma-relapsed-refractory":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"plasma-cell-leukaemia":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"mds-lower-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"mds-higher-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"cll-treatment-naive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"cll-relapsed":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"richter-transformation-cll":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"cml-chronic-phase":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"cml-advanced-phase":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"primary-myelofibrosis":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/blood-subtypes.ts"},"hr-positive-early-high-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"hr-positive-metastatic-post-cdk46":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"her2-low-metastatic-breast-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"her2-positive-early-breast-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"her2-positive-breast-brain-metastases":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"tnbc-early":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"tnbc-metastatic":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"inflammatory-breast-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"paget-disease-of-the-nipple":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"phyllodes-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/breast-subtypes.ts"},"train-2":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/breast-subtypes.ts"},"kristine":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/breast-subtypes.ts"},"olympiad":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/breast-subtypes.ts"},"embraca":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/breast-subtypes.ts"},"impassion031":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/breast-subtypes.ts"},"breast-cancer":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/cancer-parents-wave2.ts"},"lung-cancer":{"commit":"492eedeb19","date":"2026-09-17","author":"Jude Gomila","message":"Pipelines and missing rows for 29 new cancer pages","file":"src/data/cancer-parents-wave2.ts"},"leukaemia":{"commit":"492eedeb19","date":"2026-09-17","author":"Jude Gomila","message":"Pipelines and missing rows for 29 new cancer pages","file":"src/data/cancer-parents-wave2.ts"},"biliary-tract-cancer":{"commit":"492eedeb19","date":"2026-09-17","author":"Jude Gomila","message":"Pipelines and missing rows for 29 new cancer pages","file":"src/data/cancer-parents-wave2.ts"},"pleural-mesothelioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancer-subtypes.ts"},"peritoneal-mesothelioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancer-subtypes.ts"},"tnbc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"breast-hr-positive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"breast-her2-positive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"sclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"colorectal":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/cancers.ts"},"pancreatic":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/cancers.ts"},"gastric":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/cancers.ts"},"esophageal":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"hcc":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/cancers.ts"},"cholangiocarcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"prostate":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/cancers.ts"},"urothelial":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/cancers.ts"},"rcc":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"ovarian":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/cancers.ts"},"endometrial":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"cervical":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/cancers.ts"},"melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"glioblastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"head-and-neck":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"sarcoma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"thyroid":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"neuroendocrine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"mesothelioma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"neuroblastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"aml":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"all-leukemia":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"dlbcl":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"cll":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cancers.ts"},"multiple-myeloma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"hodgkin-lymphoma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"non-hodgkin-lymphoma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"skin-cancer":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/cancers.ts"},"brain-tumours":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/cancers.ts"},"childhood-cancers":{"commit":"38de09277f","date":"2026-09-18","author":"Jude Gomila","message":"After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded","file":"src/data/cancers.ts"},"extragonadal-germ-cell-tumour":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/cancers.ts"},"metastatic-cancer":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/cancers.ts"},"c-zidesamtinib-pdufa":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-galleri-pma-decision":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-harmoni-3-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-sunray-01-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-krascendo-1-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-ideate-lung02-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-rejoice-ovarian01-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-tropion-lung14-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-ascent-07-readout":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-pluvicto-mhspc-decision":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-intismeran-filing":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"c-tempus-personalis-close":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/catalysts.ts"},"sintilimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"sugemalimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"adebrelimab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/china.ts"},"envafolimab":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/china.ts"},"relmacabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"equecabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"zevorcabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"inaticabtagene-autoleucel":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/china.ts"},"fulzerasib":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/china.ts"},"garsorasib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/china.ts"},"furmonertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/china.ts"},"aumolertinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"icotinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"savolitinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/china.ts"},"anlotinib":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/china.ts"},"rivoceranib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"donafenib":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"orelabrutinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"dalpiciclib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"tucidinostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"innovent":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/china.ts"},"junshi":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/china.ts"},"zai-lab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"hutchmed":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/sponsor-aliases.ts"},"cspc":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/china.ts"},"sino-biopharm":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/china.ts"},"wuxi-apptec":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/china.ts"},"wuxi-biologics":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/china.ts"},"jw-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"iaso-bio":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/china.ts"},"cstone":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"allist":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"genfleet":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/china.ts"},"inventisbio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"alphamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"zelgen":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"innocare":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/china.ts"},"betta":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"chipscreen":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/china.ts"},"ncc-china":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"nhsa":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"caca":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/china.ts"},"ctong":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/china.ts"},"pku-peoples-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/china.ts"},"cams-hematology":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/china.ts"},"renji-hospital":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"jilin-cancer-hospital":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"jiangsu-cancer-hospital":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/china.ts"},"chongqing-university-cancer-hospital":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/china.ts"},"sichuan-cancer-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/china.ts"},"orient-11":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/china.ts"},"orient-32":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/china.ts"},"orient-16":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"rationale-302":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"camel":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/china.ts"},"jupiter-06":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"harmoni-a":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/china.ts"},"capstone-1":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"gemstone-302":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"furlong":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"aeneas":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/china.ts"},"alter-0303":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/china.ts"},"legend-2":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/china.ts"},"fumanba-1":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"lummicar-1":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"reliance":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"dawna-1":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/china.ts"},"zgdh3":{"commit":"62503ed7ab","date":"2026-09-10","author":"Jude Gomila","message":"Add structured outcomes for FUMANBA-1, LUMMICAR-1, IMAGINE, DeLLphi-305 and iStopMM","file":"src/data/china.ts"},"idh-mutant-astrocytoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"oligodendroglioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"meningioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"secondary-brain-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"paediatric-high-grade-glioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"spinal-cord-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"vestibular-schwannoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"cns-germ-cell-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/cns-subtypes.ts"},"clinicaltrials-gov":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/collections.ts"},"oncokb":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"civic":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"cbioportal":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"tcga-gdc":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"depmap":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/collections.ts"},"open-targets":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/collections.ts"},"cosmic":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/collections.ts"},"clinvar":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"drugbank-chembl":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/collections.ts"},"ttd":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"adcdb":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"nccn":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"esmo-guidelines":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"fda-approvals":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/collections.ts"},"seer":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/collections.ts"},"globocan":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/collections.ts"},"cancer-gov-pdq":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"awesome-cancer-variant-resources":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/collections.ts"},"genie":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"hpa":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"cptac":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"cellxgene-hca":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"cancer-models":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/collections.ts"},"pubmed-europepmc":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/collections.ts"},"eudract-ctis":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/collections.ts"},"newsweek-hospitals":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/collections.ts"},"nature-index":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/collections.ts"},"scimago-oncology":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/collections.ts"},"nci-cancer-centers":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/collections.ts"},"opra":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/colorectal-lymphoma-subtypes.ts"},"prospect":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/colorectal-lymphoma-subtypes.ts"},"beacon-crc":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/colorectal-lymphoma-subtypes.ts"},"keynote-170":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/colorectal-lymphoma-subtypes.ts"},"ielsg37":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/colorectal-lymphoma-subtypes.ts"},"rectal-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"msi-high-colorectal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"braf-v600e-colorectal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"her2-amplified-colorectal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"kras-g12c-colorectal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"early-onset-colorectal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"primary-mediastinal-b-cell-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/colorectal-lymphoma-subtypes.ts"},"xynomic-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"obi-pharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-makers-wave4.ts"},"aulos-bioscience":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"bioatla":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"bolt-biotherapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"faron-pharmaceuticals":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-makers-wave4.ts"},"camurus":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-makers-wave4.ts"},"lindis-biotech":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"pieris-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"crispr-therapeutics":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-makers-wave4.ts"},"excellthera":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"dren-bio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"engeneic":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"keros-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"enb-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"guerbet":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"syndevrx":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"everest-medicines":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"gracell-biotechnologies":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"globeimmune":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"greenwich-lifesciences":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"genrix-bio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"hookipa-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"huabo-biopharm":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"hummingbird-bioscience":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"hotspot-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"intensity-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"panbela-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"jubilant-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"humanigen":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"linnaeus-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"nextsource-biotechnology":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"lantern-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"lyvgen-biopharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"x4-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"phanes-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"alligator-bioscience":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"shanghai-miracogen":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"shionogi":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"cimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"netris-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"immix-biopharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"hanmi-pharmaceutical":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-makers-wave4.ts"},"cardiff-oncology":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"oncoresponse":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"canariabio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"steba-biotech":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"pellepharm":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"prestige-biopharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"pinnacle-biologics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"primmune-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"remix-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"rhovac":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"rhythm-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"surgimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"aadi-bioscience":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"fennec-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"corvus-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"alethia-biotherapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"shanghai-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"step-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"atara-biotherapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"triumvira-immunologics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"rhizen-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"theolytics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"tilt-biotherapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"oncternal-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"byondis":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"toray-industries":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"transcenta":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"i-mab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"medpacto":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"zenith-epigenetics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-makers-wave4.ts"},"abclon":{"commit":"15a0727e9e","date":"2026-09-18","author":"Jude Gomila","message":"Chinese quality pass 4 over 243 folded TL;DRs","file":"src/data/companies-makers-wave4.ts"},"minghui-pharmaceutical":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"disc-medicine":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"teclison":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"grit-bio":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"amplia-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"sichuan-huiyu-pharmaceutical":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"anbogen-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"nec-bio":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"natureceuticals":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"sunho-biopharmaceutical":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"norroy-bioscience":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"yuhan":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"gi-innovation":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"modex-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"unicar-therapy":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"a2-biotherapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"wayshine-biopharm":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"cellsight-technologies":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"eureka-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"velavigo":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"vironexis-biotherapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"precigen":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"guangzhou-virotech":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"tairx":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"tyk-medicines":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"il-yang-pharmaceutical":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"gv20-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"shanghai-jiatan-pharmatech":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"shanghai-bovax-biotechnology":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"aosaikang-pharmaceutical":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"salubris-biotherapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"suzhou-bluehorse-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"frantz-viral-therapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"radiopharm-theranostics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"torl-biotherapeutics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"lupeng-pharmaceuticals":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors-wave3.ts"},"qilu-pharmaceutical":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"mabwell-shanghai-bioscience":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-sponsors.ts"},"lanova-medicines":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"inxmed-shanghai":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"lepu-biopharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"nanjing-leads-biolabs":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"philogen-s-p-a":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"sinocelltech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"eikon-therapeutics":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"evopoint-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"nuvation-bio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"avistone-biotechnology":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"catalym":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"miltenyi-biomedicine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"oncoc4":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ryvu-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"shanghai-fosun-pharmaceutical-industrial-development":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"arcus-biosciences":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"bioinvent-international":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"haihe-biopharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"multitude-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"orion-orion-pharma":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"shenzhen-targetrx":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"bio-thera-solutions":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"crinetics-pharmaceuticals":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"ellipses-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"epicentrx":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"intra-immusg":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"kartos-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"neonc-technologies":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"oncolytics-biotech":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"rakuten-medical":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"shanghai-kechow-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"shenzhen-ionova-life-sciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"treadwell-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"urogen-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"xuanzhu-biopharmaceutical":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ap-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ascentawits-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"askgene-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"aura-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"aveta-biomics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"cebiotex":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"cellectis-s-a":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"celltrion":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"chongqing-precision-biotech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"civatech-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"corbus-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"curis":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-sponsors.ts"},"d3-bio-wuxi":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"elpiscience-suzhou-biopharma":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"forward-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"futurechem":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"genelux":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"genequantum-healthcare-suzhou":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"genprex":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"georgiamune":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"hangzhou-hanx-biopharmaceuticals":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"hangzhou-sumgen-biotech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"hinova-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"immuneering":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"immuneoncia-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ionctura":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"italfarmaco":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"krystal-biotech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"laminar-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ligachem-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"mabxience-research-s-l":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"maia-biotechnology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"mbrace-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"molecular-partners":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"olema-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"oncoverity":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"orca-biosystems":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"protara-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"qbiotics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ranok-therapeutics-hangzhou":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies-sponsors.ts"},"scancell":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"shanghai-abelzeta":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"shanghai-juncell-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"sinotau-pharmaceutical":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"spectracure":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"stcube":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"suzhou-forlong-biotechnology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"tiumbio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"vyriad":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"wigen-biomedicine-technology-shanghai":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"biocad":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"simcere":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"bebetter-med":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"dizal":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"alx-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"immunome":{"commit":"8a98de1ee2","date":"2026-09-13","author":"Jude Gomila","message":"Companies: Dizal, ALX Oncology, Immunome and InxMed added as trial sponsors with website and registry sources; industry ","file":"src/data/companies-sponsors.ts"},"inxmed":{"commit":"8a98de1ee2","date":"2026-09-13","author":"Jude Gomila","message":"Companies: Dizal, ALX Oncology, Immunome and InxMed added as trial sponsors with website and registry sources; industry ","file":"src/data/companies-sponsors.ts"},"coherus":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"geron":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"checkpoint-therapeutics":{"commit":"bbedba8433","date":"2026-09-13","author":"Jude Gomila","message":"Companies: Coherus, Geron, Checkpoint Therapeutics, Xcovery and medac added as FDA oncology applicants, wired to toripal","file":"src/data/companies-sponsors.ts"},"xcovery":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"medac":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"gamida-cell":{"commit":"e722177d44","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: omidubicel, remestemcel-L and the Hepzato melphalan kit added with FDA approval sources, plus Gamida Cell, M","file":"src/data/companies-sponsors.ts"},"mesoblast":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"delcath":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"merck-kgaa":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"innopharmax":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/companies-sponsors.ts"},"sunshine-lake-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ab-science":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ucb":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"leo-pharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"galderma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"almirall":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"argenx":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"nektar-therapeutics":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"agenus":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"ascentage-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"beyondspring":{"commit":"6fc1ccee76","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 15 of the most active phase 3 trial sponsors not yet on OnCo (AB Science, UCB, LEO, Galderma, Almirall, argen","file":"src/data/companies-sponsors.ts"},"photocure":{"commit":"6fc1ccee76","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 15 of the most active phase 3 trial sponsors not yet on OnCo (AB Science, UCB, LEO, Galderma, Almirall, argen","file":"src/data/companies-sponsors.ts"},"luye-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"r-pharm":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"dendreon":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"spectrum-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"chugai":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"inovio":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"tg-therapeutics":{"commit":"fe87d4507c","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 11 more phase 3 sponsors (Chugai, Inovio, TG Therapeutics, PharmaEssentia, AOP Health, Heidelberg Pharma, Imu","file":"src/data/companies-sponsors.ts"},"pharmaessentia":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"aop-health":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"heidelberg-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"imunon":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"polaris-group":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"securabio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"phaxiam":{"commit":"fe87d4507c","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 11 more phase 3 sponsors (Chugai, Inovio, TG Therapeutics, PharmaEssentia, AOP Health, Heidelberg Pharma, Imu","file":"src/data/companies-sponsors.ts"},"navidea":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"clovis-oncology":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"soligenix":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"veru":{"commit":"75df6dd84d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 8 more phase 3 sponsors (Clovis, Soligenix, Veru, Cellectar, GC Cell, Alaunos, 3D Medicines, ArriVent) and al","file":"src/data/companies-sponsors.ts"},"cellectar":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"gc-cell":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"alaunos":{"commit":"75df6dd84d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 8 more phase 3 sponsors (Clovis, Soligenix, Veru, Cellectar, GC Cell, Alaunos, 3D Medicines, ArriVent) and al","file":"src/data/companies-sponsors.ts"},"3d-medicines":{"commit":"f5ec5cb166","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a882e8e39f90fbc93","file":"src/data/companies-sponsors.ts"},"arrivent":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"oncopeptides":{"commit":"4d0c25ec58","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 7 more phase 3 sponsors (Oncopeptides, MEI Pharma, Protagonist, Basilea, Nippon Kayaku, Immutep, G1 Therapeut","file":"src/data/companies-sponsors.ts"},"mei-pharma":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"protagonist-therapeutics":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/companies-sponsors.ts"},"basilea":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"nippon-kayaku":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"immutep":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"g1-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"antengene":{"commit":"0a4bee9ae6","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 9 more phase 3 sponsors (Antengene, Apollomics, Aprea, Aptose, Bavarian Nordic, Accuray, BioLineRx, SOTIO, To","file":"src/data/companies-sponsors.ts"},"apollomics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"aprea-therapeutics":{"commit":"0a4bee9ae6","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 9 more phase 3 sponsors (Antengene, Apollomics, Aprea, Aptose, Bavarian Nordic, Accuray, BioLineRx, SOTIO, To","file":"src/data/companies-sponsors.ts"},"aptose":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-sponsors.ts"},"bavarian-nordic":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"accuray":{"commit":"0a4bee9ae6","date":"2026-09-14","author":"Jude Gomila","message":"Companies: 9 more phase 3 sponsors (Antengene, Apollomics, Aprea, Aptose, Bavarian Nordic, Accuray, BioLineRx, SOTIO, To","file":"src/data/companies-sponsors.ts"},"biolinerx":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"sotio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"tolmar":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"partner-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"pharmaand":{"commit":"3edcf3b583","date":"2026-09-15","author":"Jude Gomila","message":"data: phase 3 sponsor batch 7 (Neovii, ABX, Lee's Pharmaceutical) and acquisition aliases (Alza, Kythera, Repros, Gracew","file":"src/data/companies-sponsors.ts"},"neovii":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"abx-advanced-biochemical-compounds":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"lees-pharmaceutical":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"biogen":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"norgine":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"foresee-pharmaceuticals":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"nobelpharma":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"eurofarma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"changchun-genescience":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"endo":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"aeterna-zentaris":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"preglem":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"telik":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"agennix":{"commit":"64cdd36b9a","date":"2026-09-15","author":"Jude Gomila","message":"data: 38 under-linked trial sponsors now point at the pivotal-trial and clinical-trial glossary terms and their type's s","file":"src/data/companies-sponsors.ts"},"gtx":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"insys-therapeutics":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"achieve-life-sciences":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"active-biotech":{"commit":"abfe978d42","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 11 (Active Biotech, Advenchen, Merrimack, Threshold, Peregrine/Avid, Sorrento, Dong-A ST, Ha","file":"src/data/companies-sponsors.ts"},"advenchen-laboratories":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"merrimack-pharmaceuticals":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"threshold-pharmaceuticals":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-sponsors.ts"},"peregrine-avid":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"sorrento-therapeutics":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"dong-a-st":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"harbour-biomed":{"commit":"2dd202b805","date":"2026-09-16","author":"Jude Gomila","message":"data: Viatris (with Mylan and Upjohn aliases), Organon and CSL (with CSL Behring) as phase 3 sponsors; list 463 of 936","file":"src/data/companies-sponsors.ts"},"viatris":{"commit":"2dd202b805","date":"2026-09-16","author":"Jude Gomila","message":"data: Viatris (with Mylan and Upjohn aliases), Organon and CSL (with CSL Behring) as phase 3 sponsors; list 463 of 936","file":"src/data/companies-sponsors.ts"},"organon":{"commit":"67ea93d423","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-afafc18d828b2d923 (orphan trials linking round)","file":"src/data/companies-sponsors.ts"},"csl":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"pharmacosmos":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"kissei":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"zeria":{"commit":"f2e52e2f21","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 13 (Pharmacosmos, Kissei, Zeria, Rovi, Denovo Biopharma, Cancer Prevention Pharmaceuticals);","file":"src/data/companies-sponsors.ts"},"rovi":{"commit":"f2e52e2f21","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 13 (Pharmacosmos, Kissei, Zeria, Rovi, Denovo Biopharma, Cancer Prevention Pharmaceuticals);","file":"src/data/companies-sponsors.ts"},"denovo-biopharma":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"cancer-prevention-pharmaceuticals":{"commit":"4827f6736d","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 14 (photonamic, Oakwood Laboratories, Daehwa, CellSeed), Wikidata-verified; list 473 of 936","file":"src/data/companies-sponsors.ts"},"photonamic":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"oakwood-laboratories":{"commit":"4827f6736d","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 14 (photonamic, Oakwood Laboratories, Daehwa, CellSeed), Wikidata-verified; list 473 of 936","file":"src/data/companies-sponsors.ts"},"daehwa-pharmaceutical":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"cellseed":{"commit":"356e23e262","date":"2026-09-16","author":"Jude Gomila","message":"data: NICE TA1192 (mirdametinib, published today) in UK coverage; ten Wikidata-verified sponsors (Arog, Cyclacel, Galera","file":"src/data/companies-sponsors.ts"},"arog-pharmaceuticals":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"cyclacel":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-sponsors.ts"},"galera-therapeutics":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-sponsors.ts"},"idera-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"infinity-pharmaceuticals":{"commit":"356e23e262","date":"2026-09-16","author":"Jude Gomila","message":"data: NICE TA1192 (mirdametinib, published today) in UK coverage; ten Wikidata-verified sponsors (Arog, Cyclacel, Galera","file":"src/data/companies-sponsors.ts"},"halozyme":{"commit":"356e23e262","date":"2026-09-16","author":"Jude Gomila","message":"data: NICE TA1192 (mirdametinib, published today) in UK coverage; ten Wikidata-verified sponsors (Arog, Cyclacel, Galera","file":"src/data/companies-sponsors.ts"},"bellicum":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"can-fite":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"cartesian-therapeutics":{"commit":"356e23e262","date":"2026-09-16","author":"Jude Gomila","message":"data: NICE TA1192 (mirdametinib, published today) in UK coverage; ten Wikidata-verified sponsors (Arog, Cyclacel, Galera","file":"src/data/companies-sponsors.ts"},"atossa-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"argos-therapeutics":{"commit":"152c3bfbd1","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 16 (Argos, Ascletis, Delta-Fly, Diffusion, Galena, HiberCell, Isarna, Medigene, Mundipharma,","file":"src/data/companies-sponsors.ts"},"ascletis":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"delta-fly-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"diffusion-pharmaceuticals":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"galena-biopharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"hibercell":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"isarna-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"medigene":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"mundipharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"abbisko":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"acacia-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"ionis":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"emergent-biosolutions":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"grifols":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"mabion":{"commit":"c2258e5daf","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 17 (Ionis, Emergent, Grifols, Mabion, IMPACT, Blaze, JW) with GW under Jazz and McNeil under","file":"src/data/companies-sponsors.ts"},"impact-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"blaze-bioscience":{"commit":"c2258e5daf","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 17 (Ionis, Emergent, Grifols, Mabion, IMPACT, Blaze, JW) with GW under Jazz and McNeil under","file":"src/data/companies-sponsors.ts"},"jw-pharmaceutical":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"ptc-therapeutics":{"commit":"258a67cf2c","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 18 (PTC, Sunesis, SymBio, Takara Bio, Tracon, United Therapeutics, Vion, Vor, Hisun) with si","file":"src/data/companies-sponsors.ts"},"sunesis":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"symbio-pharmaceuticals":{"commit":"258a67cf2c","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 18 (PTC, Sunesis, SymBio, Takara Bio, Tracon, United Therapeutics, Vion, Vor, Hisun) with si","file":"src/data/companies-sponsors.ts"},"takara-bio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"tracon":{"commit":"258a67cf2c","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 18 (PTC, Sunesis, SymBio, Takara Bio, Tracon, United Therapeutics, Vion, Vor, Hisun) with si","file":"src/data/companies-sponsors.ts"},"united-therapeutics":{"commit":"258a67cf2c","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 18 (PTC, Sunesis, SymBio, Takara Bio, Tracon, United Therapeutics, Vion, Vor, Hisun) with si","file":"src/data/companies-sponsors.ts"},"vion-pharmaceuticals":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"vor-biopharma":{"commit":"258a67cf2c","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 18 (PTC, Sunesis, SymBio, Takara Bio, Tracon, United Therapeutics, Vion, Vor, Hisun) with si","file":"src/data/companies-sponsors.ts"},"zhejiang-hisun":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"mast-therapeutics":{"commit":"8a4ca98907","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 19 (Mast, SBI Pharmaceuticals, VasGene, Angiocrine, Wuhan YZY) with Boan under Luye and SPAR","file":"src/data/companies-sponsors.ts"},"sbi-pharmaceuticals":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/companies-sponsors.ts"},"vasgene-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"angiocrine-bioscience":{"commit":"8a4ca98907","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 19 (Mast, SBI Pharmaceuticals, VasGene, Angiocrine, Wuhan YZY) with Boan under Luye and SPAR","file":"src/data/companies-sponsors.ts"},"wuhan-yzy-biopharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"huyabio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"immunitor":{"commit":"34b72cc3a3","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 21 (Moleculin, Lisata, Monopar) with Ra Pharmaceuticals under UCB; logo for HUYABIO; list 54","file":"src/data/companies-sponsors.ts"},"moleculin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-sponsors.ts"},"lisata":{"commit":"34b72cc3a3","date":"2026-09-16","author":"Jude Gomila","message":"data: phase 3 sponsor batch 21 (Moleculin, Lisata, Monopar) with Ra Pharmaceuticals under UCB; logo for HUYABIO; list 54","file":"src/data/companies-sponsors.ts"},"monopar":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"gemini-therapeutics":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"sijbrandij-foundation":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"future-of-cancer-care-today":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"specicare":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"storemytumor":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"belay-diagnostics":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"cnside-diagnostics":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"rgcc-international":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"navignostics":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"cegat":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"oncodna":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"hartwig-medical-foundation":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"vicinity-bio":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"protean-biodiagnostics":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"travera":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"first-ascent-biomedical":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"kiyatec":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"cure-first":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"sagemedic":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"kyan-technologies":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"cancertain":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"2curex":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"pathfinder-oncology":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"jaime-leandro-foundation":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"invoke-bio":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"diakonos-oncology":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-sponsors.ts"},"ubivac":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"cartx-therapeutics":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"picnic-health":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"antidote":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"mytomorrows":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-sponsors.ts"},"klineo":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"galen":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"opencancerai":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"patient-advocators":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"private-health-management":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"sagely-health":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"outperform-cancer":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/companies-sponsors.ts"},"epistamai-biotech":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/companies-sponsors.ts"},"private-medical":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"biostar-pharmaceuticals":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/companies-sponsors.ts"},"3sbio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"juventas-cell-therapy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/companies-sponsors.ts"},"shanghai-yingli":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/companies-sponsors.ts"},"shanghai-sunway-biotech":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/companies-sponsors.ts"},"chengdu-zenitar-biomedical-technology":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"jacobio-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"beijing-konruns-pharmaceutical":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"beijing-mabworks-biotech":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"binhui-biopharmaceutical":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"beijing-pearl-biotechnology-limited-liability-company":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"beijing-scitech-mq-pharmaceuticals":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"immvira-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-sponsors.ts"},"shandong-new-time-pharmaceutical":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"beijing-gene-key-life-technology":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"beijing-tide-pharmaceutical":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"henan-genuine-biotech":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"nanjing-immunophage-biotech":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"tj-biopharma":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/companies-sponsors.ts"},"zhuhai-yufan-biotechnologies":{"commit":"5acfb682e7","date":"2026-09-16","author":"Jude Gomila","message":"China deep dive: fifteen trial sponsors as company records","file":"src/data/companies-sponsors.ts"},"scirouter":{"commit":"a422668441","date":"2026-09-17","author":"Jude Gomila","message":"Add SciRouter, a prevention-first longevity start-up","file":"src/data/companies-sponsors.ts"},"anocca":{"commit":"e189ce738f","date":"2026-09-17","author":"Jude Gomila","message":"Add Anocca; biophysics sources as data-source candidates","file":"src/data/companies-sponsors.ts"},"abdera-therapeutics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"actinium-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-startups.ts"},"adcendo":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-startups.ts"},"alentis-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"alpha-tau-medical":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"alpha-9-oncology":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"ariceum-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"artbio":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"callio-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"convergent-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"cytomx-therapeutics":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"dantari":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"emergence-therapeutics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"enlaza-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"evergreen-theragnostics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"firefly-bio":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"iksuda-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"mablink-bioscience":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"mariana-oncology":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"myricx-bio":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"mythic-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nbe-therapeutics":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"nucleus-radiopharma":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"orum-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"pheon-therapeutics":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"point-biopharma":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"precirix":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"profoundbio":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"radionetics-oncology":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"ratio-therapeutics":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"tallac-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"adicet-bio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-startups.ts"},"affini-t-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"allotera-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"amunix-pharmaceuticals":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"arcellx":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"bicara-therapeutics":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-startups.ts"},"candel-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"capstan-therapeutics":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"cargo-therapeutics":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"century-therapeutics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"compass-therapeutics":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/companies-startups.ts"},"cullinan-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"harpoon-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"igm-biosciences":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"indapta-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"janux-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"kelonia-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"lyell-immunopharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-startups.ts"},"marengo-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"marker-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"neogene-therapeutics":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"obsidian-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"onk-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"orca-bio":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/companies-startups.ts"},"poseida-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"tmunity-therapeutics":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/companies-startups.ts"},"turnstone-biologics":{"commit":"8cf9cd1cc1","date":"2026-09-13","author":"Jude Gomila","message":"Companies: website is optional; seven private biotechs no longer show an SEC filings page as their website, the filing i","file":"src/data/companies-startups.ts"},"werewolf-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"xilio-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"belong-life":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"canopy":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"careology":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"carevive-systems":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"carrum-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"color-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"deep-6-ai":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/companies-startups.ts"},"jasper-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"massive-bio":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"onc-ai":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"oncohealth":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"osara-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"outcomes4me":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"perci-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"radformation":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"reimagine-care":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"tailormed":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"thyme-care":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"trial-library":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"adela":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"ataraxis-ai":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"biodesix":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"c2i-genomics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"clearnote-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"cyted-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"elypta":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"exai-bio":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"haystack-oncology":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"helio-genomics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"ibex-medical-analytics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"imagene-ai":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"inivata":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"insight-molecular-diagnostics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"kheiron-medical-technologies":{"commit":"a96eda0ee8","date":"2026-09-13","author":"Jude Gomila","message":"Companies: duplicate Kheiron records merged into one with a redirect from the old page; Ultima Genomics preprint cited f","file":"src/data/companies-startups.ts"},"lucence":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"naveris":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nonagen-bioscience":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nucleai":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nucleix":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"owlstone-medical":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"pathos-ai":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"therapixel":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"universal-dx":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"valar-labs":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"vara":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"volitionrx":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"volpara-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"empyrean-medical-systems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"gt-medical-technologies":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"intraop-medical":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"leo-cancer-care":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"monteris-medical":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"neutron-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"p-cure":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"perimeter-medical-imaging-ai":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"quantum-surgical":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"sonalasense":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"tae-life-sciences":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"theryq":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"vergent-bioscience":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"xact-robotics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"xcision-medical-systems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"zap-surgical-systems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"aqemia":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"bighat-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"certis-oncology-solutions":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"curevac":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-startups.ts"},"cytoreason":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"evaxion":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"exscientia":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"geneos-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"iktos":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"immunai":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/companies-startups.ts"},"imugene":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-startups.ts"},"io-biotech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"kanvas-biosciences":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"maat-pharma":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"mendus":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"microbiotica":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"mission-bio":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"noetik":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nykode-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"oncohost":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"ose-immunotherapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"strand-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"transgene":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"turbine":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"valo-health":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"acrivon-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"ambagon-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"amphista-therapeutics":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"black-diamond-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"blueprint-medicines":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-startups.ts"},"boundless-bio":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"bridgebio-oncology-therapeutics":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies-startups.ts"},"captor-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"cogent-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"cullgen":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"enliven-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"erasca":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/companies-startups.ts"},"foghorn-therapeutics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies-startups.ts"},"halda-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"ideaya-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"inhibrx":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"k36-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"kumquat-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"neomorph":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-startups.ts"},"nested-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"nimbus-therapeutics":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/companies-startups.ts"},"oric-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"photys-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"plexium":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"prelude-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"proxygen":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"relay-therapeutics":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/companies-startups.ts"},"repare-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"scorpion-therapeutics":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"stablix":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"tango-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"treeline-biosciences":{"commit":"e15fa2db05","date":"2026-09-10","author":"Jude Gomila","message":"Startups: 187 venture-backed oncology companies with sourced rounds and investor links; recently funded excludes acquisi","file":"src/data/companies-startups.ts"},"triana-biomedicines":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"tyra-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-startups.ts"},"zentalis-pharmaceuticals":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"arden-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"echo-immune":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"ignitus-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"invocata":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"kernis-health":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"minuteman-therapeutics":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"palitra-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"perita-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"ranata-therapeutics":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"rarivive":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"relit-biosciences":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"stitchpoint-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"valius-sciences":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"yuga-bio":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/companies-startups.ts"},"bausch-health":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-wave1.ts"},"otsuka":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/companies-wave1.ts"},"helsinn":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-wave1.ts"},"recordati":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-wave1.ts"},"sandoz":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/companies-wave1.ts"},"teva":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-wave1.ts"},"leadiant":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/companies-wave1.ts"},"adienne":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/companies-wave1.ts"},"kyowa-kirin":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-wave1.ts"},"verity-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-wave1.ts"},"biofrontera":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/companies-wave1.ts"},"heron-therapeutics":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/companies-wave1.ts"},"acrotech-biopharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies-wave1.ts"},"citius-pharmaceuticals":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/companies-wave1.ts"},"serb-pharmaceuticals":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/companies-wave1.ts"},"tersera-therapeutics":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/companies-wave1.ts"},"sobi":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-wave1.ts"},"hansoh-pharma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies-wave1.ts"},"evive-biotech":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/companies-wave1.ts"},"pierre-fabre":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies-wave1.ts"},"biolitec":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/companies-wave1.ts"},"bikanta":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"notable-labs":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-yc.ts"},"x-zell":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"shasqi":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"zpredicta":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"cofactor-genomics":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies-yc.ts"},"isono-health":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"histowiz":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"billiontoone":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"mednet":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"delee":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"oncobox":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"cambridge-cancer-genomics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"tradewind-bioscience":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"persephone-biosciences":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"reverie-labs":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"fidocure":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"data-driven-bioscience":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"clear-gene":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"leah-labs":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"resistancebio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"atomic-alchemy":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"arpeggio-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"asher-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"altay-therapeutics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"isabl":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"algen-biotechnologies":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"known-medicine":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"kernal-biologics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"liyfe":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"valink-therapeutics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"triomics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"aoa-dx":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"ananya-health":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"reprosent":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"yemaachi-biotech":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"digistain":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"harmonic-discovery":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"humane-genomics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"luminate-medical":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"alixia":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"nearwave":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"serinus-biosciences":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"signatur-biosciences":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"guardian-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"adventris-pharmaceuticals":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-yc.ts"},"modulari-t":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"numen":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"synsorybio":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-yc.ts"},"velorum-therapeutics":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"eris-biotech":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"granza-bio":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-yc.ts"},"kopra-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"aluna":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"blank-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"nucleo-research":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"origin-bio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"strand-ai":{"commit":"ef64475cca","date":"2026-09-18","author":"Oded Falik","message":"add: Strand AI (W26) to the YC oncology list","file":"src/data/companies-yc.ts"},"adialante":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies-yc.ts"},"tarebio":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"omanta":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"gamgee":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies-yc.ts"},"merck":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"astrazeneca":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"daiichi-sankyo":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"gilead":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"bms":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"roche-genentech":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"novartis":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"pfizer":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"johnson-johnson":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"abbvie":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"amgen":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"eli-lilly":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"gsk":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"bayer":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"astellas":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"takeda":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"boehringer-ingelheim":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"sanofi":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"regeneron":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"servier":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies.ts"},"kelun-biotech":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"systimmune":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"akeso":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"summit-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"adc-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"zymeworks":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"jazz":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"beone":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"remegen":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"dualitybio":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"medilink":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies.ts"},"avenzo":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"merus":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"genmab":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"revolution-medicines":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"arvinas":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"nuvalent":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"celcuity":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"menarini":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"corcept":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"syndax":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"moderna":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"biontech":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"replimune":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"immunocore":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"iovance":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"legend-biotech":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"carsgen":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"adaptimmune":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"lantheus":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"telix":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"rayzebio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"fusion-pharma":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"itm":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"terrapower-isotopes":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"orano-med":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"foundation-medicine":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"guardant-health":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"natera":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"grail":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"exact-sciences":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"tempus":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"caris":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/companies.ts"},"bostongene":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/companies.ts"},"illumina":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"10x-genomics":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"artera":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"paige":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"pathai":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"owkin":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"novocure":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"intuitive-surgical":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"histosonics":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"insightec":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"varian":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"elekta":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"reflexion":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"iba":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies.ts"},"mevion":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/companies.ts"},"ge-healthcare":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"siemens-healthineers":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"united-imaging":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"cancer-commons":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/companies.ts"},"celldex":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/companies.ts"},"debiopharm":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"keymed":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"morphosys":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"gritstone":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"serova":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"bulsara-bioworks":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"circle-pharma":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts"},"valius":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"elucidate-bio":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"sengine":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/companies.ts"},"champions-oncology":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"navexio":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"patient-data-vault":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"more-health":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"finaldose":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/companies.ts"},"orna-therapeutics":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"umoja-biopharma":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"interius":{"commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-","file":"src/data/companies.ts"},"insilico-medicine":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"recursion":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies.ts"},"isomorphic-labs":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/companies.ts"},"generate-biomedicines":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"perspective-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"clarity-pharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"aktis-oncology":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"radiomedix":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"sutro-biopharma":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts"},"mersana":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies.ts"},"tubulis":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"araris":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"synaffix":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"kymera":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"nurix":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"c4-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"monte-rosa":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"verastem":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"frontier-medicines":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"quanta-therapeutics":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"arsenal-bio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"sana-biotechnology":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"allogene":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"caribou":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts"},"nkarta":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"fate-therapeutics":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"freenome":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts"},"delfi-diagnostics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"harbinger-health":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"personalis":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/companies.ts"},"foresight-diagnostics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"lunit":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/companies.ts"},"aidoc":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/companies.ts"},"xilis":{"commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-","file":"src/data/companies.ts"},"curesponse":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"immatics":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/companies.ts"},"tscan":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/companies.ts"},"xencor":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/companies.ts"},"sofie-biosciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"nouscom":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/companies.ts"},"acupuncture-nausea":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"acupuncture-aromatase-inhibitor-arthralgia":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"acupuncture-hot-flushes":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"acupuncture-xerostomia":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"acupuncture-chemotherapy-neuropathy":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"mindfulness-based-interventions":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"cbt-insomnia-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"cbt-fatigue-distress":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"yoga-cancer":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"tai-chi-qigong":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/complementary.ts"},"hypnosis-cancer-care":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"relaxation-guided-imagery":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"music-therapy-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"dance-movement-therapy":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"peer-support-groups":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"massage-therapy-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"aromatherapy-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"reflexology-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"reiki-energy-therapies":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"ginger-nausea":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"curcumin-turmeric":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"green-tea-egcg":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"american-ginseng-fatigue":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"melatonin-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"omega3-epa-cachexia":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"probiotics-treatment-diarrhoea":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"glutamine-mucositis-neuropathy":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"honey-radiation-mucositis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/complementary.ts"},"mistletoe-extracts":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"high-dose-vitamin-c":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"psk-krestin-adjuvant":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"medicinal-mushrooms-reishi-turkey-tail":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"traditional-chinese-herbal-medicine":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"ayurvedic-medicine-cancer":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"homeopathy-cancer":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"st-johns-wort-interaction":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"cannabinoids-nausea":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"cannabinoids-pain-appetite":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"oral-cryotherapy-mucositis":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"frozen-gloves-compression-taxane":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"photobiomodulation-mucositis":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"hyperbaric-oxygen-radiation-injury":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"lymphoedema-decongestive-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/complementary.ts"},"minoxidil-chemotherapy-alopecia":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"bimatoprost-eyelash-regrowth":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"wigs-cranial-prosthesis":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"alternative-medicine-instead-of-treatment":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"laetrile-amygdalin":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"gerson-therapy-detox-regimens":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"shark-cartilage":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"hydrazine-sulfate":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"antineoplastons":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"black-salve-escharotics":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"fenbendazole-ivermectin-repurposing-claims":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/complementary.ts"},"essiac-herbal-cancer-cures":{"commit":"9ee25147f3","date":"2026-09-10","author":"Jude Gomila","message":"Add complementary and supportive approaches area and hair-loss page","file":"src/data/complementary.ts"},"paper-johnson-alternative-medicine-jnci-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/complementary.ts"},"paper-scalp-trial-jama-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/complementary.ts"},"list-price-growth":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"hospital-markups-340b":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"biosimilar-uptake":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"generics-shortages":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"dose-and-schedule":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"oral-parity-gaps":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"prior-authorisation":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"financial-toxicity":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"travel":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"end-of-life-intensity":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"trial-access":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/cost-levers.ts"},"original-medicare-medigap":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"medicare-advantage-all":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"unitedhealthcare":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"humana":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"cvs-aetna":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"elevance":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"cigna":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"kaiser-permanente":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"centene":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"bcbs-plans":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"medicaid":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"nhs":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"bupa":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"axa-health":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"aviva":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"vitality":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/coverage-rankings.ts"},"europepmc":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"openalex":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"pubchem":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"rcsb-pdb":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"wikidata-commons":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"openfda":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nominatim":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"world-atlas":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"dailymed":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"fda-approvals-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ema-epar-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nccn-esmo-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"world-bank":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"rankings-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"jcr-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cbioportal-manual":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ctgov-results":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"eu-ctr-ctis":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"isrctn":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"who-ictrp":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"jrct":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"chictr":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ctri":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"openfda-drugsfda":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"drugs-at-fda-files":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"purple-book":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ema-data":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"mhra":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"pmda":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"nmpa-cde":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"tga-artg":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"health-canada-dpd":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cms-asp":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nadac":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"medicare-part-d-spending":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nice-api":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"smc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"iqwig-gba":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"pbs":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"pubmed-eutils":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"crossref":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"openalex-works":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"semantic-scholar":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"biorxiv-medrxiv":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/data-sources.ts"},"unpaywall":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cbioportal-api":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"gdc":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"gtex":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"uniprot":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"chembl":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"drugbank":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"pubchem-more":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"alphafold-db":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"reactome":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"kegg":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"string":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"gco-more":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cdc-wonder":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ons-ndrs":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nordcan":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ecis":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"concord":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ncdb":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cosd":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"natcan":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"care-compare":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nhs-cwt":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"girft":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"openalex-institutions":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ror":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"orcid":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"nih-reporter":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ukri-gtr":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"cordis":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"grid":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"sec-edgar":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"companies-house":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"opencorporates":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"patentsview":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"google-patents-bq":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"epo-ops":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"ctgov-sponsors":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"wikidata-sparql":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"tcia":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/foundation-models.ts"},"idc":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"wikipedia-api":{"commit":"280228652e","date":"2026-09-09","author":"Jude Gomila","message":"Open data sources: inventory, candidates and page","file":"src/data/data-sources.ts"},"patient-forums":{"commit":"e189ce738f","date":"2026-09-17","author":"Jude Gomila","message":"Add Anocca; biophysics sources as data-source candidates","file":"src/data/data-sources.ts"},"biomodels":{"commit":"e189ce738f","date":"2026-09-17","author":"Jude Gomila","message":"Add Anocca; biophysics sources as data-source candidates","file":"src/data/data-sources.ts"},"physicell-mathcancer":{"commit":"e189ce738f","date":"2026-09-17","author":"Jude Gomila","message":"Add Anocca; biophysics sources as data-source candidates","file":"src/data/data-sources.ts"},"cancer-models-org":{"commit":"e189ce738f","date":"2026-09-17","author":"Jude Gomila","message":"Add Anocca; biophysics sources as data-source candidates","file":"src/data/data-sources.ts"},"stride-dna-break-detection":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/diagnostics-wave1.ts"},"intodna":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/diagnostics-wave1.ts"},"strata-oncology":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/diagnostics-wave1.ts"},"rad51-foci-assay":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"hrd-genomic-scar-scores":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"cellsearch-ctc-count":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"parsortix-ctc-harvest":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"functional-precision-medicine-haematology":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"sarcoma-methylation-classifier":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"urine-bladder-cancer-tests":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"bladder-epicheck":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"multitarget-stool-rna-test":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"fes-pet":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"quantitative-imaging-biomarkers":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"ct-body-composition-sarcopenia":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"dpyd-genotyping":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"ugt1a1-genotyping":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"tpmt-nudt15-genotyping":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"cardiac-biomarker-monitoring":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"strain-echocardiography-gls":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"g8-geriatric-screening":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"via-cervical-screening":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"hand-held-ultrasound":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"serum-tumour-markers":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"germ-cell-tumour-markers":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"thyroid-cancer-markers":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"cea-surveillance-colorectal":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"menarini-silicon-biosystems":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"angle-plc":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"geneoscopy":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"butterfly-network":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/diagnostics-wave2.ts"},"fujirebio":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/diagnostics-wave2.ts"},"alemtuzumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"bexarotene":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"busulfan":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"capecitabine":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/drugs-approved-wave1.ts"},"carmustine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"chlorambucil":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"clofarabine":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"cytarabine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"dabrafenib":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/drugs-approved-wave1.ts"},"dacarbazine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"daunorubicin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"decitabine":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs-approved-wave1.ts"},"epirubicin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"fludarabine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"flutamide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"idarubicin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"ixabepilone":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"mechlorethamine":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"megestrol":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"mercaptopurine":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"mitoxantrone":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"nelarabine":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/drugs-approved-wave1.ts"},"omacetaxine":{"commit":"827c124c8b","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 1: 25 NCI-listed cytotoxics, antimetabolites and early hormonal/targeted agents; tar","file":"src/data/drugs-approved-wave1.ts"},"procarbazine":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/drugs-approved-wave1.ts"},"thioguanine":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"thiotepa":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"trametinib":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/drugs-approved-wave1.ts"},"valrubicin":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/drugs-approved-wave1.ts"},"vorinostat":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"nilutamide":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"toremifene":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"raloxifene":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"triptorelin":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"dexamethasone":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"prednisone":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"imiquimod":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-approved-wave1.ts"},"aminolevulinic-acid":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"denileukin-diftitox":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"ibritumomab-tiuxetan":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"iobenguane-i-131":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/drugs-approved-wave1.ts"},"necitumumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"ofatumumab":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"ziv-aflibercept":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"selumetinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"siltuximab":{"commit":"3f3d3eeded","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 2: 25 NCI-listed targeted agents, antibodies, radiopharmaceuticals, hormonal and bon","file":"src/data/drugs-approved-wave1.ts"},"sirolimus-albumin-bound":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"denosumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"zoledronic-acid":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/drugs-approved-wave1.ts"},"pamidronate":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs-approved-wave1.ts"},"tocilizumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"amifostine":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-approved-wave1.ts"},"aprepitant":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"granisetron":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"ondansetron":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"palonosetron":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"netupitant-palonosetron":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs-approved-wave1.ts"},"rolapitant":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs-approved-wave1.ts"},"dexrazoxane":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"mesna":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"glucarpidase":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"uridine-triacetate":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"palifermin":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"rasburicase":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"plerixafor":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"filgrastim":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"pegfilgrastim":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"epoetin-alfa":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-approved-wave1.ts"},"darbepoetin-alfa":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"defibrotide":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"methylnaltrexone":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-approved-wave1.ts"},"talc-sclerosant":{"commit":"46af1b4b77","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 3: 23 NCI-listed supportive-care agents and HPV vaccines; every NCI A to Z page now ","file":"src/data/drugs-approved-wave1.ts"},"hpv-bivalent-vaccine":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs-approved-wave1.ts"},"hpv-quadrivalent-vaccine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"mirdametinib":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"catumaxomab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"efbemalenograstim-alfa":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"padeliporfin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"telotristat-ethyl":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/drugs-approved-wave1.ts"},"lipegfilgrastim":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"tegafur-gimeracil-oteracil":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/drugs-approved-wave1.ts"},"vinflunine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"histamine-dihydrochloride":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"anagrelide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-approved-wave1.ts"},"temoporfin":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"thyrotropin-alfa":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/drugs-approved-wave1.ts"},"tasonermin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"samarium-153-lexidronam":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs-approved-wave1.ts"},"ibandronic-acid":{"commit":"e64a3683df","date":"2026-09-10","author":"Jude Gomila","message":"Approved therapeutics wave 1, batch 4: 18 EMA-authorised oncology medicines absent from the NCI list; NCI coverage test;","file":"src/data/drugs-approved-wave1.ts"},"dorocubicel":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-approved-wave1.ts"},"benmelstobart":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs-china-wave1.ts"},"iruplinalkib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs-china-wave1.ts"},"flumatinib":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"utidelone":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"inetetamab":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"linperlisib":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"surufatinib":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"recombinant-human-endostatin":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"h101-oncolytic-adenovirus":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"iparomlimab-tuvonralimab":{"commit":"a8863aa10e","date":"2026-09-16","author":"Jude Gomila","message":"Offline page only on real failures, China wave 1, favicon set","file":"src/data/drugs-china-wave1.ts"},"mecapegfilgrastim":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-china-wave1.ts"},"vorolanib":{"commit":"9531e1fbfa","date":"2026-09-16","author":"Jude Gomila","message":"Essential thrombocythaemia page, aspirin record, vorolanib","file":"src/data/drugs-china-wave1.ts"},"pf-08634404":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"shr-8068":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"yl201":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-pipeline-wave1.ts"},"shr-a2102":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tqb2102":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"pm8002":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"in10018":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"telisotuzumab-adizutecan":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs-pipeline-wave1.ts"},"domvanalimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"si-b001":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"oleclumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cetrelimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hs-20093":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"zg006":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"calderasib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"zanzalintinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ak117":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"qlc5508":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"kc1036":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"budigalimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ceralasertib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"abexinostat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hrs-8080":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ipatasertib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"opevesostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"dzd8586":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"rc148":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sph4336":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"lm-108":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"yl202":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/drugs-pipeline-wave1.ts"},"livmoniplimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"jdq443":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tqb3616":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"saruparib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ql1706":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"rocbrutinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"mk-1045":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"oregovomab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"monalizumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"navlimetostat":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"al8326":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hlx43":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sys6010":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"kl-a167":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"quemliclustat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"mrg003":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"shr-a1921":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"shr-1501":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"darovasertib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cevostamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hb1801":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"jskn003":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"eik1001":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"kn026":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bexobrutideg":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"gfh375":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"zipalertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs-pipeline-wave1.ts"},"aglatimagene-besadenovec":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"jnj-79635322":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ql2107":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ibi354":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"gotistobart":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/drugs-pipeline-wave1.ts"},"aaa817":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"purinostat":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"tqb2450":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"xzp-3287":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lam561":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"zl-1310":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"velzatinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"a166":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"shr-a2009":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"mrg002":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"lm-302":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"gr1803":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"io102-io103":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"pf-07248144":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"abbv-706":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"esg401":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ty-9591":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"evorpacept":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"bcd-217":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"tara-002":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tgrx-326":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hs-20089":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"uliledlimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"qls32015":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bebt-209":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"givinostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sitneprotafib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"incb123667":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"js105":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"jmt101":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"jskn016":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"acasunlimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bnt324":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cobolimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"icp-248":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"emactuzumab":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"azenosertib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"olvimulogene-nanivacirepvec":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"setidegrasib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"hlx22":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sctb41":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"d07001":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/drugs-pipeline-wave1.ts"},"sctb35":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"tersolisib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"arlocabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bezuclastinib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs-pipeline-wave1.ts"},"tqb3454":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"shr-a1912":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"hmpl-306":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"tak-928":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"clifutinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"idrx-42":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"elenestinib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs-pipeline-wave1.ts"},"glsi-100":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"int230-6":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"grt-c901":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"grt-r902":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"imp4927":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"lerotinib":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"azd5335":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tq-b3234":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"ugn-103":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"hmpl-453":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"sctc21c":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"bcd-100":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hr070803":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"nb003":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"fda018-adc":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"tbi-1301":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"d-0502":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"incb161734":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"tar-210":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hmpl-760":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"ima203":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"sim0270":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"asp2138":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"f182112":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"zovegalisib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"vc004":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"hlx11":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"atigotatug":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"sgm-101":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"precemtabart-tocentecan":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"al2846":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"sasanlimab":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"tovecimig":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"inca33890":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"rph-051":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"bms-986365":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"lns8801":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"rondecabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"jnj-87189401":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"inbrx-106":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"bomedemstat":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/drugs-pipeline-wave1.ts"},"jnj-90301900":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"m108":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"bgb-43395":{"commit":"64e01c582d","date":"2026-09-14","author":"Jude Gomila","message":"Companies: InnoPharmax and Sunshine Lake Pharma added as trial sponsors; check-date stamps removed from 31 pipeline drug","file":"src/data/drugs-pipeline-wave1.ts"},"soquelitinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"vepugratinib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"pelabresib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs-pipeline-wave1.ts"},"naporafenib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"asc40":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/drugs-pipeline-wave1.ts"},"trabedersen":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"adi-peg20":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"ro7771950":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sctb14":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ose2101":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sg301":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"navitoclax":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs-pipeline-wave1.ts"},"pf-08046054":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"varegacestat":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/drugs-pipeline-wave1.ts"},"hs-20117":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"gq1005":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ugn-104":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"qls31905":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"sofetabart-mipitecan":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ivospemin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"bnt113":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"chiauranib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"rinzimetostat":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"atebimetinib":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ibi343":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bleximenib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs-pipeline-wave1.ts"},"ibi310":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ficlatuzumab":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"azd0486":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ifupinostat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hrs-4357":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"safusidenib":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/drugs-pipeline-wave1.ts"},"iah0968":{"commit":"fc451f2cc2","date":"2026-09-13","author":"Jude Gomila","message":"Pipeline treatments: check-date stamps removed from 293 generated summaries; the record's own date field carries the che","file":"src/data/drugs-pipeline-wave1.ts"},"ibi363":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"vs-7375":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"t3011":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"fpi-2265":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"adg126":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tng462":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"mcla-129":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"trk-950":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"tqb2825":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tyra-300":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tqb6411":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tqb2930":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"krt-232":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd3470":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ssgj-705":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"avzo-021":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cusatuzumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"xnw5004":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"serabelisib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"sapanisertib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"zamtocabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ak119":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"anvumetostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"xnw27011":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd9793":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tqb2922":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cinrebafusp-alfa":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"e-edv-d682":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"abt-301":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hmbd-001":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"tc011":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"englumafusp-alfa":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd4360":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ssgj-706":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"ep0031":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"farletuzumab-exatecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"absk061":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"rilvegostomig":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bio-106":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"mavrostobart":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hb0036":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"botensilimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"ndi-219216":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"crb-701":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ssgj-612":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"jk08":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ucart22":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tri-611":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd6621":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"hdm2017":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"silevertinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"crc01":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"palacaparib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tac01-cldn18-2":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"azd9750":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lorigerlimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ep0062":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lcb02a":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ai-081":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ino-5401":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"rc118-adc":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"adi-270":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"gc101-til":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"qlh12016":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"peluntamig":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"azd4512":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"eb-nk-301":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tng456":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bcb-276":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd5492":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"jyp0015":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"bdc-4182":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"hlx26":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ba3071":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"env-501":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"gc012f":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"azd4045":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"azd7789":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"vrn110755":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cgt4859":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"jnj-90014496":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lcb84":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"eb-mf-car-nk-01":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"eb-car30-nk":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"ctx112":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"at101":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"cart84":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"nxc-201-car-t":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"sys6023":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lirafugratinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"sti-6129":{"commit":"67ea93d423","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-afafc18d828b2d923 (orphan trials linking round)","file":"src/data/drugs-pipeline-wave1.ts"},"men1703":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"allo-647":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lb1410":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"lb4330":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"dji136":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"cd19-t-hank":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"spevatamig":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"azd5863":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave1.ts"},"tbi-1501":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"js111":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave1.ts"},"olverembatinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"trastuzumab-pamirtecan":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"florastamin-f18":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/drugs-pipeline-wave2.ts"},"vebreltinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"tunlametinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"glecirasib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"glumetinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave2.ts"},"zimberelimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"tabelecleucel":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"rezvilutamide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"golidocitinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"socazolimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"pirarubicin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"girentuximab-zr89":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"psma-1007-f18":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"favezelimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"elritercept":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"adagloxad-simolenin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"retlirafusp-alfa":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"cam2029":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"m701":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"lerociclib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"limertinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"iomab-b":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"visugromab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"amrubicin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"pucotenlimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave2.ts"},"azd0120":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"utomilumab":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"alisertib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"ubamatamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"roginolisib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"regn7075":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"zalifrelimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"balstilimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"tst001":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"tno155":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"parsaclisib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"feladilimab":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"amt-116":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"azd8421":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"enb003":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"eik1005":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"gecacitinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs-pipeline-wave6.ts"},"tng260":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"onvansertib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"vistusertib":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"ct3001":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"prtx007":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"merestinib":{"commit":"d46722256a","date":"2026-09-16","author":"Jude Gomila","message":"Clickable breadcrumbs, pipeline products wave 6, checklist additions","file":"src/data/drugs-pipeline-wave6.ts"},"lvgn6051":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"amo959":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/drugs-pipeline-wave6.ts"},"sotevtamab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"tilt-123":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"au-007":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"or502":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave6.ts"},"pamiparib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"radotinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"ponsegromab":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"wjb001":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/drugs-pipeline-wave7.ts"},"mhb039a":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"mhb036c":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"flonoltinib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"samuraciclib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"jmt203":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"emavusertib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"doc1021":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"jbi-802":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"befotertinib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"camonsertib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"selicrelumab":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"fluzoparib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"evexomostat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"tst003":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"obi-902":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"cyh33":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"farletuzumab-ecteribulin":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"imp1734":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"rv001v":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"dr-01":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"lp-184":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"skb105":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"rvu120":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"tuspetinib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"avzo-023":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"vudalimab":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"np137":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"tqb3702":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"rem-422":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"upifitamab-rilsodotin":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"stp938":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"tqb3909":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"obi-992":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"theo-260":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"pbp1510":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"rnk05047":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"bexmarilimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"inlexisertib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"tenalisib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"mitazalimab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"ipg1094":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"vibostolimab":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"boserolimab":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"hst-1011":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"spartalizumab":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/drugs-pipeline-wave7.ts"},"sabatolimab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs-pipeline-wave7.ts"},"evm14":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"pimicotinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"vb15010":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"tqb2868":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"ard103":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"vactosertib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-pipeline-wave7.ts"},"adavosertib":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"nuv-1511":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/drugs-pipeline-wave7.ts"},"anastrozole":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"zanidatamab-zovodotin":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"acitretin":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"nicotinamide":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"patidegib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"hypericin-sgx301":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"daromun":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"celecoxib":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"xevinapant":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"hb-200":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"depatuxizumab-mafodotin":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"neovax":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"gsk2256098":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"mifepristone":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"memantine":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"setmelanotide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"bromocriptine":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"cabergoline":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"pasireotide":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"pegvisomant":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"osilodrostat":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"metyrapone":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"paltusotine":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"obrixtamig":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"diazoxide":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"brigimadlin":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"cediranib":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"carotuximab":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"tk216":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"gi-6301":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"poziotinib":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"aminopterin":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"pevonedistat":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"lenzilumab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"inca033989":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"danazol":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"phosphorus-32":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs-subtypes-wave.ts"},"mavorixafor":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/drugs-subtypes-wave.ts"},"isotretinoin":{"commit":"9a31bd2e42","date":"2026-09-18","author":"Jude Gomila","message":"Third Chinese quality pass: 19 of 236 TL;DRs from the biomarker, drug, maker and trial waves corrected, and the 73 trial","file":"src/data/drugs-subtypes-wave.ts"},"sacituzumab-govitecan":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"trastuzumab-deruxtecan":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"datopotamab-deruxtecan":{"commit":"eafe250685","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a83d2475223e51182","file":"src/data/drugs.ts"},"sacituzumab-tirumotecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"trastuzumab-emtansine":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"enfortumab-vedotin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"brentuximab-vedotin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"mirvetuximab-soravtansine":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/drugs.ts"},"tisotumab-vedotin":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/drugs.ts"},"telisotuzumab-vedotin":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"zynlonta":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"gemtuzumab-ozogamicin":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/drugs.ts"},"belantamab-mafodotin":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs.ts"},"izalontamab-brengitecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"patritumab-deruxtecan":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"ifinatamab-deruxtecan":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"raludotatug-deruxtecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"tilatamig-samrotecan":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/drugs.ts"},"ak146d1":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"disitamab-vedotin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"zilovertamab-vedotin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"cmg901":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"puxitatug-samrotecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"pembrolizumab":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"nivolumab":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/drugs.ts"},"ipilimumab":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"atezolizumab":{"commit":"a8555d58b2","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a304216c1dd91aeb6 (sarcoma and bone subtypes)","file":"src/data/drugs.ts"},"durvalumab":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/drugs.ts"},"relatlimab-nivolumab":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"dostarlimab":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"cemiplimab":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/drugs.ts"},"tarlatamab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"teclistamab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs.ts"},"glofitamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"tebentafusp":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"blinatumomab":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/drugs.ts"},"amivantamab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"zanidatamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"zenocutuzumab":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"ivonescimab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"ciltacabtagene-autoleucel":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs.ts"},"axicabtagene-ciloleucel":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/drugs.ts"},"satricabtagene-autoleucel":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/drugs.ts"},"lifileucel":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"afamitresgene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"pluvicto":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"lutathera":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"pylarify":{"commit":"90c2622943","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: EU approval rows on 18 more drugs, derived from the EPAR-checked regional approvals table","file":"src/data/drugs.ts"},"ryz101":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"ac225-psma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"fap-2286":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"osimertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"lorlatinib":{"commit":"ce7541a1dd","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-ac9dba378b512a392 (paediatric subtypes)","file":"src/data/drugs.ts"},"sotorasib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"adagrasib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"daraxonrasib":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/drugs.ts"},"encorafenib":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/drugs.ts"},"selpercatinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"zongertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"zidesamtinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/drugs.ts"},"olaparib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"niraparib":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/drugs.ts"},"talazoparib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"palbociclib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/drugs.ts"},"ribociclib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"abemaciclib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"capivasertib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"inavolisib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"gedatolisib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"vepdegestrant":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"elacestrant":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/drugs.ts"},"belzutifan":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"relacorilant":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"revumenib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs.ts"},"vorasidenib":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/drugs.ts"},"venetoclax":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/drugs.ts"},"imatinib":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/drugs.ts"},"trastuzumab":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/drugs.ts"},"tucatinib":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/drugs.ts"},"intismeran-autogene":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"autogene-cevumeran":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"vusolimogene-oderparepvec":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"talimogene-laherparepvec":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/drugs.ts"},"optune":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/drugs.ts"},"galleri":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/drugs.ts"},"shield":{"commit":"b758371248","date":"2026-09-12","author":"Jude Gomila","message":"Primary sources for nine treatments and tests and two targets that had none (registry entries, FDA PMA pages, UniProt)","file":"src/data/drugs.ts"},"signatera":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"foundationone-cdx":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"artera-ai-prostate":{"commit":"b758371248","date":"2026-09-12","author":"Jude Gomila","message":"Primary sources for nine treatments and tests and two targets that had none (registry entries, FDA PMA pages, UniProt)","file":"src/data/drugs.ts"},"artera-ai-breast":{"commit":"b758371248","date":"2026-09-12","author":"Jude Gomila","message":"Primary sources for nine treatments and tests and two targets that had none (registry entries, FDA PMA pages, UniProt)","file":"src/data/drugs.ts"},"carboplatin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"paclitaxel":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/drugs.ts"},"omidubicel":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/drugs.ts"},"tregzi":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/drugs.ts"},"remestemcel-l":{"commit":"e722177d44","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: omidubicel, remestemcel-L and the Hepzato melphalan kit added with FDA approval sources, plus Gamida Cell, M","file":"src/data/drugs.ts"},"hepzato":{"commit":"e722177d44","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: omidubicel, remestemcel-L and the Hepzato melphalan kit added with FDA approval sources, plus Gamida Cell, M","file":"src/data/drugs.ts"},"essential-thrombocythaemia":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/essential-thrombocythaemia.ts"},"pt-1":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/essential-thrombocythaemia.ts"},"majic-et":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/essential-thrombocythaemia.ts"},"aspirin":{"commit":"9531e1fbfa","date":"2026-09-16","author":"Jude Gomila","message":"Essential thrombocythaemia page, aspirin record, vorolanib","file":"src/data/essential-thrombocythaemia.ts"},"tiragolumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/failures.ts"},"magrolimab":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/failures.ts"},"rovalpituzumab-tesirine":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/failures.ts"},"iniparib":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/failures.ts"},"bempegaldesleukin":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/failures.ts"},"adu-s100":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/failures.ts"},"eprenetapopt":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/failures.ts"},"tusamitamab-ravtansine":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/failures.ts"},"impassion131":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/failures.ts"},"epacadostat":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/failures.ts"},"trastuzumab-duocarmazine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/failures.ts"},"melflufen":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/failures.ts"},"arc-institute":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/foundation-models.ts"},"institute-for-protein-design":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/foundation-models.ts"},"providence-health":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/foundation-models.ts"},"yale-school-of-medicine":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/foundation-models.ts"},"google-deepmind":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/foundation-models.ts"},"microsoft-research":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"nvidia":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/foundation-models.ts"},"evolutionaryscale":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"vevo-therapeutics":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"bioptimus":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"aignostics":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"kaiko-ai":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"histai":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/foundation-models.ts"},"chai-discovery":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"xaira-therapeutics":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"lila-sciences":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/foundation-models.ts"},"cradle-bio":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/foundation-models.ts"},"profluent-bio":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/foundation-models.ts"},"latent-labs":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/foundation-models.ts"},"genesis-molecular-ai":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/foundation-models.ts"},"iambic-therapeutics":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"chan-zuckerberg-initiative":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/foundation-models.ts"},"imaging-data-commons":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/foundation-models.ts"},"uk-biobank":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/foundation-models.ts"},"all-of-us":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/foundation-models.ts"},"flatiron-foundation-cgdb":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/foundation-models.ts"},"cdas-nlst-plco":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/foundation-models.ts"},"pathology-benchmarks":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"tahoe-100m":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/foundation-models.ts"},"arc-virtual-cell-atlas":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/foundation-models.ts"},"virchow":{"commit":"b6e0a0fe48","date":"2026-09-08","author":"Jude Gomila","message":"Add foundation model entities and AI roadmaps","file":"src/data/foundation-models.ts"},"uni-conch":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"titan":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"prov-gigapath":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"chief":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"musk":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"h-optimus":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"pluto":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"hibou":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"kaiko-midnight":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/foundation-models.ts"},"atlas-aignostics":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"phikon":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"merlin-ct":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"radfm":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"ct-fm":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"medsam":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"sybil":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"mirai":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"med-gemini":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"aidoc-care":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"geneformer":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"scgpt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/foundation-models.ts"},"universal-cell-embedding":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"scfoundation":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/foundation-models.ts"},"nicheformer":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"cellfm":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/foundation-models.ts"},"genept":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"c2s-scale":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"state-arc":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"transcriptformer":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"gears":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"alphafold3":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"boltz":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"chai-1":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"esm3":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"evo2":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"rfdiffusion":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"bioemu":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"nucleotide-transformer":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"enformer-borzoi":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"alphamissense":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"alphagenome":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"foresight-ehr":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"tempus-multimodal":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"bionemo":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/foundation-models.ts"},"phenom-2":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"chemistry42":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/foundation-models.ts"},"virtual-cell":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/foundation-roadmap.ts"},"ai-oncology-clinic":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/foundation-roadmap.ts"},"pancan-know-your-tumor":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"prostate-cancer-promise":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-genomic-medicine-service":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-jewish-brca-testing":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-cancer-screening-programmes":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"australia-cancer-screening-programs":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ireland-national-screening-service":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nz-time-to-screen":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cdc-nbccedp":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-hpv-vaccination":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"us-vaccines-for-children":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"gavi-hpv-programme":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nci-cancer-information-service":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"macmillan-support-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cruk-nurse-helpline":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"acs-cancer-helpline":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cancercare":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cancer-support-community":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"krebsinformationsdienst":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"breast-cancer-now-helpline":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"acs-road-to-recovery":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"acs-hope-lodge":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"corporate-angel-network":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ronald-mcdonald-house-charities":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-healthcare-travel-costs-scheme":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"young-lives-vs-cancer":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"thesecondopinion":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"lazarex-cancer-foundation":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nihr-be-part-of-research":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"force-facing-our-risk":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"sharsheret":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"maggies-centres":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"penny-brohn-uk":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"livestrong-at-the-ymca":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"look-good-feel-better":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"imerman-angels":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"first-descents":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"kesem":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"little-princess-trust":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"knitted-knockers":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"wigs-for-kids":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"know-your-tumor":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"promise-registry":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-gms":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"jewish-brca":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-screening":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"au-screening":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ie-screening":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nz-screening":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nbccedp":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"aca-preventive":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-hpv":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"vfc-hpv":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"au-nip-hpv":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"gavi-hpv":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nci-cis":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"macmillan-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cruk-nurses":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"acs-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cancercare-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"csc-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"lls-specialists":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"kid-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cancer-council-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ccs-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ics-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"bcn-line":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"road-to-recovery":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"hope-lodge":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"can-flights":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"rmhc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"ylvc-homes":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"htcs":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"cancer-commons-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"thesecondopinion-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"st-jude-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nci-paying-trials":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nih-cc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"lazarex-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"bpor":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"expanded-access":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"assistance-page":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"coverage-uk-page":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"force-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"sharsheret-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-genetics-referral":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"maggies-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"penny-brohn-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"livestrong-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"lgfb-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"imerman-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"first-descents-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"kesem-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"survivorship-page":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-wigs":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"nhs-prostheses":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"lpt-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"wfk-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"knockers-svc":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"open-data-page":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"onco-snapshots":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/free-wave.ts"},"frontier-2035":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier-roadmap.ts"},"cure-paths":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier-roadmap.ts"},"programmable-dna-targeting-therapeutics":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"fragmentomics":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"adc-payload-neutralizer":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"in-vivo-gene-editing-cancer":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"epigenetic-editing":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"self-amplifying-rna":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"stroma-directed-car":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"engineered-bacteria-therapy":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/frontier.ts"},"phage-delivery":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"microbiome-modulation-io":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/frontier.ts"},"tumour-microbiome-targeting":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"dna-origami-nanorobots":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"magnetic-nanoparticle-hyperthermia":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/frontier.ts"},"photothermal-nanoparticles":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"sonodynamic-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/frontier.ts"},"radiodynamic-therapy":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"vhee-radiotherapy":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"proton-arc-therapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/frontier.ts"},"lattice-radiotherapy":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"auger-electron-therapy":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"alpha-nanogenerators":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"radionuclide-parp-combination":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"nerve-tumour-denervation":{"commit":"4d65dd494a","date":"2026-09-08","author":"Jude Gomila","message":"Frontier technologies and roadmaps, Europe PMC latest-papers feed and trends, supporting technologies and companies; Lat","file":"src/data/frontier.ts"},"cachexia-therapy":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"chronotherapy":{"commit":"6566f80405","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front: 28 technologies, 18 terms, 14 trials, 11 ideas; existing lifestyle technologies join","file":"src/data/frontier.ts"},"metabolic-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/frontier.ts"},"senescence-targeting":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"il12-electroporation":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"de-novo-protein-design":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/frontier.ts"},"molecular-glue-platforms":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/frontier.ts"},"antibody-oligonucleotide-conjugates":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"logic-gated-therapeutics":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"in-situ-vaccination":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"interception-vaccination":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"trained-innate-immunity":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"histotripsy-immune-priming":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"mechanobiology-therapy":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"hypoxia-activated-therapy":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"digital-twins-trials":{"commit":"9f90c59a31","date":"2026-09-17","author":"Jude Gomila","message":"Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and ima","file":"src/data/frontier.ts"},"n-of-1-platforms":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/frontier.ts"},"continuous-ctdna-monitoring":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"breath-vocs":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"drug-repurposing":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"total-body-pet-screening":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/frontier.ts"},"quantum-dot-imaging":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"organoid-guided-therapy-scale":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts"},"spatial-omics-guided-therapy":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"exosome-therapeutics":{"commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts"},"nilotinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"bosutinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"luspatercept":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"imetelstat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"ruxolitinib":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/gap-fill.ts"},"fedratinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"pacritinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"momelotinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"hydroxyurea":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"ropeginterferon-alfa-2b":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"rusfertide":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/gap-fill.ts"},"glasdegib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"arsenic-trioxide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"tretinoin-atra":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"bendamustine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"tazemetostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"brexucabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"pralatrexate":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"romidepsin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"belinostat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"mogamulizumab":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"cladribine":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"leucovorin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"nogapendekin-alfa-inbakicept":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/gap-fill.ts"},"capmatinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"tepotinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"pentostatin":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/gap-fill.ts"},"moxetumomab-pasudotox":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"interferon-alfa":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"pivekimab-sunirine":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"idelalisib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"duvelisib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"copanlisib":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"umbralisib":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"ixazomib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"elotuzumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"pomalidomide":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"thalidomide":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"panobinostat":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"asparaginase":{"commit":"6c814e55f8","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: EU approval rows on 30 drugs, derived from the EPAR-checked regional approvals table so the two no longer di","file":"src/data/gap-fill.ts"},"belumosudil":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"treosulfan":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"retifanlimab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"cosibelimab":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/gap-fill.ts"},"penpulimab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"vismodegib":{"commit":"ce7541a1dd","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-ac9dba378b512a392 (paediatric subtypes)","file":"src/data/gap-fill.ts"},"sonidegib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"erlotinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"gefitinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"afatinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"dacomitinib":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"mobocertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"sunvozertinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"crizotinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"ceritinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"brigatinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"ensartinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"taletrectinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"larotrectinib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/gap-fill.ts"},"entrectinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/gap-fill.ts"},"temsirolimus":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/gap-fill.ts"},"pexidartinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"sipuleucel-t":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"aldesleukin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"leuprolide":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/gap-fill.ts"},"degarelix":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"bicalutamide":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/gap-fill.ts"},"cyclophosphamide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"vincristine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"vinblastine":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"vinorelbine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"methotrexate":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"fluorouracil":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"gemcitabine":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/gap-fill.ts"},"oxaliplatin":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/gap-fill.ts"},"irinotecan":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/gap-fill.ts"},"etoposide":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"bleomycin":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/gap-fill.ts"},"dactinomycin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"mitomycin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"melphalan":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/gap-fill.ts"},"eribulin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"mitotane":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/gap-fill.ts"},"mifamurtide":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"sodium-thiosulfate":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"pafolacianine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"pegulicianine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"aminolevulinic-acid-gleolan":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"fluciclovine-f18":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"fluoroestradiol-f18":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/gap-fill.ts"},"ga68-dotatate":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/gap-fill.ts"},"tilmanocept-tc99m":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"eltrombopag":{"commit":"a2807de12f","date":"2026-09-16","author":"Jude Gomila","message":"data: six NCI-listed supportive-care drugs (eltrombopag, romiplostim, emapalumab, fostamatinib, ravulizumab, propranolol","file":"src/data/gap-fill.ts"},"romiplostim":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"emapalumab":{"commit":"a2807de12f","date":"2026-09-16","author":"Jude Gomila","message":"data: six NCI-listed supportive-care drugs (eltrombopag, romiplostim, emapalumab, fostamatinib, ravulizumab, propranolol","file":"src/data/gap-fill.ts"},"fostamatinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"ravulizumab":{"commit":"38de09277f","date":"2026-09-18","author":"Jude Gomila","message":"After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded","file":"src/data/gap-fill.ts"},"propranolol-hemangeol":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"raltitrexed":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"vindesine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"pixantrone":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"abarelix":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"alitretinoin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"aminoglutethimide":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"diethylstilbestrol":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"estramustine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"floxuridine":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"fluoxymesterone":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"porfimer-sodium":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"sargramostim":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"lenograstim":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"eflapegrastim":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"histrelin":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/gap-fill.ts"},"buserelin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"infigratinib":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"olaratumab":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"hexaminolevulinate":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"peginterferon-alfa-2b":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"ethiodized-oil":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"technetium-sulfur-colloid":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"choline-c11":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"streptozocin":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/gap-fill.ts"},"olmutinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"methyl-aminolevulinate":{"commit":"67ea93d423","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-afafc18d828b2d923 (orphan trials linking round)","file":"src/data/gap-fill.ts"},"trilaciclib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"teniposide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"altretamine":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"plicamycin":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"formestane":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"amsacrine":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"uracil-mustard":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"mitobronitol":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"pipobroman":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"oprelvekin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"motixafortide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"dronabinol":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"nabilone":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/gap-fill.ts"},"dolasetron":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"methoxsalen-ecp":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/gap-fill.ts"},"cinacalcet":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"nedaplatin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"doxifluridine":{"commit":"602755e40b","date":"2026-09-16","author":"Jude Gomila","message":"data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indic","file":"src/data/gap-fill.ts"},"nimotuzumab":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/gap-fill.ts"},"plitidepsin":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"aldoxorubicin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/gap-fill.ts"},"anetumab-ravtansine":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/gap-fill.ts"},"zen-3694":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/gap-fill.ts"},"jak2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cd79b":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cxcr4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"ccr4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"tim3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"smoothened":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"pdgfra":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"csf1r":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"ewsr1-fli1":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"epcam":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cldn6":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cd73-adenosine":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"vista":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"muc16":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"liv1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"mdm2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"prmt5-mtap":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"wrn":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cd52":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"cd7":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/gap-fill.ts"},"palliative-care":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"hospice-end-of-life":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"pain-management":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"palliative-radiotherapy":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"psycho-oncology":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"oncology-nutrition":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"prehabilitation":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"financial-navigation":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"survivorship-care-plan":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"fertility-preservation":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"oncology-nursing":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"integrative-oncology":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/gap-fill.ts"},"antiemetic-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"bone-modifying-agents":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"g-csf-growth-factors":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/gap-fill.ts"},"transfusion-support":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"cancer-associated-thrombosis":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"epro-symptom-monitoring":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"multidisciplinary-tumour-board":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/gap-fill.ts"},"telehealth-oncology":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"electrochemotherapy":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"isolated-limb-perfusion":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/gap-fill.ts"},"percutaneous-hepatic-perfusion":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"intraoperative-radiotherapy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/gap-fill.ts"},"global-oncology-access":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/gap-fill.ts"},"rare-cancers":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/gap-fill.ts"},"cancer-health-disparities":{"commit":"3c0138f0f0","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links for thirty terms (hallmarks, regulatory, ADC chemistry, endpoints); calendar entry without an ","file":"src/data/gap-fill.ts"},"aya-oncology":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/gap-fill.ts"},"cancer-in-pregnancy":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"hereditary-cancer-syndromes":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/gap-fill.ts"},"li-fraumeni":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/gap-fill.ts"},"vhl-disease":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/gap-fill.ts"},"drug-price-transparency":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/gap-fill.ts"},"oncology-workforce":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/gap-fill.ts"},"who-essential-medicines":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/gap-fill.ts"},"plasma-ebv-dna":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/gap-fill.ts"},"nice-guidance":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/gap-fill.ts"},"asco-guidelines":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"csco-guidelines":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/gap-fill.ts"},"jsmo-jsco-guidelines":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"american-cancer-society":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/gap-fill.ts"},"leukemia-lymphoma-society":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"pancan":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/gap-fill.ts"},"mmrf":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/gap-fill.ts"},"lymphoma-research-foundation":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"national-brain-tumor-society":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/gap-fill.ts"},"alexs-lemonade-stand":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"st-baldricks":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/gap-fill.ts"},"colorectal-cancer-alliance":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"lungevity":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"melanoma-research-alliance":{"commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts"},"ovarian-cancer-research-alliance":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts"},"susan-g-komen":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/gap-fill.ts"},"prostate-cancer-foundation":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/gap-fill.ts"},"swog":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/groups.ts"},"nrg-oncology":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/groups.ts"},"alliance-oncology":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/groups.ts"},"ecog-acrin":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/groups.ts"},"childrens-oncology-group":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/groups.ts"},"cctg":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/groups.ts"},"big":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/groups.ts"},"gbg":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/groups.ts"},"jcog":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/groups.ts"},"unicancer":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/groups.ts"},"nccn-org":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/groups.ts"},"endometrial-pole-ultramutated":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"endometrial-mmr-deficient":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"endometrial-p53-abnormal":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"endometrial-nsmp":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"advanced-recurrent-endometrial-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"uterine-carcinosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"early-cervical-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"locally-advanced-cervical-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"recurrent-metastatic-cervical-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"platinum-sensitive-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"platinum-resistant-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/gynaecological-subtypes.ts"},"nivopostop":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/head-neck-hpv-subtypes.ts"},"ecog-e3311":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/head-neck-hpv-subtypes.ts"},"pathos":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/head-neck-hpv-subtypes.ts"},"captain-1st":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/head-neck-hpv-subtypes.ts"},"hpv-positive-oropharyngeal-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"hpv-negative-head-and-neck-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"recurrent-metastatic-hnscc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"hypopharyngeal-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"adenoid-cystic-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"salivary-duct-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"mucoepidermoid-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"oral-tongue-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"buccal-mucosa-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"lip-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-hpv-subtypes.ts"},"oropharyngeal-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-subtypes.ts"},"laryngeal-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-subtypes.ts"},"oral-cavity-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/head-neck-subtypes.ts"},"idea-acc-open-hardware-linac":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-linac-uptime-contracts":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-hypofractionation-default-lmic":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-remote-planning-hubs":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-modern-cobalt-bridge":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pooled-procurement-radiotherapy":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-telepathology-district-network":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-ai-first-pathology-common-cases":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-nurse-led-chemotherapy-units":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-eml-listing-price-commitments":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-biosimilar-prequalification-pool":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-chemo-stockout-early-warning":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-childhood-medicines-platform-scale":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-hub-spoke-national-networks":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-mobile-see-and-treat-units":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-hpv-self-sample-same-day-ablation":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-gbci-country-dashboards":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-infusion-sparing-regimens":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-metronomic-lmic-platform-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-global-cancer-financing-window":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-frugal-hdr-brachytherapy":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-registries-as-aid-condition":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-abandonment-stipends":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-diaspora-tele-tumour-boards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-solar-microgrids-for-cancer-units":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-clinical-officer-oncology-track":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-oncology-pharmacist-prescribing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-remote-medical-physics-qa":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-echo-tele-mentoring-oncology":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-retention-packages-oncology":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-regional-oncology-training-hubs":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-ambient-ai-documentation-oncology":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-advanced-practice-radiation-therapists":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-nurse-led-follow-up-clinics":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pathologist-assistants-and-ai-triage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-open-oncology-workforce-model":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-fast-track-relicensing-oncologists":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-mainstream-tele-genetic-counselling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-community-health-workers-oncology":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-district-surgeon-oncology-mentorship":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-one-stop-breast-diagnostic-clinic":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-28-day-diagnosis-standard":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-funded-navigator-per-diagnosis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-reflex-genomic-profiling-at-diagnosis":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-guideline-concordance-dashboards":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-national-virtual-mdt-rare-complex":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-portable-treatment-summary":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-primary-care-shared-care-agreements":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-electronic-pro-monitoring-standard":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-tumour-board-implementation-audit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-acute-oncology-assessment-units":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-diagnostic-interval-public-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-reflex-biomarker-panels-by-tumour":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-rapid-diagnostic-centres-vague-symptoms":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-embedded-decision-aids":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-financial-toxicity-screening-at-diagnosis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-universal-asynchronous-second-opinion":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-episode-payment-tied-to-concordance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-transition-handoff-medication-reconciliation":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pathway-capacity-simulation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-auto-generated-survivorship-plans":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-risk-stratified-cardio-oncology-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-default-fertility-preservation-referral":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-national-late-effects-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-risk-stratified-follow-up":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-tailored-second-cancer-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-return-to-work-rehabilitation":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-cognitive-rehabilitation-after-chemotherapy":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-cardiometabolic-clinic-hormone-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-aya-survivorship-passport":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-survivor-biobank-late-effect-prediction":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-lymphoedema-prospective-surveillance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-automatic-early-palliative-triggers":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-balanced-opioid-policy-reform":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-local-oral-morphine-production":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-neighbourhood-palliative-networks":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-tele-palliative-care-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-earmarked-palliative-budget-share":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pain-control-public-audit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-serious-illness-conversation-prompts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-single-fraction-palliative-radiotherapy-default":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-essential-palliative-package-in-uhc":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-paediatric-palliative-in-every-childhood-unit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-home-based-end-of-life-kits":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-methadone-and-alternatives-where-morphine-fails":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-geriatric-assessment-by-default":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-broad-eligibility-as-regulatory-default":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pragmatic-trials-over-75-function-endpoints":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-structured-deprescribing-at-diagnosis":{"commit":"76ca3f99b7","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: access and delivery of care worldwide","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-home-chemotherapy-older-patients":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-hospital-at-home-oncology":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-upfront-reduced-dose-trials-frail":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-electronic-frailty-index-oncology":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-geriatric-co-management-surgery":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-post-approval-evidence-over-75":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-caregiver-training-as-covered-service":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-pharmacist-interaction-review-oral-anticancer":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-time-toxicity-reporting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-prehabilitation-older-surgery":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-acc-dementia-and-cancer-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-access.ts"},"idea-bio1-multiregion-blocks-default":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-rapid-autopsy-network":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-ctdna-clone-report":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-truncal-branch-labelling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-outlier-lesion-biopsy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-barcoded-avatars-clonal-fitness":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-evolvability-index":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-adaptive-therapy-platform":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-ctdna-adaptive-tki":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-first-strike-second-strike":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-collateral-sensitivity-atlas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-evolutionary-double-bind":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-spatial-clone-immune-map":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-methylation-clone-tracking":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-clonal-clearance-endpoint":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-evolution-forecasting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-baseline-ultradeep-resistant-clones":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-cfrna-plasticity-tracking":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-evolutionary-tumour-boards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-apobec-inhibitor-adjunct":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-cin-vulnerability-kif18a":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-federated-evolution-atlas":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-clone-to-lesion-mapping":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-rebiopsy-before-switch":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-clonal-neoantigen-vaccines":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-myc-max-molecular-glue":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-omomyc-mrna":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-p53-mutant-reactivator-expansion":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-mutant-p53-degrader":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-pan-ras-covalent-g12d":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-covalent-ligandability-atlas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-glue-degrader-atlas":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-fusion-tf-degraders":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-condensate-disruptors":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-tumour-restricted-e3-atlas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-antibody-degrader-conjugates":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-lytac-surface-degraders":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-rna-targeting-small-molecules":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-epigenetic-silencing-in-vivo":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-paralog-synthetic-lethality":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-pp2a-activators":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-wrn-msi-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-macrocycle-ppi-campaign":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-arv7-degrader":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-ai-binders-disordered-regions":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-pmhc-bispecifics-public-drivers":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-mrna-intrabodies":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-translation-dependency-myc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-undruggable-open-consortium":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-undruggable-market-commitment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-immune-matched-humanised-mice":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-co-clinical-avatar-trials":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-organoid-immune-coculture":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-tumour-on-chip-penetration":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-in-silico-trials-dose":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-preclinical-preregistration":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-multicentre-mouse-trials":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-model-predictivity-benchmark":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-negative-preclinical-repository":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-tumour-slice-cultures":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-metastatic-niche-models":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-aged-comorbid-models":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-comparative-oncology-dogs":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-zebrafish-avatars":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-multi-organ-chip-tox":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-rare-cancer-organoid-bank":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-organoid-assay-clinical-validation":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-organoid-cell-therapy-potency":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-somatic-crispr-gemms":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-ctc-derived-explants":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-model-authentication-mandate":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-reverse-translation-resistance-models":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-ex-vivo-perfused-tumour":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-model-patient-matching":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-virtual-cell-perturbation":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-mandatory-progression-biopsy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-open-resistance-atlas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-upfront-bypass-combination":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-pre-randomised-sequencing-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-antigen-mapping-at-progression":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-dual-antigen-adc-escape":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-adaptive-car-antigen-switch":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-drug-holiday-resensitisation":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-persister-ferroptosis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-epigenetic-persister-blockade":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-mutagenesis-blockade-rev1":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-stress-response-blockade":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-senolytics-after-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-persister-metabolic-vulnerability":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-molecular-progression-add-on":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-alternating-schedules":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-resistance-mutation-vaccine":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-mechanism-matched-access":{"commit":"ec38dbcf9c","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 1","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-resistance-platform-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-slfn11-payload-guidance":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-stromal-resistance-blockade":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-real-world-resistance-surveillance":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-approval-linked-progression-sampling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-drug-exposure-sanctuary-mapping":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio1-immunopeptidome-timing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-1.ts"},"idea-bio2-antimetastatic-endpoint":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-ctc-clearance-go-nogo":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-net-blockade-perioperative":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-perioperative-betablocker-nsaid":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-premetastatic-niche-assay":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-inhaled-lung-niche-immunotherapy":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-liver-niche-kupffer-reprogramming":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-cxcr4-mobilise-then-kill":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-platelet-cloak-aspirin-mrd":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-rapid-autopsy-commons":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-metastasis-screen-standard":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-ctc-culture-functional-testing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-lymph-node-immune-priming":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-organotropism-atlas":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-metastasis-funding-floor":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-matrix-stiffness-prevention":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-brain-met-prevention-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-oligometastatic-signature":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-dormancy-selective-screen":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-autophagy-block-mrd":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-pro-dormancy-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-il1-awakening-blockade":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-national-mrd-platform":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mrd-reference-standards":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mrd-triggered-neoantigen-vaccine":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-nk-cells-for-mrd":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-whole-genome-mrd-depth":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-marrow-niche-on-chip":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-localise-the-mrd":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-circadian-mrd-sampling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mrd-guided-endocrine-duration":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mrd-coverage-with-evidence":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mrd-clinic-service":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-survivor-plasma-biobank":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-trem2-myeloid-reprogramming":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-in-situ-vaccination-solid":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-oncolytic-regulated-il12":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-engineered-bacteria-payloads":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-tumour-anchored-tgfbeta-trap":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-lactate-acid-axis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-radiotherapy-sting-fractionation":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-tertiary-lymphoid-induction":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-cxcr2-neutrophil-blockade":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-caf-subtype-assignment":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-implantable-microdevice-screen":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-vascular-normalisation-window":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-complement-c5ar-blockade":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-intracavitary-immunotherapy":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-myeloid-engager-bispecific":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-hypoxia-guided-adenosine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-histotripsy-immune-priming":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-trained-immunity-priming":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-sonobiopsy":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-intraventricular-car-t":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-robotic-convection-delivery":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-transferrin-shuttle-adc":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-implanted-ultrasound-repeat-dosing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-cns-cohort-mandate":{"commit":"876867b8f4","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 2","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-csf-ctdna-monitoring":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-brain-exposure-disclosure":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-intranasal-delivery":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-blood-csf-barrier-model":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-fus-for-cell-entry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-brain-penetrant-glue-degraders":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-gdf15-plus-exercise":{"commit":"876867b8f4","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 2","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-gdf15-stratified-enrolment":{"commit":"876867b8f4","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: tumour biology, part 2","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-cachexia-function-endpoint":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-prehabilitation-standard":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-exercise-reimbursement":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-anamorelin-access":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-ai-sarcopenia-from-ct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-lean-mass-dosing":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-low-dose-olanzapine-appetite":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-cachexia-pathway-code":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-protein-plus-training-during-io":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-remote-weight-step-monitoring":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-rare-cancer-umbrella-platform":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-n-of-1-framework":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-paediatric-first-development":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-rare-cancer-telepathology-network":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-functional-precision-rare":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-rare-cancer-prize-fund":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-registry-embedded-randomisation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-patient-partnered-rare-commons":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-mechanism-defined-baskets":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-shared-compound-access-pool":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-bayesian-borrowing-acceptance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-rare-tumour-model-bank":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-tcr-repertoire-early-readout":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-fmt-plus-checkpoint-phase3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-antibiotic-stewardship-io":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-spatial-signature-cdx":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-ctdna-six-week-io-switch":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-io-biomarker-data-commons":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-til-reactivity-selection":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-antigen-presentation-triage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-epigenetic-priming-cold-tumours":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-neoadjuvant-biomarker-engine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-steroid-sparing-irae":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-bio2-fibre-diet-io-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-biology-2.ts"},"idea-cost-asp-flat-fee":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-site-neutral-infusion":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-340b-pass-through":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-indication-based-pricing":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-inflation-rebates-commercial":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-part-b-cap":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-biosimilar-default-substitution":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-interchangeable-oncology-biosimilars":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-nonprofit-generic-oncology":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-transparent-generic-pricing":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-low-dose-abiraterone-food":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-low-dose-immunotherapy-trials":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-optimus-legacy-drugs":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-extended-interval-default":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-shorter-course-trials":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-hypofractionation-payment":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-subcutaneous-community":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-vial-sharing-dose-rounding":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-gold-card-oncology":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-real-time-pa-fhir":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-federal-oral-parity":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-financial-toxicity-screening":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-travel-teleoncology":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-early-palliative-default":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-trial-enrolment-cost-lever":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-value-scale-in-coverage":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-managed-access-everywhere":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-pooled-procurement-essential":{"commit":"0b4b7eb93e","date":"2026-09-10","author":"Jude Gomila","message":"Add plan rankings (/coverage/rankings/) and cost-reduction section (/costs/) with wave-costs ideas","file":"src/data/ideas-waves/wave-costs.ts"},"idea-cost-voluntary-licensing-oncology":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-costs.ts"},"idea-data-mcode-payment-condition":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-oncology-api-certification":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-national-cancer-data-space":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-federated-analytics-network":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-federated-learning-imaging":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-donor-card":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-dynamic-consent-app":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-consent-in-the-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-accredited-tre-network":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-synthetic-companion-datasets":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-deidentification-pipeline":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-national-slide-archive":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-structured-genomic-reports":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-automatic-outcome-linkage":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-pro-as-structured-standard":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-line-of-therapy-algorithms":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-point-of-care-randomisation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-procurement-open-api-clauses":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-privacy-preserving-linkage-tokens":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-registry-in-a-box":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-trial-to-registry-bridge":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-atlas-to-outcome-linkage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-radiotherapy-dose-repository":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-surgical-video-commons":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ipd-deposit-enforcement":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-common-biobank-consent-mta":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-patient-held-cancer-record":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-cross-border-rare-cancer-pool":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-quality-scorecards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-structured-radiology-response":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-target-trial-emulation-standard":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-rwe-rct-calibration-library":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-accelerated-approval-registry-condition":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-rwpfs-validation-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-registry-based-rcts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-coverage-with-evidence-development":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-off-label-outcomes-registry":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-real-world-dose-intensity":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-excluded-populations-rwe-mandate":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-linked-pharmacovigilance-interactions":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-access-programme-outcomes":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-registry-genomics-linkage-programme":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-observational-study-registration":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-gcp-for-real-world-data":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-registry-follow-up-of-trial-participants":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-wearable-endpoints-validation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-external-control-arm-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-paediatric-rwe-consortium":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-sequencing-analysis-per-approval":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-outcome-based-price-reassessment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-computable-living-guidelines":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-evidence-knowledge-graph":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-funded-living-systematic-reviews":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-plain-language-summary-mandate":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-structured-trial-results-deposit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-provenance-first-decision-support":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-tumour-board-evidence-assistant":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-guideline-concordance-dashboards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-thirty-day-practice-change-learning":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-patient-explainers-per-recommendation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-evidence-to-adoption-tracker":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-retraction-propagation":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-licensed-guidelines":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-unanswered-questions-registry":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-living-llm-oncology-benchmark":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-rapid-guideline-translation":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-offline-cds-lmic-generalists":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-toxicity-cds-for-nurses":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-72-hour-second-opinion-network":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-standard-of-care-change-alerts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-full-data-with-abstract":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-implementation-trials-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-wikipedia-oncology-editors":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-order-set-defaults-30-days":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-standard-of-care-api":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-prospective-ai-trials-fund":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-clinical-ai-model-registry":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-post-market-performance-reporting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-drift-monitoring-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-sequestered-prospective-benchmarks":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-neutral-ai-evaluator":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-regulatory-sandbox-adaptive-ai":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-liability-safe-harbour":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-reimbursement-tied-to-outcomes":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-silent-trial-before-deployment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-subgroup-performance-reporting-mandate":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-cell-foundation-model":{"commit":"edc978c8af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: data, knowledge and AI","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-precompetitive-cancer-foundation-model":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-open-weights-for-public-funded-ai":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-digital-twin-predict-then-observe":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-in-silico-trials-calibrated":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-pathology-evaluation-standard":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-screening-endpoints":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-multisite-validation-precondition":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-patient-facing-model-cards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-red-team-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-audit-trail-in-ehr":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-decommissioning-rules":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-llm-documentation-rct-oncology":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-data.ts"},"idea-data-ai-vs-tumour-board-rct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-data.ts"},"idea-fund-burden-weighted-portfolio":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-metastasis-moonshot":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-prevention-moonshot":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-dollars-per-death-dashboard":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-implementation-quota":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-lmic-burden-match":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-neglected-cancer-lottery":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-ten-year-hard-problem-awards":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-survivorship-endowment-levy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-non-drug-trial-quota":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-replication-set-aside":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-white-space-map":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-programme-officer-incentives":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-patient-burden-review-criterion":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-global-cancer-fund":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-cachexia-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-cross-funder-portfolio-registry":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-older-patients-trial-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-fast-grants-oncology":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-brain-metastases-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-cure-prize":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-first-in-class-prize":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-amc-paediatric-rare":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-conditional-transferable-voucher":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-value-based-patent-extension":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-benefit-indexed-exclusivity":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-pay-for-cure-annuities":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-nonprofit-pharma":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-public-option-generic-oncology":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-public-car-t-manufacturing":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-mcbs-linked-pricing":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-head-to-head-mandate":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-health-impact-fund-oncology":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-sovereign-first-in-class-coinvestment":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-academic-promotion-reform":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-trial-completion-bonus":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-payer-funded-pragmatic-trials":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-duration-trial-exclusivity":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-paediatric-deferral-escrow":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-abbreviated-pathway-me-too-biologics":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-open-source-repurposing-leads":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-repurposing-indication-exclusivity":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-social-impact-bonds-prevention":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-global-access-licensing-royalties":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-phase-two-failure-reinsurance":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-translational-institutes-gmp":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-ind-enabling-fund":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-milestone-venture-philanthropy":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-phase-zero-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-public-nonprofit-cro":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-translational-fellowships":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-target-validation-consortium":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-academic-adc-bispecific-platform":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-hospital-exemption-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-academic-radiopharma-pipeline":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-stalled-asset-registry":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-national-drug-development-office":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-device-and-technique-translation-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-biomarker-validation-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-organoid-translation-gate":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-shared-personalised-therapy-gmp":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-protected-time-physician-scientists":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-royalty-pool-academic-assets":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-global-academic-phase-one-network":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-academic-sponsor-indemnity-pool":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-combination-patent-pool":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-compulsory-combination-access":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-standard-combination-agreement":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-precompetitive-undruggable-consortium":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-trial-data-trust":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-control-arm-commons":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-universal-mta-fast-lane":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-antitrust-safe-harbour":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-open-results-bonus":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-shelved-asset-escrow":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-federated-learning-consortium":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-trial-biospecimen-commons":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-neutral-platform-sponsor":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-portable-patient-consent":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-scoop-protection-policy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-surgical-trials-network":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-radiotherapy-trials-infrastructure":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-device-technique-registry":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-surgical-ai-robotics-evaluation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-flash-evidence-programme":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-proton-coverage-with-evidence":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-surgeon-scientist-pathway":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-course-based-radiotherapy-payment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-surgical-video-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-organ-preservation-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-omission-deescalation-trials":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-lmic-radiotherapy-finance":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-intraoperative-imaging-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-rt-io-platform":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-adaptive-radiotherapy-evidence":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-surgical-outcomes-public-reporting":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-rt-planning-ai-capacity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-ablation-versus-surgery-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-radiotherapy-innovation-pathway":{"commit":"4a839d7cb3","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: funding, incentives and collaboration","file":"src/data/ideas-waves/wave-funding.ts"},"idea-fund-technique-innovation-prize":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-funding.ts"},"idea-moon-navigation-as-a-right":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-plain-language-consent":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-results-in-plain-words":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-pro-monitoring-standard":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-certified-decision-aids":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-patient-designed-trials":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-financial-toxicity-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-goals-conversation-trigger":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-patient-held-cancer-record":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-funded-second-opinion":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-recorded-consultations":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-question-prompt-lists":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-patient-experience-label":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-results-back-to-participants":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-peer-navigator-workforce":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-time-toxicity-reporting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-preference-studies-before-phase3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-caregiver-in-the-plan":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-literacy-first-design-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-trial-eligibility-at-every-decision":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-toxicity-first-endpoints":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-pro-ctcae-in-every-pivotal-trial":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-supportive-care-arpa":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-neuropathy-prevention-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-cardioprotection-by-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-olanzapine-antiemetic-everywhere":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-post-approval-dose-deescalation":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-quality-adjusted-pricing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-adult-late-effects-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-cognitive-toxicity-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-irae-prediction-and-prevention":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-fertility-preservation-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-hearing-protection-cisplatin":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-hair-preservation-for-all":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-oncology-hospital-at-home":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-supportive-care-platform-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-open-pro-data-commons":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-mucositis-taste-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-sexual-health-as-toxicity-domain":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-quality-adjusted-survival-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-misinformation-rapid-response":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-verified-information-layer":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-clinician-creator-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-prebunking-at-diagnosis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-unproven-clinic-registry":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-supplement-interaction-database":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-ban-unproven-therapy-ads":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-integrative-oncology-bridge":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-ai-cancer-answer-audit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-wikipedia-oncology-fellowships":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-hpv-vaccine-confidence":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-hype-index":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-patient-community-moderators":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-living-plain-evidence-summaries":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-treatment-refusal-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-population-interception":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-universal-sequencing-learning-system":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-lynch-vaccine-phase3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-in-vivo-cart-generic-price":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-closed-loop-adaptive-therapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-global-open-trials-os":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-open-cancer-cell-state-model":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-cure-prizes":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-engineered-immune-surveillance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-synthetic-lethality-map-every-driver":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-radiotherapy-for-everyone-2040":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-eliminate-infection-cancers":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-mrd-weather-service":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-dormancy-eradication-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-validated-digital-twins":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-negative-results-ledger":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-generics-for-cancer-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-pooled-procurement-licensing-pool":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-brain-delivery-platform":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-rare-cancer-global-network":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-cold-to-hot-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-cachexia-as-treatable-disease":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-individualised-dosing-all-oral-drugs":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-automated-combination-discovery":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-indolence-classifiers-with-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-biomarker-validation-utility":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-open-degrader-consortium":{"commit":"d97c884413","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: patients, culture and cross-cutting moonshots","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-metastasis-prevention-indication":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-survivor-lifelong-care-model":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-palliative-care-from-diagnosis-everywhere":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-geriatric-assessment-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-self-driving-cancer-labs":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-task-shifting-ai-oncology-capacity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-federated-rwe-network":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-pay-for-cure-contracts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-open-source-oncology-drug-discovery":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-public-phase1-factory":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-neoantigen-vaccines-at-scale":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-image-guided-surgery-everywhere":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-compact-flash-proton":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-population-germline-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-living-machine-readable-guidelines":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-continuous-ai-validation-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-reciprocal-tumour-agnostic-approvals":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-moon-independent-replication-institute":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-people-moonshots.ts"},"idea-prev-mced-stage-endpoint-surrogate":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mced-registry-randomised":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mced-change-control-plan":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mced-positive-resolution-pathway":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-interval-cancer-audit-blood-tests":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ai-mammogram-risk-intervals":{"commit":"6c527727af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: prevention and early detection","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-lung-screening-risk-model-eligibility":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ldct-ai-negative-triage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mammography-ai-stepped-wedge":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-opportunistic-ct-ai-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-pancreas-ai-prediagnostic-ct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-new-onset-diabetes-pancreas-pathway":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-breath-voc-symptomatic-ruleout":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-urine-dna-haematuria-triage":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-weight-loss-auto-alert":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-cgm-glycaemic-drift-pancreas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ehr-symptom-signature-prompts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mced-non-specific-symptom-triage":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-blood-count-trend-flags":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-fit-risk-adapted-thresholds":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-blood-crc-test-for-non-responders":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-capsule-sponge-pharmacy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-gastric-serology-migrant-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hcc-blood-surveillance-cirrhosis":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mri-first-prostate-screening-prs":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-oral-cancer-community-smartphone-ai":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-lmic-five-cancer-methylation-test":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-fragmentomics-first-tier":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-live-stage-dashboard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-open-stage-shift-microsimulation":{"commit":"6c527727af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: prevention and early detection","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-emergency-department-cancer-test":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mobile-lung-screening-deprived-areas":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ebv-dna-npc-screening-scaleup":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-dental-oral-exam-standard":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-bundled-cancer-check-at-60":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-thyroid-no-screening-no-small-biopsy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ptmc-active-surveillance-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-low-risk-dcis-surveillance-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-indolent-lesion-nomenclature-body":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-gleason6-terminology-rct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-prostate-as-triggered-biopsy":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-small-renal-mass-surveillance":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-lung-nodule-ai-discharge":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-blood-precursor-watch-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-annual-overdiagnosis-reporting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-screening-stop-by-life-expectancy":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-mced-pretest-decision-aid":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-barrett-surveillance-deescalation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-melanoma-ai-thick-melanoma-metric":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-incidentaloma-natural-history-cohort":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ipmn-surveillance-stop-rule":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-pathology-ai-borderline-anchor":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-frail-elderly-primary-endocrine-breast":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-omit-radiotherapy-low-risk-breast-default":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-modern-autopsy-reservoir-studies":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpv-single-dose-switch-catchup":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpv-vaccinate-at-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpv-self-sampling-mailed-default":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpv-same-day-screen-and-treat":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-therapeutic-hpv-vaccine-cin":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hbv-treat-all-hcc":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hcv-test-treat-surveillance-linkage":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpylori-family-test-and-treat":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpylori-stool-resistance-guided":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpylori-childhood-vaccine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-smokefree-generation-evaluation":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-very-low-nicotine-mandate":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-opt-out-cessation-in-lung-screening":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-cytisine-essential-medicine":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-alcohol-cancer-warning-labels":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-minimum-unit-pricing-cancer-endpoints":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-glp1-cancer-prevention-rct":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-glp1-endometrial-hyperplasia":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-chemoprevention-master-protocol":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-low-dose-tamoxifen-uptake":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-opportunistic-salpingectomy-default":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-commercial-sunbed-ban":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-radon-testing-at-property-sale":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-clean-air-never-smoker-endpoints":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-screening-default-appointments":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-pharmacy-prevention-hub":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-pay-for-prevention-outcomes":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-precursor-endpoints-for-approval":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-hpv-male-catchup-oropharynx":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-ebv-vaccine":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-cascade-direct-contact-relatives":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-population-germline-screening-at-30":{"commit":"6c527727af","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: prevention and early detection","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-deferred-disclosure-newborn-genomes":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-prs-screening-start-age":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-prs-ancestry-portability-standard":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-lynch-frameshift-vaccine-rct":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-brca1-denosumab-prevention":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-lynch-aspirin-implementation":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-reflex-germline-testing":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-traceback-deceased-probands":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-vus-saturation-editing-consortium":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-li-fraumeni-mri-plus-cfdna":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-genetic-counselling-chatbot":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-family-history-auto-match":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-prev-genetic-non-discrimination-insurance":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-prevention.ts"},"idea-reg-orbis-work-sharing":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-reliance-90-day-lmic":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-single-global-dossier":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-joint-scientific-advice-default":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-realtime-streaming-submission":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-conditional-approval-sunset":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-confirmatory-trial-escrow":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-public-assessment-reports-all":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-mutual-recognition-inspections-atmp":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-global-trial-application-portal":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-diagnostic-reliance-pathway":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-single-paediatric-plan":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-tumour-agnostic-reliance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-label-divergence-index":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-approval-access-lag-tracker":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-joint-regulator-hta-plan":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-mrct-no-bridging":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-african-medicines-agency-oncology":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-open-source-dossier-tools":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-shared-ai-review-assistant":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-shared-postmarketing-registry-condition":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-manufacturing-change-passport":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-orphan-designation-reciprocity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-publish-all-rejections":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-global-dose-optimisation-guideline":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-point-of-care-cart-network":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-in-vivo-cart-off-the-shelf-vial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-two-day-cart-rapid-release":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-ipsc-master-bank-qualified-once":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-closed-manufacturing-interop-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-cart-potency-reference-standards":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-vein-to-vein-public-benchmark":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-legacy-radium-recovery-ac225":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-ac225-accelerator-pharmacopoeia":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-yb176-enrichment-capacity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-medical-isotope-reactor-reserve":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-alpha-emitter-portfolio":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-regional-radiopharmacy-hubs":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-adc-platform-designation":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-hpapi-continuous-flow":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-open-source-lentiviral-vectors":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-non-viral-cart-manufacturing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-manufacturing-slot-exchange":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-hospital-exemption-harmonised":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-lmic-public-cart-manufacturing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-ai-process-control-cell-manufacturing":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-early-apheresis-banking":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-public-cell-therapy-foundries":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-comparability-by-design-digital-twin":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-isotope-supply-observatory":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-cart-outcomes-refund":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-io-subscription-national":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-indication-specific-pricing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-pooled-procurement-adult-essentials":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-biosimilar-no-efficacy-trial":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-pd1-biosimilar-advance-commitment":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-patent-pool-oncology-eml":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-price-anchored-to-mcbs":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-weight-based-io-dosing-label":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-public-deescalation-trials-for-cost":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-financial-toxicity-vital-sign":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-net-price-transparency-registry":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-rd-cost-disclosure-condition":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-provisional-price-until-os":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-patent-buyout-prize":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-secondary-patent-thicket-limits":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-nonprofit-generic-chemo-manufacturer":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-academic-cart-at-cost-coverage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-combination-price-attribution":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-middle-income-negotiation-bloc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-tiered-pricing-for-exclusivity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-biosimilar-first-default-switching":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-annuity-payment-durable-therapies":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-social-impact-bond-switching":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-market-expansion-repricing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-global-repurposing-fund":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-third-party-label-update":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-repurposing-prize":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-repurposing-social-impact-bond":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-aspirin-pik3ca-implementation":{"commit":"eb9008658b","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: regulation, manufacturing, pricing and repurposing","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-recovery-style-platform-repurposing":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-perioperative-propranolol-etodolac":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-statin-hcc-prevention-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-evidence-gate-before-repurposing-phase3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-target-trial-emulation-pipeline":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-new-indication-exclusivity-off-patent":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-delinked-market-entry-reward":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-generic-targeted-therapy-drup":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-antihistamine-plus-io-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-vitamin-d-digestive-cancer-biomarker-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-losartan-pancreatic-stroma":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-regulator-ready-repurposing-dossiers":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-guideline-fast-track-repurposed":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-payer-coverage-off-label-generic-commitment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-nonprofit-marketing-authorisation-holder":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-metronomic-lmic-phase3-to-label":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-generic-chemo-strategic-reserve":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-factorial-addon-arms-cooperative-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-olanzapine-cachexia-global-confirmation":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-reg-preregistered-ai-repurposing-scoring":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-regulation.ts"},"idea-tr1-justify-every-exclusion":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-brain-mets-default-included":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-pk-informed-organ-thresholds":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-prior-cancer-hiv-hepatitis-inclusion":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ehr-point-of-care-trial-alert":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-tumour-board-trial-line-item":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ngs-report-live-trial-match":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-just-in-time-site-network":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-national-master-trial-agreement":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-mutual-recognition-ethics-review":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-home-infusion-trial-drugs":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-remote-consent-tele-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-community-site-quota":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-travel-lodging-in-every-budget":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-pay-participants-for-time":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-lay-trial-navigators":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-opt-out-research-contact-register":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-registry-embedded-randomisation":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-rare-cancer-trial-in-a-box":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-pre-consented-cohort-randomisation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-public-screen-fail-reasons":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-eligibility-impact-statement":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-live-trial-slot-api":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-pathology-triggered-referral":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-evening-weekend-trial-clinics":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-universal-routine-cost-coverage":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-protected-physician-time-for-enrolment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-open-trials-inside-guidelines":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-mobile-research-units":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-drop-non-essential-biopsies":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-external-control-rulebook":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-bayesian-borrowing-smaller-controls":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-seamless-2-3-with-prespecified-go":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-standing-platform-per-cancer":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-surrogate-validation-programme":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-crossover-adjusted-survival-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ttf-and-qol-coprimary":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-win-ratio-net-benefit-endpoint":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-public-de-escalation-trial-fund":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-immunotherapy-stop-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ctdna-guided-stop-in-metastatic-disease":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-mams-for-sequencing-questions":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-post-approval-pragmatic-trial-in-excluded":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-shared-control-arms-across-sponsors":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-tolerability-estimands":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-power-for-meaningful-benefit":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-registry-linked-os-followup":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-shrinkage-subgroup-analysis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ai-central-imaging-reads":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-public-trial-cost-benchmarks":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-esource-ehr-to-edc":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-aggregated-n-of-1-supportive-care":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-aggressive-futility-boundaries":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-window-of-opportunity-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-randomised-phase-2-before-phase-3":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-smart-designs-for-adaptive-strategies":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-target-trial-emulation-to-prioritise-rcts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-tumour-agnostic-approval-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-open-protocol-and-sap-library":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-validate-real-world-progression-endpoints":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-diversity-plans-with-consequences":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-incidence-weighted-enrolment-targets":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ancestry-aware-pharmacology-programme":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-duffy-null-neutrophil-threshold":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-mandatory-older-adult-cohort":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-parallel-comorbidity-cohorts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-lmic-sites-in-pivotal-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-community-health-worker-recruitment":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-language-access-in-trials":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-site-equity-index":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-include-pregnancy-capable-people-sensibly":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-age-floor-twelve-for-adult-trials":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-sex-stratified-pk-and-dosing":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-disability-and-mental-illness-inclusion":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-representativeness-in-the-label":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-diverse-investigator-pipeline":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-paid-community-advisory-boards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-post-marketing-safety-by-ancestry-and-sex":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-ecog-2-dedicated-cohorts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-trial-desert-map":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-randomised-dose-comparison-before-pivotal":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-exposure-response-before-dose-selection":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-public-dose-reduction-trials-of-approved-drugs":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-weight-based-vs-flat-dosing-trials":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-extended-interval-checkpoint-dosing":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-intermittent-dosing-to-delay-resistance":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-adaptive-therapy-randomised-phase-2":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-start-low-titrate-up-oral-agents":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-pre-emptive-pharmacogenomic-testing":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-geriatric-dose-finding-cohorts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-model-based-dose-finding-with-late-toxicity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-adc-dose-and-schedule-optimisation":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-dose-evidence-statement-in-label":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-patient-reported-toxicity-dose-algorithms":{"commit":"c9201d8b2f","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials, part 1","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-food-effect-dose-reduction":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-factorial-dose-finding-for-combinations":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-organ-impairment-pk-before-approval":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-low-dose-immunotherapy-for-lmic":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr1-response-adapted-dose-reduction":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-1.ts"},"idea-tr2-perpetual-platforms":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-shared-control-network":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-synergy-ranking-engine":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combination-template-agreement":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-public-combination-formulary":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-smart-sequencing-adc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-organoid-coclinical-arms":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-organoid-matrix-atlas":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combo-dose-matrix":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-neoadjuvant-combo-platform":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-pragmatic-sequence-randomisation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-alternating-vs-concurrent":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-rwe-combination-emulation":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-factorial-adjuvant-generics":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-ctdna-futility-gates":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-platform-single-ethics":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-resistance-mechanism-baskets":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combination-utility":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combination-patent-pool":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-sequence-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-bandit-allocation":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-qsp-combo-dosing":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combo-readiness-dossier":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-rt-drug-platform":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-paediatric-combo-prea":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-payer-combo-cwe":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-combination-forecast-tournament":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-antagonism-surveillance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-contribution-of-components-mandate":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-window-of-opportunity-triplets":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-preclinical-negative-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-negative-results-journal":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-fdaaa-enforcement":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-irb-results-gate":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-termination-reports":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-shelved-asset-commons":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-outcome-switching-monitor":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-material-failure-disclosure":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-failed-trial-biobank":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-failed-trial-ipd-default":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-writeup-grants":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-null-result-reporting":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-negative-plenaries":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-failure-taxonomy":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-model-report-cards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-off-label-outcome-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-retraction-propagation":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-reversal-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-sponsor-transparency-score":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-target-failure-index":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-her2-low-reference-materials":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-pdl1-digital-calibration":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-marker-stratified-default":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-cdx-mutual-recognition":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-open-cdx-validation-sets":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-ctdna-mrd-qualification":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-psma-volume-qualification":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-bicr-discordance-public":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-biomarker-evidence-grading":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-eqa-public-results":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-ctdna-reference-plasma":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-tmb-calibration-standard":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-hrd-functional-standard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-preanalytics-in-report":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-cutpoint-lock":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-prospective-retrospective-path":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-spatial-biomarker-standards":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-liquid-biopsy-challenge":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-radiomics-ibsi-mandate":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-biomarker-study-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-biomarker-cwe":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-ai-cdx-change-control":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-label-assay-concordance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-biomarker-negative-arms":{"commit":"6ee172c0ab","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 78 idea TL;DRs and 33 idea summary openings rewritten with the specific facts behind their qualifier","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-positivity-rate-surveillance":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-cell-line-authentication-mandate":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-cell-line-passport":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-preclinical-registered-reports":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-replication-set-aside":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-replication-before-ind":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-automated-stats-check":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-raw-image-deposit":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-arrive-audit":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-multilab-preclinical":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-replication-bounties":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-antibody-validation-mandate":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-reference-compound-panels":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-timestamped-eln":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-animal-power-mandate":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-tenure-replication-credit":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-random-audit":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-replication-status-badge":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-data-link-enforcement":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-paid-statistical-review":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-reference-model-panels":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-ai-external-validation-registry":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-two-lab-rule":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-preclinical-living-reviews":{"commit":"2cf3bbff36","date":"2026-09-08","author":"Jude Gomila","message":"Ideas wave: clinical trials part 2 and scientific rigour","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-reagent-lot-ledger":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-tr2-phd-replication-year":{"commit":"5717f3693b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 60 more idea TL;DRs and 45 idea summary openings rewritten with the specific facts behind their qual","file":"src/data/ideas-waves/wave-trials-2.ts"},"idea-trop2-pet-selection":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"idea-payload-switching":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"idea-post-neoadjuvant-adc":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/ideas.ts"},"idea-ctdna-escalation-tnbc":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/ideas.ts"},"idea-efflux-agnostic":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas.ts"},"idea-fap-theranostics-pancancer":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-in-vivo-car-solid":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-neoadjuvant-adc-io":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/ideas.ts"},"idea-til-guided-deescalation":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-ai-her2-low-scoring":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"idea-alpha-after-adc":{"commit":"f877b62101","date":"2026-09-11","author":"Jude Gomila","message":"Expand 90 short summaries: ideas, sections and roadmaps","file":"src/data/ideas.ts"},"idea-shared-kras-vaccine-adjuvant":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-mced-plus-fapi":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"idea-total-body-pet-dosimetry":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"idea-organoid-guided-adc":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/ideas.ts"},"idea-dual-payload-first":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/ideas.ts"},"idea-cd8-pet-io":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/ideas.ts"},"idea-exercise-as-adjuvant":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-multimodal-foundation-model":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/ideas.ts"},"idea-interception-vaccines":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/ideas.ts"},"biocon":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/india.ts"},"biocon-biologics":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"syngene":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"dr-reddys":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/india.ts"},"aurigene":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"sun-pharma":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/india.ts"},"natco":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/india.ts"},"cipla":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/india.ts"},"zydus":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/india.ts"},"lupin":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"intas":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/india.ts"},"glenmark":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"immunoact":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"immuneel":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"cellogen":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/india.ts"},"hetero":{"commit":"3f988f4706","date":"2026-09-18","author":"Jude Gomila","message":"Add official websites to 15 sponsor records and fetch nine logos","file":"src/data/india.ts"},"serum-institute-of-india":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"talicabtagene-autoleucel":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"varnimcabtagene-autoleucel":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"cervavac":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"isb-2001":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"low-dose-nivolumab-tmh":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/india.ts"},"metronomic-vs-cisplatin-tmh":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/india.ts"},"metro-plus-varanasi":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/india.ts"},"gefitinib-chemo-tmh":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/india.ts"},"progesterone-preop-tmh":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"lidocaine-peritumoral-tmh":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"elective-neck-dissection-tmh":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/india.ts"},"osmanabad-hpv-screening":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"kerala-oral-screening":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/india.ts"},"mumbai-via-screening":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"iarc-india-hpv-dose-study":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"talicel-phase-1-2":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"imagine-varnimcabtagene":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/india.ts"},"paper-patil-low-dose-nivolumab-jco-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-sankaranarayanan-hpv-screening-nejm-2009":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-sankaranarayanan-oral-screening-lancet-2005":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-basu-single-dose-hpv-lancet-oncol-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-badwe-progesterone-jco-2011":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-dcruz-elective-neck-dissection-nejm-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-jain-talicabtagene-lancet-haem-2025":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/india.ts"},"paper-mathur-ncrp-cancer-statistics-2020":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/india.ts"},"paper-pramesh-ncg-pooled-procurement-2023":{"commit":"62503ed7ab","date":"2026-09-10","author":"Jude Gomila","message":"Add structured outcomes for FUMANBA-1, LUMMICAR-1, IMAGINE, DeLLphi-305 and iStopMM","file":"src/data/india.ts"},"dktk":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institution-networks-wave.ts"},"jeffrey-bluestone":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/institution-networks-wave.ts"},"karen-knudsen":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/institution-networks-wave.ts"},"santosh-kesari":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institution-networks-wave.ts"},"richard-baum":{"commit":"3892a65cf6","date":"2026-09-17","author":"Jude Gomila","message":"One papers block per person after the two paper waves met","file":"src/data/institution-networks-wave.ts"},"ebrahim-delpassand":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institution-networks-wave.ts"},"sant-chawla":{"commit":"3892a65cf6","date":"2026-09-17","author":"Jude Gomila","message":"One papers block per person after the two paper waves met","file":"src/data/institution-networks-wave.ts"},"charles-simone":{"commit":"3892a65cf6","date":"2026-09-17","author":"Jude Gomila","message":"One papers block per person after the two paper waves met","file":"src/data/institution-networks-wave.ts"},"abcsg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"wjog":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/institutions/bodies.ts"},"kcsg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"trog":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/bodies.ts"},"anzup":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"agitg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"breast-cancer-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"geicam":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/bodies.ts"},"solti":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"hovon":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"gimema":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"ielsg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"lysa":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/bodies.ts"},"german-lymphoma-alliance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"ghsg":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts"},"nordic-lymphoma-group":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cclg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"siop-europe":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/bodies.ts"},"etop-ibcsg":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"ifct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"arcagy-gineco":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"gog-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"nsabp-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"fondation-arc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"ligue-contre-le-cancer":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"deutsche-krebshilfe":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/bodies.ts"},"kwf":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"airc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cancer-council-australia":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"canadian-cancer-society":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/bodies.ts"},"irish-cancer-society":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/bodies.ts"},"worldwide-cancer-research":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"wellcome":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"hhmi":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/bodies.ts"},"damon-runyon":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"v-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"stand-up-to-cancer":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/institutions/bodies.ts"},"bcrf":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"lustgarten-foundation":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/institutions/bodies.ts"},"cprit":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/bodies.ts"},"mark-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"emerson-collective":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cz-biohub":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"gates-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cancer-grand-challenges":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/bodies.ts"},"arpa-h":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"movember":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"macmillan-cancer-support":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"marie-curie-uk":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"uicc":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"who":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/bodies.ts"},"iaea":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/bodies.ts"},"fda-oce":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"ema":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"nice":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"tga":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"health-canada":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"swissmedic":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"has-france":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"g-ba-iqwig":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"pbac":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"anvisa":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"cofepris":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cdsco":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"ash":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/bodies.ts"},"astro":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"estro":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"snmmi":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"eanm":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"sitc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"sso":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"esso":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"jsmo":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/institutions/bodies.ts"},"csco":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"ispor":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/bodies.ts"},"iaslc":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/institutions/bodies.ts"},"sgo":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"esgo":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"eha":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/bodies.ts"},"isoqol":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"mascc":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"espen":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"cdisc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"hl7":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/bodies.ts"},"vivli":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"yoda-project":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/bodies.ts"},"yale-cancer-center":{"commit":"94094514cd","date":"2026-09-10","author":"Jude Gomila","message":"Add wave 3 cancer centres: Yale (NCI), OECI accredited centres, UK, Canada, Africa, Middle East, Latin America, South As","file":"src/data/institutions/centres-wave3.ts"},"az-groeninge-kortrijk":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"vejle-cancer-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"tartu-university-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"kuopio-university-hospital":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"turku-university-hospital":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"tays-cancer-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"linkoping-university-hospital":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/centres-wave3.ts"},"riga-east-university-hospital":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"nci-vilnius":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"icm-montpellier":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"centre-jean-perrin":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"centre-henri-becquerel":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"centre-eugene-marquis":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"ico-angers-nantes":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/institutions/centres-wave3.ts"},"centre-francois-baclesse":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"aphp-nord-cancer-institute":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"iuc-aphp-sorbonne":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"carpem-aphp-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"trinity-st-jamess-cancer-institute":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"st-vincents-ucd-cancer-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"cork-university-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"galway-university-hospital-cancer-centre":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"beaumont-rcsi-cancer-centre":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"spedali-civili-brescia":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"sacro-cuore-don-calabria":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"crob-rionero":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"istituto-tumori-bari":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"san-martino-genoa":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"ausl-irccs-reggio-emilia":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"cro-aviano":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"ipo-coimbra":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/institutions/centres-wave3.ts"},"fundacion-jimenez-diaz":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/institutions/centres-wave3.ts"},"ico-catalonia":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"ivo-valencia":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"umcg-groningen":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/centres-wave3.ts"},"maastricht-umc":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/centres-wave3.ts"},"oncozon":{"commit":"af06ee1131","date":"2026-09-15","author":"Jude Gomila","message":"data: three OECI representatives matched by hand (INCLIVA Valencia, Oslo University Hospital, Maastricht UMC and OncoZON","file":"src/data/institutions/centres-wave3.ts"},"rijnstate-arnhem":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"radboudumc":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/centres-wave3.ts"},"amsterdam-umc":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/centres-wave3.ts"},"anadolu-medical-center":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"saint-savvas-athens":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/centres-wave3.ts"},"clatterbridge":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/centres-wave3.ts"},"weston-park-sheffield":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"mount-vernon-cancer-centre":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"nottingham-cancer-centre":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"bristol-haematology-oncology-centre":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"northern-ireland-cancer-centre":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"imperial-cancer-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"cruk-city-of-london-centre":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"cruk-convergence-science-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"queens-centre-hull":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"anchor-centre-aberdeen":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"leicester-cancer-research-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"cancercare-manitoba":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"saskatchewan-cancer-agency":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"ontario-health-cancer-care-ontario":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"ciusss-emtl-maisonneuve-rosemont":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"muhc-cedars-cancer-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"lhsc-verspeeten":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"nova-scotia-cancer-care":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"chu-de-quebec":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"terry-fox-research-institute":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"aga-khan-university-hospital-nairobi":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"tygerberg-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"cancer-diseases-hospital-lusaka":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"inkosi-albert-luthuli-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"steve-biko-academic-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"chris-hani-baragwanath":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"moi-teaching-referral-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"tikur-anbessa-hospital":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"komfo-anokye-teaching-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"uch-ibadan":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"aubmc-basile-cancer-institute":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"bahrain-oncology-centre":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"sultan-qaboos-cccrc":{"commit":"94094514cd","date":"2026-09-10","author":"Jude Gomila","message":"Add wave 3 cancer centres: Yale (NCI), OECI accredited centres, UK, Canada, Africa, Middle East, Latin America, South As","file":"src/data/institutions/centres-wave3.ts"},"rabin-davidoff-center":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"soroka-medical-center":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"icesp":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"erasto-gaertner":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"bp-beneficencia-portuguesa":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"hospital-italiano-buenos-aires":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/centres-wave3.ts"},"instituto-roffo":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"inc-argentina":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"inca-uruguay":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"inc-chile":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"fundacion-valle-del-lili":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"imss-oncologia-siglo-xxi":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"inor-cuba":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/centres-wave3.ts"},"shaukat-khanum":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"aku-karachi":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/centres-wave3.ts"},"nicrh-dhaka":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/institutions/centres-wave3.ts"},"ludwig-cancer-research":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"parker-institute":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/donor-foundations.ts"},"pcf":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"alsf":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/institutions/donor-foundations.ts"},"st-baldricks-foundation":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/donor-foundations.ts"},"bowelbabe-fund":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/institutions/donor-foundations.ts"},"teenage-cancer-trust":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/institutions/donor-foundations.ts"},"lasker-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"terry-fox-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"mra":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/donor-foundations.ts"},"jimmy-fund":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"pan-mass-challenge":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"ellison-institute":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"li-ka-shing-foundation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"tata-trusts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/donor-foundations.ts"},"institut-bergonie":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"centre-leon-berard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"institut-paoli-calmettes":{"commit":"741fb73e2f","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: OECI accreditation names as aliases on Charité, Rigshospitalet, Candiolo and Institut Paoli-Calmettes (OEC","file":"src/data/institutions/europe.ts"},"iuct-oncopole":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/europe.ts"},"centre-oscar-lambret":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"centre-antoine-lacassagne":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"inca":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"institut-pasteur":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"tum-munich":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"essen-wtz":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"nct-dresden":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"uct-frankfurt":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"ccc-freiburg":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/europe.ts"},"ccc-tuebingen":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"ccc-wuerzburg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"uct-mainz":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"uk-duesseldorf":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"mdc-berlin":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"barts-cancer-institute":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"uclh":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"guys-st-thomas":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"leeds-cancer-centre":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"newcastle-cancer-centre":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"beatson-glasgow":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"edinburgh-cancer-centre":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"velindre-cardiff":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"oxford-cancer":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/europe.ts"},"cruk-cambridge-centre":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"southampton-cancer":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"cruk-manchester-institute":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"great-ormond-street":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"wellcome-sanger":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"embl-ebi":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"birmingham-cancer-centre":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"erasmus-mc":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"umc-utrecht":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/institutions/europe.ts"},"princess-maxima":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/europe.ts"},"lumc-leiden":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"uz-leuven":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/europe.ts"},"institut-jules-bordet":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"uz-gent":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"hospital-clinic-barcelona":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/institutions/europe.ts"},"12-de-octubre":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"la-fe-valencia":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/europe.ts"},"cun-navarra":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/institutions/europe.ts"},"cnio":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"incliva-valencia":{"commit":"af06ee1131","date":"2026-09-15","author":"Jude Gomila","message":"data: three OECI representatives matched by hand (INCLIVA Valencia, Oslo University Hospital, Maastricht UMC and OncoZON","file":"src/data/institutions/europe.ts"},"hospital-del-mar":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"candiolo":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"pascale-naples":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"regina-elena-rome":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"humanitas":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"iov-veneto":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"sant-orsola-bologna":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/europe.ts"},"irst-meldola":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"san-raffaele":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"rigshospitalet":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"aarhus-university-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"oslo-radium-hospital":{"commit":"af06ee1131","date":"2026-09-15","author":"Jude Gomila","message":"data: three OECI representatives matched by hand (INCLIVA Valencia, Oslo University Hospital, Maastricht UMC and OncoZON","file":"src/data/institutions/europe.ts"},"helsinki-hus":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"uppsala-akademiska":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"lund-skane":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"sahlgrenska":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"usz-zurich":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"chuv-lausanne":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"hug-geneva":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"inselspital-bern":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"usb-basel":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"ccc-vienna":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/institutions/europe.ts"},"ipo-porto":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"ipo-lisboa":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/europe.ts"},"champalimaud":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"nio-warsaw":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"mou-brno":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"noi-budapest":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"onkoloski-institut-ljubljana":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/europe.ts"},"sheba":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"hadassah":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"tel-aviv-sourasky":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"rambam":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"weizmann":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"shaare-zedek":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"hacettepe-cancer-institute":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/europe.ts"},"istanbul-oncology-institute":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/europe.ts"},"ecco":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"eacr":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/europe.ts"},"oeci":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/europe.ts"},"odense-university-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"aalborg-university-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"oulu-university-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"landspitali":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"motol-university-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"mater-misericordiae":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"institut-godinot":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"centre-georges-francois-leclerc":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"institut-de-cancerologie-de-lorraine":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"north-estonia-medical-centre":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"east-tallinn-central-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"fondazione-poliambulanza":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"policlinico-san-matteo":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"haukeland-university-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"akershus-university-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"pauls-stradins-clinical-university-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"santaros-klinikos":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"klaipeda-university-hospital":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"orebro-university-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"hospital-de-sant-pau":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"hospital-sant-joan-de-reus":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"uck-gdansk":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"polish-mothers-memorial-hospital":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"oncology-institute-of-vojvodina":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"mater-private":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"iknl":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"bank-of-cyprus-oncology-centre":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"zealand-university-hospital":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"uz-brussel-cancer-centre":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"sestre-milosrdnice-tumors":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"german-oncology-center-limassol":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"metaxa-cancer-hospital":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"university-hospital-waterford":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"mediterranean-institute-of-oncology":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"kauno-klinikos":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"oncological-institute-moldova":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"university-clinic-radiotherapy-oncology-skopje":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"oncosalud-auna":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"iasi-regional-oncology-institute":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"clara-campal-oncology-centre":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"virgen-de-la-victoria-malaga":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"doctor-peset-valencia":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"umea-university-hospital":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"aga-khan-hospital-dar-es-salaam":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"dokuz-eylul-institute-of-oncology":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions/europe.ts"},"kavetsky-institute-kyiv":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/institutions/europe.ts"},"northern-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"lancashire-south-cumbria-cancer-alliance":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"west-yorkshire-harrogate-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"humber-north-yorkshire-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"cheshire-merseyside-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"greater-manchester-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"south-yorkshire-bassetlaw-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"west-midlands-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"east-midlands-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"east-of-england-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"north-central-london-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"north-east-london-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"south-east-london-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"kent-medway-cancer-alliance":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"surrey-sussex-cancer-alliance":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/europe.ts"},"wessex-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"thames-valley-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"swag-cancer-alliance":{"commit":"b62be08ded","date":"2026-09-15","author":"Jude Gomila","message":"data: the nineteen remaining NHS England Cancer Alliances as institutions, linked to the hospitals in their footprints (","file":"src/data/institutions/europe.ts"},"peninsula-cancer-alliance":{"commit":"1d8211e848","date":"2026-09-15","author":"Jude Gomila","message":"data: nine OECI member organisations with Wikidata-backed records (Tirana, Avignon, Athens, Budapest, Rome, Gliwice, War","file":"src/data/institutions/europe.ts"},"mother-teresa-hospital-tirana":{"commit":"1d8211e848","date":"2026-09-15","author":"Jude Gomila","message":"data: nine OECI member organisations with Wikidata-backed records (Tirana, Avignon, Athens, Budapest, Rome, Gliwice, War","file":"src/data/institutions/europe.ts"},"institut-sainte-catherine":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"hellenic-cancer-federation":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"koranyi-institute-budapest":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"favo":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"nio-gliwice":{"commit":"1d8211e848","date":"2026-09-15","author":"Jude Gomila","message":"data: nine OECI member organisations with Wikidata-backed records (Tirana, Avignon, Athens, Budapest, Rome, Gliwice, War","file":"src/data/institutions/europe.ts"},"institute-of-mother-and-child":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"biomedical-research-center-sas":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/institutions/europe.ts"},"aecc":{"commit":"6c701c44ec","date":"2026-09-15","author":"Jude Gomila","message":"data: fourteen more OECI member organisations (list 188 of 193); institution ranking no longer counts membership links f","file":"src/data/institutions/europe.ts"},"tatarstan-cancer-center":{"commit":"6c701c44ec","date":"2026-09-15","author":"Jude Gomila","message":"data: fourteen more OECI member organisations (list 188 of 193); institution ranking no longer counts membership links f","file":"src/data/institutions/europe.ts"},"mid-western-cancer-centre":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/institutions/europe.ts"},"nmrrc-moscow":{"commit":"6c701c44ec","date":"2026-09-15","author":"Jude Gomila","message":"data: fourteen more OECI member organisations (list 188 of 193); institution ranking no longer counts membership links f","file":"src/data/institutions/europe.ts"},"aidport":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"institut-strauss":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"capio-st-goran":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"heart-and-brain-pleven":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"bjcn":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"iba-masaryk":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"fondazione-the-bridge":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"cancer-free-future-association":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/europe.ts"},"sgccn":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/europe.ts"},"ramon-y-cajal":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"clinico-san-carlos":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"la-princesa":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/europe.ts"},"puerta-de-hierro":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/institutions/europe.ts"},"herlev-hospital":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/institutions/europe.ts"},"greater-poland-cancer-centre":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/institutions/europe.ts"},"henri-mondor":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/institutions/europe.ts"},"king-albert-ii-cancer-institute":{"commit":"2ce1296a7c","date":"2026-09-15","author":"Jude Gomila","message":"data: King Albert II Cancer Institute (Saint-Luc, Brussels) and its OECI representative; logos for Herlev and Greater Po","file":"src/data/institutions/europe.ts"},"blokhin-cancer-center":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/institutions/europe.ts"},"aphp-paris-saclay-cancer-institute":{"commit":"309e63ab8f","date":"2026-09-15","author":"Jude Gomila","message":"data: Blokhin cancer centre (Moscow) and AP-HP Paris-Saclay cancer institute (Bicêtre) with their OECI representatives, ","file":"src/data/institutions/europe.ts"},"inc-luxembourg":{"commit":"4ba2bd8eed","date":"2026-09-15","author":"Jude Gomila","message":"data: INC Luxembourg, National Cancer Institute of Ukraine and FICAN with their OECI representatives (seats from the org","file":"src/data/institutions/europe.ts"},"nci-ukraine":{"commit":"4ba2bd8eed","date":"2026-09-15","author":"Jude Gomila","message":"data: INC Luxembourg, National Cancer Institute of Ukraine and FICAN with their OECI representatives (seats from the org","file":"src/data/institutions/europe.ts"},"fican":{"commit":"4ba2bd8eed","date":"2026-09-15","author":"Jude Gomila","message":"data: INC Luxembourg, National Cancer Institute of Ukraine and FICAN with their OECI representatives (seats from the org","file":"src/data/institutions/europe.ts"},"national-cancer-grid":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/institutions/india.ts"},"homi-bhabha-cancer-hospital-varanasi":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/institutions/india.ts"},"aiims-network":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/india.ts"},"icmr":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/india.ts"},"icmr-ncrp":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/institutions/india.ts"},"icmr-nicpr":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/india.ts"},"dbt-india":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/india.ts"},"nha-pmjay":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/india.ts"},"iit-bombay":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/india.ts"},"iisc":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/india.ts"},"ncbs":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/india.ts"},"instem":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/india.ts"},"max-healthcare":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/india.ts"},"narayana-health":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/institutions/india.ts"},"oneal-uab":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"arizona-cancer-center":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"uci-chao":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"uc-davis-cancer":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"ucsd-moores":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"usc-norris":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"colorado-cancer-center":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/us.ts"},"georgetown-lombardi":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"emory-winship":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"northwestern-lurie":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"uchicago-cancer":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"iu-simon":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"iowa-holden":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"ku-cancer-center":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"kentucky-markey":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"maryland-greenebaum":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"karmanos":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"minnesota-masonic":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"dartmouth-cancer-center":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/us.ts"},"rutgers-cinj":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"unm-cancer-center":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"montefiore-einstein":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"columbia-hicc":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"nyu-perlmutter":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"duke-cancer-institute":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"unc-lineberger":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"wake-forest-cancer":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"case-ccc":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"osu-james":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"ohsu-knight":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"fox-chase":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"jefferson-kimmel":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"upmc-hillman":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"vanderbilt-ingram":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"baylor-duncan":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"utsw-simmons":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"huntsman":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"vcu-massey":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"uva-cancer-center":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"uw-carbone":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"st-jude":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"sylvester-miami":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"uf-health-cancer-center":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"hawaii-cancer-center":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"nebraska-buffett":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"wilmot":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"stephenson-oklahoma":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"musc-hollings":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"mays-cancer-center":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/us.ts"},"salk-institute":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"sanford-burnham-prebys":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"cancer-center-at-illinois":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"purdue-cancer-research":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"jackson-laboratory":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"mit-koch":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"wistar":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/us.ts"},"nci-ccr":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"frederick-national-lab":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"mayo-clinic-florida":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/us.ts"},"mayo-clinic-arizona":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"city-of-hope-orange-county":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"cedars-sinai-cancer":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"northwell-cancer-institute":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/us.ts"},"intermountain-cancer":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"kaiser-permanente-research":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"chop":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"texas-childrens":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/us.ts"},"nationwide-childrens":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"bc-cancer":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"cancer-care-alberta":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"chum":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"mcgill-goodman":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/us.ts"},"ottawa-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"sunnybrook-odette":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/us.ts"},"juravinski":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"oicr":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/us.ts"},"sickkids":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/us.ts"},"pumch":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"pku-cancer-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"shanghai-chest-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"shanghai-pulmonary-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"zhongshan-hospital-fudan":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/institutions/world.ts"},"ruijin-hospital":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"sysu-first-affiliated-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"tmucih":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"zhejiang-cancer-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"hunan-cancer-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"pla-general-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"henan-cancer-hospital":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"shandong-cancer-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"guangdong-provincial-peoples-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"tongji-hospital-wuhan":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"union-hospital-wuhan":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"queen-mary-hospital-hku":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"prince-of-wales-hospital-cuhk":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"ntuh":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"chang-gung-memorial-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"taipei-veterans-general-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"koo-foundation-sun-yat-sen-cancer-center":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"kyoto-university-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"osaka-international-cancer-institute":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"aichi-cancer-center":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/world.ts"},"shizuoka-cancer-center":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"kyushu-university-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"hokkaido-university-hospital":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"tohoku-university-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"keio-university-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"gunma-heavy-ion-medical-center":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"ncc-hospital-east":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"qst-hospital":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"ncc-korea":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"seoul-st-marys-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"nccs":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"nuh-ncis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"aiims-delhi":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"rgci":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"kidwai-memorial-institute-of-oncology":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"cancer-institute-adyar":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"tata-medical-center-kolkata":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"hcg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"apollo-hospitals":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"cmc-vellore":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"pgimer-chandigarh":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"actrec":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions/world.ts"},"chris-obrien-lifehouse":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"onj-cancer-centre":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"garvan-institute":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/world.ts"},"wehi":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"qimr-berghofer":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"sydney-childrens-hospitals-network":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"royal-adelaide-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"auckland-city-hospital":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/world.ts"},"siriraj-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"chulabhorn-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"ramathibodi-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"dharmais-cancer-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"ummc-kuala-lumpur":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"philippine-general-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"k-hospital-hanoi":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/institutions/world.ts"},"hcmc-oncology-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"khcc":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"kfshrc":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"tawam-hospital":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"cleveland-clinic-abu-dhabi":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"hamad-medical-corporation":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"tehran-cancer-institute":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"inca-brazil":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"ac-camargo":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"hospital-de-amor-barretos":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"hcpa-porto-alegre":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"incan-mexico":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"inc-colombia":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/world.ts"},"inen-peru":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"instituto-alexander-fleming":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"falp-chile":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions/world.ts"},"groote-schuur-uct":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/world.ts"},"wits-charlotte-maxeke":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/institutions/world.ts"},"kenyatta-national-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"uganda-cancer-institute":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"ocean-road-cancer-institute":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"korle-bu-teaching-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"luth-lagos":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/institutions/world.ts"},"nci-cairo":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/world.ts"},"cche-57357":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions/world.ts"},"institut-national-oncologie-rabat":{"commit":"c8ed1dfe69","date":"2026-09-11","author":"Jude Gomila","message":"House style: institution and collection names without dashes, no as-of stamps","file":"src/data/institutions/world.ts"},"institut-salah-azaiez":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions/world.ts"},"butaro-cancer-center":{"commit":"6c701c44ec","date":"2026-09-15","author":"Jude Gomila","message":"data: fourteen more OECI member organisations (list 188 of 193); institution ranking no longer counts membership links f","file":"src/data/institutions/world.ts"},"blida-anti-cancer-center":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/institutions/world.ts"},"jinshazhou-hospital":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/institutions/world.ts"},"new-york-proton-center":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"excel-diagnostics-nuclear-oncology":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"curanosticum":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"cecurio":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"immunocine":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/institutions/world.ts"},"houston-methodist-rna-therapeutics":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions/world.ts"},"center-for-metabolic-oncology":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/institutions/world.ts"},"asthra-health":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"sarcoma-oncology-center":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions/world.ts"},"docrates":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions/world.ts"},"krankenhaus-nordwest":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"kliniken-essen-mitte":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"lungenclinic-grosshansdorf":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"university-hospital-leipzig":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"klinikum-stuttgart-olgahospital":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"ulm-university-hospital":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"st-anna-ccri-vienna":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"iosi-bellinzona":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"ap-hm-timone":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"chu-nantes":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"chu-lille":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"antwerp-university-hospital":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"niguarda-cancer-center":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"fondazione-michelangelo":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"ospedali-galliera":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"university-of-pisa":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"hospital-universitario-salamanca":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"nkua-athens":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"royal-free-hospital":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"weill-cornell-meyer-cancer-center":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"seattle-childrens":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"carilion-clinic":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"tennessee-oncology":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"us-oncology-network":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"orlando-health-cancer-institute":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"baylor-sammons-dallas":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"tgen":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"houston-methodist-neal-cancer-center":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"childrens-national-hospital":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"cincinnati-cancer-center":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"mcw-cancer-center":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"university-of-alberta":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"queens-university-kingston":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"osaka-university":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"kindai-university-hospital":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"snu-bundang-hospital":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"melanoma-institute-australia":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"saigenci-adelaide":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"alfred-health-monash":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/institutions-wave-investigators.ts"},"university-of-western-australia":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions-wave-investigators.ts"},"uq-frazer-institute":{"commit":"15a0727e9e","date":"2026-09-18","author":"Jude Gomila","message":"Chinese quality pass 4 over 243 folded TL;DRs","file":"src/data/institutions-wave-investigators.ts"},"mskcc":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"md-anderson":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"samsung-medical-center":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"asan-medical-center":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"mayo-clinic":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"gustave-roussy":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"royal-marsden":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions.ts"},"snuh":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"princess-margaret":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"johns-hopkins":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"ieo-milan":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions.ts"},"charite":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"ncc-japan":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"peter-mac":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"dana-farber":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"mgh":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"einstein-sao-paulo":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"heidelberg-nct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"sirio-libanes":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"cleveland-clinic":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"institut-curie":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"severance":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"the-christie":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"uke-hamburg":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"jfcr":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"int-milan":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"vall-dhebron":{"commit":"6cedadbc40","date":"2026-09-14","author":"Jude Gomila","message":"Cancers: umbrella pages for non-Hodgkin lymphoma, skin cancer, brain and spinal cord tumours and childhood cancers (GLOB","file":"src/data/institutions.ts"},"gemelli":{"commit":"e6ba96e724","date":"2026-09-15","author":"Jude Gomila","message":"data: provenance rebuilt for 8047 entities; institution pages name their thirty new OECI representatives; four cancer al","file":"src/data/institutions.ts"},"stanford":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"lmu-munich":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/institutions.ts"},"uniklinik-koeln":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"ucsf":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"mount-sinai":{"commit":"a9999bad27","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: NCI A-Z names matched as aliases on 12 cancer records (121 of 128) and the Tisch Cancer Center name on Mou","file":"src/data/institutions.ts"},"la-paz":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"karolinska":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"gregorio-maranon":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"nci":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions.ts"},"fred-hutch":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"penn-abramson":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"city-of-hope":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions.ts"},"moffitt":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"michigan-rogel":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"wustl-siteman":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"ucla-jonsson":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/institutions.ts"},"roswell-park":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"broad-institute":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"cold-spring-harbor":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"francis-crick":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"icr-london":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"cruk":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions.ts"},"nki":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/institutions.ts"},"dkfz":{"commit":"9cd6988dc8","date":"2026-09-17","author":"Jude Gomila","message":"Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institu","file":"src/data/institutions.ts"},"sysucc":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"fuscc":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"west-china":{"commit":"f6051982d8","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API","file":"src/data/institutions.ts"},"cams-cancer-hospital":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/institutions.ts"},"tata-memorial":{"commit":"b34e1ed73f","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API","file":"src/data/institutions.ts"},"curie-nki-eortc":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/institutions.ts"},"asco":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"esmo":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"aacr":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"iarc":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/institutions.ts"},"lazertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"alectinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"repotrectinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"pralsetinib":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/nsclc.ts"},"capmatinib-tepotinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"dabrafenib-trametinib":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/spikes/nsclc.ts"},"vemurafenib":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"tovorafenib":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/spikes/glioblastoma.ts"},"lapatinib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"neratinib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"alpelisib":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"tamoxifen":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/breast-hr-positive.ts"},"letrozole":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/breast-hr-positive.ts"},"exemestane":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/breast-hr-positive.ts"},"abiraterone":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/spikes/prostate.ts"},"enzalutamide":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/prostate.ts"},"apalutamide":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/prostate.ts"},"darolutamide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"ibrutinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cll.ts"},"acalabrutinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"zanubrutinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"pirtobrutinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"lenalidomide":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"bortezomib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"dasatinib":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"asciminib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/all-leukemia.ts"},"midostaurin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/aml.ts"},"gilteritinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"quizartinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"ivosidenib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"selinexor":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/endometrial.ts"},"rucaparib":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"cabozantinib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"lenvatinib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"sunitinib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/neuroendocrine.ts"},"pazopanib":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/spikes/sarcoma.ts"},"axitinib":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/rcc.ts"},"sorafenib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"regorafenib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"everolimus":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"docetaxel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"doxorubicin":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/sarcoma.ts"},"cisplatin":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/cervical.ts"},"pemetrexed":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/mesothelioma.ts"},"temozolomide":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/glioblastoma.ts"},"trabectedin":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/ovarian.ts"},"bevacizumab":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/spikes/colorectal.ts"},"polatuzumab-vedotin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"ketoconazole":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"posaconazole":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"voriconazole":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"fluconazole":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"clarithromycin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"ritonavir":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"diltiazem":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"grapefruit":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"rifampicin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"carbamazepine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"st-johns-wort":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"omeprazole":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"famotidine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"antacid":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"warfarin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"apixaban":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"domperidone":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"haloperidol":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"methadone":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"amiodarone":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"ciprofloxacin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"paroxetine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"escitalopram":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"gemfibrozil":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"simvastatin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"rosuvastatin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"digoxin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"midazolam":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"cyclosporine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"hormonal-contraceptive":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"metformin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"nsaid":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"aminoglycoside":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"trimethoprim":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"penicillin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"probenecid":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"theophylline":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"tizanidine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"phenytoin":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"valproate":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"allopurinol":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"brivudine":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"furosemide":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"metoprolol":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"atazanavir":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"paracetamol":{"commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts"},"cetuximab":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/spikes/colorectal.ts"},"y-combinator":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/investors.ts"},"third-rock-ventures":{"commit":"bdf8642078","date":"2026-09-10","author":"Jude Gomila","message":"YC oncology: 61 Y Combinator companies from the open YC directory, checked against profiles and websites; universe list ","file":"src/data/investors.ts"},"amgen-ventures":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/investors.ts"},"a16z-bio-health":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"arch-venture-partners":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"flagship-pioneering":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"atlas-venture":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"versant-ventures":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"orbimed":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"ra-capital":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"casdin-capital":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"polaris-partners":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"5am-ventures":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"sofinnova-partners":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/investors.ts"},"medicxi":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"syncona":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"forbion":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"frazier-life-sciences":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"bain-capital-life-sciences":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"deerfield-management":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"foresite-capital":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"lux-capital":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"khosla-ventures":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"founders-fund":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"general-catalyst":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"cancer-research-horizons":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"mpm-bioimpact":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"vida-ventures":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"omega-funds":{"commit":"d74f7f2003","date":"2026-09-14","author":"Jude Gomila","message":"Companies: relation arrays on 17 weakly linked pharma, investor and AI protein-design records, derived from their own su","file":"src/data/investors.ts"},"samsara-biocapital":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"cormorant-asset-management":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"perceptive-advisors":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"boxer-capital":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"gv":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"novo-holdings":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"sr-one":{"commit":"ef6b9d13fc","date":"2026-09-12","author":"Jude Gomila","message":"Investors and partners: portfolio and licensing relations already stated in 20 company records wired as graph links","file":"src/data/investors.ts"},"pfizer-ventures":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"novartis-venture-fund":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"jjdc":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"roche-venture-fund":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"msd-global-health-innovation-fund":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"lilly-ventures":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"abbvie-ventures":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"leaps-by-bayer":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"sanofi-ventures":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"takeda-ventures":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"lls-therapy-acceleration-program":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/investors.ts"},"mmrf-myeloma-investment-fund":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/investors.ts"},"break-through-cancer":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"venrock":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"sv-health-investors":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"eqt-life-sciences":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"andera-partners":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"illumina-ventures":{"commit":"e3e489d715","date":"2026-09-10","author":"Jude Gomila","message":"Investors: 55 venture funds, corporate venture arms, accelerator and foundations backing oncology, checked against their","file":"src/data/investors.ts"},"alexandria-venture-investments":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"logos-capital":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"jeito-capital":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"tcgx":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"ecor1-capital":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"gilde-healthcare":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"lightspeed-venture-partners":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"bpifrance":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/investors.ts"},"f-prime-capital":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"section-32":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"dcvc":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"longwood-fund":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"mckesson-ventures":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"acs-brightedge":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/investors.ts"},"sante-ventures":{"commit":"965c4c9058","date":"2026-09-10","author":"Jude Gomila","message":"Investors: fourteen more funds that recur in sourced oncology rounds (Logos, Jeito, TCGX, EcoR1, Gilde, Lightspeed, Bpif","file":"src/data/investors.ts"},"evenone-ventures":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/investors.ts"},"lu-177":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/isotopes.ts"},"ac-225":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/isotopes.ts"},"pb-212":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/isotopes.ts"},"ra-223":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/isotopes.ts"},"ga-68":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/isotopes.ts"},"f-18":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/isotopes.ts"},"zr-89":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/isotopes.ts"},"cu-64":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/isotopes.ts"},"i-131":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/isotopes.ts"},"y-90":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/isotopes.ts"},"i-spy-1":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/ispy-wave.ts"},"i-spy-2":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/ispy-wave.ts"},"i-spy-2-2":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/ispy-wave.ts"},"wisdom-trial":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/ispy-wave.ts"},"quantum-leap-healthcare-collaborative":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/ispy-wave.ts"},"acta-oncologica":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"advances-in-cancer-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"american-journal-of-clinical-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"asco-educational-book":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"analytical-cellular-pathology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"annals-of-surgical-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"anticancer-research":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals-wave2.ts"},"asia-pacific-journal-of-clinical-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"asian-pacific-journal-of-cancer-prevention":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"bba-reviews-on-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"blood-cancer-discovery":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"blood-cancer-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"bmc-cancer":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"brain-tumor-pathology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"breast-cancer-jbcs":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"breast-cancer-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"breast-cancer-research-and-treatment":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"bulletin-du-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-biology-and-medicine":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals-wave2.ts"},"cancer-biology-and-therapy":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-biomarkers":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-biotherapy-and-radiopharmaceuticals":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-causes-and-control":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-chemotherapy-and-pharmacology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-communications":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-control":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals-wave2.ts"},"cancer-cytopathology":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals-wave2.ts"},"cancer-epidemiology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-gene-therapy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-genetics":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-genomics-and-proteomics":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals-wave2.ts"},"cancer-imaging":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-immunology-immunotherapy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-investigation":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-letters":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-medicine":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"cancer-metastasis-reviews":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-nursing":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/journals-wave2.ts"},"cancer-prevention-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-radiotherapie":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-reports":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-research-and-treatment":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-research-communications":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-science":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cancer-treatment-and-research":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"cancer-treatment-and-research-communications":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"cancer-treatment-reviews":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"carcinogenesis":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"cellular-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"chinese-clinical-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"clinical-and-experimental-metastasis":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-and-translational-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-advances-in-hematology-and-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"clinical-breast-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-colorectal-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-genitourinary-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-journal-of-oncology-nursing":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/journals-wave2.ts"},"clinical-lung-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-lymphoma-myeloma-and-leukemia":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"clinical-oncology-rcr":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"cns-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"critical-reviews-in-oncogenesis":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"critical-reviews-in-oncology-hematology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"current-cancer-drug-targets":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"current-hematologic-malignancy-reports":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"current-oncology-mdpi":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"current-oncology-reports":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"current-opinion-in-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"current-problems-in-cancer":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"current-treatment-options-in-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"endocrine-related-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"esophagus-journal":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"european-journal-of-cancer-prevention":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"european-journal-of-oncology-nursing":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/journals-wave2.ts"},"european-journal-of-surgical-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"european-thyroid-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"experimental-oncology":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/journals-wave2.ts"},"expert-review-of-anticancer-therapy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"familial-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"future-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"gan-to-kagaku-ryoho":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"gastric-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"genes-chromosomes-and-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"head-and-neck-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"head-and-neck-pathology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"hematological-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"hematology-oncology-and-stem-cell-therapy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"hematology-oncology-clinics-of-north-america":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"in-vivo":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"indian-journal-of-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"integrative-cancer-therapies":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"international-journal-of-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"international-journal-of-clinical-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"international-journal-of-gynecological-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"international-journal-of-hyperthermia":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"international-journal-of-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"japanese-journal-of-clinical-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"jco-clinical-cancer-informatics":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"jco-global-oncology":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/journals-wave2.ts"},"jmir-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"jnci-cancer-spectrum":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"journal-of-adolescent-and-young-adult-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-breast-imaging":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-cachexia-sarcopenia-and-muscle":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-cancer-education":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-cancer-policy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-cancer-research-and-clinical-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-cancer-research-and-therapeutics":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"journal-of-cancer-survivorship":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-environmental-pathology-toxicology-and-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"journal-of-experimental-and-clinical-cancer-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-gastric-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-gastrointestinal-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-geriatric-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-gynecologic-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-hematology-and-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-immunotherapy":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-mammary-gland-biology-and-neoplasia":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-medical-imaging-and-radiation-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-neuro-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-oncology-pharmacy-practice":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-pediatric-hematology-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-pediatric-hematology-oncology-nursing":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-psychosocial-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-radiation-research":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"journal-of-registry-management":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-surgical-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"journal-of-the-egyptian-national-cancer-institute":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"jnci-monographs":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"klinicka-onkologie":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"leukemia-and-lymphoma":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"leukemia-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"lung-cancer-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"magyar-onkologia":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"medical-oncology":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"melanoma-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"molecular-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"molecular-cancer-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"molecular-carcinogenesis":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"molecular-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"nar-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"neoplasia":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"neoplasma":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/journals-wave2.ts"},"nutrition-and-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"oncogene-journal":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"oncoimmunology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"oncology-williston-park":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"oncology-karger":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"oncology-nursing-forum":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"oncology-reports":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"oncology-research":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"oncology-research-and-treatment":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"oncotarget":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"oral-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"pathology-and-oncology-research":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"pediatric-hematology-and-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"pigment-cell-and-melanoma-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"practical-radiation-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"prostate-cancer-and-prostatic-diseases":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"psycho-oncology-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"radiation-and-environmental-biophysics":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"radiation-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"radiology-and-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"radiology-imaging-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"recent-patents-on-anti-cancer-drug-discovery":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"recent-results-in-cancer-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"seminars-in-cancer-biology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"seminars-in-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"seminars-in-oncology-nursing":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"seminars-in-radiation-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"strahlentherapie-und-onkologie":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"supportive-care-in-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"surgical-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"surgical-oncology-clinics-of-north-america":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"targeted-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"technology-in-cancer-research-and-treatment":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"the-breast":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"the-breast-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"the-cancer-journal":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"gulf-journal-of-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"international-journal-of-biological-markers":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"the-oncologist":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"thoracic-cancer":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals-wave2.ts"},"trends-in-cancer":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals-wave2.ts"},"tumori":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"tumour-biology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"tumour-virus-research":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"urologic-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"veterinary-and-comparative-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"world-journal-of-surgical-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals-wave2.ts"},"chinese-journal-of-lung-cancer":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"chinese-journal-of-oncology":{"commit":"22e110f0fb","date":"2026-09-10","author":"Jude Gomila","message":"Add 192 MEDLINE oncology journals (wave 2) and link JCO Global Oncology paper","file":"src/data/journals-wave2.ts"},"nejm":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"lancet":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"jama":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"jama-internal-medicine":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"bmj":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"annals-internal-medicine":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"plos-medicine":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals.ts"},"lancet-global-health":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"lancet-oncology":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"jco":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"jco-precision-oncology":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"jco-oncology-practice":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"annals-of-oncology":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"esmo-open":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"jama-oncology":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"jnci":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"cancer-wiley":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"ca-cancer-journal":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"british-journal-of-cancer":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals.ts"},"european-journal-of-cancer":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"jnccn":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"journal-of-thoracic-oncology":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"gynecologic-oncology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"european-urology":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"european-urology-oncology":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/journals.ts"},"neuro-oncology":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"radiotherapy-and-oncology":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"ijrobp":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"journal-of-nuclear-medicine":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"radiology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"pediatric-blood-and-cancer":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"blood":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"blood-advances":{"commit":"275e74f0a1","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 13 weakly linked targets, pipeline drugs, NAVIGATE trial and Blood Advances linked from their own text","file":"src/data/journals.ts"},"leukemia":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"lancet-haematology":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"haematologica":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"nature":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"science":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"cell":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/journals.ts"},"cancer-cell":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"cell-stem-cell":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals.ts"},"nature-medicine":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"nature-cancer":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"nature-reviews-cancer":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"nature-reviews-clinical-oncology":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"nature-reviews-drug-discovery":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"nature-genetics":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"nature-biotechnology":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/journals.ts"},"nature-communications":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/journals.ts"},"science-translational-medicine":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"cancer-discovery":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"cancer-research":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"clinical-cancer-research":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"cancer-immunology-research":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"molecular-cancer-therapeutics":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"cancer-epidemiology-biomarkers-prevention":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"jitc":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"jci":{"commit":"4b9c5eb344","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 26 more weakly linked titles linked to the glossary terms their scope statements name","file":"src/data/journals.ts"},"genes-and-development":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"pnas":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"elife":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/journals.ts"},"cancers-mdpi":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals.ts"},"clinical-pharmacology-and-therapeutics":{"commit":"37c60aa094","date":"2026-09-14","author":"Jude Gomila","message":"Journals: 30 weakly linked titles linked to the glossary terms, cancers and societies their scope statements name","file":"src/data/journals.ts"},"lancet-digital-health":{"commit":"3d932e7abd","date":"2026-09-09","author":"Jude Gomila","message":"Journals: records for every venue cited by key papers","file":"src/data/journals.ts"},"nejm-evidence":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/journals.ts"},"medrxiv":{"commit":"1082193316","date":"2026-09-11","author":"Jude Gomila","message":"Merge source collections that duplicated journal and PanCAN records","file":"src/data/journals.ts"},"biorxiv":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/journals.ts"},"paper-druker-imatinib-phase1-nejm-2001":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-iris-imatinib-nejm-2003":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cll14-venetoclax-obinutuzumab-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-elevate-tn-acalabrutinib-lancet-2020":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-amplify-acalabrutinib-venetoclax-nejm-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-murano-venetoclax-rituximab-nejm-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-maia-daratumumab-rd-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-perseus-dara-vrd-transplant-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cepheus-dara-vrd-natmed-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cartitude-1-cilta-cel-lancet-2021":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cartitude-4-cilta-cel-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-karmma-3-ide-cel-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-majestec-1-teclistamab-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-magnetismm-3-elranatamab-natmed-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-zuma-7-axi-cel-second-line-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-transform-liso-cel-lancet-2022":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-polarix-polatuzumab-rchp-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-echelon-1-brentuximab-avd-nejm-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-swog-s1826-nivolumab-avd-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-epcore-nhl-1-epcoritamab-jco-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-viale-a-venetoclax-azacitidine-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-admiral-gilteritinib-flt3-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-quantum-first-quizartinib-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-agile-ivosidenib-azacitidine-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-augment-101-revumenib-menin-nature-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-aall1731-blinatumomab-children-nejm-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-ino-vate-inotuzumab-all-nejm-2016":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-commands-luspatercept-mds-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-imerge-imetelstat-mds-lancet-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-momentum-momelotinib-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-maude-ctl019-all-nejm-2014":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-eliana-tisagenlecleucel-nejm-2018":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-zuma-1-axi-cel-nejm-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-ucart19-allogeneic-car-t-lancet-2020":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-c-144-01-lifileucel-melanoma-jco-2021":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-rohaas-til-vs-ipilimumab-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-spearhead-1-afami-cel-sarcoma-lancet-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-hodi-ipilimumab-melanoma-nejm-2010":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-topalian-anti-pd1-nejm-2012":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-le-mmr-deficiency-pd1-nejm-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-le-mmr-deficiency-science-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-niche-2-neoadjuvant-colon-nejm-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cercek-dostarlimab-rectal-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-checkmate-067-ten-year-nejm-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-asco-irae-guideline-jco-2021":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-pardoll-immune-checkpoint-blockade-nrc-2012":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-rizvi-mutational-landscape-pd1-science-2015":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-galon-immune-contexture-colorectal-science-2006":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-schreiber-cancer-immunoediting-science-2011":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-thorsson-immune-landscape-of-cancer-immunity-2018":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-darnell-jak-stat-science-1994":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-binnewies-tumor-immune-microenvironment-natmed-2018":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-cella-fact-g-jco-1993":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-chen-mellman-cancer-immunity-cycle-immunity-2013":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-ribas-wolchok-checkpoint-blockade-science-2018":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-li-timer2-nar-2020":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/blood-immune-cell.ts"},"paper-nlst-nejm-2011":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-nelson-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-nordicc-nejm-2022":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-minnesota-fobt-nejm-1993":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hpv-vaccine-sweden-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hpv-vaccine-england-lancet-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hpv-self-sampling-bmj-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-masai-lancet-oncol-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-pathfinder-lancet-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-nhs-galleri-design-cancers-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-detect-a-science-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-imvigor011-nejm-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-dynamic-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-galaxy-signatera-nat-med-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-challenge-exercise-nejm-2025":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-predimed-breast-jama-im-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-body-fatness-iarc-nejm-2016":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-capp2-aspirin-lynch-lancet-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-ibis-i-tamoxifen-lancet-oncol-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-brca-risk-reducing-surgery-jama-2010":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-lynch-frameshift-vaccine-ccr-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-doll-hill-smoking-lung-cancer-bmj-1950":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-doll-peto-50-year-doctors-bmj-2004":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-alcohol-cancer-burden-lancet-oncol-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-basch-epro-survival-jama-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-temel-early-palliative-care-nejm-2010":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-gap70-geriatric-assessment-lancet-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-drug-dosing-conundrum-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hallmarks-of-cancer-cell-2000":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hallmarks-new-dimensions-cancer-discov-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-tcga-pancancer-atlas-cell-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-vogelstein-cancer-genome-landscapes-science-2013":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-gerlinger-intratumour-heterogeneity-nejm-2012":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-tracerx-100-nejm-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-tracerx-evolution-nature-2023":{"commit":"c53b85e8e8","date":"2026-09-18","author":"Jude Gomila","message":"TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-martincorena-somatic-mutations-normal-skin-science-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jaiswal-chip-nejm-2014":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-depmap-tsherniak-cell-2017":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-alphafold2-jumper-nature-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-ostrem-kras-g12c-nature-2013":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-protac-concept-sakamoto-pnas-2001":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-leach-allison-ctla4-blockade-science-1996":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-iwai-pdl1-tumour-escape-pnas-2002":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-reproducibility-project-cancer-biology-elife-2021":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-prasad-surrogate-endpoints-jama-im-2015":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-unger-trial-participation-barriers-jnci-2019":{"commit":"9f8f59e734","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: six landmark top-cited records (GLOBOCAN 2022, Slamon 1987 and 2001, Hurwitz 2004, KEYNOTE-024, CheckMate 05","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-bray-globocan-2022-cacancer-2024":{"commit":"9f8f59e734","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: six landmark top-cited records (GLOBOCAN 2022, Slamon 1987 and 2001, Hurwitz 2004, KEYNOTE-024, CheckMate 05","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-slamon-her2-amplification-science-1987":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-coussens-werb-inflammation-cancer-nature-2002":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-reya-cancer-stem-cells-nature-2001":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-esteva-skin-cancer-deep-learning-nature-2017":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-therasse-recist-jnci-2000":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-aaronson-eortc-qlq-c30-jnci-1993":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-sung-globocan-2020-cacancer-2021":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-bray-globocan-2018-cacancer-2018":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2024-cacancer-2024":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-chen-cancer-statistics-china-2015-cacancer-2016":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-calle-obesity-cancer-mortality-nejm-2003":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-hollstein-p53-mutations-science-1991":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-al-hajj-breast-cancer-stem-cells-pnas-2003":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-bao-glioma-stem-cells-radioresistance-nature-2006":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-slamon-her2-breast-ovarian-science-1989":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-allemani-concord-3-lancet-2018":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-torre-global-cancer-statistics-2012-cacancer-2015":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-kalluri-weinberg-emt-basics-jci-2009":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-mani-emt-stem-cell-properties-cell-2008":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-thiery-emt-tumour-progression-nrc-2002":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-quail-joyce-microenvironment-metastasis-natmed-2013":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-grivennikov-immunity-inflammation-cancer-cell-2010":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-balkwill-mantovani-inflammation-virchow-lancet-2001":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-levine-p53-gatekeeper-cell-1997":{"commit":"77f83cf873","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited biology landmarks (EMT reviews by Thiery, Kalluri and Weinberg, Mani 2008, Quail and Joyce 2","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-el-deiry-waf1-p21-cell-1993":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-lemmon-schlessinger-rtk-signalling-cell-2010":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-vogelstein-surfing-p53-network-nature-2000":{"commit":"a8651f6c41","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Lamouille 2014 EMT, Lemmon and Schlessinger 2010 RTKs, Vogelstein 2000 p53 networ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-sherr-roberts-cdk-inhibitors-genesdev-1999":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jemal-global-cancer-statistics-2011-cacancer":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-parkin-global-cancer-statistics-2002-cacancer-2005":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-ferlay-globocan-2012-methods-ijc-2015":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-ferlay-globocan-2018-methods-ijc-2019":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-ferlay-cancer-statistics-2020-overview-ijc-2021":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2019-cacancer-2019":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2022-cacancer-2022":{"commit":"ae57f641c2","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited statistics reports (Global cancer statistics 2002 and 2008, GLOBOCAN 2012, 2018 and 2020 met","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2023-cacancer-2023":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2012-cacancer-2012":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2015-cacancer-2015":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2016-cacancer-2016":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2017-cacancer-2017":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2018-cacancer-2018":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2021-cacancer-2021":{"commit":"11142e1d8c","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited records (US Cancer statistics 2012, 2015, 2016, 2017, 2018 and 2021; Veber 2002 oral bioavai","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-veber-oral-bioavailability-jmedchem-2002":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-singh-brain-tumour-initiating-cells-nature-2004":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-sato-lgr5-organoids-nature-2009":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-yarden-sliwkowski-erbb-network-nrmcb-2001":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jemal-cancer-statistics-2007-cacancer-2007":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jemal-cancer-statistics-2008-cacancer-2008":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jemal-cancer-statistics-2009-cacancer-2009":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-jemal-cancer-statistics-2010-cacancer-2010":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2013-cacancer-2013":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-siegel-cancer-statistics-2014-cacancer-2014":{"commit":"b3a2908d38","date":"2026-09-16","author":"Jude Gomila","message":"data: six earlier Cancer Statistics reports (2007 to 2010, 2013, 2014) as key papers from their abstracts; top-100 list ","file":"src/data/key-papers/prevention-detection-biology.ts"},"paper-keynote-522-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-destiny-breast03-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-destiny-breast04-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-destiny-breast06-nejm-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-monarche-jco-2020":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-natalee-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-olympia-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-katherine-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-tropion-breast01-jco-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-ascent-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-flaura-nejm-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-mariposa-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-adaura-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-crown-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-189-nejm-2018":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-checkmate-816-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-pacific-nejm-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-adriatic-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-dellphi-301-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-codebreak-200-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-harmoni-2-lancet-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-napoli-3-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-spotlight-lancet-2023":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-checkmate-649-lancet-2021":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-imbrave150-nejm-2020":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-177-nejm-2020":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/solid-tumours.ts"},"paper-breakwater-nejm-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-codebreak-300-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-niche-2-nejm-2024":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/solid-tumours.ts"},"paper-cercek-dmmr-rectal-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-vision-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-stampede-abiraterone-nejm-2017":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-ev-302-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-niagara-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-clear-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-564-nejm-2021":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-sunrise-1-jco-2025":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-paola-1-nejm-2019":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-solo-1-nejm-2018":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-a18-lancet-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-ruby-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-checkmate-067-10-year-nejm-2025":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-nadina-nejm-2024":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-relativity-047-nejm-2022":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-942-lancet-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-indigo-nejm-2023":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-stupp-temozolomide-nejm-2005":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/key-papers/solid-tumours.ts"},"paper-netter-2-lancet-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-spearhead-1-lancet-2024":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-048-lancet-2019":{"commit":"280ef734c8","date":"2026-09-18","author":"Jude Gomila","message":"Add DOIs and PMIDs to 35 key papers that had neither","file":"src/data/key-papers/solid-tumours.ts"},"paper-slamon-trastuzumab-nejm-2001":{"commit":"9f8f59e734","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: six landmark top-cited records (GLOBOCAN 2022, Slamon 1987 and 2001, Hurwitz 2004, KEYNOTE-024, CheckMate 05","file":"src/data/key-papers/solid-tumours.ts"},"paper-hurwitz-bevacizumab-crc-nejm-2004":{"commit":"9f8f59e734","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: six landmark top-cited records (GLOBOCAN 2022, Slamon 1987 and 2001, Hurwitz 2004, KEYNOTE-024, CheckMate 05","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-024-nejm-2016":{"commit":"9f8f59e734","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: six landmark top-cited records (GLOBOCAN 2022, Slamon 1987 and 2001, Hurwitz 2004, KEYNOTE-024, CheckMate 05","file":"src/data/key-papers/solid-tumours.ts"},"paper-checkmate-057-nejm-2015":{"commit":"d5e3bf6523","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: seven top-cited landmarks (Coussens and Werb 2002, Reya 2001, Esteva 2017, RECIST 2000, EORTC QLQ-C30 1993, ","file":"src/data/key-papers/solid-tumours.ts"},"paper-checkmate-017-nejm-2015":{"commit":"5997da34e9","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (GLOBOCAN 2020 and 2018, US Cancer statistics 2024, China 2015, FOLFIRINOX, Rizvi ","file":"src/data/key-papers/solid-tumours.ts"},"paper-conroy-folfirinox-pancreatic-nejm-2011":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/solid-tumours.ts"},"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-001-pembrolizumab-nsclc-nejm-2015":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-010-lancet-2016":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/solid-tumours.ts"},"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015":{"commit":"ec665e667f","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (MPACT, KEYNOTE-001, KEYNOTE-010, KEYNOTE-006, Sauer 2004 rectal, Galon 2006, Schr","file":"src/data/key-papers/solid-tumours.ts"},"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004":{"commit":"bec3e723b1","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Al-Hajj 2003, Bao 2006, Slamon 1989, CONCORD-3, GBD 2015, Global cancer statistic","file":"src/data/key-papers/solid-tumours.ts"},"paper-burris-gemcitabine-pancreatic-jco-1997":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/solid-tumours.ts"},"paper-toga-trastuzumab-gastric-lancet-2010":{"commit":"b0bbe1f294","date":"2026-09-14","author":"Jude Gomila","message":"Key papers: eight top-cited landmarks (Singh 2004 brain tumour stem cells, ToGA, Rahib 2014 projections, Sato 2009 organ","file":"src/data/key-papers/solid-tumours.ts"},"clear-cell-rcc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/kidney-subtypes.ts"},"papillary-rcc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/kidney-subtypes.ts"},"chromophobe-rcc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/kidney-subtypes.ts"},"fdca":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"fdora-2022":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"fdasia-2012":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"21st-century-cures-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"orphan-drug-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"bpca-prea":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"right-to-try":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"abigail-alliance":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"hatch-waxman":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"bpcia":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/law-wave.ts"},"us-regulatory-exclusivity":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"inflation-reduction-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"medicare-ced":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"hipaa":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"gina":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"common-rule":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"myriad-ruling":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"state-biomarker-testing-laws":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"tobacco-control-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"tobacco-21":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-regulation-726-2004":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-orphan-regulation":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-paediatric-regulation":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-clinical-trials-regulation":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/law-wave.ts"},"gdpr":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"european-health-data-space":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-hta-regulation":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-pharma-package":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"spc":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"eu-data-exclusivity":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"ilap":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"cancer-drugs-fund":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"nice-methods":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"innovative-medicines-fund":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"medicines-medical-devices-act-2021":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"uk-data-protection-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"amnog":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/law-wave.ts"},"france-early-access":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"sakigake":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"japan-conditional-early-approval":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"china-drug-administration-law":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"pipl":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"china-hgr-rules":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"china-vbp-nrdl":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"india-new-drugs-rules-2019":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"nexavar-compulsory-licence":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"novartis-glivec-ruling":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"trips-doha":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"declaration-of-helsinki":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/law-wave.ts"},"ich-gcp":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/law-wave.ts"},"flaura":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"alex":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"alta-1l":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"keynote-042":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"empower-lung-1":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"geometry-mono-1":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"pharos":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"destiny-lung02":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"beamion-lung-1":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"calgb-140503":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/lung-subtypes.ts"},"egfr-mutant-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"alk-positive-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"kras-g12c-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"ros1-positive-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"met-altered-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"ret-fusion-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"braf-v600e-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"her2-mutant-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"ntrk-fusion-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"pdl1-high-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"resectable-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"stage-iii-unresectable-nsclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"limited-stage-sclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"extensive-stage-sclc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/lung-subtypes.ts"},"x-ray-radiography-fluoroscopy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"photon-counting-ct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"dual-energy-spectral-ct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"ultrasound-elastography-ceus":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"mri-field-strengths":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"spect-ct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"intraoperative-mri-ct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"c-arm-linac":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"ring-gantry-linac":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"tomotherapy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"cyberknife":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/machines-wave.ts"},"gamma-knife":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/machines-wave.ts"},"zap-x":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"biology-guided-radiotherapy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"brachytherapy-afterloaders":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"proton-therapy-systems":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"carbon-ion-synchrotrons":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"cryoablation-systems":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"microwave-rf-ablation":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"surgical-robot-platforms":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"flow-cytometers":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"hitachi":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"viewray":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"medtronic":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave.ts"},"cmr-surgical":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/machines-wave.ts"},"angiodynamics":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/machines-wave.ts"},"fujifilm":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"shimadzu":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"sumitomo-heavy-industries":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"toshiba-energy-systems":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"mediso":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave.ts"},"carl-zeiss-meditec":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/machines-wave.ts"},"profound-medical":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"icecure-medical":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"beckman-coulter":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"cytek-biosciences":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"mindray":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave.ts"},"protom":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/machines-wave.ts"},"bnct-accelerator-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"flash-research-accelerators":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"electron-beam-therapy-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"oncology-information-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"patient-positioning-surface-guidance-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"respiratory-gating-tumour-tracking-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"in-room-imaging-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"radiotherapy-qa-phantoms-dosimeters":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"hyperthermia-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"photodynamic-therapy-lasers":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"litt-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"transcranial-focused-ultrasound-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"electrochemotherapy-devices":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"hipec-pipac-devices":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"intraoperative-fluorescence-imaging-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"gamma-probes-dose-calibrators":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"endoscopic-ultrasound-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"capsule-endoscopy-systems":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"colposcopes-digital-cervical-screening":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"confocal-oct-skin-imaging":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"contrast-enhanced-mammography":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"breast-mri-coils-abbreviated-mri":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"closed-system-transfer-devices":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"stella-pharma":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"neuboron-medtech":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/machines-wave2.ts"},"pyrexar-medical":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"oncotherm":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave2.ts"},"modulight":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"carthera":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"igea":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"belmont-medical-technologies":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"capnomed":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"stryker":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"karl-storz":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"olympus":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave2.ts"},"pentax-medical":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/machines-wave2.ts"},"cook-medical":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/machines-wave2.ts"},"capsovision":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"lightpoint-medical":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"mammotome":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"dysis-medical":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"mobileodt":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"canfield-scientific":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"fotofinder":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"caliber-imaging-diagnostics":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"michelson-diagnostics":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"damae-medical":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"vision-rt":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"c-rad":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"ptw-freiburg":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"standard-imaging":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"icu-medical":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/machines-wave2.ts"},"equashield":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"loccioni":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"paxman":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"dignitana":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/machines-wave2.ts"},"small-molecule-api-synthesis":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"oral-solid-dose-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"sterile-injectable-generics-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"bcg-vaccine-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"downstream-purification-chromatography":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"single-use-bioprocessing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"biosimilar-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"pharmaceutical-gmp-inspections":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"adc-supply-chain":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"car-t-manufacturing-process":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"allogeneic-cell-banks":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"mrna-lnp-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"research-reactor-isotope-production":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"cyclotron-isotope-production":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"actinium-225-supply":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"radiopharmaceutical-gmp-release":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"radiotherapy-equipment-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"medical-imaging-scanner-manufacturing":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"sterling-pharma-solutions":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"sartorius":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"hikma":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/manufacturing-wave.ts"},"amneal":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/manufacturing-wave.ts"},"samsung-bioepis":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"cellectis":{"commit":"6fe3659f41","date":"2026-09-17","author":"Jude Gomila","message":"One Hitachi record (machines wave)","file":"src/data/manufacturing-wave.ts"},"ntp-radioisotopes":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"ansto":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"ire":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"nordion":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"bruce-power":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/manufacturing-wave.ts"},"nusano":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"isotopia":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"small-molecules":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"biologics":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"adcs":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"cell-therapy":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"mrna":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"isotopes":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"machines":{"commit":"c9e6e9d261","date":"2026-09-17","author":"Jude Gomila","message":"Manufacturing wave: seven supply chains, 18 technologies, 14 makers","file":"src/data/manufacturing-wave.ts"},"lonza-visp":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"wuxi-xdc-wuxi":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"wuxi-xdc-singapore":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"samsung-biologics-songdo-adc":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"abzena-sanford":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"piramal-grangemouth":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"catalent-bloomington":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"fujifilm-holly-springs":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"daiichi-hiratsuka":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"kite-el-segundo":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"kite-frederick":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"kite-hoofddorp":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"novartis-morris-plains":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"bms-devens":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"legend-raritan":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"legend-ghent":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"cellares-south-sf":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"oxford-biomedica-oxford":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"aldevron-fargo":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"miltenyi-bergisch-gladbach":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"itm-garching":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"novartis-millburn":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"novartis-indianapolis":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"novartis-zaragoza":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"orano-med-plano":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"terrapower-isotopes-philadelphia":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"eckert-ziegler-berlin":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"curium-petten":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"northstar-beloit":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"shine-janesville":{"commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/manufacturing.ts"},"basement-membrane-tissue-barriers":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/mechanics-pathways.ts"},"cancer-immunity-cycle":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanics-pathways.ts"},"extrinsic-apoptosis-death-receptors":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"p53-mdm2-axis":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/mechanics-pathways.ts"},"mutagenesis-signatures":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"oncogene-activation-two-hit":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"oncogenic-viruses":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"cell-cycle-engine-cdks":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"dna-replication-licensing":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/mechanics-pathways.ts"},"mitotic-spindle-checkpoint":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"rtk-activation":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"transcription-addiction":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"ubiquitin-proteasome-system":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"homologous-recombination-repair":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"mismatch-repair-msi":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"base-excision-repair-parp":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"synthetic-lethality-map":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"glutamine-metabolism":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"lipid-metabolism-cancer":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"angiogenic-switch":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"nutrient-competition-tme":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"t-cell-exhaustion":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"immune-desert-exclusion":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"myeloid-suppression-axis":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"complement-in-cancer":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"nk-cell-recognition":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"invasion-ecm-degradation":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"intravasation-ctc-survival":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"pre-metastatic-niche":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"organ-tropism-seed-soil":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"blood-brain-barrier-metastasis":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanics-pathways.ts"},"caf-activation-desmoplasia":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"resistance-routes-map":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"drug-tolerant-persisters":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"drug-efflux-pumps":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/mechanics-pathways.ts"},"lineage-plasticity-neuroendocrine":{"commit":"76003b0996","date":"2026-09-09","author":"Jude Gomila","message":"Mechanics of cancer atlas","file":"src/data/mechanics-pathways.ts"},"metastatic-cascade":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"tumor-microenvironment":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"antigen-presentation-immunoediting":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"cancer-metabolism":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"replication-stress":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"chromosomal-instability":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"telomere-maintenance":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/mechanisms.ts"},"autophagy":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/mechanisms.ts"},"ferroptosis-cell-death":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/mechanisms.ts"},"senescence":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"cancer-stem-cells-plasticity":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"clonal-evolution":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"inflammation-nfkb":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"hedgehog":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/mechanisms.ts"},"notch":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"jak-stat":{"commit":"d6625dd92d","date":"2026-09-17","author":"Jude Gomila","message":"Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers","file":"src/data/mechanisms.ts"},"tgf-beta":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"hippo-yap":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"myc":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/mechanisms.ts"},"keap1-nrf2":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"swi-snf-chromatin":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"epigenetic-reprogramming":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"rna-splicing":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/mechanisms.ts"},"mrna-translation-eif4f":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"circadian-control":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"microbiome-tumour":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"cancer-neuroscience":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/mechanisms.ts"},"cachexia-biology":{"commit":"a01207de6c","date":"2026-09-08","author":"Jude Gomila","message":"Mechanism research map: 31 pathway diagrams (metastasis, TME, metabolism, CIN, dormancy, MYC, Hippo, splicing…), 14 hall","file":"src/data/mechanisms.ts"},"clonal-haematopoiesis":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"field-cancerisation":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"tumor-dormancy":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/mechanisms.ts"},"hallmarks-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"sustaining-proliferative-signaling":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"evading-growth-suppressors":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"resisting-cell-death":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"enabling-replicative-immortality":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"inducing-angiogenesis":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"activating-invasion-metastasis":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/mechanisms.ts"},"deregulating-cellular-energetics":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"avoiding-immune-destruction":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"genome-instability-mutation":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"tumor-promoting-inflammation":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"unlocking-phenotypic-plasticity":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"nonmutational-epigenetic-reprogramming":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"polymorphic-microbiomes":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"senescent-cells":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/mechanisms.ts"},"disseminated-tumor-cells":{"commit":"8a68b0a5ff","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 23 more terms (516 of 594)","file":"src/data/mechanisms.ts"},"warburg-effect":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/mechanisms.ts"},"immune-exclusion":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/mechanisms.ts"},"cancer-associated-fibroblasts":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/mechanisms.ts"},"tumor-associated-macrophages":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/mechanisms.ts"},"myeloid-derived-suppressor-cells":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/mechanisms.ts"},"whole-genome-doubling":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/mechanisms.ts"},"idea-dtc-colonisation-determinants":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/mechanisms.ts"},"idea-immune-exclusion-drivers":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-drugging-myc":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/mechanisms.ts"},"idea-targeting-aneuploidy":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-neoantigen-immunogenicity-rules":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-dormancy-maintenance-therapy":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-metabolic-vulnerability-mapping":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-senolytics-after-chemo":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-microbiome-io-fmt":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-nerve-tumour-blockade":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-cachexia-gdf15-prevention":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-chip-risk-modifiers":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/mechanisms.ts"},"idea-field-interception":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/mechanisms.ts"},"idea-ferroptosis-persisters":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-splice-neoantigens":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-chronotherapy-immunotherapy":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"idea-ecdna-targeting":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/mechanisms.ts"},"gompertzian-growth-model":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"log-kill-hypothesis":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"norton-simon-hypothesis":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"goldie-coldman-model":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"drug-resistance-dynamics":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"adaptive-therapy-dynamics":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"evolutionary-game-theory-cancer":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"clonal-evolution-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"reaction-diffusion-glioma-model":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"agent-based-tumour-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"immune-tumour-dynamics-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"quantitative-systems-pharmacology":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"pkpd-modelling":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"body-surface-area-dosing":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"tumour-control-probability-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"fractionation-repopulation-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"tumour-doubling-time":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"angiogenesis-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"tumour-mechanics-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"metastasis-seeding-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"mrd-kinetics-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"digital-twin-patient-models":{"commit":"06ac07bf12","date":"2026-09-17","author":"Jude Gomila","message":"Mathematical and biophysical models: 22 model technologies, a third type on the models page","file":"src/data/models-wave.ts"},"mathematical-oncology":{"commit":"32cfb851f3","date":"2026-09-17","author":"Jude Gomila","message":"Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per canc","file":"src/data/models-wave.ts"},"small-intestinal-net":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/neuroendocrine-subtypes.ts"},"pancreatic-net":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/neuroendocrine-subtypes.ts"},"lung-net":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/neuroendocrine-subtypes.ts"},"extrapulmonary-nec":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/neuroendocrine-subtypes.ts"},"grade-3-net":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/neuroendocrine-subtypes.ts"},"structured-exercise-survivorship":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"exercise-during-chemotherapy":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"resistance-training-cachexia":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"eras-perioperative-nutrition":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"nutrition-screening-mnt":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"enteral-parenteral-nutrition":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"immunonutrition-perioperative":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"fasting-mimicking-diet":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"ketogenic-diet-glioblastoma":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"time-restricted-eating":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"mediterranean-plant-forward-diet":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/nutrition.ts"},"dietary-fibre-microbiome-io":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"fmt-checkpoint-nonresponders":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"probiotics-antibiotic-stewardship-io":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"glp1-agonists-cancer-risk":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"bariatric-surgery-cancer-incidence":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"alcohol-reduction-labelling":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"vitamin-d-omega3-supplementation":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"aspirin-cancer-prevention":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"coffee-intake-cancer":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"red-processed-meat-reduction":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"ultra-processed-food-ssb":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"smoking-cessation-after-diagnosis":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"sleep-circadian-interventions":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"cachexia-appetite-pharmacotherapy":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"dietitian-led-weight-loss-breast":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"soy-breast-cancer":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/nutrition.ts"},"dietary-supplements-treatment-interactions":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"cachexia":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/nutrition.ts"},"sarcopenia":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"immunonutrition":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/nutrition.ts"},"glycaemic-index":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"warburg-effect-diet-claims":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/nutrition.ts"},"unproven-diet-claims":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"ultra-processed-food":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/nutrition.ts"},"metabolic-syndrome":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"prehabilitation-term":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"met-hours":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"body-composition":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"gut-microbiome-diversity":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"dietary-pattern-scores":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/nutrition.ts"},"nutrition-impact-symptoms":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"malnutrition-screening":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/nutrition.ts"},"obesity-related-cancers":{"commit":"d6625dd92d","date":"2026-09-17","author":"Jude Gomila","message":"Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers","file":"src/data/nutrition.ts"},"energy-balance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"alcohol-attributable-cancer":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/nutrition.ts"},"challenge":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"bwel":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"vital":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"aspree":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"alascca":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"add-aspirin":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"romana-1-2":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"ponsegromab-phase-2":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/nutrition.ts"},"olanzapine-appetite-tmh":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/nutrition.ts"},"fmt-pd1-refractory-melanoma-pitt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"mimic-01":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"ergo2":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"prehab-trial":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts"},"whel":{"commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts"},"idea-nl-exercise-dose-finding":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-glp1-adjuvant-hr-breast":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-ketogenic-gbm-definitive-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-diet-covariates-io-trials":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-alcohol-minimum-pricing-cancer-endpoints":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-upf-controlled-feeding-trial":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-antioxidant-supplement-harm-confirmation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-bariatric-cancer-registry-linkage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-sleep-circadian-survivorship-rct":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-dietitian-in-every-mdt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/nutrition.ts"},"idea-nl-ask-about-diet-prebunking":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/nutrition.ts"},"breast":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/organ-schematics.ts"},"lung":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"colorectum":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"stomach-oesophagus":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/organ-schematics.ts"},"pancreas-biliary":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/organ-schematics.ts"},"liver":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/organ-schematics.ts"},"kidney-bladder-adrenal":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"female-pelvis":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"testis":{"commit":"4d5e63ba0e","date":"2026-09-17","author":"Jude Gomila","message":"Subtype pages: kidney, testicular, oesophageal, bladder","file":"src/data/organ-schematics.ts"},"skin":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/organ-schematics.ts"},"eye":{"commit":"b46b24df27","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch G: visuals","file":"src/data/organ-schematics.ts"},"brain":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/organ-schematics.ts"},"head-neck":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"haematopoietic":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/organ-schematics.ts"},"musculoskeletal":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/organ-schematics.ts"},"high-grade-serous-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/ovarian-subtypes.ts"},"low-grade-serous-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/ovarian-subtypes.ts"},"clear-cell-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/ovarian-subtypes.ts"},"mucinous-ovarian-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/ovarian-subtypes.ts"},"granulosa-cell-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/ovarian-subtypes.ts"},"firefly-1":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/paediatric-fronts.ts"},"tadpole":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/paediatric-fronts.ts"},"action-dmg":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"pediatric-match":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"acns0331":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/paediatric-fronts.ts"},"aren0533":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"euramos-1":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"aaml0531":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/paediatric-fronts.ts"},"inter-b-nhl-ritux-2010":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"lch-iii":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/paediatric-fronts.ts"},"ccss":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/paediatric-fronts.ts"},"accelerate-platform":{"commit":"b4207c2a3b","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: calicheamicin and 79 institution TL;DRs rewritten as full sentences with concrete facts; 16 institut","file":"src/data/paediatric-fronts.ts"},"itcc":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/paediatric-fronts.ts"},"histiocyte-society":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/paediatric-fronts.ts"},"race-for-children-act":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/paediatric-fronts.ts"},"all-paediatric-standard-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"all-paediatric-high-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"all-paediatric-ph-positive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"all-ph-like":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"all-infant":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"all-paediatric-relapsed":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"aml-paediatric":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/paediatric-subtypes.ts"},"neuroblastoma-low-risk":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/paediatric-subtypes.ts"},"neuroblastoma-intermediate-risk":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/paediatric-subtypes.ts"},"neuroblastoma-high-risk":{"commit":"036a9f1ca0","date":"2026-09-18","author":"Jude Gomila","message":"Merge key papers for subtype pages","file":"src/data/paediatric-subtypes.ts"},"medulloblastoma-wnt":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/paediatric-subtypes.ts"},"medulloblastoma-shh":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/paediatric-subtypes.ts"},"medulloblastoma-group-3-4":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/paediatric-subtypes.ts"},"aya-cancers":{"commit":"1ead9ec759","date":"2026-09-18","author":"Jude Gomila","message":"Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English","file":"src/data/paediatric-subtypes.ts"},"adc-plus-io":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"cdk46-plus-endocrine":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"braf-plus-mek":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"kras-plus-egfr-crc":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"io-plus-vegf":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"parp-plus-arpi":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/pairings.ts"},"vaccine-plus-pd1":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"radiation-plus-io":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"oncolytic-plus-pd1":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/pairings.ts"},"platinum-plus-hrd":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/pairings.ts"},"psma-pet-to-rlt":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"trop2-pet-to-adc":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/pairings.ts"},"ctdna-mrd-to-adjuvant":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"her2-low-to-tdxd":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"germline-to-parp":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/pairings.ts"},"ai-pathology-to-adt":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/pairings.ts"},"tki-then-adc-lung":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/pairings.ts"},"io-then-til":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"beta-then-alpha":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/pairings.ts"},"adc-after-adc-caution":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/pairings.ts"},"tigit-plus-pd1-caution":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/pairings.ts"},"ild-overlap-caution":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/pairings.ts"},"resectable-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"borderline-resectable-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"locally-advanced-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"metastatic-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"kras-g12c-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"kras-wild-type-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"brca-palb2-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"msi-high-pdac":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"pancreatic-acinar-cell-carcinoma":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"ipmn-cystic-precursors":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pancreatic-subtypes.ts"},"pancreatoblastoma":{"commit":"95feca2cd8","date":"2026-09-18","author":"Jude Gomila","message":"Chinese TL;DR pass 5: fix 14 rare and pancreatic subtype entries","file":"src/data/pancreatic-subtypes.ts"},"paper-anchor-anal-hsil-treatment-nejm-2022":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-ians-anal-cancer-screening-guidelines-ijc-2024":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-esmo-anal-cancer-guideline-ann-oncol-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-interaact-anal-cancer-carboplatin-paclitaxel-jco-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-eau-asco-penile-cancer-guideline-eur-urol-2023":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-masaoka-thymoma-clinical-staging-cancer-1981":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-adiuvo-adjuvant-mitotane-acc-lancet-diabetes-endocrinol-2023":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-erdheim-chester-disease-consensus-recommendations-blood-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-emile-revised-classification-of-histiocytoses-blood-2016":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-badalian-very-braf-mutations-lch-blood-2010":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/papers-rare-wave.ts"},"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-trophimmun-avelumab-chemoresistant-gtn-jco-2020":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-froeling-pstt-ett-intensified-therapy-bjc-2019":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-firstmappp-sunitinib-metastatic-ppgl-lancet-2024":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/papers-rare-wave.ts"},"paper-amit-induction-chemotherapy-response-snuc-jco-2019":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/papers-rare-wave.ts"},"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/papers-rare-wave.ts"},"paper-swog-8710-neoadjuvant-mvac-nejm-2003":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-javelin-bladder-100-nejm-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-057-lancet-oncol-2021":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-nadofaragene-firadenovec-lancet-oncol-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-sylvester-eortc-risk-tables-eur-urol-2006":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eau-nmibc-guideline-eur-urol-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aza-aml-001-dombret-blood-2015":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-eln-2022-aml-dohner-blood-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-apl0406-lo-coco-nejm-2013":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-tallman-atra-apl-nejm-1997":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eln-apl-sanz-blood-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-pace-ponatinib-nejm-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eln-2020-cml-hochhaus-leukemia-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ratify-midostaurin-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aza-001-fenaux-lancet-oncol-2009":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/papers-subtypes-wave.ts"},"paper-ipss-m-bernard-nejm-evidence-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-who-2022-myeloid-khoury-leukemia-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-icc-2022-arber-blood-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ivosidenib-idh1-dinardo-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-enasidenib-idh2-stein-blood-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cassiopeia-lancet-2019":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-ifm-2009-attal-nejm-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-r-iss-palumbo-jco-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-falini-npm1-nejm-2005":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ivey-npm1-mrd-nejm-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-royer-plasma-cell-leukaemia-ifm-jco-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-monumental-1-talquetamab-nejm-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rossi-richter-syndrome-blood-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-who-2022-lymphoid-alaggio-leukemia-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cpx-351-study-301-lancet-je-jco-2018":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-aquila-daratumumab-smouldering-nejm-2025":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/papers-subtypes-wave.ts"},"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-imwg-criteria-rajkumar-lancet-oncol-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mateos-20-2-20-smouldering-bcj-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aphinity-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-apt-tolaney-nejm-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-train-2-lancet-oncol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-her2climb-nejm-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-her2climb-brain-lin-jco-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-tailorx-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-emerald-elacestrant-jco-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-capitello-291-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-solar-1-alpelisib-nejm-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rueth-inflammatory-breast-trimodality-jco-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-355-nejm-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-olympiad-nejm-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-kothari-paget-disease-nipple-multifocal-cancer-2002":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tan-phyllodes-consensus-histopathology-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-743-lancet-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-vogelzang-pemetrexed-mesothelioma-jco-2003":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mars-2-lancet-respir-med-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-483-lancet-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-who-2021-cns-louis-neuro-oncology-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-9802-buckner-nejm-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-catnon-lancet-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-alliance-n0574-brown-jama-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-n107c-brown-lancet-oncol-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-nrg-cc001-brown-jco-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-quartz-lancet-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-acns1123-germinoma-neuro-oncology-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eano-meningioma-goldbrunner-neuro-oncology-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-sahm-meningioma-methylation-lancet-oncol-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-9402-cairncross-jco-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eortc-26951-van-den-bent-jco-2013":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/papers-subtypes-wave.ts"},"paper-mackay-paediatric-hgg-cancer-cell-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-belzutifan-vhl-jonasch-nejm-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-plotkin-bevacizumab-nf2-nejm-2009":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-carlson-link-vestibular-schwannomas-nejm-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-beacon-crc-kopetz-nejm-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cms-guinney-nat-med-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-sinicrope-early-onset-crc-nejm-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-uspstf-crc-screening-45-jama-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-siegel-crc-incidence-1974-2013-jnci-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mountaineer-lancet-oncol-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-heracles-lancet-oncol-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-destiny-crc01-lancet-oncol-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-krystal-1-crc-yaeger-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-sunlight-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-8hw-lancet-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ielsg37-pmbcl-martelli-jco-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-rapido-lancet-oncol-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-prodige-23-lancet-oncol-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-prospect-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-nrg-gy018-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-775-nejm-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-duo-e-jco-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-lacc-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-shape-nejm-2024":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-promise-talhouk-cancer-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-portec-2-lancet-2010":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-esgo-estro-esp-endometrial-concin-ijgc-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tcga-endometrial-nature-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-interlace-lancet-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-outback-lancet-oncol-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-garnet-dostarlimab-oaknin-jama-oncol-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-portec-3-molecular-leon-castillo-jco-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-portec-3-lancet-oncol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-fader-trastuzumab-uterine-serous-jco-2018":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-destiny-pantumor02-jco-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mirasol-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aurelia-jco-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rosella-relacorilant-lancet-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-prima-niraparib-nejm-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-desktop-iii-nejm-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-church-pole-endometrial-jnci-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-826-nejm-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-innovatv-301-tisotumab-nejm-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-empower-cervical-1-cemiplimab-nejm-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-gog-240-bevacizumab-cervical-nejm-2014":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-gog-0261-carcinosarcoma-powell-jco-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-persson-myb-nfib-pnas-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-bonner-cetuximab-radiotherapy-nejm-2006":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-bernier-eortc-22931-nejm-2004":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cooper-rtog-9501-nejm-2004":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-689-nejm-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ang-hpv-oropharyngeal-nejm-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-1016-lancet-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-de-escalate-lancet-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-e3311-transoral-surgery-ferris-jco-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-empower-cscc-1-cemiplimab-migden-nejm-2018":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-tonon-crtc1-maml2-nat-genet-2003":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-laurie-licitra-salivary-systemic-jco-2006":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-extreme-vermorken-nejm-2008":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-141-ferris-nejm-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-tpextreme-lancet-oncol-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-91-11-forastiere-nejm-2003":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-91-11-long-term-forastiere-jco-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-va-larynx-induction-chemotherapy-nejm-1991":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-who-2022-gu-moch-eur-urol-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tcga-chromophobe-davis-cancer-cell-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aspen-armstrong-lancet-oncol-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-426-nejm-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-214-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-papmet-pal-lancet-2021":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-tcga-papillary-rcc-nejm-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-pharos-encorafenib-binimetinib-riely-jco-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-destiny-lung01-nejm-2022":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-destiny-lung02-goto-jco-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-beamion-lung-1-zongertinib-nejm-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-geometry-mono-1-capmatinib-nejm-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-vision-tepotinib-paik-nejm-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-frampton-met-exon-14-cancer-discov-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-drilon-larotrectinib-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-doebele-entrectinib-ntrk-lancet-oncol-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-trident-1-repotrectinib-nejm-2024":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-libretto-001-selpercatinib-nsclc-nejm-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-libretto-431-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-arrow-pralsetinib-gainor-lancet-oncol-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-shaw-crizotinib-ros1-nejm-2014":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-drilon-entrectinib-ros1-lancet-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-nordic-nec-sorbye-ann-oncol-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rindi-common-classification-framework-mod-pathol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-heetfeld-grade-3-net-erc-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-radiant-4-everolimus-lancet-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cabinet-cabozantinib-nejm-2024":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-enets-lung-net-consensus-caplin-ann-oncol-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-clarinet-lanreotide-nejm-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-radiant-3-everolimus-pnet-yao-nejm-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-raymond-sunitinib-pnet-nejm-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-netter-1-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-promid-rinke-jco-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-shah-foxl2-granulosa-nejm-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-wiegand-arid1a-clear-cell-nejm-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-jones-arid1a-clear-cell-science-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tcga-ovarian-nature-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-morice-mucinous-ovarian-carcinoma-nejm-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aaml0531-gemtuzumab-gamis-jco-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aaml1031-sorafenib-flt3-pollard-jco-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-bolouri-paediatric-aml-genomics-nat-med-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-acns0331-michalski-jco-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-acns0332-leary-jama-oncol-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-aall0232-larsen-jco-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-hunger-mullighan-all-children-nejm-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-inrg-cohn-jco-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-yu-anti-gd2-neuroblastoma-nejm-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-anbl0532-tandem-transplant-park-jama-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-interfant-06-pieters-jco-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-interfant-99-lancet-2007":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-anbl0531-twist-jco-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-p9641-low-risk-neuroblastoma-strother-jco-2012":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-roberts-ph-like-all-nejm-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mullighan-ikzf1-nejm-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-esphall-imatinib-biondi-lancet-oncol-2012":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-zhukova-tp53-medulloblastoma-jco-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-embark-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-radicals-rt-lancet-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-propsma-hofman-lancet-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-stampede-abiraterone-high-risk-attard-lancet-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-bolla-eortc-22863-nejm-1997":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-damico-risk-groups-jama-1998":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-protect-nejm-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-protect-15-year-nejm-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-chhip-lancet-oncol-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-rtog-9408-short-term-adt-jones-nejm-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-klotz-active-surveillance-jco-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-precision-mri-targeted-biopsy-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-profound-nejm-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-cou-aa-301-abiraterone-de-bono-nejm-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-alsympca-radium-223-nejm-2013":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-latitude-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-arasens-nejm-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-chaarted-nejm-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-beltran-nepc-divergent-evolution-nat-med-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aggarwal-t-sccpc-jco-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-aparicio-aggressive-variant-ccr-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-spartan-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-prosper-nejm-2018":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-aramis-nejm-2019":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ladanyi-aspl-tfe3-oncogene-2001":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-young-angiosarcoma-review-lancet-oncol-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-amary-idh-cartilaginous-tumours-j-pathol-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-errani-wwtr1-camta1-ehe-gcc-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ehe-consensus-stacchiotti-esmo-open-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-sirolimus-ehe-stacchiotti-cancer-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-lee-prc2-mpnst-nat-genet-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-esmo-sts-guideline-gronchi-ann-oncol-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-myxofibrosarcoma-mentzel-ajsp-1996":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-wagner-sirolimus-pecoma-jco-2010":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-strass-lancet-oncol-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-isg-sts-1001-gronchi-lancet-oncol-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-mavoric-mogamulizumab-lancet-oncol-2018":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-alcanza-brentuximab-vedotin-lancet-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-olsen-mycosis-fungoides-staging-blood-2007":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-eribulin-liposarcoma-schoffski-lancet-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-trabectedin-vs-dacarbazine-demetri-jco-2016":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-wotherspoon-h-pylori-malt-lancet-1993":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-magnolia-zanubrutinib-mzl-ccr-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-augment-lenalidomide-rituximab-leonard-jco-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hayward-melanoma-whole-genome-nature-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-curtin-melanoma-genetic-alterations-nejm-2005":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-c-post-adjuvant-cemiplimab-nejm-2025":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-dreamseq-jco-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-combi-d-long-lancet-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-columbus-lancet-oncol-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-combi-ad-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-chapman-vemurafenib-nejm-2011":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-erivance-vismodegib-sekulic-nejm-2012":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-bolt-sonidegib-migden-lancet-oncol-2015":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-dangelo-mucosal-melanoma-pooled-jco-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hodi-imatinib-kit-melanoma-jco-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-curtin-kit-melanoma-jco-2006":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-716-lancet-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-76k-nat-med-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ajcc-8-melanoma-gershenwald-ca-2017":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-mslt-ii-faries-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-238-nejm-2017":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-054-eggermont-nejm-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-igcccg-classification-jco-1997":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-igcccg-update-gillessen-jco-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-getug-13-fizazi-lancet-oncol-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-williams-bep-vs-pvb-nejm-1987":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-flot4-lancet-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-cross-nejm-2012":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-648-nejm-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-590-lancet-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-checkmate-577-nejm-2021":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-sempet-de-santis-jco-2004":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-subbiah-dabrafenib-trametinib-atc-jco-2018":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-select-lenvatinib-nejm-2015":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-decision-sorafenib-lancet-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-libretto-531-nejm-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-exam-cabozantinib-mtc-elisei-jco-2013":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-zeta-vandetanib-mtc-wells-jco-2012":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-estimabl2-leboulleux-nejm-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-himalaya-nejm-evidence-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-sharp-sorafenib-nejm-2008":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-reflect-lenvatinib-lancet-2018":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-glow-zolbetuximab-nat-med-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-klass-01-kim-jama-oncol-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-mazzaferro-milan-criteria-nejm-1996":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-bclc-2022-reig-j-hepatol-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-imbrave050-lancet-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-bilcap-lancet-oncol-2019":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-abc-02-gemcitabine-cisplatin-nejm-2010":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-topaz-1-nejm-evidence-2022":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-966-lancet-2023":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-fight-202-pemigatinib-lancet-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-811-janjigian-lancet-2023":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-destiny-gastric01-nejm-2020":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-demetri-sunitinib-gist-lancet-2006":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-grid-regorafenib-gist-lancet-2013":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-invictus-ripretinib-lancet-oncol-2020":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-intrigue-ripretinib-vs-sunitinib-jco-2022":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-llovet-tace-lancet-2002":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-emerald-1-lancet-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-leap-012-lancet-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-demetri-imatinib-gist-nejm-2002":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-hirota-kit-gist-science-1998":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-heinrich-kit-mutation-imatinib-response-jco-2003":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-062-shitara-jama-oncol-2020":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/papers-subtypes-wave.ts"},"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-tcga-gastric-nature-2014":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-keynote-859-lancet-oncol-2023":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-matterhorn-nejm-2025":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/papers-subtypes-wave.ts"},"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-navigator-avapritinib-heinrich-lancet-oncol-2020":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"paper-heinrich-pdgfra-gist-science-2003":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/papers-subtypes-wave.ts"},"aml-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"cml-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"basal-cell-carcinoma-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"melanoma-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"renal-cell-carcinoma-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"bladder-cancer-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"prostate-cancer-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"endometrial-cancer-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"breast-cancer-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"sclc-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"nsclc-signalling":{"commit":"64f809d58b","date":"2026-09-10","author":"Jude Gomila","message":"Add 21 KEGG cancer pathway maps and map them in completeness","file":"src/data/pathways-kegg.ts"},"pi3k-akt-mtor":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"ras-mapk":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"p53-cell-cycle":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/pathways.ts"},"ddr":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/pathways.ts"},"pd1-checkpoint":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/pathways.ts"},"cgas-sting":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/pathways.ts"},"er-signaling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"ar-signaling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"apoptosis-bcl2":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"vegf-angiogenesis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"hif-vhl":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"wnt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"emt":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/pathways.ts"},"bcr-signalling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"idh-2hg":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"fgfr-signalling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"menin-kmt2a":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"bcr-abl1-signalling":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/pathways.ts"},"cd47-sirpa":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/pathways.ts"},"sn-38":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/payloads.ts"},"dxd":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"exatecan":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"t030":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"mmae":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"mmaf":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"dm1":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"dm4":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"pbd-sg3199":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"calicheamicin":{"commit":"d82f5269dc","date":"2026-09-11","author":"Jude Gomila","message":"House style: remove dashes from mechanism, pathway and idea copy","file":"src/data/payloads.ts"},"duocarmycin":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"cl2a":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"ggfg":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"mc-vc-pabc":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"smcc":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"sulfo-spdb":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"hydrazone":{"commit":"504f15547c","date":"2026-09-10","author":"Jude Gomila","message":"Fix: Wikipedia link belongs on the hydrazone glossary term, not the linker registry row","file":"src/data/payloads.ts"},"val-ala":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"mc-non-cleavable":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"hydrophilic-next-gen":{"commit":"5302e06e65","date":"2026-09-06","author":"Jude Gomila","message":"Pipeline intelligence: readout calendar, conference digests, failure museum, resistance atlas, payload/linker registry, ","file":"src/data/payloads.ts"},"devimistat":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"pamrevlumab":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"eryaspase":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"algenpantucel-l":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"elraglusib":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"avenger-500":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/pdac-wave.ts"},"lapis-trial":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/pdac-wave.ts"},"trybeca-1":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/pdac-wave.ts"},"impress-trial":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"notable-trial":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pdac-wave.ts"},"actuate-1801":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/pdac-wave.ts"},"cornerstone-pharmaceuticals":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"fibrogen":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/pdac-wave.ts"},"newlink-genetics":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"actuate-therapeutics":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/pdac-wave.ts"},"ahn-myung-ju":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"park-yeon-hee":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"lee-jeeyun":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"kang-won-ki":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"lim-ho-yeong":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"park-woong-yang":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"kim-sung-bae":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"kang-yoon-koo":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"ryu-min-hee":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"kim-tae-won":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"lee-jae-lyun":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"lee-dae-ho":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"lee-sung-gyu":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"bang-yung-jue":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"im-seock-ah":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"oh-do-youn":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"kim-tae-you":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"kim-dong-wan":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"lee-se-hoon":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"cho-byoung-chul":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"rha-sun-young":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"kim-hye-ryun":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/asia-pacific.ts"},"shin-sang-joon":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"sohn-joohyuk":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"nakagama-hitoshi":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"ohe-yuichiro":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"yamamoto-noboru":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"yonemori-kan":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"kohno-takashi":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"goto-koichi":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"yoshino-takayuki":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"shitara-kohei":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"doi-toshihiko":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/people/asia-pacific.ts"},"sano-takeshi":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"takahashi-shunji":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"ohno-shinji":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"ueno-takayuki":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"fukuda-haruhiko":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"kitagawa-yuko":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"hofman-michael":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"mcarthur-grant":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"loi-sherene":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"solomon-benjamin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"sandhu-shahneen":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"dawson-sarah-jane":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"trapani-joseph":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"kaliks-rafael":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"hoff-paulo":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"katz-artur":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"barrios-carlos":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"ma-jun":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"xu-rui-hua":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"zhang-li-sysucc":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"fang-wenfeng":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"zeng-mu-sheng":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"wang-feng-sysucc":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"shao-zhi-ming":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/people/asia-pacific.ts"},"jiang-yi-zhou":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"hu-xichun":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"song-shaoli":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"ye-dingwei":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"li-jin-fuscc":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"wei-yuquan":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"lu-you":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"li-weimin":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/asia-pacific.ts"},"he-jie":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"shi-yuankai":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"xu-binghe":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"wang-jie-cams":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/asia-pacific.ts"},"ma-fei":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"huang-jing-cams":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"zhou-caicun":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"shen-lin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"qi-changsong":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/asia-pacific.ts"},"wu-yi-long":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/asia-pacific.ts"},"lu-shun":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"gupta-sudeep":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"badwe-rajendra":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"patil-vijay":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"prabhash-kumar":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"noronha-vanita":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"chaturvedi-pankaj":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/asia-pacific.ts"},"shastri-surendra":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"dancey-janet":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"tu-dongsheng":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"parulekar-wendy":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"weiderpass-elisabete":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/asia-pacific.ts"},"bray-freddie":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"basu-partha":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/asia-pacific.ts"},"cree-ian":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"ilbawi-andre":{"commit":"d5929847a7","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in asia-pacific (90 records)","file":"src/data/people/asia-pacific.ts"},"huang-xiaojun":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"chen-saijuan":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"chen-zhu":{"commit":"cae8630421","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: fix lint, duplicate keys and dangling refs","file":"src/data/people/china.ts"},"qin-shukui":{"commit":"cae8630421","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: fix lint, duplicate keys and dangling refs","file":"src/data/people/china.ts"},"fan-jia":{"commit":"f3dd1e2297","date":"2026-09-11","author":"Jude Gomila","message":"Merge reversed-name people twins","file":"src/data/people/china.ts"},"xu-jianming":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/china.ts"},"cheng-ying":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"guo-jun":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/china.ts"},"li-zonghai":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/china.ts"},"oyler-john":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"xia-michelle":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/china.ts"},"yu-michael":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"sun-piaoyang":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/china.ts"},"du-samantha":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/china.ts"},"li-ge":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"su-weiguo":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/china.ts"},"zhang-fangliang":{"commit":"62feb35352","date":"2026-09-10","author":"Jude Gomila","message":"China deep dive: NMPA-approved domestic drugs, companies, institutions, people, trials, deals and /countries/china/ page","file":"src/data/people/china.ts"},"fabrice-barlesi":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"fabrice-andre":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/europe.ts"},"jean-charles-soria":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"benjamin-besse":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"aurelien-marabelle":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"karim-fizazi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"laurence-zitvogel":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/europe.ts"},"nicholas-turner":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"johann-de-bono":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"andrew-tutt":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"nicholas-james":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"david-cunningham":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"james-larkin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"uwe-oelfke":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"kristian-helin":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"paul-workman":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/europe.ts"},"chris-lord":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"kevin-harrington":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"mel-greaves":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"charles-swanton":{"commit":"c53b85e8e8","date":"2026-09-18","author":"Jude Gomila","message":"TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)","file":"src/data/people/europe.ts"},"paul-nurse":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"caetano-reis-e-sousa":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"erik-sahai":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"michelle-mitchell":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"iain-foulkes":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"ruth-plummer":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/europe.ts"},"caroline-dive":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"fiona-blackhall":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"andrew-wardley":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"ananya-choudhury":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"uwe-haberkorn":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"frederik-giesel":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"clemens-kratochwil":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"stefan-froehling":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"juergen-debus":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"andreas-von-deimling":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"michael-baumann":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"stefan-pfister":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/europe.ts"},"hermann-brenner":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"andreas-trumpp":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"steven-le-gouill":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"francois-clement-bidard":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"sergio-roman-roman":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"olivier-delattre":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"eliane-piaggio":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"giuseppe-curigliano":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"paolo-veronesi":{"commit":"bb498fc625","date":"2026-09-14","author":"Jude Gomila","message":"Copy: remove en dashes from institutional names in nine people summaries (IEO Milan, Charite Berlin, Tuebingen role)","file":"src/data/people/europe.ts"},"roberto-orecchia":{"commit":"bb498fc625","date":"2026-09-14","author":"Jude Gomila","message":"Copy: remove en dashes from institutional names in nine people summaries (IEO Milan, Charite Berlin, Tuebingen role)","file":"src/data/people/europe.ts"},"pier-giuseppe-pelicci":{"commit":"bb498fc625","date":"2026-09-14","author":"Jude Gomila","message":"Copy: remove en dashes from institutional names in nine people summaries (IEO Milan, Charite Berlin, Tuebingen role)","file":"src/data/people/europe.ts"},"alessandro-gronchi":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"filippo-de-braud":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"marco-guzzo":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"josep-tabernero":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"javier-cortes":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"elena-garralda":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"enriqueta-felip":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"elena-elez":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"joaquin-arribas":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"ulrich-keilholz":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"lars-bullinger":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"angelika-eggert":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"christof-von-kalle":{"commit":"bb498fc625","date":"2026-09-14","author":"Jude Gomila","message":"Copy: remove en dashes from institutional names in nine people summaries (IEO Milan, Charite Berlin, Tuebingen role)","file":"src/data/people/europe.ts"},"markus-graefen":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"carsten-bokemeyer":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"klaus-pantel":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"volker-heinemann":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"peter-bartenstein":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"michael-von-bergwelt":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/europe.ts"},"claus-belka":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/europe.ts"},"michael-hallek":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"juergen-wolf":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"reinhard-buettner":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"roman-thomas":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"giovanni-scambia":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"anna-fagotti":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"giampaolo-tortora":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"vincenzo-valentini":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"jonas-bergh":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"per-hall":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"rolf-kiessling":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"hans-gustaf-ljunggren":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"christian-blank":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"myriam-chalabi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"john-haanen":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"emile-voest":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"ton-schumacher":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"rene-bernards":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/europe.ts"},"sabine-linn":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"jaime-feliu":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"enrique-espinosa":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"beatriz-castelo":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"miguel-martin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"sara-lopez-tarruella":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"pilar-garrido":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/europe.ts"},"denis-lacombe":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"alexander-eggermont":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"martine-piccart":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"michael-weller":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"roger-stupp":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"nathan-cherny":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"andres-cervantes":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"solange-peters":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"david-cameron":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"evandro-de-azambuja":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"sibylle-loibl":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"gunter-von-minckwitz":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"carsten-denkert":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"jean-yves-blay":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/europe.ts"},"thomas-bachelot":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"christophe-le-tourneau":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/europe.ts"},"anthony-goncalves":{"commit":"4f630751af","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in europe (111 records)","file":"src/data/people/europe.ts"},"daniel-ludwig":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"sean-parker":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"michael-bloomberg":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"sidney-kimmel":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"david-koch":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"eli-broad":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"jon-huntsman":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"phil-knight":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"gert-boyle":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"larry-ellison":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"herbert-irving":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"mortimer-zuckerman":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"helen-diller":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"leonard-abramson":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"richard-rogel":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"sanford-weill":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"john-jacob-astor-iii":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"john-d-rockefeller-jr":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"alfred-sloan":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"charles-kettering":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"monroe-anderson":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"robert-woodruff":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"lucille-markey":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"martha-ingram":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"ann-lurie":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"goh-cheng-liang":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"michael-milken":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"leon-black":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"debra-black":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"albert-lasker":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"walter-winchell":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes-donors.ts"},"sherry-lansing":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes-donors.ts"},"marc-lustgarten":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"priscilla-chan":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"bill-gates":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"li-ka-shing":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"dorabji-tata":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"ratan-tata":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"ted-williams":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes-donors.ts"},"billy-starr":{"commit":"310f7da910","date":"2026-09-10","author":"Jude Gomila","message":"Heroes: donors and philanthropists group with 41 donor records, 15 recipient foundations, gifts strip and Donors chip","file":"src/data/people/heroes-donors.ts"},"chris-hoy":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes-donors.ts"},"emily-whitehead":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"henrietta-lacks":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"einar-gustafson":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"terry-fox":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/heroes.ts"},"stephen-sutton":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/heroes.ts"},"angelina-jolie":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"katie-couric":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"chadwick-boseman":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"jade-goody":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"lance-armstrong":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"steve-jobs":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"randy-pausch":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"deborah-james":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/heroes.ts"},"kris-hallenga":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"ashya-king":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"kate-granger":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"betty-ford":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"audre-lorde":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"rose-kushner":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"gilda-radner":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"jim-valvano":{"commit":"ad61ca44f9","date":"2026-09-11","author":"Jude Gomila","message":"Heroes: patients first, pioneers next, donors last, celebrities moved out, Sid Sijbrandij added; Ask OnCo hidden from na","file":"src/data/people/heroes.ts"},"alex-scott":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/heroes.ts"},"barbara-bradfield":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"bud-romine":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"sharon-belvin":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"robert-sandler":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"mary-lasker":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"nancy-brinker":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"evelyn-lauder":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"fran-visco":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"susan-love":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"cicely-saunders":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"elisabeth-kubler-ross":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"sidney-farber":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"gertrude-elion":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"jane-cooke-wright":{"commit":"4b8ac857cd","date":"2026-09-09","author":"Jude Gomila","message":"Heroes and heroines","file":"src/data/people/heroes.ts"},"emil-freireich":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"emil-frei":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"donald-pinkel":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"bernard-fisher":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"jimmie-holland":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/heroes.ts"},"judah-folkman":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/heroes.ts"},"brian-druker":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/heroes.ts"},"tasuku-honjo":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/heroes.ts"},"harald-zur-hausen":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/heroes.ts"},"ian-frazer":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/heroes.ts"},"jian-zhou":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"mary-claire-king":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"janet-rowley":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/heroes.ts"},"sid-sijbrandij":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/people/heroes.ts"},"pramesh-c-s":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/people/india.ts"},"dcruz-anil":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/people/india.ts"},"raina-vinod":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/india.ts"},"shanta-v":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/india.ts"},"sankaranarayanan-rengaswamy":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/india.ts"},"mazumdar-shaw-kiran":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/india.ts"},"purwar-rahul":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/people/india.ts"},"jain-hasmukh":{"commit":"566bda0a94","date":"2026-09-10","author":"Jude Gomila","message":"India deep dive: IN region (CDSCO), 15 institutions, 17 companies, 4 products, 13 trials, 9 key papers, 13 people, /coun","file":"src/data/people/india.ts"},"narula-gaurav":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/india.ts"},"kapoor-akhil":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/india.ts"},"mathur-prashant":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/india.ts"},"shetty-devi":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/india.ts"},"ajaikumar-b-s":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/india.ts"},"richard-finn":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"massimo-cristofanilli":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"gabriel-hortobagyi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"stephen-johnston":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"komal-jhaveri":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"joseph-sparano":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"kevin-kalinsky":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"prudence-francis":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"nadia-harbeck":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"mitch-dowsett":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jack-cuzick":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"charles-perou":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"sandra-swain":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ian-krop":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"shanu-modi":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"cristina-saura":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"helena-earl":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"aleix-prat":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"eleftherios-mamounas":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"peter-schmid":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"aditya-bardia":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"lajos-pusztai":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"elizabeth-mittendorf":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"monica-morrow":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"armando-giuliano":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"roy-herbst":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"martin-reck":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"scott-antonia":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"charles-rudin":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ross-camidge":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ferdinandos-skoulidis":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"tina-cascone":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"qing-zhou":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jonathan-spicer":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"harry-de-koning":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"denise-aberle":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"robert-timmerman":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"joe-chang":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"david-palma":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jeffrey-bradley":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"corinne-faivre-finn":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"thierry-andre":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"scott-kopetz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"eric-van-cutsem":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"heinz-josef-lenz":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"jeanne-tie":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"julio-garcia-aguilar":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"angelita-habr-gama":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/key-opinion-leaders.ts"},"michael-bretthauer":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"aimery-de-gramont":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"thierry-conroy":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"daniel-von-hoff":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"vinod-balachandran":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"talia-golan":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"hedy-kindler":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"zev-wainberg":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"marc-besselink":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jaffer-ajani":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"florian-lordick":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jan-van-lanschot":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ronan-kelly":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ken-kato":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"mitsuru-sasako":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/key-opinion-leaders.ts"},"josep-llovet":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ann-lii-cheng":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"masatoshi-kudo":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ghassan-abou-alfa":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"juan-valle":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"lipika-goyal":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"christopher-sweeney":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"oliver-sartor":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"matthew-smith":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"kim-chi":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"maha-hussain":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"andrew-armstrong":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"freddie-hamdy":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"mark-emberton":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"hashim-ahmed":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"anthony-damico":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"louise-emmett":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"declan-murphy":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"daniel-spratt":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"silke-gillessen":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"thomas-powles":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jonathan-rosenberg":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"dean-bajorin":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"joaquim-bellmunt":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"arjun-balar":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ashish-kamat":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"andrea-necchi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"robert-motzer":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"brian-rini":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"laurence-albiges":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"sumanta-pal":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"arnaud-mejean":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"kathleen-moore":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"isabelle-ray-coquard":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"jonathan-ledermann":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"robert-coleman":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"andreas-du-bois":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"willemien-van-driel":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ignace-vergote":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"usha-menon":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"mansoor-raza-mirza":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ramez-eskander":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"carien-creutzberg":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"douglas-levine":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"domenica-lorusso":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"nicoletta-colombo":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"bradley-monk":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"pedro-ramirez":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"mary-mccormack":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"linda-mileshkin":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"georgina-long":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jedd-wolchok":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"caroline-robert":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"hussein-tawbi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"paolo-ascierto":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"michael-postow":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jeffrey-weber":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"sapna-patel":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"jason-luke":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"mark-faries":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"reinhard-dummer":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"paul-nathan":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"richard-carvajal":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jennifer-wargo":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ingo-mellinghoff":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"patrick-wen":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"martin-van-den-bent":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"monika-hegi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"mitchel-berger":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"timothy-cloughesy":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"michelle-monje":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"michael-taylor":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"barbara-burtness":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jan-vermorken":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"maura-gillison":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"hisham-mehanna":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ezra-cohen":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ravindra-uppaluri":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jean-bourhis":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"george-demetri":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"william-tap":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"sandra-dangelo":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"winette-van-der-graaf":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"silvia-stacchiotti":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"stefan-bielack":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"lori-wirth":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"martin-schlumberger":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"marcia-brose":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"maria-cabanillas":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"jonathan-strosberg":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"simron-singh":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"martyn-caplin":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"james-yao":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"paul-baas":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"dean-fennell":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"anna-nowak":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ruth-ladenstein":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"john-maris":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"yael-mosse":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"nai-kong-cheung":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"stephen-hunger":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ching-hon-pui":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"sumit-gupta":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jeffrey-dome":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"amar-gajjar":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"courtney-dinardo":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"richard-stone":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"alexander-perl":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"hartmut-dohner":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"eytan-stein":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ghayas-issa":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"andrew-wei":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"uwe-platzbecker":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"pierre-fenaux":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"claire-harrison":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"timothy-hughes":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"elias-jabbour":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"nicola-gokbuget":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"gilles-salles":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"herve-tilly":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"laurie-sehn":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"sattva-neelapu":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"stephen-schuster":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jason-westin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"michael-dickinson":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"catherine-thieblemont":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"michael-wang":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"martin-dreyling":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"joseph-connors":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"peter-borchmann":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"andreas-engert":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"kara-kelly":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"wyndham-wilson":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"steven-treon":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"steven-horwitz":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"andres-ferreri":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"john-byrd":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jennifer-woyach":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jennifer-brown":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"kirsten-fischer":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"barbara-eichhorst":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"peter-hillmen":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"john-seymour":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"william-wierda":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"constantine-tam":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"philippe-moreau":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"thierry-facon":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"pieter-sonneveld":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"maria-victoria-mateos":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"nikhil-munshi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"jesus-berdeja":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"sagar-lonial":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"noopur-raje":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ajai-chari":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ola-landgren":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"sigurdur-kristinsson":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"graham-jackson":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"meletios-dimopoulos":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"michel-sadelain":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"stephan-grupp":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"marcela-maus":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"waseem-qasim":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"katy-rezvani":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"inge-marie-svane":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"robbie-majzner":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ken-herrmann":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"wolfgang-weber":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"jason-lewis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"lieping-chen":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"gordon-freeman":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"thomas-gajewski":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"shimon-sakaguchi":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ugur-sahin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"catherine-wu":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"howard-kaufman":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"ignacio-melero":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"michael-berger":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"serena-nik-zainal":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ludmil-alexandrov":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"carlos-caldas":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"christina-curtis":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"nickolas-papadopoulos":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"alberto-bardelli":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"nitzan-rosenfeld":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"viktor-adalsteinsson":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"thomas-helleday":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"alan-dandrea":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"razelle-kurzrock":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people/key-opinion-leaders.ts"},"charlotte-coles":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"murray-brunt":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"timothy-whelan":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"marie-catherine-vozenin":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"bas-raaymakers":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"anthony-zietman":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"quynh-thu-le":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/people/key-opinion-leaders.ts"},"shankar-siva":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"cornelis-van-de-velde":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"yuman-fong":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"valerie-rusch":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"rebecca-fitzgerald":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"peter-sasieni":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"nubia-munoz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"mark-schiffman":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"kristina-lang":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"constance-lehman":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/key-opinion-leaders.ts"},"eric-klein":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"deb-schrag":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/key-opinion-leaders.ts"},"faisal-mahmood":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"thomas-fuchs":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"jakob-nikolas-kather":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"regina-barzilay":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"jennifer-temel":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"ethan-basch":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"supriya-mohile":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"kerry-courneya":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"christopher-booth":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"ian-tannock":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"joseph-unger":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"richard-gray":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/key-opinion-leaders.ts"},"richard-peto":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"mahesh-parmar":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/key-opinion-leaders.ts"},"judith-bliss":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"rolf-stahel":{"commit":"8c079df03b","date":"2026-09-10","author":"Jude Gomila","message":"People: key opinion leaders per cancer and modality","file":"src/data/people/key-opinion-leaders.ts"},"iwona-lugowska":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"claudio-lombardo":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/leaders-wave2.ts"},"matthew-hurles":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people/leaders-wave2.ts"},"michael-stratton":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"david-probert":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"sandra-demaria":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"ziyu-li":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"yuqin-song":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"barbara-jereczek-fossa":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"matthias-guckenberger":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"dirk-schadendorf":{"commit":"a586e683cf","date":"2026-09-10","author":"Jude Gomila","message":"India and China deep dives, site language in eight languages, homepage schematics, insurance rankings and cost levers, d","file":"src/data/people/leaders-wave2.ts"},"martin-schuler":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"emer-cooke":{"commit":"5460dec4b9","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for five agency and institute leaders via Europe PMC author and affiliation match (Cooke, O'Shea, Mogelvang","file":"src/data/people/leaders-wave2.ts"},"matthew-powell":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"karen-lu":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"josep-maria-campistol":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"susana-puig":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"thomas-herzog":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"robert-mannel":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"ian-davis":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"samantha-oakes":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"monika-janicke":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"virginia-pappas":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"yitshak-kreiss":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"daniel-aebersold":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"adrian-ochsenbein":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"karen-kelly":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"nicolaas-schaap":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"marc-raaijmakers":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"paola-anna-erba":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"tedros-adhanom-ghebreyesus":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"yoram-weiss":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"konstanze-doehner":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"brian-huntly":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"anna-sapino":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"luis-paz-ares":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"joaquin-martinez-lopez":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"alon-chen":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"wouter-de-laat":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"jurgen-kuball":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"chong-jen-yu":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"lawrence-tallon":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"linda-tantawi":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"jalid-sehouli":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"ane-gerda-eriksson":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"jason-carroll":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"james-brenton":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"fernando-pelaez":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"madeline-bell":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"susan-furth":{"commit":"610c816633","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for eleven research-trained leaders via Europe PMC author and affiliation match (Kile, Birney, Martino, Ina","file":"src/data/people/leaders-wave2.ts"},"sunil-lakhani":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"donna-mckay":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"dorraya-el-ashry":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"kirsten-schmieder":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"sascha-dietrich":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"kenneth-tanabe":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"tari-king":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"rasmus-mogelvang":{"commit":"5460dec4b9","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for five agency and institute leaders via Europe PMC author and affiliation match (Cooke, O'Shea, Mogelvang","file":"src/data/people/leaders-wave2.ts"},"kjetil-tasken":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"norman-wolmark":{"commit":"a586e683cf","date":"2026-09-10","author":"Jude Gomila","message":"India and China deep dives, site language in eight languages, homepage schematics, insurance rankings and cost levers, d","file":"src/data/people/leaders-wave2.ts"},"priya-rastogi":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"lim-soon-thye":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"rebecca-dent":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"alexandre-chan":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"franck-morschhauser":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"simona-sancini":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"armando-santoro":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"nu-zhang":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"wen-zhao-zhong":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"samra-turajlic":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"tim-somervaille":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"geoff-parnell":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"christos-karapetis":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"rakesh-padiyath":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"astrid-beiglbock":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"benjamin-kasenda":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"martin-siess":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"julian-adams":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"chiara-gibertoni":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"gianvito-martino":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"beata-jagielska":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"michal-mikula":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"andrzej-kawecki":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"martin-jan-schalij":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"rafael-mariano-grossi":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"marco-vignetti":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"antonio-cuneo":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"shahrokh-f-shariat":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/people/leaders-wave2.ts"},"nicole-concin":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"shane-degaris":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"ken-smith":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"marianne-van-rooijen":{"commit":"ae5f383261","date":"2026-09-13","author":"Jude Gomila","message":"People: cancers and technologies named in eight leaders' own text wired as relations; SG301 wording says cleared to ente","file":"src/data/people/leaders-wave2.ts"},"kunle-odunsi":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"ralph-weichselbaum":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"purnima-sundaresan":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"hien-le":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"tammy-kang":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"peter-johnson":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"mafalda-oliveira":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"eva-ciruelos":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"ofer-merin":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"giovanni-blandino":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"steven-clifford":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"martin-bornhauser":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"hanno-glimm":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"jurgen-weitz":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"han-kwang-yang":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"marek-svoboda":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"tomas-kazda":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"igor-kiss":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"akifumi-takaori":{"commit":"a8120dac82","date":"2026-09-16","author":"Jude Gomila","message":"data: OpenAlex-matched papers for three institution leaders (Kyoto, Bari, Riga), disambiguated by institution id","file":"src/data/people/leaders-wave2.ts"},"hidetoshi-hayashi":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"alexis-cortot":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"david-planchard":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"sonja-optendrenk":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"thomas-kaiser":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"geerard-beets":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"isabel-rubio":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"ewan-birney":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"julio-saez-rodriguez":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"charlie-gourley":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"antonio-gonzalez-martin":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"bruno-sangro":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"jesus-san-miguel":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"chris-decker":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave2.ts"},"maximilian-niyazi":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"lars-zender":{"commit":"bb498fc625","date":"2026-09-14","author":"Jude Gomila","message":"Copy: remove en dashes from institutional names in nine people summaries (IEO Milan, Charite Berlin, Tuebingen role)","file":"src/data/people/leaders-wave2.ts"},"sara-brucker":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"sharon-armstrong":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"owen-sansom":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"nikhil-tandon":{"commit":"610c816633","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for eleven research-trained leaders via Europe PMC author and affiliation match (Kile, Birney, Martino, Ina","file":"src/data/people/leaders-wave2.ts"},"rebecca-li":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"jackson-orem":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"diane-simeone":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"rana-mckay":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave2.ts"},"j-silvio-gutkind":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"cathryn-cox":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"louis-chesler":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"james-r-downing":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"uta-dirksen":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"gilles-vassal":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave2.ts"},"ronald-cohn":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"stephen-scherer":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"meredith-irwin":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"boubou-hallberg":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"vivek-lal":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"jin-seok-ahn":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"jean-pierre-delord":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"beth-devine":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"rob-abbott":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"alfredo-addeo":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"jaume-raventos-i-monjo":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave2.ts"},"karl-munslow-ong":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave2.ts"},"sophia-varadkar":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"elisabetta-zanon":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"georges-pascal-haber":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave2.ts"},"florian-roser":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"leonor-beleza":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"teresa-cotta-dias":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"patrick-mehlen":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"thomas-balle-kristensen":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"jens-overgaard":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/people/leaders-wave2.ts"},"harlan-krumholz":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"joseph-ross":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"nobuyuki-yamamoto":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"shabir-madhi":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"karim-vermaelen":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"thomas-kindler":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"christian-brandts":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"florian-greten":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/leaders-wave2.ts"},"hubert-serve":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"philip-chiu":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"tony-mok":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"anthony-chan":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"yasuhiro-fujiwara":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"zlata-stiblar-kisic":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave2.ts"},"janja-ocvirk":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave2.ts"},"shivaani-kummar":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"chee-cheng-ean":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave2.ts"},"goh-boon-cher":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"jimmy-so":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"matthew-vander-heiden":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"robert-langer":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"maike-sander":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"nikolaus-rajewsky":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"wasiu-lanre-adeyemo":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"carolina-samuelsson":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave2.ts"},"asem-mansour":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"majid-alfayyadh":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"richard-lesiyampe":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave2.ts"},"koichi-fukunaga":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"rachel-ramoni":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave2.ts"},"theodore-levin":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"le-van-quang":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"patrizia-simionato":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"antonio-rosato":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"roberto-de-almeida-gil":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"suzette-delaloge":{"commit":"8ce6255b45","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for pioneer heroes and remaining leaders; drop one mismatched record","file":"src/data/people/leaders-wave2.ts"},"nicolas-scotte":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave2.ts"},"bradley-cairns":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"erin-oshea":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"brasil-silva-neto":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"lionel-collet":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave2.ts"},"jean-lessi":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"mark-suzman":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"trevor-mundel":{"commit":"5460dec4b9","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for five agency and institute leaders via Europe PMC author and affiliation match (Cooke, O'Shea, Mogelvang","file":"src/data/people/leaders-wave2.ts"},"benjamin-kile":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"susan-clark":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"jay-schnitzer":{"commit":"3892a65cf6","date":"2026-09-17","author":"Jude Gomila","message":"One papers block per person after the two paper waves met","file":"src/data/people/leaders-wave2.ts"},"suresh-ramalingam":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"richard-schulick":{"commit":"dd9051b7f7","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 2, India and China people","file":"src/data/people/leaders-wave2.ts"},"michael-gnant":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave2.ts"},"christian-singer":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave2.ts"},"john-arne-rottingen":{"commit":"e4cd504435","date":"2026-09-10","author":"Jude Gomila","message":"People: leaders and senior clinicians for institutions that had none","file":"src/data/people/leaders-wave2.ts"},"shalene-curtis-micallef":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"diep-bao-tuan":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"yasuyuki-nasuhara":{"commit":"610c816633","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for eleven research-trained leaders via Europe PMC author and affiliation match (Kile, Birney, Martino, Ina","file":"src/data/people/leaders-wave3.ts"},"henrique-prata":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"johanna-mattson":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"nicolas-penel":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"renaud-witmeur":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"norbert-vey":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"yasmine-belkaid":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"senda-tounsi":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"david-baker":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave3.ts"},"bernardo-rubinstein":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"chen-wei-ming":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"sultan-mohamed-alkaram":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"eli-sprecher":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"ryan-schoenfeld":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"rebecca-auer":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"brandi-williams-broome":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"anthony-lawler":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"takashi-kamei":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"cary-adams":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"jonathan-brotherton":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"mohd-zukiflee-abu-bakar":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave3.ts"},"paul-herijgers":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"carl-james":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave3.ts"},"laura-brady":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"laurene-powell-jobs":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"johanna-joyce":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/leaders-wave3.ts"},"stanislaw-klek":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"r-angelo-de-claro":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave3.ts"},"dominique-bazy":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"andrea-sironi":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"cristian-ayala-munita":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"christiane-pott":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"tatsuya-ohno":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"amanda-pritchard":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"kadir-mutlu-hayran":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"robyn-ward":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"gerardo-legaspi":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"erik-wexler":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave3.ts"},"brandon-wainwright":{"commit":"ae5f383261","date":"2026-09-13","author":"Jude Gomila","message":"People: cancers and technologies named in eight leaders' own text wired as relations; SG301 wording says cleared to ente","file":"src/data/people/leaders-wave3.ts"},"hitoshi-ishikawa":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"chak-sing-lau":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"atiporn-ingsathit":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave3.ts"},"michal-mekel":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"john-stagg":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"robert-peel":{"commit":"88a5177b53","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, first 54 institution leaders","file":"src/data/people/leaders-wave3.ts"},"yoon-seung-kew":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"katsuhiko-uesaka":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"yongyut-sirivatanauksorn":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"monika-krzyzanowska":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"vincenza-trivigno":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"brendan-brown":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"philippe-bergerot":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"gemma-peters":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"matthew-reed":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"andrew-little":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"mohamed-abdel-moaty-samra":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"jonathan-benger":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"magdolna-dank":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"timothy-robinson":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"senthil-muthuswamy":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"sirpa-leppa":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"richard-barakat":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"diwani-msemo":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"marco-herold":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"nariaki-matsuura":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave3.ts"},"mark-middleton":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"alicia-jackson":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"leandro-pinheiro-safatle":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"yasumasa-niwa":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"robert-negrin":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"silvana-konermann":{"commit":"610c816633","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for eleven research-trained leaders via Europe PMC author and affiliation match (Kile, Birney, Martino, Ina","file":"src/data/people/leaders-wave3.ts"},"sebastien-armanet":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"paris-ann-ingledew":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"nadine-karema":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"andrea-seale":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"brenda-hubley":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"jacinta-reddan":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"seyed-rouhollah-miri":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"oscar-arrieta-rodriguez":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"francisco-berrospi-espinoza":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"carla-goncalo":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"julio-oliveira":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"derrick-haslem":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"franco-cavalli":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"sandra-nolte":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"cristina-marchesi":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"nikki-gallagher":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"maurizio-di-mauro":{"commit":"412af729a5","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batches aa, ae, af (97 leaders)","file":"src/data/people/leaders-wave3.ts"},"chris-hillis":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"nei-min-chu":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"yakubu-seidu-adam":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"carla-van-gils":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"yasuharu-nakashima":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"robert-figlin":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"emmanuel-barranger":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/leaders-wave3.ts"},"marie-eve-desrosiers":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"ashley-ball-gamble":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"michael-boyer":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"princess-chulabhorn":{"commit":"96e2189493","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batch ab (110 leaders)","file":"src/data/people/leaders-wave3.ts"},"annette-walker":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave3.ts"},"victor-hugo-borja-aburto":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave3.ts"},"elisabeth-schorb":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave3.ts"},"ralf-c-bargou":{"commit":"f65beea60a","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for leaders wave 3 people","file":"src/data/people/leaders-wave3.ts"},"yung-s-lie":{"commit":"96e2189493","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 3, batch ab (110 leaders)","file":"src/data/people/leaders-wave3.ts"},"rita-schmutzler":{"commit":"0a47b2513c","date":"2026-09-10","author":"Jude Gomila","message":"people: add verified publications for twelve society leaders via employer affiliations","file":"src/data/people/leaders-wave3.ts"},"eniarti":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave3.ts"},"wayne-roberts":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"tariq-enver":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"axel-behrens":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"kent-stobart":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"ramon-salazar-soler":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"rajeev-singh-raghuvanshi":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"renaud-de-crevoisier":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"roman-rouzier":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"pierre-vera":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"frederique-penault-llorca":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"giuseppe-tonutti":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"richard-van-etten":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"sandile-mfenyana":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"biju-george":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"martin-beaumont":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"pavan-reddy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"john-kennedy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"pia-vihinen":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"jesse-otegbayo":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"ate-van-der-zee":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"dan-theodorescu":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"thomas-george":{"commit":"ae5f383261","date":"2026-09-13","author":"Jude Gomila","message":"People: cancers and technologies named in eight leaders' own text wired as relations; SG301 wording says cleared to ente","file":"src/data/people/leaders-wave4.ts"},"michael-kerin":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"naoto-ueno":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"christian-capitini":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"thomas-loughran":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"robert-winn":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"christian-sauvr":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"tammy-quigley":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"kirsten-major":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"valdas-peceliunas":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"ls-shashidhara":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"sunil-kumar-barnwal":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"mostafa-aziz-sumon":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"huang-guo":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave4.ts"},"anthony-may":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"nicole-boutilier":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"valery-lemmens":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave4.ts"},"jon-irish":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"zhang-shuyang":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"lyn-simpson":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"bertine-lahuis":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"dharmendra-singh-gangwar":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"vadims-beluns":{"commit":"b416e55d7a","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, first 46 institution leaders and two re-links","file":"src/data/people/leaders-wave4.ts"},"steven-k-libutti":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"christos-fasianos":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"nicole-scobie":{"commit":"d239296e72","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 6 weakly linked companies linked to the drugs and cancers in their trial text, 7 people linked to institution","file":"src/data/people/leaders-wave4.ts"},"farhat-abbas":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"rashid-khalani":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"ali-taher":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"hans-van-goudoever":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"timur-atsuren":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"luigi-cajazzo":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"ruben-mesa":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"dale-bramley":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"davide-fornaciari":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"inge-buyse":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"boris-pasche":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"patrick-morris":{"commit":"5b2627e13a","date":"2026-09-18","author":"Jude Gomila","message":"Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass","file":"src/data/people/leaders-wave4.ts"},"denise-soares-dos-santos":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"maria-kane":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"rohit-bhargava":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"monica-calamai":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"claudio-cracco":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"paa-kwesi-baidoo":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"satu-tiainen":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"richard-mitchell":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"ida-danmark":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"helen-mertens":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"jeffrey-miller":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"abhay-soi":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"lei-zheng":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave4.ts"},"lucie-opatrny":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"philip-kirwa":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"ulrich-steidl":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"martin-armstrong":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"raymond-dubois":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"erez-barenboim":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"rajesh-gokhale":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"xiao-haipeng":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"robert-uzzo":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"joann-sweasy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"antonio-llombart-bosch":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"vicente-borrero":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"zhang-jiangong":{"commit":"e801c9a400","date":"2026-09-10","author":"Jude Gomila","message":"people: expand short summaries in china and leaders waves 2-4 (15 records)","file":"src/data/people/leaders-wave4.ts"},"vasanta-nanduri":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"mark-burkard":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"jean-francois-fortin-verreault":{"commit":"da9340f2b1","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batches 0, 2 and 4 (89 leaders, five re-links)","file":"src/data/people/leaders-wave4.ts"},"flavio-tomasich":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"reuben-shaw":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"paul-boutros":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"deb-bulych":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave4.ts"},"yu-jinming":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"faisal-sultan":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"lin-tongyu":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"shlomi-codish":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"david-fennelly":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave4.ts"},"kathleen-ruddy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"lehlohonolo-majake":{"commit":"e160e383ef","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 6 (108 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"priit-perens":{"commit":"e160e383ef","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 6 (108 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"annika-auranen":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"jim-woodgett":{"commit":"d239296e72","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 6 weakly linked companies linked to the drugs and cancers in their trial text, 7 people linked to institution","file":"src/data/people/leaders-wave4.ts"},"joan-spencer":{"commit":"ae5f383261","date":"2026-09-13","author":"Jude Gomila","message":"People: cancers and technologies named in eight leaders' own text wired as relations; SG301 wording says cleared to ente","file":"src/data/people/leaders-wave4.ts"},"karolina-palucka":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"ankita-mishra-bundela":{"commit":"e160e383ef","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 6 (108 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"dario-altieri":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"jihui-hao":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"hu-junbo":{"commit":"8eef0ae44c","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 3 (122 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"julian-redhead":{"commit":"8eef0ae44c","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 3 (122 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"govindan-rangarajan":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"d-wade-clapp":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"pamela-kearns":{"commit":"d239296e72","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 6 weakly linked companies linked to the drugs and cancers in their trial text, 7 people linked to institution","file":"src/data/people/leaders-wave4.ts"},"mario-campone":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"marc-ychou":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"pierre-laurent-puig":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"brahim-lakhal":{"commit":"8eef0ae44c","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 3 (122 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"maneesha-inamdar":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"tao-cheng":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"roxana-del-aguila":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"arthur-violante-sapia":{"commit":"8eef0ae44c","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 3 (122 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"susana-blanco":{"commit":"8eef0ae44c","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, batch 3 (122 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"mauricio-cuello":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"ander-urruticoechea":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave4.ts"},"mohammed-bin-khalifa-al-suwaidi":{"commit":"6e749a5ac0","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry pass B and Groote Schuur (133 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"rachel-dunscombe":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"zoe-robledo":{"commit":"6e749a5ac0","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry pass B and Groote Schuur (133 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"esteban-langlois":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"jose-luis-poveda-andres":{"commit":"6e749a5ac0","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry pass B and Groote Schuur (133 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"javier-arcos":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/people/leaders-wave4.ts"},"massimo-de-fino":{"commit":"6e749a5ac0","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry pass B and Groote Schuur (133 leaders so far)","file":"src/data/people/leaders-wave4.ts"},"alessandro-delle-donne":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"t-naveen":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"shaheem-de-vries":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"xiang-hua":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"shalini-singh":{"commit":"96aff41624","date":"2026-09-14","author":"Jude Gomila","message":"People: affiliation links for 17 weakly linked leaders and scientists, taken from the institutions and colleagues named ","file":"src/data/people/leaders-wave4.ts"},"lp-mtshali":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"joseph-gligorov":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"luis-eduardo-martin-rodriguez":{"commit":"dd2b78204b","date":"2026-09-14","author":"Jude Gomila","message":"People: 30 weakly linked leaders and scientists linked to the glossary terms their own summaries name","file":"src/data/people/leaders-wave4.ts"},"berta-cerda-alvarez":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"maria-margarida-torres-de-ornelas":{"commit":"3e0256c44b","date":"2026-09-18","author":"Jude Gomila","message":"Merge five duplicate person records and add a duplicate-person finder","file":"src/data/people/leaders-wave4.ts"},"victor-piana-de-andrade":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"laura-skaife-knight":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"shaikh-fahad-bin-khalifa-al-khalifa":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"susan-msadabwe":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"nicolas-revel":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"chen-chien-tzung":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"sherif-abouel-naga":{"commit":"d239296e72","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 6 weakly linked companies linked to the drugs and cancers in their trial text, 7 people linked to institution","file":"src/data/people/leaders-wave4.ts"},"fan-daiming":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"wang-ying":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"dearbhaile-collins":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"jennifer-welsh":{"commit":"ccff000754","date":"2026-09-10","author":"Jude Gomila","message":"people: leaders wave 4, retry passes A and C (161 institutions covered)","file":"src/data/people/leaders-wave4.ts"},"rene-medema":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"andrew-mesecar":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"geraline-leusink":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/leaders-wave4.ts"},"xia-jiahong":{"commit":"687e4b6faa","date":"2026-09-11","author":"Jude Gomila","message":"Papers second pass: 99 more people get Europe PMC/Crossref papers (363 to 264 without)","file":"src/data/people/leaders-wave4.ts"},"taofeek-owonikoko":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"tan-weihong":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"niels-norgaard-pedersen":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"lars-dahl-pedersen":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"ricco-norman-dyhr":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"kristo-erikson":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"tarmo-bakler":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"sirkku-jyrkkio":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"juha-korpelainen":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"gerard-zalcman":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"jean-philippe-spano":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"yacine-merrouche":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"didier-peiffert":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"vigdis-hallgrimsdottir":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"maeve-lowery":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"anne-coyle":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"jerome-coffey":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"emma-browne":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"ilaria-panzini":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"carlo-cimbri":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"andrea-agnelli":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"mario-taccolini":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"alessandro-venturi":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"tomas-jovaisa":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"audrius-simaitis":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"jakub-kraszewski":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"iwona-maroszynska":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"jasna-trifunovic":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"albert-salazar-soler":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"anton-benet-catala":{"commit":"fab028c91c","date":"2026-09-14","author":"Jude Gomila","message":"Schematic thumbnails no longer draw the cycling phase caption; 30 OECI member representatives added as people linked to ","file":"src/data/people/leaders-wave4.ts"},"adria-comella-carnice":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"mark-de-ridder":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"nikolaos-zamboglou":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"ben-o-sullivan":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"renaldas-jurkevicius":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"ruslan-baltaga":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"igor-stojkovski":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"giuliana-cardenas-gamarra":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"mirela-grosu":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"cesar-gregorio-munoz-sanchez-miguel":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"jesus-fernandez-galan":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"luis-ibanez-gadea":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"patrik-rossi":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"jonas-claesson":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"pia-nasvall":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"rosaline-den-blanken":{"commit":"2ab70836fc","date":"2026-09-14","author":"Jude Gomila","message":"Institutions: 18 OECI members from Brussels to Kyiv, Lima and Dar es Salaam; 19 more OECI representatives linked to thei","file":"src/data/people/leaders-wave4.ts"},"haiko-bloemendal":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"ernst-j-kuipers":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"refik-emre-cecen":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"rob-bristow":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"sacha-gougnard":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"frank-vermassen":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"rolando-medeiros":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"carolina-wiesner":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"robert-separovic":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"panos-ergatoudes":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"petr-poloucek":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"jannick-brennum":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"arto-mannermaa":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"eric-felix-lartigau":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"charles-coutant":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"panagiotis-klirides":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"sarantos-efstathopoulos":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"joseph-martin":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"tracey-fitzpatrick":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"gustavo-galmozzi":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"livio-de-angelis":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"marco-centenari":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"riccardo-bui":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"roberto-cunsolo":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"nicola-normanno":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"daniele-piacentini":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"alinta-hegmane":{"commit":"a8120dac82","date":"2026-09-16","author":"Jude Gomila","message":"data: OpenAlex-matched papers for three institution leaders (Kyoto, Bari, Riga), disambiguated by institution id","file":"src/data/people/leaders-wave4.ts"},"lauris-vidzis":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"oddbjorn-straume":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"oystein-maeland":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"helena-isabal-roca":{"commit":"1cbf6c62f2","date":"2026-09-15","author":"Jude Gomila","message":"data: thirty more OECI member-centre representatives from the membership list, linked to their institutions (list 132 of","file":"src/data/people/leaders-wave4.ts"},"manuel-llombart-fuertes":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/people/leaders-wave4.ts"},"carmen-martinez-de-pancorbo-gonzalez":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/people/leaders-wave4.ts"},"rafael-perez-santamarina":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"sonia-garcia-de-san-jose":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"pamela-buchwald":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"erik-johnsson":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/people/leaders-wave4.ts"},"karl-landergren":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/people/leaders-wave4.ts"},"markus-g-manz":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"daniel-staub":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"sulaiman-shahabuddin":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"maurice-van-den-bosch":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"h-m-w-verheul":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"lukas-b-been":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"vasyl-f-chekhun":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"hugo-ford":{"commit":"042184cdb9","date":"2026-09-15","author":"Jude Gomila","message":"data: sixteen more OECI member-centre representatives with institution links (list 147 of 186)","file":"src/data/people/leaders-wave4.ts"},"jacinta-abraham":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"daniel-serin":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"georgios-kapetanakis":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/people/leaders-wave4.ts"},"krisztina-bogos":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"francesco-de-lorenzo":{"commit":"6d009b0b3f","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI representatives for the newly added member organisations, linked both ways (list 154 of 186)","file":"src/data/people/leaders-wave4.ts"},"tomasz-maciejewski":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"miroslav-chovanec":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"ramon-reyes-bori":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/people/leaders-wave4.ts"},"adda-bounedjar":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"toni-vekov":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"assia-konsoulova":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"wensheng-liu":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/people/leaders-wave4.ts"},"ladislav-dusek":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"xavier-pivot":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"breda-duggan":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/people/leaders-wave4.ts"},"maria-rosaria-iardino":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"joanna-lorenc":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/people/leaders-wave4.ts"},"delia-nicoara":{"commit":"3e3ea5f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: eleven OECI representatives for the organisations added last tick, linked both ways (list 165 of 186)","file":"src/data/people/leaders-wave4.ts"},"gustaf-storm":{"commit":"af06ee1131","date":"2026-09-15","author":"Jude Gomila","message":"data: three OECI representatives matched by hand (INCLIVA Valencia, Oslo University Hospital, Maastricht UMC and OncoZON","file":"src/data/people/leaders-wave4.ts"},"alvaro-bonet-pla":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"bjorn-atle-bjornbeth":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"r-r-w-j-van-der-hulst":{"commit":"df90f7c250","date":"2026-09-17","author":"Jude Gomila","message":"People papers: 36 more research-trained people via OpenAlex and Europe PMC","file":"src/data/people/leaders-wave4.ts"},"carlos-mingo-rodriguez":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/people/leaders-wave4.ts"},"cesar-adolfo-gomez-derch":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/people/leaders-wave4.ts"},"jose-julian-diaz-melguizo":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/people/leaders-wave4.ts"},"julio-garcia-pondal":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/people/leaders-wave4.ts"},"lisbet-isenbeg-ravn":{"commit":"2a6ce8a363","date":"2026-09-15","author":"Jude Gomila","message":"data: seven OECI member centres (four Madrid university hospitals, Herlev, Greater Poland Cancer Centre, Henri-Mondor) a","file":"src/data/people/leaders-wave4.ts"},"julian-malicki":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"christophe-tournigand":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"philippe-leroy":{"commit":"2ce1296a7c","date":"2026-09-15","author":"Jude Gomila","message":"data: King Albert II Cancer Institute (Saint-Luc, Brussels) and its OECI representative; logos for Herlev and Greater Po","file":"src/data/people/leaders-wave4.ts"},"ivan-s-stilidi":{"commit":"8622e83573","date":"2026-09-16","author":"Jude Gomila","message":"data: replace nine dead organisation websites and their link entries with verified current addresses (ICO, Uganda Cancer","file":"src/data/people/leaders-wave4.ts"},"pascal-hammel":{"commit":"028a93708b","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-two leaders and OECI representatives via Europe PMC author and affiliation match, each set check","file":"src/data/people/leaders-wave4.ts"},"nikolai-goncharenko":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/leaders-wave4.ts"},"olena-yefimenko":{"commit":"4ba2bd8eed","date":"2026-09-15","author":"Jude Gomila","message":"data: INC Luxembourg, National Cancer Institute of Ukraine and FICAN with their OECI representatives (seats from the org","file":"src/data/people/leaders-wave4.ts"},"tomi-p-makela":{"commit":"e6a0f6204e","date":"2026-09-16","author":"Jude Gomila","message":"data: papers for twenty-three OECI representatives via Europe PMC author match with institution and city affiliations, e","file":"src/data/people/leaders-wave4.ts"},"poornima-parameswaran":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/people/leaders-wave4.ts"},"bayli-divita-dean":{"commit":"abd0b1bf08","date":"2026-09-16","author":"Jude Gomila","message":"data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and","file":"src/data/people/leaders-wave4.ts"},"selwyn-vickers":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"andrea-cercek":{"commit":"a57083c65a","date":"2026-09-08","author":"Jude Gomila","message":"People: 129 leading clinicians and scientists at 15 US-East, Midwest and Toronto cancer centres","file":"src/data/people/us-east.ts"},"luis-diaz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"charles-sawyers":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"howard-scher":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"michael-morris":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"bob-li":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"alexander-drilon":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"helena-yu":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"yelena-janjigian":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"eileen-oreilly":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"ross-levine":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"jae-park":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"saad-usmani":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"david-solit":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"benjamin-ebert":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"sara-tolaney":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"nancy-lin":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"pasi-janne":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"kenneth-anderson":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"paul-richardson":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"ursula-matulonis":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"toni-choueiri":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"f-stephen-hodi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"william-kaelin":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"eliezer-van-allen":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"judy-garber":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"ann-partridge":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"daniel-haber":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"keith-flaherty":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"lecia-sequist":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"justin-gainor":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"ryan-corcoran":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"ryan-sullivan":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"theodore-hong":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"leif-ellisen":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"william-nelson":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"bert-vogelstein":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"kenneth-kinzler":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"drew-pardoll":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"suzanne-topalian":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"julie-brahmer":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"dung-le":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"elizabeth-jaffee":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"patrick-forde":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"stephen-baylin":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"kellie-smith":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"robert-vonderheide":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"carl-june":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"bruce-levine":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"drew-weissman":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"susan-domchek":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"angela-demichele":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"charu-aggarwal":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"robert-mach":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"david-porter":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"anthony-letai":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"douglas-lowy":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"steven-rosenberg":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"louis-staudt":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"james-gulley":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"brigitte-widemann":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"nirali-shah":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"raffit-hassan":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"ramon-parsons":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/people/us-east.ts"},"miriam-merad":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"sundar-jagannath":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"joshua-brody":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/people/us-east.ts"},"matthew-galsky":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"nina-bhardwaj":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"thomas-marron":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"candace-johnson":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"renier-brentjens":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"igor-puzanov":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"robert-fenstermaker":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"eunice-wang":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"pawel-kalinski":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"todd-golub":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"gad-getz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"matthew-meyerson":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"francisca-vazquez":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"andrew-aguirre":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"feng-zhang":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"bradley-bernstein":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"bruce-stillman":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"david-tuveson":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"christopher-vakoc":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"adrian-krainer":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"tobias-janowitz":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"semir-beyaz":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"timothy-eberlein":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"timothy-ley":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/people/us-east.ts"},"li-ding":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"malachi-griffith":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"obi-griffith":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"john-dipersio":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"ramaswamy-govindan":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"robert-schreiber":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"eric-fearon":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"arul-chinnaiyan":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"shaomeng-wang":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"max-wicha":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"weiping-zou":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"theodore-lawrence":{"commit":"72a2dc77f0","date":"2026-09-18","author":"Jude Gomila","message":"Merge identifiers pass four","file":"src/data/people/us-east.ts"},"costas-lyssiotis":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"vincent-tuohy":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"timothy-chan":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"jame-abraham":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"justin-lathia":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"jaroslaw-maciejewski":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"shilpa-gupta":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"nathan-pennell":{"commit":"1186af8280","date":"2026-09-18","author":"Jude Gomila","message":"Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people","file":"src/data/people/us-east.ts"},"patrick-hwu":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/us-east.ts"},"amod-sarnaik":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"frederick-locke":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"robert-gatenby":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"eric-haura":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"hatem-soliman":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"christine-chung":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"shari-pilon-thomas":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"keith-stewart":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"john-dick":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"lillian-siu":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"tak-mak":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"pamela-ohashi":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"aaron-schimmer":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"natasha-leighl":{"commit":"521ac7489a","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-east (126 records)","file":"src/data/people/us-east.ts"},"amit-oza":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-east.ts"},"trevor-pugh":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"eric-winer":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-east.ts"},"peter-pisters":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"giulio-draetta":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"james-allison":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"padmanee-sharma":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"christopher-flowers":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"debu-tripathy":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"john-heymach":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"hagop-kantarjian":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"funda-meric-bernstam":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"anirban-maitra":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"jennifer-litton":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"albert-koong":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"mariana-chavez-macgregor":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"cheryl-willman":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"evanthia-galanis":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"vincent-rajkumar":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"shaji-kumar":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"matthew-goetz":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"tanios-bekaii-saab":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"alan-ashworth":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"eric-small":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"rahul-aggarwal":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"alan-venook":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"laura-esserman":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"thomas-hope":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"kevan-shokat":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"frank-mccormick":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"emily-bergsland":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/us-west.ts"},"katherine-matthay":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"steven-artandi":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/us-west.ts"},"crystal-mackall":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"irving-weissman":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"ronald-levy":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"heather-wakelee":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"ash-alizadeh":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"maximilian-diehn":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"michael-teitell":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"antoni-ribas":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"dennis-slamon":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"johannes-czernin":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"jeremie-calais":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"owen-witte":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"amar-kishan":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"robert-stone":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"steven-rosen":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"michael-caligiuri":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"christine-brown":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"behnam-badie":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"hope-rugo":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"alex-herrera":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"virginia-sun":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"stephen-forman":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"thomas-lynch":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"stanley-riddell":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"sara-hurvitz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"michael-leblanc":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"philip-greenberg":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"denise-galloway":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"hans-peter-kiem":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"gary-lyman":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"dawn-hershman":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"primo-lara":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"charles-blanke":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"neeraj-agarwal":{"commit":"d254d2c51e","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 2 journals from the people who published in them","file":"src/data/people/us-west.ts"},"kathy-albain":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"priyanka-sharma":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"anne-chiang":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"hagen-kennecke":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"charles-geyer":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"lori-pierce":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"deborah-bruner":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"peter-odwyer":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"mitchell-schnall":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"mark-litzow":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"douglas-hawkins":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"rachel-rau":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"susan-cohn":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"julie-park":{"commit":"c3eff56d61","date":"2026-09-18","author":"Jude Gomila","message":"Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass","file":"src/data/people/us-west.ts"},"alice-yu":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"clifford-hudis":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"robin-zon":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"lynn-schuchter":{"commit":"5cb8dc0f56","date":"2026-09-11","author":"Jude Gomila","message":"people: expand short summaries in us-west (84 records)","file":"src/data/people/us-west.ts"},"everett-vokes":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people/us-west.ts"},"margaret-foti":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/people/us-west.ts"},"matthew-hellmann":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"keunchil-park":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"alice-shaw":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"robert-doebele":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"gregory-riely":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"paul-paik":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"salah-eddin-al-batran":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"yuichiro-doki":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jong-mu-sun":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"peter-thuss-patience":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"jens-hoeppner":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"hyung-ho-kim":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"hitoshi-katai":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"manish-shah":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"hansjochen-wilke":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jordi-bruix":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"john-primrose":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"robin-kate-kelley":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"angela-lamarca":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"andrew-zhu":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"michael-heinrich":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"sebastian-bauer":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"heikki-joensuu":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"herve-dombret":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"francesco-lo-coco":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"miguel-sanz":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"michel-attal":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jeffrey-lancet":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jan-burger":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"srdan-verstovsek":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"raajit-rampal":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"amer-zeidan":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"john-leonard":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"philippe-armand":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"caron-jacobson":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"miles-prince":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"youn-kim":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"rashmi-murthy":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"rupert-bartsch":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"mark-robson":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"andrea-decensi":{"commit":"279dcae6db","date":"2026-09-18","author":"Jude Gomila","message":"Fill institutions for 78 trial investigators and add 41 institution records","file":"src/data/people-investigators-wave.ts"},"shelley-hwang":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"luca-gianni":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"jose-baselga":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"paul-chapman":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"michael-atkins":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"john-kirkwood":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jeffrey-gershenwald":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"piotr-rutkowski":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"aleksandar-sekulic":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"alexander-stratigos":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"michael-migden":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jean-jacques-grob":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"danny-rischin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"neil-gross":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"ralf-gutzmer":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"shailender-bhatia":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"robert-ferris":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"joel-guigay":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jean-pascal-machiels":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"anthony-nichols":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"rossella-elisei":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"samuel-wells":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"bryan-haugen":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"keith-bible":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"julien-hadoux":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"vivek-subbiah":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"stephen-freedland":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"chris-parker":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"gerhardt-attard":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"david-dearnaley":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"fred-saad":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"stephen-boorjian":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"krishnansu-tewari":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"david-gershenson":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"vicky-makker":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"shannon-westin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"marie-plante":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"remi-nout":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"ana-oaknin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"amanda-fader":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"susana-banerjee":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"paul-brown":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"jan-buckner":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"eric-jonasch":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"scott-plotkin":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"andrew-lassman":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"olivier-chinot":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"jacques-grill":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"darren-hargrave":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"giles-robinson":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"sarah-leary":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"kimberly-dunsmore":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"rob-pieters":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"inge-van-der-sluis":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"sylvie-bonvalot":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"andrew-wagner":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"patricia-pautier":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"patrick-schoffski":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"alice-chen":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"antoine-italiano":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/people-investigators-wave.ts"},"florence-duffaud":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"robin-jones":{"commit":"59b229ca65","date":"2026-09-18","author":"Jude Gomila","message":"Add 188 ORCIDs and 22 Wikipedia links to people records","file":"src/data/people-investigators-wave.ts"},"jennifer-chan":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"john-strickler":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"andrea-sartore-bianchi":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"salvatore-siena":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"rona-yaeger":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"gerald-prager":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"quincy-chu":{"commit":"16be9b88da","date":"2026-09-18","author":"Jude Gomila","message":"Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%","file":"src/data/people-investigators-wave.ts"},"maria-de-santis":{"commit":"15a0727e9e","date":"2026-09-18","author":"Jude Gomila","message":"Chinese quality pass 4 over 243 folded TL;DRs","file":"src/data/people-investigators-wave.ts"},"symbiotic-gi-03":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"symbiotic-gi-16":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"symbiotic-lung-04":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"symbiotic-lung-01":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06980272":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07229625":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"taishan-301":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave2.ts"},"nct06612151":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07739758":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07418749":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07003074":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06561607":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07008976":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07043725":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06616532":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06419621":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07174908":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07525206":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06614192":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07155187":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07005102":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05211895":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05502237":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05020769":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05221840":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04658862":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"hr-nmibc":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06935409":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06498479":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07189455":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07554339":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06345729":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07431827":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06997497":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07190248":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06943755":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct06082167":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct07227402":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07489495":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06601335":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07463573":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06954246":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06194734":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06109272":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nsclc-2":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct05450692":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"renaviv":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07354022":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07024173":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07349069":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05862285":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06136624":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06136650":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"tai-shan6":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"sqnsclc":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05744687":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05860465":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07362186":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07416994":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07461454":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05132075":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05780567":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05365178":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06952803":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06120491":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05487391":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06686576":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave2.ts"},"nct05690945":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07377578":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07342478":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07570173":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07634471":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct04498117":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04590963":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07063745":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"mountaintap-30":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06247605":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07459751":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06927986":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05294172":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave2.ts"},"nct06608927":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05751512":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06394492":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07424287":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07726992":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07804186":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07015190":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07555938":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05838066":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07441460":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06747338":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06079983":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06846437":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06697301":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07365319":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07516093":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07262567":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07668752":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05973773":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07128199":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"aurora":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07258511":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07518186":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06754644":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07377643":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06834672":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05671510":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06855277":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06780670":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07011056":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave2.ts"},"nct04523272":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05077449":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct04250922":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"dllevate":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07585266":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06968585":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06671379":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05754853":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07385703":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07452198":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05155254":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07062965":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07365241":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06732323":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06383767":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"fleteo":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"aspen-06":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05732805":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05751928":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07480356":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nsclc-3":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06855069":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06984588":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave2.ts"},"nct07138209":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07544056":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06998108":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06093672":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06416410":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07214779":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07207070":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06735391":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07533123":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06635824":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07365995":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct04655976":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"apex-03":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05417789":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct03768063":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07546500":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05281471":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07409272":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07566052":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06532006":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07662395":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05065957":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06622057":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07570823":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07562022":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"pik3ca-2":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"quintessential-2":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05208047":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct05987358":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06929624":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06387069":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07217301":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05586074":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07218926":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04910685":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave2.ts"},"nct05232916":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"invincible-3":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05141721":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct04169997":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04415853":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07218809":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07407803":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06331299":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04353375":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07297329":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05945901":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07379047":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct06519370":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07174427":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06954961":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07522073":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06919965":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07409428":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06743126":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"simrise":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07673887":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07579234":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06982521":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06658353":{"commit":"b823e3ea74","date":"2026-09-14","author":"Jude Gomila","message":"Relations: 17 weakly linked ideas, UK and global cancer centres, single-cell models and a trial linked to the terms, can","file":"src/data/pipeline-trials-wave2.ts"},"nct05346224":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06646276":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct03659448":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"proceade-crc-03":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06860971":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct04165317":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"companion-002":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07284849":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07386938":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06764485":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06624644":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07188558":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"mcrpc":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06295731":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06351631":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct04892173":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06177041":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07492641":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06561048":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07218380":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06401356":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"seacraft-2":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05118776":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06079346":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05317819":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct07413939":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct07362459":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06472245":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06508983":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct04468984":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nsclc-4":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04871282":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06417008":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07673029":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct06774131":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07079228":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07213804":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct05254171":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct04534205":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave2.ts"},"nct04921527":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"himalayas-1":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07562152":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"g-hope-002":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave2.ts"},"nct06852222":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07490262":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct06064877":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct07215585":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06792253":{"commit":"2e05619049","date":"2026-09-13","author":"Jude Gomila","message":"Sponsors and pipeline trials: check-date stamps removed from 330 generated summaries; the record date field carries the ","file":"src/data/pipeline-trials-wave2.ts"},"nct07311694":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"nct05303519":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave2.ts"},"nct06504732":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave2.ts"},"anetumab-vs-vinorelbine-mpm":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/pipeline-trials-wave2.ts"},"nci-anetumab-pembrolizumab-mpm":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/pipeline-trials-wave2.ts"},"aldoxorubicin-phase-3-sts":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/pipeline-trials-wave2.ts"},"ucl-proton-hemithoracic-mpm":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/pipeline-trials-wave2.ts"},"tazemetostat-doxorubicin-es":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/pipeline-trials-wave2.ts"},"tiger-trial":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/pipeline-trials-wave2.ts"},"zen-3694-platinum-nut":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/pipeline-trials-wave2.ts"},"zen-3694-abemaciclib-nut":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/pipeline-trials-wave2.ts"},"cemiplimab-nut":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/pipeline-trials-wave2.ts"},"sabr-comet":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/pipeline-trials-wave2.ts"},"nct06423911":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06640361":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06051409":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06265428":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06018337":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct05936658":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct05004285":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct06105619":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct05989542":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06008106":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct06008119":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave3.ts"},"nct06829459":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct05798819":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct03394365":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct07241416":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct07234162":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06459687":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct06750419":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06122584":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct03486873":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct06499285":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct03562637":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct04950322":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct05050942":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct06432296":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct05851014":{"commit":"15ed9ef5a2","date":"2026-09-17","author":"Jude Gomila","message":"Cancer links for 20 unlinked trials; Chinese version complete for trials","file":"src/data/pipeline-trials-wave3.ts"},"nct04143607":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave3.ts"},"nct02665065":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave3.ts"},"nct07112196":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave3.ts"},"nct05652894":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave3.ts"},"nct06212752":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06097364":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06199973":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06828354":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05059522":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave4.ts"},"nct04639180":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06350097":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05089734":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06348199":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04351555":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06712355":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04854668":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07625644":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07010263":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06758401":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06216301":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04442022":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct03873402":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04529772":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06838273":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06767527":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06313086":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06868654":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05920356":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07502300":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04094311":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07044336":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06717347":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06054555":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07226752":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05730036":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06952478":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06340568":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05120349":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06464991":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06581406":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04940052":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct03844048":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06629779":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06430866":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06670196":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06788756":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06382129":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06305754":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05170204":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04842617":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06692738":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06448312":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05348577":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04384484":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06801834":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04002297":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02152631":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05939414":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07154706":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05445778":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04810078":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06520345":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06956170":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07221357":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06899126":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05438043":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05572515":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05320692":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06584032":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07775287":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04379635":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06698042":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07216703":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04884360":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07518173":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06435429":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04712097":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04194775":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07028853":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07491445":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave4.ts"},"nct06246916":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07219238":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02411448":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06830889":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct03755791":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05429268":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06549595":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05353257":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06699212":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06041776":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05727904":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/pipeline-trials-wave4.ts"},"nct05800015":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07318558":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04613596":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/pipeline-trials-wave4.ts"},"nct07805954":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06149286":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07183189":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06765109":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07640789":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07541170":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04674683":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06994195":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05489289":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct01436968":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06585410":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05623020":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05827016":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06956001":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04422366":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave4.ts"},"nct06152575":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07228832":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03539744":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05519085":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07412613":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave4.ts"},"nct06508658":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06824467":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06191744":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06468033":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05009836":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06356311":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06564844":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06417814":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07168200":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07005128":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07509151":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06514508":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07361510":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06928389":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06170788":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06459180":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04717414":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06640530":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06072781":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06911502":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06452277":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06430437":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06316531":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct03390686":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05654454":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06311721":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct03706365":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave4.ts"},"nct05116462":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04076059":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04975997":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04162210":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07252232":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave4.ts"},"nct06989112":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03800134":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05884398":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05804370":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06300177":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07621718":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02767804":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07170995":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06413498":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05425940":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06422143":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05607550":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07213674":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05215340":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06496178":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/pipeline-trials-wave4.ts"},"nct06158841":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06230224":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06976190":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave4.ts"},"nct04446117":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05317858":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05020236":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04224493":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06711900":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06252649":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04687241":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07473128":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04969731":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07391657":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06396065":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04129502":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07095452":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06712316":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06312137":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct01804686":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07604766":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06486441":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07166094":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03246529":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06921785":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04951635":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05608291":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06947928":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06952504":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05625399":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06496048":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05555732":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05785767":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04547166":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06208150":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06077760":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05797831":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05043090":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07185997":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07361497":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05862337":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06679101":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06819007":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06118333":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave4.ts"},"nct04421963":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03016819":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct01933932":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06132958":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06868667":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05870319":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04680052":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07764978":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06726265":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07462143":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06746116":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03164616":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07472517":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05468489":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02362594":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03690388":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06561386":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04624204":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06091865":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06091254":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07011719":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05883644":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06465914":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave4.ts"},"nct06767514":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03847428":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06619236":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06128837":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06925737":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05552976":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07052214":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02486718":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/pipeline-trials-wave4.ts"},"nct05722015":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05047250":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06123884":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05171816":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07642024":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06793215":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06174987":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06506955":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07454720":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05270044":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06357533":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06687369":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07722494":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04099251":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/pipeline-trials-wave4.ts"},"nct06074588":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05388669":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05048797":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06497985":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06117774":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07611110":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05317416":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05904886":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05022901":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05552222":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06045806":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04404283":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07778316":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03383458":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06617416":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06627647":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06742996":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05549297":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06564324":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05100862":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04657991":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07225270":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06363994":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct04956692":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct07291037":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07702032":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05888493":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07182682":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07196774":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05984277":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05409066":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07361003":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05455320":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07393282":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07513376":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06915025":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04793958":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04974398":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave4.ts"},"nct06881784":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct03178552":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave4.ts"},"nct04691804":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct05557838":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05794906":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07777822":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07178795":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06097728":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06371157":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07100080":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07195695":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct06500026":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05668988":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04765059":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct02489318":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07564141":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct07022483":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04712643":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct06891833":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct04316364":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct07676162":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct05371093":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05987332":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct04923906":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave4.ts"},"nct06382116":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave4.ts"},"nct05840016":{"commit":"22119f5c55","date":"2026-09-16","author":"Jude Gomila","message":"trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recor","file":"src/data/pipeline-trials-wave4.ts"},"nct03556228":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04619004":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07491497":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07258979":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct05222555":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06703398":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07527858":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05180799":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06475300":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04606771":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06445062":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06498986":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05652686":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct02227251":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06710288":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06188520":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05643742":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct02343042":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05256290":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05422911":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06879717":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04205227":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct06140524":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05952024":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06589778":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06601504":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05128825":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07059221":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05446298":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05784688":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07266441":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06465329":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06535607":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06014528":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06463028":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03970746":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04986423":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02332668":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04152499":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07790510":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07084896":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05658562":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06514027":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07545603":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct01081951":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06686030":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06134232":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct02768363":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05751798":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05482893":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05283226":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05822752":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07560111":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07023289":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05775159":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07219459":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05955391":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07332000":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02213926":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07287150":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04140526":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct02568267":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07262619":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06668961":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06194656":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05830123":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06512051":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06550895":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04430738":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04930432":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04843098":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07024784":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06769152":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07080216":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07306624":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07081633":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06780137":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07446322":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06502977":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03162536":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06437522":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05801029":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06448754":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07589634":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04083599":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06785636":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06228053":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06946797":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06107413":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07111520":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05423262":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03600441":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07054567":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04827953":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct03314181":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05887492":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05372354":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06235229":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct03069469":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07519772":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06962865":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03228667":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06792695":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07805551":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04590326":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07479485":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07659782":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04414475":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07079631":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07253142":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06690775":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07049926":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05932212":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct06114511":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07654400":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03972657":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05633667":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07586124":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05009069":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06682988":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04501120":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06101134":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06829771":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05846867":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06646055":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05925530":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03407144":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct06820463":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07230106":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07284758":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04077723":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06099782":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07098988":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06797297":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05970497":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04663347":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct03564340":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06106308":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct04745689":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05676931":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06689163":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07486089":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04050436":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct02628067":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07227012":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04133636":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03611868":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03334617":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06172478":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05880706":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06606847":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07397338":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06090539":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07192614":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct04895709":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05112991":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04644289":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06697184":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06344052":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07288177":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04440735":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05997017":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05583617":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05956587":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05601752":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06030258":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06693336":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04586426":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05219500":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04752826":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06598007":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct06948448":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06679985":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04542824":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05593094":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07208773":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06161974":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05338931":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04895722":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02960022":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03157128":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06480565":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04792489":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07049055":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07659795":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06463665":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07325136":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06873763":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03989414":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07680764":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05081609":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06731907":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06784648":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04068597":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05990803":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05789082":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07291076":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07189065":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct07235293":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05978284":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06253663":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03634540":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06566547":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05605535":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07005336":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05421663":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07071714":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05557591":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05951959":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05608044":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06699836":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06219941":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04291105":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06922591":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04068610":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06284590":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05458297":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05320588":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05904379":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07133750":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03960840":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07255664":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05739981":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07387471":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06521567":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05086692":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07124936":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07052253":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07181161":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06522828":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05853575":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03775486":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07169994":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03709680":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07476287":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05826535":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06943820":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06577025":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04701476":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct07162181":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04396821":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct07807163":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03897881":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07255404":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05950165":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07296809":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05919264":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06283719":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06241846":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07468071":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06526793":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05716087":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct05712902":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06365853":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05651022":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05471843":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05413850":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04421820":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07227415":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05797168":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07565285":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07714668":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04585750":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05367440":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07269782":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07239596":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07609862":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct05351788":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06991556":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06006169":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06644768":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03785249":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04302025":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06081920":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07452224":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07288203":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05280470":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07745361":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06915246":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07245446":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05535244":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05533775":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03915184":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05201248":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07589543":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05551507":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05451810":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06265025":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07221474":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05585320":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07098338":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05024214":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct05431270":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03974022":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07288879":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07326566":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07450599":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06988488":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04787042":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06568094":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07432295":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05609370":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07229729":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06362369":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct02711553":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct04924075":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct05949606":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06568939":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05194995":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave5.ts"},"nct06087653":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06378177":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07483554":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06445400":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04920617":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05456685":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07730515":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04616443":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct07510815":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07170644":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05620134":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct05635708":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05913089":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07293351":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07622186":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07123454":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04675294":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03936153":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07680439":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06162572":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04471727":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06434610":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02180711":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07150091":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06996782":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05123482":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06496490":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06706076":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05607420":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06161441":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05379985":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05098132":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05060016":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05440708":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06281678":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07082686":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04639219":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06297226":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07617753":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07079475":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06534437":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05877430":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04782687":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05661955":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03907852":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06726148":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06560112":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04280081":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03393884":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06500884":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06162221":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03526835":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04728893":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07264816":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07590934":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05924841":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05186753":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct07149857":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04711135":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05565417":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06589440":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05669482":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07226986":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04246086":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04657068":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07005154":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07246863":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05468697":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03916627":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04736173":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07042802":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04868877":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04844866":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07244705":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave5.ts"},"nct06190951":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04733183":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05734066":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07594106":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06115135":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07059650":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05735080":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07175220":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07336446":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04180371":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06792435":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05144698":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07521852":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06128551":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave5.ts"},"nct06754930":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06008054":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06727565":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06892522":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct02861573":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04938583":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06427941":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07051486":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06014190":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05394103":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07617805":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04557449":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06343064":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct03647163":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06810544":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07227298":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06848699":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05805501":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05126719":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct05067140":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06956690":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06909825":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05318573":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05816252":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07287917":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06307431":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03932331":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05442060":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06096779":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07474727":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06225843":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03947385":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06607458":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04988555":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05103358":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06437509":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04553133":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06890338":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04644068":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct03767348":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06119685":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05271318":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07044908":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06953960":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05267626":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05632939":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07465757":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05061550":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05207670":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05006716":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06961006":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07310784":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07563738":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07312188":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06840002":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07623356":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06708663":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04996875":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct06859775":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07217119":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06324357":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct02864992":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/pipeline-trials-wave5.ts"},"nct06481592":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05565807":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07480928":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03260023":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct07644559":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06228326":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07155174":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04606446":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04495153":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07449754":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06090266":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05682443":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07288359":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07023627":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05382442":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct02955940":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06730347":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07202364":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05257993":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06205706":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05704049":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07122687":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05074810":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07070440":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05283720":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03075696":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03671018":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06390995":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04661007":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct04245839":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07473167":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04502394":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05020457":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07087158":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07329322":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07102381":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05546866":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07227311":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07206498":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05063565":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04370587":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05733598":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04024696":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04669171":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07459634":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07020221":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06841055":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04730258":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06449209":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06155396":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06137144":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct04665206":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05335993":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03836352":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07018050":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07259590":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave5.ts"},"nct01843374":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06277154":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05867251":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05379595":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06933329":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07198633":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06362252":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07254585":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07407283":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05910827":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03888105":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05288205":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07590531":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05642455":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05955508":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave5.ts"},"nct06669247":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06992258":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05703971":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05128487":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06093841":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05217446":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07489066":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04478279":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07310173":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06632262":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05841472":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06921928":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06295432":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04268706":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct05246514":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07564401":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06106945":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07699328":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07217184":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02899052":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03436485":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07164170":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05828511":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07627711":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06190899":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03259867":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05195632":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05093907":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05655312":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04836507":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06843447":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05358249":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04417621":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06040099":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06564038":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct04675333":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07115043":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05247684":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05907954":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07029737":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07174583":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07322094":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03930953":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05714839":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07190300":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct04126200":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06493760":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06413680":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct04036682":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07553988":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05438420":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07227597":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06589830":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave5.ts"},"nct06758557":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05824975":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06005493":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06769698":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07500220":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06895031":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct04110301":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct03899792":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct07455851":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06894511":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05294731":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07681596":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06047379":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04495296":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct05186974":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07669779":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07038096":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05044897":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06558227":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04104776":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05592626":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05403385":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07109726":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05061134":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05903833":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct07406633":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06479356":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04919811":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct05489211":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06787612":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04198766":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct06530251":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06007729":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05276726":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct04977453":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06702995":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct03944772":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct03476681":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05280314":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct03175224":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct03731260":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave5.ts"},"nct05297890":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct05257590":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06745323":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05309421":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06428409":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct07627698":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct05117242":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04931342":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct02519348":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06395103":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07223047":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04973605":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06004661":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06695845":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct05142696":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06710132":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct06623136":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05742607":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07641036":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave5.ts"},"nct06787664":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct05054439":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct02773030":{"commit":"fb7154a70e","date":"2026-09-16","author":"Jude Gomila","message":"Header signup, trial wave 5 and Ask weighting","file":"src/data/pipeline-trials-wave5.ts"},"nct04524871":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave5.ts"},"nct07150104":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct07059845":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct06564272":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave5.ts"},"nct07551349":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave5.ts"},"nct06574347":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave5.ts"},"nct07610798":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05125016":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05684965":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07100730":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07321574":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04567420":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05287113":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04165590":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02908906":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04914598":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06973187":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06373406":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04416984":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07567521":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04130516":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06483334":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05994131":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07227870":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05615623":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07002203":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06595186":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06922383":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06650566":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06081959":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07326488":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07589569":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05120596":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06386146":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05192486":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07459998":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04956640":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06043817":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07589517":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04077099":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03866525":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07441174":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06500676":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06581432":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03878849":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06393374":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07486817":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03301168":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05243550":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07158918":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06112704":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03769506":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06496971":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05466799":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05235516":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05667506":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06750185":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06985147":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05565378":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06818643":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02174549":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct02704858":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07070349":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04464226":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06640049":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05609578":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05170958":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06382168":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06542250":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04752813":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05673057":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07700667":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06062420":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06123754":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06222879":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04853342":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05229497":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05427383":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05501886":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07701486":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06623422":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04145622":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07815665":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07196644":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06460298":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07811037":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07007312":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04807257":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06948981":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct05898399":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05498428":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05304481":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06459973":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05663866":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07678957":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06943872":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06293651":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06267729":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04305795":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05768139":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05118789":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07209813":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07328217":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06131450":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04094610":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07026279":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07069062":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05688280":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07569042":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04752722":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06361888":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06365840":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03945162":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06265727":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07192120":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07501559":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07450859":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04233346":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct05802225":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct01761968":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04008797":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05636618":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07216560":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07612280":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05532696":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06864169":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05300269":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03725059":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04521231":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06125522":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04562389":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05909436":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06795412":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07213830":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06994507":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07181499":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03934567":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05458674":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06015048":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07211958":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07143604":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05435248":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05914116":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07554521":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04685226":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06244771":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06525298":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04616209":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03155191":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07362940":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07612891":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07354074":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05980481":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06731478":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06246110":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07100106":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06155084":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06667076":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05491525":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06703255":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07232849":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06256588":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06631092":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04349436":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07669467":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07692204":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06668103":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06839066":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05888831":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07523529":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07765446":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06206837":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06979596":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07197827":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05991583":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06179524":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06022861":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06223841":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05287945":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05774951":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04589845":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04906395":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04588922":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06453902":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03379428":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07382531":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06465433":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05875168":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05302284":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07114315":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06567015":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06908304":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07129252":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04485949":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05020015":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06245915":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06413706":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07720284":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06465563":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07108309":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04270409":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct06609005":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05773820":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06578624":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct01744223":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07263594":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05363280":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06202261":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07497386":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07130383":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06065748":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07213817":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04486833":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06383052":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07488676":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06904235":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07023731":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05765812":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05944978":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03257033":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03899155":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct06725758":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05319314":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct02912949":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06474455":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07280832":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06665100":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06953999":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07276399":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07070232":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02677922":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06187402":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03067051":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05947851":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05702229":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06938867":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06469944":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05296798":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07455734":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07502287":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06986811":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07648264":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06514534":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct05849298":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06422936":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06330064":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06234098":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07374419":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07589530":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06727630":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07108270":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07405151":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07510802":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06010342":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06155383":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05814354":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04271644":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06049290":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06035497":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06515990":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06975410":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct06567782":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05037279":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07314294":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07429266":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06634875":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07266428":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct04183166":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06163430":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07439094":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06868849":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05546268":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06776952":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06693375":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05120271":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06590857":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06679036":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06581419":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05941507":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06533644":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06795022":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05481151":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02979522":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct04557059":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct01594723":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07744256":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05334823":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06732531":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06042894":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07512583":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07232602":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03424005":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07415031":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02503423":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06554795":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05624554":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06901531":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct02966756":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07030257":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05316701":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05804045":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07648030":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06084936":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07172802":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06209580":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07283835":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06926920":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06208410":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07766018":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06359860":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05326243":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07229586":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06492005":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07496229":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07165886":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03348670":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06643754":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07249905":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05009329":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06737081":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05455619":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05883956":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05768529":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04725474":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct01872260":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct06249048":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07294508":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03706690":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07331155":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06227117":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07523555":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06038578":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06317311":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03091192":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06011109":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06942234":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07672236":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05731271":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07102901":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07341100":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07346144":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05765032":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05413018":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07160725":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05381103":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07391813":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06736704":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06682793":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06319963":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07122063":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03816163":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03579836":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07475806":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04075292":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07710885":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05224141":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06276283":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05263583":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05771480":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05785741":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05133882":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03778229":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07036250":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct06566079":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05890742":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04626479":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06631989":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07124117":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06057610":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07678684":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05394831":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07252739":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05440786":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05043922":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06157151":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03547973":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct02763566":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06921837":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05999994":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07427394":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06247956":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05142423":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06312176":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07047118":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06062810":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05168566":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07446153":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06903377":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05490472":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06974812":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07286331":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07419295":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06764875":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05645692":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06061809":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05094336":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05405595":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05840211":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07630974":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06343948":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06084806":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct05985655":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07558733":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07432633":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06710847":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06016738":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04718883":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04300556":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04488822":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06977737":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06593522":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06253130":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04771130":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05596409":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07129993":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07243340":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct03682068":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06971614":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06783647":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06943833":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05696626":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06634849":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05710848":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05768919":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06764628":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06995677":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07280377":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07498478":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct02952508":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05485948":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04208178":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05498155":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07302347":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05844150":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02584244":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07282587":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct06008093":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06643884":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05459844":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05709249":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06504147":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04851717":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07629726":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04585035":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07469774":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06206174":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06214143":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04969315":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07151040":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07489716":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05668858":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04538664":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04114825":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07436728":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05948943":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06951503":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04864054":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05687266":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06235151":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06118788":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05862324":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06314373":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06971523":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06771622":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06555068":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06151574":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06702618":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05475925":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04262466":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06895928":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04404595":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave6.ts"},"nct06399757":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03671044":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04589234":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04587830":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07277231":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07586202":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05862272":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06687681":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04521413":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04025879":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/pipeline-trials-wave6.ts"},"nct06730750":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05945823":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06414460":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06384807":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05261399":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05329532":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06568692":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07228247":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06119581":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06428019":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05933265":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07192107":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07169851":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06538857":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04762069":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07689201":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07126665":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07002177":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07229612":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07547553":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07146672":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07380386":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06909877":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07415863":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06389006":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07258121":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04634357":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06911333":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07111832":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07225621":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06966700":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06232096":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06380660":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07480213":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06060613":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07185880":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct03148418":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05867420":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05833724":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06144671":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct07795034":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05434234":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07169734":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06598787":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05748171":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02346747":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06191263":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04971226":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/pipeline-trials-wave6.ts"},"nct07518147":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06588478":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06769113":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06111235":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07299747":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct05601726":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07286149":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05523947":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct07147348":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05700084":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05347134":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07448116":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04121455":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct02477696":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07278479":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06533579":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06712680":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct03591510":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06857175":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05315167":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06846671":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06305767":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05645107":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07193511":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07060807":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07213609":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07327034":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07575191":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05262010":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05518045":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06116136":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06166836":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06940739":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03444844":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02257736":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06083207":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06055439":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06973564":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct02938299":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/pipeline-trials-wave6.ts"},"nct06990880":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02107703":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05299424":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06038396":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07538804":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05544552":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06784752":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06635447":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07253116":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06431243":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04925479":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06807359":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05023980":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06957379":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04538742":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04724980":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04229979":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03686124":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06669117":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06980480":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06349980":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06319820":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07008703":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07359066":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07070219":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05562830":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07421700":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06211764":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05482971":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06467357":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07582432":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05429632":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06398444":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06449222":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07297212":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06778031":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06669975":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06906471":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06885281":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07605728":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05119907":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06003231":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07148128":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04665856":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07341737":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05876754":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07112222":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06622486":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06797986":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07566156":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05827796":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06840483":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06033586":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06244992":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07617493":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05417321":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03036098":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07093970":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05482568":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07492680":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06385925":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct04256317":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07268040":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06292208":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05563220":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07231068":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03850574":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06797635":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06898450":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02671435":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07028268":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06877650":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02970318":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04603807":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07171606":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05227664":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07033598":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06868199":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06824064":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06844357":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07392736":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06105021":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05704244":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06938321":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06440057":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06797999":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07743112":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03485209":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05205330":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06139575":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07615101":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct05970016":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06636682":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05678270":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07629960":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07102004":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06431490":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07287098":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07109414":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07324304":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02516241":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06657222":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04078295":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07056777":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06998407":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07271667":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04509700":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06855771":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06245330":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06668792":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07106892":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07742215":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03381274":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06220318":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04299191":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06510374":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct01874353":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07131202":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05934331":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06012695":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04554914":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06082102":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07548177":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/pipeline-trials-wave6.ts"},"nct06863272":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05943106":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05032040":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05944224":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05642780":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06745908":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07259317":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06120140":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04939610":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03386513":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06468358":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07060989":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06126510":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07227350":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06662786":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05261750":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06055959":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05322590":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05263960":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04652076":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04044768":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05923008":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05609968":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05265091":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06639347":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04980885":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05445843":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03897543":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07481058":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06221748":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06858618":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05658003":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05902169":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06953323":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06385080":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07192588":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06566586":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06959082":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06008288":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave6.ts"},"nct05584670":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05646862":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06109779":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06118086":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/pipeline-trials-wave6.ts"},"nct05479994":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07110571":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04977024":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06667908":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07359820":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05548296":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06178159":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03812874":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02453282":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04774718":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06549946":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05732103":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct05623982":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06378242":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04873362":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07644039":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03319628":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05112965":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06157892":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06962267":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07085767":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06960577":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06385678":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06754085":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06545955":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04915755":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04684147":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06634589":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05463263":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07221149":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct01906385":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07339176":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06246643":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04683250":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06635785":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05664243":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06341114":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06781567":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/pipeline-trials-wave6.ts"},"nct07093814":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07011186":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07468851":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07109219":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07761533":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct03600233":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05727176":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05803018":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06569420":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06970847":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06652633":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct02734004":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07217704":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06194448":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05320198":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04821622":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06737731":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07230405":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07541079":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02781883":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05653453":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave6.ts"},"nct05377996":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/pipeline-trials-wave6.ts"},"nct06726161":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05379946":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07134088":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06850623":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04699188":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06914128":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06805305":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07047365":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03505320":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07669454":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07724756":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct00781612":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02586857":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05319730":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05329766":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03040973":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct07109531":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05688605":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05456256":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07736937":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04954001":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05211570":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06369831":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06193902":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct00099437":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06772623":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07572396":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07467863":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05907057":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05563844":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct03673501":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03837899":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02138734":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07154264":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06760819":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04503265":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07136142":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06926075":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06596694":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06117566":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05584800":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02650401":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06938880":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06616389":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04711252":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03567889":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06188702":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05144854":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05473156":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06072131":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07173751":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05804669":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06823427":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06637423":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05627856":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06041802":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03934372":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07387081":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05902988":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06015503":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06821503":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07007559":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04492488":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04686682":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct03972488":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07567846":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04581512":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06526819":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04214288":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05566795":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04225117":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06126640":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05499013":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04724369":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06686394":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07480954":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04219254":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07114861":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06480240":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07636785":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07389733":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05965856":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04586231":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06130553":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07510828":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05308264":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct06618235":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05732831":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05669430":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct02320435":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04241185":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05899049":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06592326":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06947291":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06950086":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05548127":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07697586":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03533283":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06095505":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07448922":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06600022":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07691775":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06080776":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06764940":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05204862":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05254743":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07582315":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04938817":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07335497":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06941272":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05101070":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05417594":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06888921":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06492616":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07805252":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct02747004":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07606599":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06378593":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct02716116":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07075328":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05949619":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06580301":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05520567":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05583552":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05141149":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04891198":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07216443":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct06819735":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04703192":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04976634":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02542293":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04965493":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03459534":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct01954992":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07125872":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07136181":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07431281":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05745623":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07332455":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04974008":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04895358":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06861088":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07105215":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04626518":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06112379":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05886920":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07356973":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06590246":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07499674":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06387342":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07544654":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/pipeline-trials-wave6.ts"},"nct05101096":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03478488":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05487170":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06911827":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03833154":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06111274":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06812260":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06520488":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06934538":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06873555":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05428969":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04999969":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05288166":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03519230":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06616766":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07581002":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06514794":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06107686":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06107374":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct06957886":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06750094":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04959903":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04486378":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07169552":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct03933735":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07023315":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06747585":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04365374":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07315750":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06405425":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03431350":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06682780":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05587296":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06678659":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05761223":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05683886":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct07070518":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04379596":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07702292":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07069712":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05957367":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06332092":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05908734":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05406401":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07209111":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05850234":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03328078":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07024706":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05488314":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06298916":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07299825":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06780098":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04115306":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06806033":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05316155":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04586478":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05951608":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07598955":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct07367516":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04454437":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05948475":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06842498":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03742895":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07232875":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06752811":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07099898":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06079671":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05262400":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04390737":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06644781":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03937154":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03722420":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04170283":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07136779":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct03003962":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05230810":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct06247995":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07055594":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04614103":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06605222":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06428396":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07597629":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05689853":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06189209":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07646626":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06735144":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06757634":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04888312":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07288112":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05315700":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06439771":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06922357":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06827236":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07368998":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06630234":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05558007":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06127407":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04862663":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04086264":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05771584":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07229638":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06212076":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07168226":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04829604":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07586943":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07508761":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05755113":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07679360":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07225946":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06631079":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct05909397":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05514054":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03876769":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05163041":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07605962":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06353386":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06692166":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04165070":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03949283":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06906341":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04576455":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06184035":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06969430":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06508931":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05882058":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06505395":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07639450":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06915142":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05963074":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct02180724":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07276789":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07314723":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct03964727":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07295821":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06239155":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05173987":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06375733":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07038343":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06117540":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05662397":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct02934568":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct05038735":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05361174":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04041310":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06875310":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07466160":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07471789":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04023526":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06959615":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06833008":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05451602":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03967977":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06799637":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07298772":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04623541":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06939283":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05023486":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05057494":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05986851":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07087054":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06896890":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07641023":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07256782":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07111546":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06016920":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06031584":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07744763":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06279364":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07308106":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07407933":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05384587":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07116616":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06679634":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06305247":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05201066":{"commit":"bfdc426ef4","date":"2026-09-17","author":"Jude Gomila","message":"Fold a doubled relation line after the sponsor merge","file":"src/data/pipeline-trials-wave6.ts"},"nct05190445":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07229599":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06890884":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06376136":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06667544":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct04497844":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05701306":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07324629":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct05806099":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04414163":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06064812":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07028281":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06780111":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06742892":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07545265":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04895436":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05868707":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct03315364":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05908409":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04817007":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07032077":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05911295":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05410145":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04721977":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06854445":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05950945":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05456191":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct07591090":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06985355":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05920135":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07462650":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06943521":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06810804":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07446855":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07095868":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06717126":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05673785":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05615974":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04668690":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04785196":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07222969":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05966194":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06271837":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06225596":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04494503":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04980222":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06706713":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04802759":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05374603":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06867705":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07554456":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05893888":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06445972":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07015242":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07751042":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04443010":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06656390":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06756269":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06303505":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06471205":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06506643":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05466149":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04274426":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07235176":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07498725":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07265674":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07499362":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05885464":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03767244":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06992609":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04390399":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06975293":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05736406":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07003321":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06819215":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07529717":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06260774":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07232290":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04632108":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05608876":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07227025":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06434597":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave6.ts"},"nct06499350":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03865082":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06016062":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05533697":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06154291":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05205850":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06137118":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct03459846":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05594797":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03602859":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07393542":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07300943":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04579380":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06667960":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04064060":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06767813":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05948813":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06868277":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07285694":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07255872":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04458272":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04988295":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06680752":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06084884":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06452706":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07284433":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06824168":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04496349":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04868604":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07387926":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06243458":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct06885034":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07602777":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06500273":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06710756":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05987956":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07649122":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct06632951":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05838729":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05438329":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06417554":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07398339":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05521802":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05460273":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05720130":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03290534":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06413745":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06947967":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05607004":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06425926":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06978114":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06474806":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05872347":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07669519":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06050122":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06389292":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05629234":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06788912":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05251714":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07396584":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06127238":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07220616":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04662255":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07150663":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05269316":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07823049":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03711032":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06777316":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04539496":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06782334":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02637687":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05443126":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05630209":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct02717611":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07405164":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06534060":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07189871":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05573555":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05884255":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05150691":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06780085":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07195591":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07155226":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05367778":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07444437":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07006077":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06380751":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06522737":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06989437":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05415072":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct03742102":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07221253":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07589257":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06277219":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06660654":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07454187":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07145255":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06892548":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07390383":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06313983":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06825494":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07238283":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04928222":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06057922":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06970639":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07522151":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06425302":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07154290":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05852691":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06697197":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03093116":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05201404":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07222488":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05547061":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06764186":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06345482":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct03997123":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05631262":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07290088":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05744427":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06940401":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05855200":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/pipeline-trials-wave6.ts"},"nct07730021":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04651634":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04489771":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07283367":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06079112":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05759728":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07647328":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04524000":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct06088004":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06868485":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct04641247":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06591520":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07664150":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04098744":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05566041":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06937177":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06993844":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07241767":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07019675":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04906993":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03182244":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05579132":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06879145":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06962787":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07140393":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06730009":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07033026":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06618287":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07811193":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05918133":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06391944":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07122414":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04960709":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06359847":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct07208149":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05990452":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07669415":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05636215":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07520006":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06150885":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04626635":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05879055":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02531516":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05588648":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06472076":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06930794":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04079166":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07354711":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct05257395":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07287995":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05543330":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07258407":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06241781":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06549465":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06474468":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05312710":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05787613":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05951179":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04150497":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04561362":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct03667170":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07186842":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06041061":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06833073":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct02029443":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct04879043":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06649708":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04570423":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02365597":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07259213":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07103668":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05941897":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04834024":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05239741":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06637501":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06485219":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05801237":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07405801":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02340117":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06493552":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05027776":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06456463":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07371663":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct01946204":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07281976":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06782555":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05864014":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07205718":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06012435":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04643418":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06600789":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03441113":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct05967689":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05277168":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06970743":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05652920":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05827081":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct06703177":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06966453":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04514419":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06642545":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06243354":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct06123494":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07231211":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct01064466":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06524375":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06484829":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07072728":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03862430":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05879822":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07700160":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct03435796":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07019779":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04879329":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07106762":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04270591":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06147570":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05879068":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06336291":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05053880":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07444541":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06066203":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05589896":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct02972840":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03473743":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06654440":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04550260":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06619509":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06907043":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05526755":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06014658":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07648914":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06556563":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06296706":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07157033":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06760637":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06056830":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct02843945":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07071337":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07460375":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06632912":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06939595":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04014205":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct04996121":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06464055":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07145333":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct03330847":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07022002":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05952037":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04725994":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct06639256":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct05918445":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03899636":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07541001":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06741644":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07221734":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05147467":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06987500":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06840119":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05208944":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07357519":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07761429":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct07265622":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06751329":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04910022":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05541822":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04576156":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/pipeline-trials-wave6.ts"},"nct06603844":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06334432":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct06149559":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07197580":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05706129":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06907615":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03815643":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05968326":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/pipeline-trials-wave6.ts"},"nct06682572":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05894239":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07640295":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct05845814":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06790693":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07172919":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04639986":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05671822":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07206056":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04581473":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04673942":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct04452955":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07450976":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03851640":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03736889":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04995523":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct03793478":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05859750":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07529808":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct05386108":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05197426":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07417189":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06007690":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07054190":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06343311":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct00248287":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07241936":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05874414":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04380636":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06196736":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06088290":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06539182":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05503797":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct04342910":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07551362":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05934513":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06953089":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04544189":{"commit":"cd0cc8189b","date":"2026-09-17","author":"Jude Gomila","message":"Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people","file":"src/data/pipeline-trials-wave6.ts"},"nct04285086":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05736731":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05958121":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct04851613":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/pipeline-trials-wave6.ts"},"nct07286266":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03980054":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06841354":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07050641":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07221500":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct03669965":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04819100":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04931654":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct03491683":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07293754":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07749586":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04592653":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06800313":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06239194":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06974929":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06369285":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct06077877":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07296341":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06925581":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05327530":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07367529":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07439653":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct06832202":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06262139":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07541430":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/pipeline-trials-wave6.ts"},"nct07276373":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06010329":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04395677":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/pipeline-trials-wave6.ts"},"nct04634877":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06827613":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct07073534":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06140836":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06075264":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/pipeline-trials-wave6.ts"},"nct07777211":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/pipeline-trials-wave6.ts"},"nct04325828":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct07336732":{"commit":"208ecec6da","date":"2026-09-18","author":"Jude Gomila","message":"A further 160 trial acronyms added as aliases to registry trial records","file":"src/data/pipeline-trials-wave6.ts"},"nct05355298":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04140500":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06968221":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07623616":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06028074":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07083323":{"commit":"df53238f2b","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a5382dd3e7ef16308 (backlinks round)","file":"src/data/pipeline-trials-wave6.ts"},"nct07609823":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07602842":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06883526":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05908643":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06927687":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct07192432":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04776330":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct04329728":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06890598":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct04243499":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct07734116":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06256328":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06796907":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05374915":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04919226":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05573126":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06777433":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06567743":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07205822":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct05199272":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06051695":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct05785039":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06072612":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06612281":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06478719":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"nct06395519":{"commit":"f4127b8545","date":"2026-09-18","author":"Jude Gomila","message":"Add 115 registry trial acronyms from the CT.gov acronym field","file":"src/data/pipeline-trials-wave6.ts"},"nct06663137":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct07562581":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct06198751":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct06167694":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct05226871":{"commit":"a337dbb3f6","date":"2026-09-16","author":"Jude Gomila","message":"Registry trials wave 6 and products wave 7","file":"src/data/pipeline-trials-wave6.ts"},"nct04655092":{"commit":"1d2a6555d5","date":"2026-09-18","author":"Jude Gomila","message":"Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens","file":"src/data/pipeline-trials-wave6.ts"},"nct03096093":{"commit":"9e6c3738a2","date":"2026-09-18","author":"Jude Gomila","message":"Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases","file":"src/data/pipeline-trials-wave6.ts"},"ascent-05":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/pipeline-trials.ts"},"tropion-breast03":{"commit":"9cf38454b2","date":"2026-09-11","author":"Jude Gomila","message":"House style: trial, coverage and calendar copy without dashes, as-of stamps or 'spike'","file":"src/data/pipeline-trials.ts"},"master-protocol":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"lung-map":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"lung-map-s1400i":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/platform-trials-wave.ts"},"lung-map-s1800a":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/platform-trials-wave.ts"},"national-lung-matrix-trial":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/platform-trials-wave.ts"},"alchemist":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/platform-trials-wave.ts"},"nci-match":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"combomatch":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"tapur":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"dart-s1609":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/platform-trials-wave.ts"},"mypathway":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"i-predict":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/platform-trials-wave.ts"},"winther":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/platform-trials-wave.ts"},"cupisco":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/platform-trials-wave.ts"},"plasmamatch":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/platform-trials-wave.ts"},"target-national":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"determine-trial":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"focus4":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"gbm-agile":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"precision-promise":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"beat-aml-master-trial":{"commit":"410f657860","date":"2026-09-17","author":"Jude Gomila","message":"Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella tria","file":"src/data/platform-trials-wave.ts"},"polycythaemia-vera":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/polycythaemia-vera.ts"},"cyto-pv":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/polycythaemia-vera.ts"},"response":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"response-2":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"proud-pv":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/polycythaemia-vera.ts"},"low-pv":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"majic-pv":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"verify":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/polycythaemia-vera.ts"},"jak2-v617f":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"phlebotomy":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"haematocrit":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"erythrocytosis":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/polycythaemia-vera.ts"},"hepcidin":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"aquagenic-pruritus":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"erythromelalgia":{"commit":"9531e1fbfa","date":"2026-09-16","author":"Jude Gomila","message":"Essential thrombocythaemia page, aspirin record, vorolanib","file":"src/data/polycythaemia-vera.ts"},"post-pv-myelofibrosis":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"idea-pv-clone-directed-therapy":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"idea-pv-hepcidin-first":{"commit":"b1a7b81a40","date":"2026-09-16","author":"Jude Gomila","message":"Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas","file":"src/data/polycythaemia-vera.ts"},"prostate-low-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-intermediate-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-high-risk":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-bcr":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-mhspc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-nmcrpc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-mcrpc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"prostate-nepc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/prostate-subtypes.ts"},"vmat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/radiation-wave1.ts"},"radiosurgery-srs":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave1.ts"},"adaptive-radiotherapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/radiation-wave1.ts"},"surface-guided-radiotherapy":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"respiratory-motion-management":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/radiation-wave1.ts"},"hypofractionated-radiotherapy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/radiation-wave1.ts"},"sabr-oligometastases":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"hdr-brachytherapy":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/radiation-wave1.ts"},"ldr-seed-brachytherapy":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"intensity-modulated-proton-therapy":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/radiation-wave1.ts"},"total-body-irradiation":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"total-skin-electron-therapy":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/radiation-wave1.ts"},"superficial-radiotherapy":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"cobalt-60-teletherapy":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radiotherapy-access-gap":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radiosensitisers":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radioprotectors":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/radiation-wave1.ts"},"linear-quadratic-model":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/radiation-wave1.ts"},"tumour-hypoxia-modification":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"dose-painting":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"knowledge-based-planning":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"in-vivo-dosimetry":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radiogenomics":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"alpha-beta-ratio":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/radiation-wave1.ts"},"biologically-effective-dose":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/radiation-wave1.ts"},"planning-target-volume":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"organs-at-risk":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"deep-inspiration-breath-hold":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"fiducial-markers":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"tumour-hypoxia":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"oxygen-enhancement-ratio":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/radiation-wave1.ts"},"radiation-dermatitis":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radiation-pneumonitis":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"radiation-necrosis":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"second-cancers-after-radiotherapy":{"commit":"98e0a84888","date":"2026-09-17","author":"Jude Gomila","message":"Mobile search opens into the box; radiation wave 1","file":"src/data/radiation-wave1.ts"},"start-b":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave2.ts"},"fast-forward":{"commit":"34f7cddd67","date":"2026-09-17","author":"Jude Gomila","message":"Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112","file":"src/data/radiation-wave2.ts"},"chhip":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/radiation-wave2.ts"},"pace-b":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/radiation-wave2.ts"},"hypo-rt-pc":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/radiation-wave2.ts"},"rtog-0617":{"commit":"34f7cddd67","date":"2026-09-17","author":"Jude Gomila","message":"Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112","file":"src/data/radiation-wave2.ts"},"calgb-9343":{"commit":"34f7cddd67","date":"2026-09-17","author":"Jude Gomila","message":"Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112","file":"src/data/radiation-wave2.ts"},"prime-ii":{"commit":"34f7cddd67","date":"2026-09-17","author":"Jude Gomila","message":"Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112","file":"src/data/radiation-wave2.ts"},"lumina":{"commit":"34f7cddd67","date":"2026-09-17","author":"Jude Gomila","message":"Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112","file":"src/data/radiation-wave2.ts"},"import-low":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave2.ts"},"nsabp-b39":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave2.ts"},"chisel":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/radiation-wave2.ts"},"jcog0403":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/radiation-wave2.ts"},"alliance-n0574":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave2.ts"},"nrg-cc001":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave2.ts"},"quartz":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave2.ts"},"catnon":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave2.ts"},"dahanca-5":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/radiation-wave2.ts"},"nimorazole":{"commit":"cbe769fe34","date":"2026-09-17","author":"Jude Gomila","message":"Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs","file":"src/data/radiation-wave3.ts"},"nbtxr3":{"commit":"cbe769fe34","date":"2026-09-17","author":"Jude Gomila","message":"Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs","file":"src/data/radiation-wave3.ts"},"pilocarpine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/radiation-wave3.ts"},"avasopasem-manganese":{"commit":"cbe769fe34","date":"2026-09-17","author":"Jude Gomila","message":"Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs","file":"src/data/radiation-wave3.ts"},"evofosfamide":{"commit":"cbe769fe34","date":"2026-09-17","author":"Jude Gomila","message":"Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs","file":"src/data/radiation-wave3.ts"},"nanobiotix":{"commit":"cbe769fe34","date":"2026-09-17","author":"Jude Gomila","message":"Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs","file":"src/data/radiation-wave3.ts"},"int-0116":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave4.ts"},"cao-aro-aio-94":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/radiation-wave4.ts"},"rapido":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/radiation-wave4.ts"},"prodige-23":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/radiation-wave4.ts"},"act-ii":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/radiation-wave4.ts"},"rtog-91-11":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/radiation-wave4.ts"},"bonner-cetuximab-rt":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/radiation-wave4.ts"},"rtog-1016":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/radiation-wave4.ts"},"de-escalate":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/radiation-wave4.ts"},"rtog-9601":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave4.ts"},"horrad":{"commit":"675b9415fb","date":"2026-09-17","author":"Jude Gomila","message":"Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge","file":"src/data/radiation-wave4.ts"},"pop-rt":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave4.ts"},"slotman-pci-es-sclc":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/radiation-wave4.ts"},"takahashi-pci":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/radiation-wave4.ts"},"eortc-22922":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave4.ts"},"ma-20":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/radiation-wave4.ts"},"dbcg-82bc":{"commit":"4d75e66fa1","date":"2026-09-17","author":"Jude Gomila","message":"Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug","file":"src/data/radiation-wave4.ts"},"rtog-9402":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave4.ts"},"eortc-26951":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave4.ts"},"eortc-22033":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/radiation-wave4.ts"},"anal-hsil-precursor":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"localised-anal-cancer":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"metastatic-anal-cancer":{"commit":"758614384b","date":"2026-09-18","author":"Jude Gomila","message":"Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers","file":"src/data/rare-subtypes.ts"},"localised-penile-cancer":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"node-positive-penile-cancer":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"hpv-associated-vulvar-cancer":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"hpv-independent-vulvar-cancer":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"vaginal-squamous-cell-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"vaginal-adenocarcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"thymoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"thymic-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"localised-adrenocortical-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"advanced-adrenocortical-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"low-grade-appendiceal-mucinous-neoplasm":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"appendiceal-adenocarcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"goblet-cell-adenocarcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"localised-small-bowel-adenocarcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"advanced-small-bowel-adenocarcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"cup-favourable-subsets":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"cup-unfavourable":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"erdheim-chester-disease":{"commit":"758614384b","date":"2026-09-18","author":"Jude Gomila","message":"Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers","file":"src/data/rare-subtypes.ts"},"rosai-dorfman-disease":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"lch-single-system":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"lch-multisystem":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"indolent-systemic-mastocytosis":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"advanced-systemic-mastocytosis":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"early-stage-classical-hodgkin-lymphoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"advanced-stage-classical-hodgkin-lymphoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"nodular-lymphocyte-predominant-hodgkin-lymphoma":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/rare-subtypes.ts"},"relapsed-refractory-hodgkin-lymphoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"low-risk-gtn":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"high-risk-gtn":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"placental-site-trophoblastic-tumour":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"hereditary-ppgl":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"metastatic-ppgl":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"locoregionally-advanced-nasopharyngeal-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"recurrent-metastatic-nasopharyngeal-carcinoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"esthesioneuroblastoma":{"commit":"a3801e9dfe","date":"2026-09-18","author":"Jude Gomila","message":"Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR","file":"src/data/rare-subtypes.ts"},"sinonasal-undifferentiated-carcinoma":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/rare-subtypes.ts"},"mfolfox6":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"capox":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/colorectal.ts"},"folfiri":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/spikes/colorectal.ts"},"folfirinox":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"mfolfirinox-adjuvant":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"gem-nabpac":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"gemcitabine-mono":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"nalirifox":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"gemcis":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"flot":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/gastric.ts"},"cross":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/spikes/esophageal.ts"},"nivo-folfox-gastric":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"pembro-cis-fu-esophageal":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"tas102-bev":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"atezo-bev-hcc":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"stride":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"mitomycin-fu-crt-anal":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"captem":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"lutathera-prrt":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"everolimus-net":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"ddac-t":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"tc4":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"keynote-522":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"tchp":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"apt":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"thp-cleopatra":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"tdxd-breast":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"sacituzumab":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"capecitabine-create-x":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"olaparib-adjuvant":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cdk46-ai":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"keynote-189":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"keynote-407":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"checkmate-9la":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cis-vinorelbine-adjuvant":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"pacific":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"ep-sclc":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"ce-atezo":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"topotecan-sclc":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cis-pem-meso":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"nivo-ipi-meso":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"ddmvac":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"ev-pembro":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"bcg-induction-maintenance":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"docetaxel-prostate":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cabazitaxel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"lu-psma":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"bep":{"commit":"fb92d7f624","date":"2026-09-14","author":"Jude Gomila","message":"Aliases: PEB for the BEP regimen; subcutaneous and co-pack product names on rituximab, trastuzumab, niraparib and riboci","file":"src/data/regimens.ts"},"nivo-ipi-rcc":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"pembro-axitinib":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"carbo-taxol":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"carbo-taxol-bev":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"weekly-paclitaxel-ovarian":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"pld-ovarian":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"olaparib-maintenance":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"niraparib-maintenance":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"mirvetuximab":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cisplatin-crt-cervical":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"keynote-826":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"r-chop":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"pola-r-chp":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"r-ice":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"abvd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"bv-avd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"n-avd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"br":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"ven-obi":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"vrd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"d-vrd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"drd":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"melphalan-asct":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"lenalidomide-maintenance":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"7-3":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"ven-aza":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"atra-ato":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"inotuzumab":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"flu-cy-car-t":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"nivo-ipi-melanoma":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"pembrolizumab-flat":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"dab-tram":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"nivo-rela":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"doxorubicin-sts":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"vdc-ie":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"map":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"stupp":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"cisplatin-crt-hn":{"commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts"},"tpf":{"commit":"3f74538fc1","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: regimen pages count towards the NCI drug list, biologic-suffix stripping no longer swallows regimen acrony","file":"src/data/regimens.ts"},"keynote-048":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"gp-npc":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"cvp":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"ice":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"da-epoch-r":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/regimens.ts"},"hyper-cvad":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"escalated-beacopp":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"mopp":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"fec":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"cmf":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"tac":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"vip":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"veip":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"xeliri":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"gemox":{"commit":"d42dcc800c","date":"2026-09-14","author":"Jude Gomila","message":"Data: 15 OECI member centres and 6 aliases, 15 classic regimens (CHOP, CVP, ICE, DA-EPOCH-R, hyper-CVAD, escalated BEACO","file":"src/data/regimens.ts"},"fu-lv":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"ade":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"caf":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"off":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"vac":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"jeb":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"pad":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"stanford-v":{"commit":"e47aac90a1","date":"2026-09-15","author":"Jude Gomila","message":"Regimens: ADE, CAF, OFF, VAC, JEB, PAD, Stanford V and ABVE-PC with doses, schedules and primary sources (NCI drug list ","file":"src/data/regimens.ts"},"abve-pc":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"ac":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"bumel":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"cem":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"oepa":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"copdac":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"pcv":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"vamp":{"commit":"0f71b2a330","date":"2026-09-15","author":"Jude Gomila","message":"data: seven more NCI regimens (AC, BuMel, CEM, OEPA, COPDAC, PCV, VAMP) and leucovorin","file":"src/data/regimens.ts"},"cev":{"commit":"d2eeb072ef","date":"2026-09-15","author":"Jude Gomila","message":"data: CEV chemoreduction regimen for retinoblastoma (Friedman, JCO 2000)","file":"src/data/regimens.ts"},"chlorambucil-prednisone":{"commit":"7615455df0","date":"2026-09-16","author":"Jude Gomila","message":"data: chlorambucil-prednisone regimen from the ECOG trial; NCI list credits two-letter regimen acronyms (AC); list 381 o","file":"src/data/regimens.ts"},"breast-histology":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-size":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-grade":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-er":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-pr":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-her2-ihc":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-her2-ish":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-ki67":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-margins":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-dcis-margin-source":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-pn":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-m":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-oncotype":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"breast-rcb":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-psa":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-grade-group":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-pattern4":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-cores":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-pn":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"prostate-psa-post-op":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-site":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-pt":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-pn":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-nodes-examined":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-grade":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-budding":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-crm":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-mmr":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-ras":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"crc-cea":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-histology":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-size":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-pn":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-pdl1":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-egfr":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-kras":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-other-drivers":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lung-grade":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-type":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-coo":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-ki67":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-double-hit":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-stage":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-deauville":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-ipi":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-fl-grade":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"lym-ene":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-mprotein":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-flc-ratio":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-bmpc":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-crab":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-iss":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-riss":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"mm-cyto":{"commit":"9162ff99c2","date":"2026-09-09","author":"Jude Gomila","message":"Improvements batch A: Patients and families","file":"src/data/report-fields.ts"},"diagnostics-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"surgery-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"chemotherapy-roadmap":{"commit":"bd21f646fa","date":"2026-09-10","author":"Jude Gomila","message":"Roadmaps wave 2: diagnostics, surgery, chemotherapy, hormonal therapy, epigenetics","file":"src/data/roadmaps-wave2.ts"},"hormonal-therapy-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"epigenetics-roadmap":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/roadmaps-wave2.ts"},"survivorship-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"ai-oncology-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"nutrition-lifestyle-roadmap":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/roadmaps-wave2.ts"},"devices-roadmap":{"commit":"7cb9f7f1a0","date":"2026-09-10","author":"Jude Gomila","message":"Roadmaps wave 2: survivorship, AI in oncology, diet and lifestyle, devices, radiotherapy","file":"src/data/roadmaps-wave2.ts"},"radiation-roadmap":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/roadmaps-wave2.ts"},"targeted-therapy-roadmap":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/roadmaps-wave2.ts"},"drug-discovery-roadmap":{"commit":"86c9b0b7c2","date":"2026-09-10","author":"Jude Gomila","message":"Roadmaps wave 2: targeted therapy, drug discovery, prevention, paediatric oncology, global access, trial modernisation; ","file":"src/data/roadmaps-wave2.ts"},"prevention-roadmap":{"commit":"86c9b0b7c2","date":"2026-09-10","author":"Jude Gomila","message":"Roadmaps wave 2: targeted therapy, drug discovery, prevention, paediatric oncology, global access, trial modernisation; ","file":"src/data/roadmaps-wave2.ts"},"paediatric-oncology-roadmap":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/roadmaps-wave2.ts"},"global-access-roadmap":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/roadmaps-wave2.ts"},"trial-modernisation-roadmap":{"commit":"86c9b0b7c2","date":"2026-09-10","author":"Jude Gomila","message":"Roadmaps wave 2: targeted therapy, drug discovery, prevention, paediatric oncology, global access, trial modernisation; ","file":"src/data/roadmaps-wave2.ts"},"adc-generations":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"trop2-adc-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"tnbc-history":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"radiopharma-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"cell-therapy-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"molecular-imaging-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"early-detection-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"immunotherapy-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"kras-roadmap":{"commit":"8f410c5970","date":"2026-09-12","author":"Jude Gomila","message":"Roadmaps: landmark key paper DOIs as the primary source on 11 roadmaps that had none","file":"src/data/roadmaps.ts"},"chondrosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"angiosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"undifferentiated-pleomorphic-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"myxofibrosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"alveolar-soft-part-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"pecoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"epithelioid-haemangioendothelioma":{"commit":"a09bf99931","date":"2026-09-18","author":"Jude Gomila","message":"Add key papers to 147 cancer subtype pages","file":"src/data/sarcoma-bone-subtypes.ts"},"malignant-peripheral-nerve-sheath-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"retroperitoneal-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"extremity-soft-tissue-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-bone-subtypes.ts"},"strass":{"commit":"201db66d36","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to STRASS from its Lancet Oncology 2020 abstract","file":"src/data/sarcoma-bone-subtypes.ts"},"eortc-62012":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/sarcoma-bone-subtypes.ts"},"lms-04":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/sarcoma-bone-subtypes.ts"},"angiotax":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/sarcoma-bone-subtypes.ts"},"enliven":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/sarcoma-bone-subtypes.ts"},"ampect":{"commit":"1ead9ec759","date":"2026-09-18","author":"Jude Gomila","message":"Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English","file":"src/data/sarcoma-bone-subtypes.ts"},"leiomyosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-lymphoma-subtypes.ts"},"liposarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-lymphoma-subtypes.ts"},"synovial-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-lymphoma-subtypes.ts"},"marginal-zone-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-lymphoma-subtypes.ts"},"cutaneous-t-cell-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/sarcoma-lymphoma-subtypes.ts"},"imaging":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"diagnostics":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"early-detection":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"surgery":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"radiation":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"chemotherapy":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"targeted-therapy":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"immunotherapy":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"radiopharma":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"hormonal":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"epigenetics":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"supportive-care":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"ai-computation":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"drug-discovery":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"prevention":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"nutrition-lifestyle":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/sections.ts"},"devices":{"commit":"396209109f","date":"2026-09-12","author":"Jude Gomila","message":"Fronts: NCI and FDA reference pages as the primary source on the 18 fronts that had none","file":"src/data/sections.ts"},"combi-d":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"cobrim":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"checkmate-238":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"checkmate-204":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"empower-cscc-1":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"keynote-629":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"erivance":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"bolt":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"javelin-merkel-200":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"keynote-017":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/skin-subtypes.ts"},"braf-v600-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"stage-iii-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"stage-ii-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"advanced-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"mucosal-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"acral-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"advanced-cutaneous-scc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"locally-advanced-bcc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"dermatofibrosarcoma-protuberans":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/skin-subtypes.ts"},"src-npj-precision-oncology":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/sources.ts"},"src-ema-chmp":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/sources.ts"},"src-nice-ta":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-asco-post":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-onclive":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/sources.ts"},"src-targeted-oncology":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-cancer-network":{"commit":"8c9ad9ede6","date":"2026-09-11","author":"Jude Gomila","message":"Merge the last 475 summaries (keep incoming text, keep linking-pass relations); summary gauge clear","file":"src/data/sources.ts"},"src-cancer-letter":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-endpoints-news":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/sources.ts"},"src-fierce-biotech":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/sources.ts"},"src-stat-news":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-biocentury":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-evaluate":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-adc-review":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/sources.ts"},"src-urotoday":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-oncodaily":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/sources.ts"},"src-healio-hemonc":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-medscape-oncology":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-biopharma-dive":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-asco-meeting-library":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/sources.ts"},"src-esmo-congress":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-aacr-annual":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-ash-annual":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-sabcs":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-astro":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-snmmi":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-asco-daily-news":{"commit":"560baace9b","date":"2026-09-14","author":"Jude Gomila","message":"Journals and collections: 13 weakly linked records linked to their societies, publishers' sibling titles and related res","file":"src/data/sources.ts"},"src-nature-briefing-cancer":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-cruk-about-cancer":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-macmillan":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-lbbc":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"src-bcrf":{"commit":"8dbbc80465","date":"2026-09-12","author":"Jude Gomila","message":"Sources and collections: societies, publishers and journals behind 13 source records wired as graph relations","file":"src/data/sources.ts"},"src-tnbc-foundation":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/sources.ts"},"src-semantic-scholar":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/sources.ts"},"src-dimensions":{"commit":"201da32ab4","date":"2026-09-14","author":"Jude Gomila","message":"Journals and source collections: 16 weakly linked records cross-linked to sibling titles, societies, cancers and related","file":"src/data/sources.ts"},"autolus":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/all-leukemia.ts"},"adaptive-biotechnologies":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/all-leukemia.ts"},"inotuzumab-ozogamicin":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"tisagenlecleucel":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"obecabtagene-autoleucel":{"commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/spikes/all-leukemia.ts"},"ponatinib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/all-leukemia.ts"},"e1910":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"aall1731":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"tower":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/all-leukemia.ts"},"ino-vate":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/all-leukemia.ts"},"eliana":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"felix":{"commit":"964d920bf8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 13 more numeric outcome rows across eight trials (CAPTIVATE, CEPHEUS, DESTINY-Breas","file":"src/data/spikes/all-leukemia.ts"},"phallcon":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/all-leukemia.ts"},"d-alba":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/all-leukemia.ts"},"interfant-06":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"tki-plus-blinatumomab-ph-all":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"blinatumomab-frontline-consolidation":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"inotuzumab-then-transplant-caution":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/all-leukemia.ts"},"idea-transplant-free-ph-all":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/all-leukemia.ts"},"idea-menin-infant-all":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/all-leukemia.ts"},"kura-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/aml.ts"},"taiho-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/aml.ts"},"rigel-pharmaceuticals":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/aml.ts"},"kmt2a":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/aml.ts"},"npm1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/aml.ts"},"cd22":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/aml.ts"},"btk":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/aml.ts"},"bcr-abl":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/aml.ts"},"allogeneic-hsct":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/spikes/aml.ts"},"flow-cytometry-mrd":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/spikes/aml.ts"},"ngs-mrd-clonoseq":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/spikes/aml.ts"},"cytogenetics-fish":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/aml.ts"},"bh3-profiling":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/spikes/aml.ts"},"eln-risk":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/aml.ts"},"flt3-itd-allelic-ratio":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/aml.ts"},"ighv-status":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/aml.ts"},"del17p-tp53":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/aml.ts"},"richter-transformation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/aml.ts"},"mrd-negative-cr":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/aml.ts"},"tumor-lysis-syndrome":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/spikes/aml.ts"},"differentiation-syndrome":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/aml.ts"},"ph-positive-all":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/aml.ts"},"azacitidine":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"decitabine-cedazuridine":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/spikes/aml.ts"},"cytarabine-7-3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/aml.ts"},"cpx-351":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"enasidenib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/aml.ts"},"olutasidenib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"ziftomenib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"tagraxofusp":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/aml.ts"},"ratify":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"viale-a":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"quantum-first":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"admiral":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"agile":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"alfa-0701":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/aml.ts"},"augment-101":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"komet-001":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"cpx-351-301":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/aml.ts"},"ascertain-v":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/aml.ts"},"myelomatch":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/aml.ts"},"venetoclax-plus-hma":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/aml.ts"},"flt3i-plus-7-3":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/aml.ts"},"menin-plus-venetoclax-hma":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/aml.ts"},"idea-mrd-guided-transplant-aml":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/aml.ts"},"idea-shortened-venetoclax":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/spikes/aml.ts"},"hengrui":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/breast-her2-positive.ts"},"puma-biotechnology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"macrogenics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"hera-b31-n9831":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"cleopatra":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/breast-her2-positive.ts"},"aphinity":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"katherine":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"destiny-breast05":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"her2climb":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"her2climb-02":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"her2climb-05":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"destiny-breast12":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"phergain":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"persephone":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"apt-trial":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"horizon-breast01":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/breast-her2-positive.ts"},"ace-breast-02":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/breast-her2-positive.ts"},"pertuzumab":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-her2-positive.ts"},"pyrotinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"margetuximab":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/spikes/breast-her2-positive.ts"},"trastuzumab-rezetecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"trastuzumab-brengitecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"arx788":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-her2-positive.ts"},"trastuzumab-biosimilars":{"commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/spikes/breast-her2-positive.ts"},"dual-her2-blockade":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/breast-her2-positive.ts"},"her2-brain-metastases":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/breast-her2-positive.ts"},"trastuzumab-cardiotoxicity":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/breast-her2-positive.ts"},"biosimilar":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/spikes/breast-her2-positive.ts"},"tucatinib-triplet-brain-mets":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/breast-her2-positive.ts"},"pet-adapted-her2-deescalation":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/breast-her2-positive.ts"},"idea-tdxd-first-then-nothing":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/breast-her2-positive.ts"},"idea-cns-first-adc-strategy":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/breast-her2-positive.ts"},"idea-her2-adc-sequencing-payload":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/breast-her2-positive.ts"},"monaleesa-2":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/breast-hr-positive.ts"},"monarch-3":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/breast-hr-positive.ts"},"paloma-2":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/breast-hr-positive.ts"},"solar-1":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"capitello-291":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"inavo120":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"emerald":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"ember-3":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"serena-6":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"evera":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"persevera":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/breast-hr-positive.ts"},"lidera":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"postmonarch":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"tailorx":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"rxponder":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"soft-text":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"pallas-penelope-b":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"tropics-02":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"fourlight-1":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/breast-hr-positive.ts"},"cambria":{"commit":"e44afe9d61","date":"2026-09-13","author":"Jude Gomila","message":"Trials: registry status and phase updates applied from the fact check (AlphaBreak, CAMBRIA, MOUNTAINEER, NCT05208047), l","file":"src/data/spikes/breast-hr-positive.ts"},"fulvestrant":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/breast-hr-positive.ts"},"camizestrant":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"imlunestrant":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"giredestrant":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-hr-positive.ts"},"atirmociclib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/breast-hr-positive.ts"},"goserelin":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"mammaprint":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/spikes/breast-hr-positive.ts"},"esr1-mutation":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/breast-hr-positive.ts"},"oral-serd":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/breast-hr-positive.ts"},"endocrine-resistance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/breast-hr-positive.ts"},"ovarian-function-suppression":{"commit":"62f8a1cef3","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links for IVDR, SMCC and limited-stage SCLC; primary sources for 19 unlinked terms","file":"src/data/spikes/breast-hr-positive.ts"},"late-recurrence":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/spikes/breast-hr-positive.ts"},"oral-serd-plus-cdk46-after-esr1":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/breast-hr-positive.ts"},"pi3k-pathway-plus-endocrine":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/breast-hr-positive.ts"},"genomic-assay-to-chemo-omission":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/breast-hr-positive.ts"},"idea-ctdna-switch-generalised":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/breast-hr-positive.ts"},"idea-cdk4-selective-first-line":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/breast-hr-positive.ts"},"idea-late-recurrence-interception":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/spikes/breast-hr-positive.ts"},"keynote-a18":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"interlace":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"beatcc":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"compassion-16":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"innovatv-301":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"empower-cervical-1":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"outback":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"lacc":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"ken-she":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/cervical.ts"},"senticol-iii":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/cervical.ts"},"cadonilimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cervical.ts"},"gardasil-9":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/cervical.ts"},"cin-hsil":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/cervical.ts"},"hpv-testing":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/spikes/cervical.ts"},"colposcopy-excision":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/cervical.ts"},"precancer-ablation":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/spikes/cervical.ts"},"induction-chemo-then-crt":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/cervical.ts"},"io-plus-crt-cervical":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/cervical.ts"},"caution-mis-radical-hysterectomy":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/cervical.ts"},"idea-single-dose-hpv-self-sampling-elimination":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/cervical.ts"},"idea-hpv-ctdna-cervical":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/cervical.ts"},"incyte":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/spikes/cholangiocarcinoma.ts"},"taiho":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/cholangiocarcinoma.ts"},"transthera":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cholangiocarcinoma.ts"},"biliary-stenting-drainage":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/cholangiocarcinoma.ts"},"biliary-anatomy-subtypes":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/cholangiocarcinoma.ts"},"fgfr2-fusion":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/cholangiocarcinoma.ts"},"gemcitabine-cisplatin":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/cholangiocarcinoma.ts"},"pemigatinib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"futibatinib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"tinengotinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cholangiocarcinoma.ts"},"abc-02":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/cholangiocarcinoma.ts"},"bilcap":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"topaz-1":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"keynote-966":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"fight-202":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"foenix-cca2":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"claridhy":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/cholangiocarcinoma.ts"},"herizon-btc-302":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/cholangiocarcinoma.ts"},"first-308":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/cholangiocarcinoma.ts"},"naliricc":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/cholangiocarcinoma.ts"},"gemcis-plus-io-btc":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/cholangiocarcinoma.ts"},"idea-btc-ctdna-fgfr-resistance":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/cholangiocarcinoma.ts"},"obinutuzumab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"rituximab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/cll.ts"},"lisocabtagene-maraleucel":{"commit":"870c77641f","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a3393cb84495b4705 (blood cancer states)","file":"src/data/spikes/cll.ts"},"sonrotoclax":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cll.ts"},"bgb-16673":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cll.ts"},"nemtabrutinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/cll.ts"},"resonate":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"cll14":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"cll13-gaia":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"elevate-tn":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"sequoia":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"alpine":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"captivate":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"glow":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"amplify":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"bruin-cll-321":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"transcend-cll-004":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"celestial-tncll":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/cll.ts"},"cadance-304":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/cll.ts"},"bellwave-011":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/cll.ts"},"btki-plus-venetoclax-fixed-duration":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/cll.ts"},"venetoclax-plus-obinutuzumab":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/cll.ts"},"cit-in-del17p-caution":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/cll.ts"},"btki-ibrutinib-cardiac-caution":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/cll.ts"},"idea-mrd-guided-stop-cll":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/cll.ts"},"idea-btk-degrader-frontline":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/spikes/cll.ts"},"keynote-177":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"checkmate-8hw":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"niche-2":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"atomic":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"azur-1":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"breakwater":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"paradigm":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/colorectal.ts"},"crystal-fire3":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/colorectal.ts"},"mountaineer":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/spikes/colorectal.ts"},"destiny-crc02":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"sunlight":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/colorectal.ts"},"fresco-2":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/colorectal.ts"},"circulate-japan":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/colorectal.ts"},"panitumumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/colorectal.ts"},"trifluridine-tipiracil":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/colorectal.ts"},"fruquintinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/colorectal.ts"},"folfox":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/colorectal.ts"},"colorectal-screening":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/spikes/colorectal.ts"},"sidedness":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/colorectal.ts"},"cms-subtypes":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/spikes/colorectal.ts"},"lynch-syndrome":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/colorectal.ts"},"fit-test":{"commit":"ef9ce52198","date":"2026-09-11","author":"Jude Gomila","message":"Expand 60 short summaries across seventeen cancer files","file":"src/data/spikes/colorectal.ts"},"clinical-complete-response":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/spikes/colorectal.ts"},"anti-egfr-left-sided":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/colorectal.ts"},"neoadjuvant-io-dmmr":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/colorectal.ts"},"idea-ctdna-guided-adjuvant-crc":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/colorectal.ts"},"idea-immunotherapy-mss-crc":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/colorectal.ts"},"ctdna-lymphoma-monitoring":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/spikes/dlbcl.ts"},"ipi-score":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/dlbcl.ts"},"cell-of-origin":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/dlbcl.ts"},"double-hit-lymphoma":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/dlbcl.ts"},"lugano-classification":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/dlbcl.ts"},"epcoritamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"tafasitamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"mosunetuzumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"odronextamab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"golcadomide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/dlbcl.ts"},"polarix":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"zuma-7":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/dlbcl.ts"},"transform":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"starglo":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"epcore-nhl-1":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/dlbcl.ts"},"epcore-dlbcl-1":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"epcore-dlbcl-2":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"frontmind":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"l-mind":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/dlbcl.ts"},"lotis-2":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/dlbcl.ts"},"waveline-003":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/dlbcl.ts"},"sunmo":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/dlbcl.ts"},"golseek-1":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/dlbcl.ts"},"belinda":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/dlbcl.ts"},"bispecific-plus-adc-lymphoma":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/dlbcl.ts"},"car-t-before-transplant-lbcl":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/dlbcl.ts"},"idea-ctdna-guided-dlbcl-frontline":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/dlbcl.ts"},"idea-bispecific-vs-car-t-second-line":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/dlbcl.ts"},"ruby":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"nrg-gy018-keynote-868":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"duo-e":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"keynote-775":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"portec-3":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"destiny-pantumor02":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"xport-ec-042":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/endometrial.ts"},"fires-sentor":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/endometrial.ts"},"megestrol-progestins":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/spikes/endometrial.ts"},"eisai":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/spikes/hcc.ts"},"endometrial-molecular-classes":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/endometrial.ts"},"fertility-sparing-endometrial":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/spikes/endometrial.ts"},"chemo-io-first-line-endometrial":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/endometrial.ts"},"lenvatinib-plus-pembrolizumab":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/endometrial.ts"},"idea-molecular-class-adjuvant-endometrial":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/endometrial.ts"},"idea-her2-adc-serous-endometrial":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/endometrial.ts"},"sano":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/esophageal.ts"},"checkmate-577":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/esophageal.ts"},"keynote-590":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/esophageal.ts"},"checkmate-648":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/esophageal.ts"},"rationale-306":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/esophageal.ts"},"escort-1st":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/esophageal.ts"},"panku-esophagus01":{"commit":"0991a49534","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: colorectal, gastric, oesophageal cancer deep dives (69 new entities, structured outcomes, guideline mapping)","file":"src/data/spikes/esophageal.ts"},"tislelizumab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/esophageal.ts"},"camrelizumab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/esophageal.ts"},"endoscopic-resection":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/esophageal.ts"},"barretts-esophagus":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/spikes/esophageal.ts"},"escc-vs-eac":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/esophageal.ts"},"cross-then-nivolumab":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/esophageal.ts"},"idea-organ-preservation-esophageal":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/esophageal.ts"},"idea-non-endoscopic-barretts-screening":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/esophageal.ts"},"cml":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"mds":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/gap-cancers.ts"},"myeloproliferative-neoplasms":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/spikes/gap-cancers.ts"},"follicular-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"mantle-cell-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"peripheral-t-cell-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"primary-cns-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"waldenstrom":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"hairy-cell-leukemia":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"bpdcn":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"merkel-cell-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"cutaneous-scc":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"basal-cell-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"uveal-melanoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"testicular":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/spikes/gap-cancers.ts"},"anal":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/spikes/gap-cancers.ts"},"gist":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"appendiceal":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/spikes/gap-cancers.ts"},"vulvar":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/gap-cancers.ts"},"gestational-trophoblastic":{"commit":"a9999bad27","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: NCI A-Z names matched as aliases on 12 cancer records (121 of 128) and the Tisch Cancer Center name on Mou","file":"src/data/spikes/gap-cancers.ts"},"medulloblastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"osteosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"ewing-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"wilms-tumor":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"retinoblastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"rhabdomyosarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"hepatoblastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"cancer-of-unknown-primary":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/gap-cancers.ts"},"nasopharyngeal":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/gap-cancers.ts"},"thymic-epithelial":{"commit":"a9999bad27","date":"2026-09-13","author":"Jude Gomila","message":"Completeness: NCI A-Z names matched as aliases on 12 cancer records (121 of 128) and the Tisch Cancer Center name on Mou","file":"src/data/spikes/gap-cancers.ts"},"adrenocortical":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/gap-cancers.ts"},"salivary-gland":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/spikes/gap-cancers.ts"},"kaposi-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/gap-cancers.ts"},"toga":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/gastric.ts"},"checkmate-649":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/gastric.ts"},"keynote-859":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/gastric.ts"},"spotlight-glow":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/spikes/gastric.ts"},"matterhorn":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/spikes/gastric.ts"},"fortitude-101":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/gastric.ts"},"herizon-gea-01":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/gastric.ts"},"destiny-gastric04":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/gastric.ts"},"rainbow":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/gastric.ts"},"clarity-gastric01":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/gastric.ts"},"zolbetuximab":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/spikes/gastric.ts"},"ramucirumab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/hcc.ts"},"bemarituzumab":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/spikes/gastric.ts"},"siewert-classification":{"commit":"ef9ce52198","date":"2026-09-11","author":"Jude Gomila","message":"Expand 60 short summaries across seventeen cancer files","file":"src/data/spikes/gastric.ts"},"lauren-classification":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/gastric.ts"},"peritoneal-metastasis":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/gastric.ts"},"her2-gastric-sequence":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/gastric.ts"},"cldn18-antibody-then-adc":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/gastric.ts"},"idea-biomarker-quadruplet-gastric":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/gastric.ts"},"idea-peritoneal-directed-gastric":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/gastric.ts"},"lomustine":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/glioblastoma.ts"},"bevacizumab-glioma":{"commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/spikes/glioblastoma.ts"},"dordaviprone":{"commit":"49486fd519","date":"2026-09-13","author":"Jude Gomila","message":"Dordaviprone cites the pooled JCO 2024 analysis behind its accelerated approval and links the ACTION confirmatory trial;","file":"src/data/spikes/glioblastoma.ts"},"dcvax-l":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/glioblastoma.ts"},"rindopepimut":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/glioblastoma.ts"},"eortc-26981":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/glioblastoma.ts"},"ef-14":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/glioblastoma.ts"},"indigo":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/spikes/glioblastoma.ts"},"checkmate-143":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"checkmate-498":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"checkmate-548":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"cctg-ce6":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"act-iv":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/spikes/glioblastoma.ts"},"litt":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/spikes/glioblastoma.ts"},"bbb-focused-ultrasound":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/spikes/glioblastoma.ts"},"glioma-car-t":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/spikes/glioblastoma.ts"},"mgmt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/glioblastoma.ts"},"h3k27m":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/glioblastoma.ts"},"egfrviii":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/glioblastoma.ts"},"blood-brain-barrier":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"extent-of-resection":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"day-one-biopharmaceuticals":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/glioblastoma.ts"},"northwest-biotherapeutics":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/spikes/glioblastoma.ts"},"idea-neoadjuvant-io-glioblastoma":{"commit":"a55e44413e","date":"2026-09-17","author":"Erion de Andrade","message":"fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6","file":"src/data/spikes/glioblastoma.ts"},"idea-fus-plus-adc-glioma":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/spikes/glioblastoma.ts"},"exelixis":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/spikes/hcc.ts"},"elevar-therapeutics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/hcc.ts"},"sirtex":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/hcc.ts"},"boston-scientific":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/spikes/hcc.ts"},"tace":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/spikes/hcc.ts"},"radioembolisation-tare":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/hcc.ts"},"liver-transplant-oncology":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/hcc.ts"},"hcc-surveillance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/hcc.ts"},"afp":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/spikes/hcc.ts"},"child-pugh-albi":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/hcc.ts"},"bclc-staging":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/hcc.ts"},"hbv-hcv":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/hcc.ts"},"camrelizumab-rivoceranib":{"commit":"b71f065c3c","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: camrelizumab plus rivoceranib, ivonescimab and sacituzumab tirumotecan marked approved, matching their recor","file":"src/data/spikes/hcc.ts"},"sharp":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"reflect":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"resorce":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"celestial":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"imbrave150":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"himalaya":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"checkmate-9dw":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"leap-002":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/hcc.ts"},"cares-310":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/hcc.ts"},"imbrave050":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"emerald-1":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"leap-012":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"emerald-3":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/hcc.ts"},"sarah-sirvenib":{"commit":"6500e40f2e","date":"2026-09-13","author":"Jude Gomila","message":"Trials: each outcome row of the combined RADIANT, SARAH, HERA/B-31 and SANET records now cites the publication of the tr","file":"src/data/spikes/hcc.ts"},"tace-plus-systemic":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/hcc.ts"},"io-varices-caution":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/hcc.ts"},"idea-hcc-io-before-transplant":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/spikes/hcc.ts"},"idea-hcc-blood-surveillance":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/spikes/hcc.ts"},"keynote-689":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"extreme":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"checkmate-141":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"rtog-0129":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"nrg-hn002-hn005":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"javelin-hn-100":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"trilynx":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"jupiter-02":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/head-and-neck.ts"},"liger-hn1":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"fortifi-hn01":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"toripalimab":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/head-and-neck.ts"},"petosemtamab":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"ficerafusp-alfa":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/head-and-neck.ts"},"cetuximab-sarotalocan":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/head-and-neck.ts"},"tors":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"cthpv-dna":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"hpv-p16":{"commit":"b30654112d","date":"2026-09-18","author":"Jude Gomila","message":"Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic","file":"src/data/spikes/head-and-neck.ts"},"lgr5":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/head-and-neck.ts"},"io-before-surgery-hnscc":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/head-and-neck.ts"},"egfr-bispecific-plus-pd1-hnscc":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/head-and-neck.ts"},"hpv-deescalation-caution":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/head-and-neck.ts"},"idea-cthpv-adapted-deescalation":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/head-and-neck.ts"},"idea-photoimmunotherapy-plus-pd1":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/head-and-neck.ts"},"cd30":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/hodgkin-lymphoma.ts"},"pet-adapted-therapy":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/spikes/hodgkin-lymphoma.ts"},"deauville-score":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/spikes/hodgkin-lymphoma.ts"},"reed-sternberg-cell":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/hodgkin-lymphoma.ts"},"echelon-1":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"swog-s1826":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"hd21":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"rathl":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"keynote-204":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"checkmate-205":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"ahod2131":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"aethera":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/hodgkin-lymphoma.ts"},"pd1-plus-avd-hodgkin":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/hodgkin-lymphoma.ts"},"bleomycin-omission-caution":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/hodgkin-lymphoma.ts"},"idea-chemo-free-hodgkin":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/hodgkin-lymphoma.ts"},"idea-cd30-car-t-hodgkin":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/hodgkin-lymphoma.ts"},"keynote-006":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"relativity-047":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"nadina":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"swog-s1801":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"keynote-716":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"combi-ad":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"columbus":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"dreamseq":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"c-144-01":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"imcgp100-202":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/melanoma.ts"},"mslt-ii":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"prism-mel-301":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/melanoma.ts"},"fianlimab-phase3-melanoma":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/melanoma.ts"},"relativity-098":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/melanoma.ts"},"binimetinib":{"commit":"afae218e88","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-accd7d146eb7ae9ad","file":"src/data/spikes/melanoma.ts"},"cobimetinib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/melanoma.ts"},"brenetafusp":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/melanoma.ts"},"fianlimab":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/melanoma.ts"},"dermoscopy-ai":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/spikes/melanoma.ts"},"breslow-thickness":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/melanoma.ts"},"ulceration-melanoma":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/melanoma.ts"},"major-pathological-response":{"commit":"62f8a1cef3","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links for IVDR, SMCC and limited-stage SCLC; primary sources for 19 unlinked terms","file":"src/data/spikes/melanoma.ts"},"hla-a02-restriction":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/melanoma.ts"},"io-first-then-braf-mek":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/melanoma.ts"},"neoadjuvant-io-response-adapted":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/melanoma.ts"},"lag3-adjuvant-caution":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/melanoma.ts"},"idea-ctdna-guided-adjuvant-melanoma":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/melanoma.ts"},"idea-prame-tcr-beyond-a02":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/melanoma.ts"},"prame":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/melanoma.ts"},"checkmate-743":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/mesothelioma.ts"},"keynote-483":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/mesothelioma.ts"},"maps":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/mesothelioma.ts"},"mars-2":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/mesothelioma.ts"},"lume-meso":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/mesothelioma.ts"},"beat-meso":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/mesothelioma.ts"},"dream3r":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/mesothelioma.ts"},"stellar":{"commit":"964d920bf8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 13 more numeric outcome rows across eight trials (CAPTIVATE, CEPHEUS, DESTINY-Breas","file":"src/data/spikes/mesothelioma.ts"},"nintedanib":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/mesothelioma.ts"},"pleurectomy-decortication":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/mesothelioma.ts"},"epithelioid-vs-sarcomatoid":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/mesothelioma.ts"},"histology-directs-first-line-meso":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/mesothelioma.ts"},"idea-adc-for-mesothelioma":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/spikes/mesothelioma.ts"},"idea-mtap-prmt5-mesothelioma":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/mesothelioma.ts"},"idea-mesothelin-car-t-regional":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/spikes/mesothelioma.ts"},"autologous-stem-cell-transplant":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/spikes/multiple-myeloma.ts"},"r-iss":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"high-risk-myeloma":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/multiple-myeloma.ts"},"mrd-negativity-myeloma":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/spikes/multiple-myeloma.ts"},"smoldering-myeloma":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"carfilzomib":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"daratumumab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"isatuximab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"idecabtagene-vicleucel":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"anitocabtagene-autoleucel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/multiple-myeloma.ts"},"elranatamab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"talquetamab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"linvoseltamab":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"iberdomide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/multiple-myeloma.ts"},"mezigdomide":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/multiple-myeloma.ts"},"perseus":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"cepheus":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"imroz":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"cartitude-1":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"cartitude-4":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"karmma-3":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"majestec-1":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"majestec-3":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"magnetismm-3":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"monumental-1":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"linker-mm1":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"dreamm-7":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"dreamm-8":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"immagine-1":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/multiple-myeloma.ts"},"cartitude-5":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/multiple-myeloma.ts"},"istopmm":{"commit":"f962323ae9","date":"2026-09-18","author":"Jude Gomila","message":"Blood cancers by driver, state and phase: nineteen subtype pages","file":"src/data/spikes/multiple-myeloma.ts"},"cd38-plus-triplet":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/multiple-myeloma.ts"},"bcma-then-gprc5d":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/multiple-myeloma.ts"},"bispecific-infection-prophylaxis":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/multiple-myeloma.ts"},"idea-mrd-guided-stop-myeloma":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/multiple-myeloma.ts"},"idea-car-t-replaces-transplant":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/multiple-myeloma.ts"},"paediatric-low-grade-glioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"dipg-dmg":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"atrt":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"ependymoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"craniopharyngioma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"pleuropulmonary-blastoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"paediatric-germ-cell-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"langerhans-cell-histiocytosis":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/spikes/nci-paediatric.ts"},"burkitt-lymphoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"rare-childhood-cancers":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-paediatric.ts"},"gallbladder":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-other.ts"},"ampullary":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-other.ts"},"small-bowel":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/spikes/nci-rare-other.ts"},"penile":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/nci-rare-other.ts"},"urethral":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/spikes/nci-rare-other.ts"},"vaginal":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/nci-rare-other.ts"},"male-breast-cancer":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/nci-rare-other.ts"},"ductal-carcinoma-in-situ":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-other.ts"},"hiv-associated-lymphoma":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/nci-rare-other.ts"},"cmml":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-other.ts"},"systemic-mastocytosis":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/spikes/nci-rare-other.ts"},"histiocytoses":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/spikes/nci-rare-other.ts"},"post-transplant-lymphoproliferative-disorder":{"commit":"0cef9d235e","date":"2026-09-18","author":"Jude Gomila","message":"DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added","file":"src/data/spikes/nci-rare-other.ts"},"chordoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"desmoid-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"tenosynovial-giant-cell-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"epithelioid-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"inflammatory-myofibroblastic-tumour":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"vascular-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"uterine-sarcoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"nut-carcinoma":{"commit":"ebd8e3a151","date":"2026-09-16","author":"Jude Gomila","message":"cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer,","file":"src/data/spikes/nci-rare-solid.ts"},"sinonasal":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/spikes/nci-rare-solid.ts"},"pheochromocytoma-paraganglioma":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/spikes/nci-rare-solid.ts"},"parathyroid-carcinoma":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/spikes/nci-rare-solid.ts"},"pituitary-tumours":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/spikes/nci-rare-solid.ts"},"multiple-endocrine-neoplasia":{"commit":"b189b74030","date":"2026-09-10","author":"Jude Gomila","message":"NCI A to Z coverage: 36 paediatric and rare cancer records, paediatric fronts, organ drawings and tests","file":"src/data/spikes/nci-rare-solid.ts"},"y-mabs":{"commit":"1ae828916f","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies","file":"src/data/spikes/neuroblastoma.ts"},"gd2":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/spikes/neuroblastoma.ts"},"tandem-transplant":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"mibg-theranostics":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/neuroblastoma.ts"},"inrg-staging":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/spikes/neuroblastoma.ts"},"mycn-amplification":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"dinutuximab":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"naxitamab":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"eflornithine":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"i131-mibg":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/neuroblastoma.ts"},"anbl0032":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"anbl0532":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"hr-nbl1":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"anbl1531":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"gd2-cart01":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"naxitamab-201":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"nmtrc003":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"anti-gd2-plus-chemo-relapse":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"il2-anti-gd2-caution":{"commit":"376cf3806e","date":"2026-09-18","author":"Jude Gomila","message":"Add paediatric cancers by type and risk group","file":"src/data/spikes/neuroblastoma.ts"},"idea-gd2-car-t-frontline-consolidation":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/neuroblastoma.ts"},"idea-mfbg-pet-replaces-mibg":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/neuroblastoma.ts"},"sstr-pet":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/spikes/neuroendocrine.ts"},"prrt":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/neuroendocrine.ts"},"net-grade-ki67":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"chromogranin-a":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/neuroendocrine.ts"},"carcinoid-syndrome":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"men1-hereditary-net":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"octreotide-lanreotide":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/neuroendocrine.ts"},"itm-11":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"alphamedix":{"commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, ","file":"src/data/spikes/neuroendocrine.ts"},"capecitabine-temozolomide":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"promid":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"clarinet":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"radiant-3-4":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"cabinet":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"compete":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/neuroendocrine.ts"},"alphamedix-02":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/neuroendocrine.ts"},"action-1":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/neuroendocrine.ts"},"sanet":{"commit":"6500e40f2e","date":"2026-09-13","author":"Jude Gomila","message":"Trials: each outcome row of the combined RADIANT, SARAH, HERA/B-31 and SANET records now cites the publication of the tr","file":"src/data/spikes/neuroendocrine.ts"},"sstr-pet-to-prrt":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/neuroendocrine.ts"},"prrt-then-alpha-net":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/neuroendocrine.ts"},"idea-net-dosimetry-prrt":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/neuroendocrine.ts"},"idea-net-antagonist-ligands":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/neuroendocrine.ts"},"nlst-nelson":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/nsclc.ts"},"crown":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"alina":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"laura":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"checkmate-816":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"keynote-671":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"keynote-024-189":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"harmoni-2":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"harmoni-3":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"herthena-lung02":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"tropion-lung05":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"krystal-12":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"codebreak-200":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"krascendo-1":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"libretto-431":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"telimet-nsclc-01":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"alkove-1":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"soho-01":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"sevabertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"divarasib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"olomorasib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/nsclc.ts"},"neladalkib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"tremelimumab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"ros1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/nsclc.ts"},"low-dose-ct-screening":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/spikes/nsclc.ts"},"robotic-bronchoscopy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/nsclc.ts"},"tps":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/nsclc.ts"},"egfr-exon19-l858r":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/nsclc.ts"},"egfr-exon20-insertion":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/nsclc.ts"},"c797s":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/nsclc.ts"},"met-amplification":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/nsclc.ts"},"histologic-transformation":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/spikes/nsclc.ts"},"oligoprogression":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/spikes/nsclc.ts"},"amivantamab-plus-lazertinib":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/nsclc.ts"},"pd1-plus-chemo-pdl1-low":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/nsclc.ts"},"targeted-before-io-nsclc":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/spikes/nsclc.ts"},"solo-1":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"prima":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"paola-1":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"athena-mono":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"duo-o":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/ovarian.ts"},"gog-0218-icon7":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/ovarian.ts"},"ovhipec-1":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/ovarian.ts"},"desktop-iii":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"mirasol":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"rosella":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"keynote-b96":{"commit":"fbbfd3af8f","date":"2026-09-18","author":"Jude Gomila","message":"Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or re","file":"src/data/spikes/ovarian.ts"},"ramp-201":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/ovarian.ts"},"rejoice-ovarian01":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/ovarian.ts"},"rainfol-01":{"commit":"afc6af185b","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: ovarian, endometrial, cervical cancer deep dives (74 new entities with structured outcomes, dosing, toxicity, re","file":"src/data/spikes/ovarian.ts"},"ukctocs":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/spikes/ovarian.ts"},"avutometinib-defactinib":{"commit":"402dd51c83","date":"2026-09-18","author":"Jude Gomila","message":"Add drugs named by the cancer subtype pages (drugs-subtypes-wave)","file":"src/data/spikes/ovarian.ts"},"pegylated-liposomal-doxorubicin":{"commit":"6688c47c42","date":"2026-09-18","author":"Jude Gomila","message":"Merge duplicate trial records onto their named keepers","file":"src/data/spikes/ovarian.ts"},"luveltamab-tazevibulin":{"commit":"afc6af185b","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: ovarian, endometrial, cervical cancer deep dives (74 new entities with structured outcomes, dosing, toxicity, re","file":"src/data/spikes/ovarian.ts"},"rinatabart-sesutecan":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/ovarian.ts"},"karyopharm":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/ovarian.ts"},"ca-125":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/ovarian.ts"},"lgsoc":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/ovarian.ts"},"hgsoc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/ovarian.ts"},"risk-reducing-salpingectomy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/ovarian.ts"},"parp-plus-bevacizumab":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/ovarian.ts"},"hipec-at-interval-surgery":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/ovarian.ts"},"caution-pd1-first-line-ovarian":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/ovarian.ts"},"idea-fra-adc-sequencing-ovarian":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/ovarian.ts"},"idea-ctdna-guided-parp-duration":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/ovarian.ts"},"gemcitabine-nab-paclitaxel":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"zoldonrasib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"elironrasib":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"mrtx1133":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"eli-002-7p":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"rasolute-302":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/spikes/pancreatic.ts"},"napoli-3":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"prodige-24":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"preopanc":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"polo":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"panova-3":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"amplify-7p":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"pancreatic-surveillance":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"pdac-organoid-pharmacotyping":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/spikes/pancreatic.ts"},"ca19-9":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/spikes/pancreatic.ts"},"desmoplasia":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/pancreatic.ts"},"ipsen":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/spikes/pancreatic.ts"},"elicio-therapeutics":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/pancreatic.ts"},"idea-ras-inhibitor-neoadjuvant-pdac":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/pancreatic.ts"},"idea-mced-new-onset-diabetes":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/pancreatic.ts"},"g12d-plus-pan-ras":{"commit":"77251167c8","date":"2026-09-17","author":"Jude Gomila","message":"Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancre","file":"src/data/spikes/pancreatic.ts"},"curium":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"sumitomo-pharma":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/prostate.ts"},"veracyte":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/prostate.ts"},"blue-earth-diagnostics":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"essa-pharma":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/prostate.ts"},"steap1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/prostate.ts"},"klk2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/prostate.ts"},"grpr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/spikes/prostate.ts"},"active-surveillance":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"mp-mri":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/spikes/prostate.ts"},"psa":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/prostate.ts"},"gleason-grade-group":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/spikes/prostate.ts"},"castration-resistance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/prostate.ts"},"biochemical-recurrence":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/prostate.ts"},"psa50":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/spikes/prostate.ts"},"ar-v7":{"commit":"584701800f","date":"2026-09-11","author":"Jude Gomila","message":"Expand 162 short summaries: collections, sources and twelve cancer files","file":"src/data/spikes/prostate.ts"},"relugolix":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"radium-223":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"lu177-psma-it":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"xaluritamig":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"pasritamig":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"ga68-psma-11":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"flotufolastat":{"commit":"ad62c62202","date":"2026-09-10","author":"Jude Gomila","message":"Summaries expanded for cancers, treatments, targets, technologies and pathways","file":"src/data/spikes/prostate.ts"},"mevrometostat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/prostate.ts"},"masofaniten":{"commit":"b62c3a04f8","date":"2026-09-06","author":"Jude Gomila","message":"Prostate cancer spike: 57 entities (trials, products, targets, terms, companies, ideas) and deep patch of the prostate r","file":"src/data/spikes/prostate.ts"},"decipher-prostate":{"commit":"b758371248","date":"2026-09-12","author":"Jude Gomila","message":"Primary sources for nine treatments and tests and two targets that had none (registry entries, FDA PMA pages, UniProt)","file":"src/data/spikes/prostate.ts"},"protect":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"precision-mri":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"stampede":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"chaarted":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"latitude":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"arches":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"arasens":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"peace-1":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"embark":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"profound":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"propel":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"talapro-2":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"magnitude":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"capitello-281":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"alsympca":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"propsma":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"therap":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"psmaddition":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"splash":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"eclipse-psma":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"alphabreak":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"xalute":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"mevpro-1":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/spikes/prostate.ts"},"idea-psma-pet-guided-mdt":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/prostate.ts"},"idea-alpha-first-mhspc":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/prostate.ts"},"checkmate-214":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/rcc.ts"},"keynote-426":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/rcc.ts"},"checkmate-9er":{"commit":"e4525049c8","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 numeric outcome rows across 28 landmark trials (ABC-02 to TOWER), each DOI check","file":"src/data/spikes/rcc.ts"},"clear":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/rcc.ts"},"keynote-564":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/rcc.ts"},"litespark-022":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/rcc.ts"},"litespark-005":{"commit":"9fd9c4e669","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 15 more numeric outcome rows across 13 trials (AMPLIFY, AUGMENT-101, CheckMate 9DW,","file":"src/data/spikes/rcc.ts"},"litespark-012":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/rcc.ts"},"cosmic-313":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/rcc.ts"},"contact-03":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/spikes/rcc.ts"},"tinivo-2":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/rcc.ts"},"tivozanib":{"commit":"90c2622943","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: EU approval rows on 18 more drugs, derived from the EPAR-checked regional approvals table","file":"src/data/spikes/rcc.ts"},"partial-nephrectomy-active-surveillance":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/rcc.ts"},"caix-pet":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/spikes/rcc.ts"},"imdc-risk":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/spikes/rcc.ts"},"sarcomatoid-rcc":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/rcc.ts"},"aveo":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/spikes/rcc.ts"},"io-rechallenge-caution-rcc":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/rcc.ts"},"risk-directed-first-line-rcc":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/rcc.ts"},"idea-adjuvant-selection-rcc":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/rcc.ts"},"idea-caix-theranostics":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/rcc.ts"},"deciphera":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/sarcoma.ts"},"springworks":{"commit":"5783767ea2","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 78 institutions, 36 companies","file":"src/data/spikes/sarcoma.ts"},"us-worldmeds":{"commit":"e722177d44","date":"2026-09-13","author":"Jude Gomila","message":"Treatments: omidubicel, remestemcel-L and the Hepzato melphalan kit added with FDA approval sources, plus Gamida Cell, M","file":"src/data/spikes/sarcoma.ts"},"limb-salvage-surgery":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/spikes/sarcoma.ts"},"fnclcc-grade":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/spikes/sarcoma.ts"},"sarcoma-histotype-tailoring":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/spikes/sarcoma.ts"},"ifosfamide":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/sarcoma.ts"},"ripretinib":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/sarcoma.ts"},"avapritinib":{"commit":"93b15e6069","date":"2026-09-18","author":"Jude Gomila","message":"Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adren","file":"src/data/spikes/sarcoma.ts"},"nirogacestat":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/sarcoma.ts"},"vimseltinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/sarcoma.ts"},"letetresgene-autoleucel":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/sarcoma.ts"},"isg-sts-1001":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/spikes/sarcoma.ts"},"announce":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/spikes/sarcoma.ts"},"invictus":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/sarcoma.ts"},"insight-gist":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/sarcoma.ts"},"voyager":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/spikes/sarcoma.ts"},"defi":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/sarcoma.ts"},"motion":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/spikes/sarcoma.ts"},"ignyte-eso":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/sarcoma.ts"},"euro-ewing-2012":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/sarcoma.ts"},"int-0091":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/sarcoma.ts"},"ssgxviii":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/spikes/sarcoma.ts"},"ctdna-genotype-gist-tki":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/sarcoma.ts"},"doxorubicin-cardio-caution":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/sarcoma.ts"},"idea-tcr-t-beyond-hla-a2":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/sarcoma.ts"},"idea-desmoid-intermittent-dosing":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/sarcoma.ts"},"impower133":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"caspian":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"adriatic":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"imforte":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"atlantis":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/sclc.ts"},"dellphi-305":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"ideate-lung02":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/spikes/sclc.ts"},"astrum-005":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"convert":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"platinum-etoposide":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/spikes/sclc.ts"},"lurbinectedin":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"topotecan":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/sclc.ts"},"serplulimab":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/spikes/sclc.ts"},"prophylactic-cranial-irradiation":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/sclc.ts"},"pharmamar":{"commit":"7f73c54094","date":"2026-09-18","author":"Jude Gomila","message":"Link 193 company-less drugs to their makers and add 74 maker records","file":"src/data/spikes/sclc.ts"},"henlius":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/sclc.ts"},"chemo-io-then-maintenance-sclc":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/sclc.ts"},"tarlatamab-vs-idxd-sequence":{"commit":"ef9ce52198","date":"2026-09-11","author":"Jude Gomila","message":"Expand 60 short summaries across seventeen cancer files","file":"src/data/spikes/sclc.ts"},"idea-sclc-subtype-directed":{"commit":"89a91967aa","date":"2026-09-12","author":"Jude Gomila","message":"Pairings and ideas: on-topic corpus trials and landmark papers as the primary source on 12 pairings and 18 ideas that ha","file":"src/data/spikes/sclc.ts"},"idea-mri-surveillance-replaces-pci":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/sclc.ts"},"select-lenvatinib":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"decision-sorafenib":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"libretto-531":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"arrow-thyroid":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/thyroid.ts"},"estimabl2":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"ion-trial":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/spikes/thyroid.ts"},"hilo":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"roar-atc":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"astra":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/thyroid.ts"},"radioactive-iodine":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/thyroid.ts"},"vandetanib":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/thyroid.ts"},"radioiodine-therapy":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/thyroid.ts"},"thyroid-fna-molecular":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/spikes/thyroid.ts"},"active-surveillance-thyroid":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/spikes/thyroid.ts"},"rai-refractory":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/thyroid.ts"},"low-risk-dtc":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/spikes/thyroid.ts"},"bethesda-category":{"commit":"8a68b0a5ff","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 23 more terms (516 of 594)","file":"src/data/spikes/thyroid.ts"},"tsh-suppression":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/thyroid.ts"},"tert-promoter":{"commit":"ff0a722cce","date":"2026-09-12","author":"Jude Gomila","message":"Glossary and pairings: landmark trial and guideline papers as the primary source on 17 terms and 9 pairings that had non","file":"src/data/spikes/thyroid.ts"},"braf-mek-neoadjuvant-atc":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/thyroid.ts"},"redifferentiation-rai":{"commit":"a093df1d49","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on 30 pairings that had none","file":"src/data/spikes/thyroid.ts"},"idea-thyroid-overdiagnosis-reversal":{"commit":"8fae02ad90","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: landmark papers as the primary source on 33 ideas that had none","file":"src/data/spikes/thyroid.ts"},"idea-atc-triplet-io":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/thyroid.ts"},"niagara":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/urothelial.ts"},"ev-303":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/spikes/urothelial.ts"},"ev-304":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/spikes/urothelial.ts"},"checkmate-274":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/urothelial.ts"},"potomac":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/urothelial.ts"},"sunrise-1":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/urothelial.ts"},"bond-003":{"commit":"39a59d2e45","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on seven more outcome rows (CELESTIAL, LINKER-MM1, ASCENT-04, QUILT 3.032, BOND-003)","file":"src/data/spikes/urothelial.ts"},"quilt-3-032":{"commit":"39a59d2e45","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on seven more outcome rows (CELESTIAL, LINKER-MM1, ASCENT-04, QUILT 3.032, BOND-003)","file":"src/data/spikes/urothelial.ts"},"thor":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/urothelial.ts"},"javelin-bladder-100":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/spikes/urothelial.ts"},"bcg-intravesical":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/urothelial.ts"},"tar-200":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"cretostimogene":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"nogapendekin-alfa":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"nadofaragene-firadenovec":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"erdafitinib":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"avelumab":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/spikes/urothelial.ts"},"zelenectide-pevedotin":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"bcg-and-intravesical-therapy":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/spikes/urothelial.ts"},"cystoscopy-turbt":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/spikes/urothelial.ts"},"nmibc-vs-mibc":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/urothelial.ts"},"bcg-unresponsive":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/spikes/urothelial.ts"},"fgfr3":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/spikes/urothelial.ts"},"cg-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"immunitybio":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"ferring":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/spikes/urothelial.ts"},"bicycle-therapeutics":{"commit":"813344f111","date":"2026-09-18","author":"Jude Gomila","message":"Merge worktree-agent-a92b346da6e5b3a8a (orphan trials content)","file":"src/data/spikes/urothelial.ts"},"ev-pembro-continuum":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/urothelial.ts"},"durvalumab-plus-bcg":{"commit":"1ff0854468","date":"2026-09-12","author":"Jude Gomila","message":"Pairings: registry entry of the linked trial as the primary source on the remaining 29 pairings","file":"src/data/spikes/urothelial.ts"},"idea-bladder-preservation-mibc":{"commit":"7ad93e5e1b","date":"2026-09-12","author":"Jude Gomila","message":"Ideas: registry entry of the cited trial as the primary source on 30 ideas that had none","file":"src/data/spikes/urothelial.ts"},"idea-urine-ctdna-surveillance":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/spikes/urothelial.ts"},"galapagos":{"commit":"51485c66a9","date":"2026-09-18","author":"Jude Gomila","message":"Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (","file":"src/data/sponsor-aliases.ts"},"nsclc-tnm8":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"sclc-valg":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/staging.ts"},"colorectal-tnm8":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"breast-tnm8":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"melanoma-ajcc8":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"prostate-nccn-risk":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"gleason-grade-groups":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"lugano":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"iss-riss":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"bclc-2022":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"figo-ovarian-2014":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"figo-cervical-2018":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"binet":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"nmibc-risk":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"who-cns5-glioma":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"r-ipi":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"flipi":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"imdc":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"cll-ipi":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"mipi-s":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"child-pugh":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"khorana":{"commit":"d8f398a077","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/staging.ts"},"closed-automated-cell-manufacturing":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"point-of-care-cell-manufacturing":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"viral-vector-manufacturing":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"plasmid-dna-manufacturing":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"adc-cdmo-manufacturing":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"radiopharmacy-network":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"therapy-isotope-supply-chain":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/supporting.ts"},"long-read-sequencing":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"next-gen-short-read-platforms":{"commit":"a96eda0ee8","date":"2026-09-13","author":"Jude Gomila","message":"Companies: duplicate Kheiron records merged into one with a redirect from the old page; Ultima Genomics preprint cited f","file":"src/data/supporting.ts"},"spatial-biology-instruments":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"whole-slide-scanners":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/supporting.ts"},"treatment-planning-systems":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"auto-contouring-ai":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"oncology-real-world-data":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/supporting.ts"},"clinical-trial-software":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"decentralised-clinical-trials":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/supporting.ts"},"community-oncology-networks":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/supporting.ts"},"contract-research-organisations":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"imaging-core-labs":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"biobanking":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"reference-laboratories":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/supporting.ts"},"pet-tracer-manufacturing":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/supporting.ts"},"nuclear-medicine-hardware":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"remote-patient-monitoring":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/supporting.ts"},"pharmacy-automation":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/supporting.ts"},"ai-compute-platforms":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/supporting.ts"},"sterile-fill-finish":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"generic-drug-shortage-response":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"hospital-information-systems-oncology":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"high-potency-payload-synthesis":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"apheresis-starting-material":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"cell-therapy-cold-chain":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"cell-therapy-orchestration-software":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"cell-therapy-release-testing":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"allogeneic-cell-banking":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"monoclonal-antibody-manufacturing":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"medical-cyclotrons-synthesis-modules":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"radionuclide-generators-kits":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"ngs-bioinformatics-software":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/supporting.ts"},"genomics-cloud-platforms":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"variant-knowledgebases":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/supporting.ts"},"cancer-registries-surveillance":{"commit":"d6625dd92d","date":"2026-09-17","author":"Jude Gomila","message":"Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers","file":"src/data/supporting.ts"},"proteomics-platforms":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"structural-biology-infrastructure":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/supporting.ts"},"high-throughput-screening-libraries":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"preanalytics-sample-stabilisation":{"commit":"df56926256","date":"2026-09-13","author":"Jude Gomila","message":"Sources on 11 more records: SKYSCRAPER-01 and CITYSCAPE for the TIGIT caution, the ADC-after-ADC series, and cGMP, tissu","file":"src/data/supporting.ts"},"ihc-autostainers-histology-automation":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/supporting.ts"},"infusion-devices-vascular-access":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/supporting.ts"},"federated-learning-medical-ai":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"telemedicine-teleoncology":{"commit":"84973ce492","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: FDA guidance, ICH GCP, ASCO and ESGO standards as the primary source on 17 manufacturing and service techn","file":"src/data/supporting.ts"},"miltenyi-biotec":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"lonza":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"cellares":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"cytiva":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"oxford-biomedica":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"thermo-fisher":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"charles-river":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"aldevron":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"touchlight":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"wuxi-xdc":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"samsung-biologics":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"piramal-pharma-solutions":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"abzena":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"catalent":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"petnet-solutions":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"cardinal-health":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"jubilant-radiopharma":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"northstar-medical-radioisotopes":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"shine-technologies":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"eckert-ziegler":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"pacbio":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"oxford-nanopore":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"ultima-genomics":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"element-biosciences":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"mgi-tech":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"bruker":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"vizgen":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"akoya-biosciences":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"leica-biosystems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"hamamatsu":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"3dhistech":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"philips":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"sectra":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"proscia":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"indica-labs":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"raysearch":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"sun-nuclear":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"brainlab":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"limbus-ai":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"mim-software":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"therapanacea":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"mvision-ai":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"flatiron-health":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"concertai":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"cota-healthcare":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"trinetx":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"komodo-health":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"datavant":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"medidata":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"veeva-systems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"oracle-health-sciences":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"epic-systems":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"medable":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"science-37":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"mckesson-us-oncology":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"oneoncology":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"florida-cancer-specialists":{"commit":"055be94863","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 90 more companies (supply chain, diagnostics, software)","file":"src/data/supporting.ts"},"sarah-cannon-research-institute":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"iqvia":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"icon-plc":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"parexel":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"fortrea":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"medpace":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"calyx":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"clario":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"discovery-life-sciences":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/supporting.ts"},"indivumed":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"hub-organoids":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"labcorp":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"quest-diagnostics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/supporting.ts"},"neogenomics":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"agilent":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"canon-medical":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"kaiku-health":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"omnicell":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"becton-dickinson":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"microsoft":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"google-health":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"civica-rx":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"terumo-bct":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"fresenius-kabi":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"cryoport":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"biolife-solutions":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"fujifilm-diosynth":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/supporting.ts"},"boehringer-ingelheim-biox":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"trasis":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"comecer":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"sophia-genetics":{"commit":"7f47a07875","date":"2026-09-17","author":"Jude Gomila","message":"Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall th","file":"src/data/supporting.ts"},"qiagen":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"velsera":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"dnanexus":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/supporting.ts"},"standard-biotools":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"streck":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"sakura-finetek":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/supporting.ts"},"baxter":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"b-braun":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/supporting.ts"},"project-optimus":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/supporting.ts"},"project-orbis":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"real-time-oncology-review":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"project-frontrunner":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"340b-program":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/supporting.ts"},"nccn-compendium":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/supporting.ts"},"icer-value-assessment":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/supporting.ts"},"omop-ohdsi":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"mcode":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"bicr":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"cdmo":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/supporting.ts"},"biosecure-act":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/supporting.ts"},"mek":{"commit":"809532f8df","date":"2026-09-15","author":"Jude Gomila","message":"data: sourced alteration prevalence for XPO1 (Hodgkin lymphoma) and MEK (Langerhans cell histiocytosis)","file":"src/data/targets-wave1.ts"},"hdac":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/targets-wave1.ts"},"rxr":{"commit":"6a098ba59c","date":"2026-09-17","author":"Jude Gomila","message":"Prevalence rows for 20 more targets","file":"src/data/targets-wave1.ts"},"rankl":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets-wave1.ts"},"il6":{"commit":"c5ac6f68f9","date":"2026-09-11","author":"Jude Gomila","message":"Prevalence rows for cd25, il6, mtor, rankl; notes for mek, hdac, rxr","file":"src/data/targets-wave1.ts"},"cd25":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets-wave1.ts"},"mtor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets-wave1.ts"},"trop2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"her2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"her3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"egfr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"nectin4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"b7h3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cldn18-2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"psma":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"fap":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"sstr2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"dll3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"folr1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tissue-factor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cdh6":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ceacam5":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gpc3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"mesothelin":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd70":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ror1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd19":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd20":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"bcma":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gprc5d":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd38":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd33":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cd123":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"mage-a4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gp100":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pd1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pdl1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ctla4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"lag3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tigit":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"kras":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"braf":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"alk":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"met":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ret":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ntrk":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/targets.ts"},"fgfr2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"kit":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"flt3":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pik3ca":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"akt":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/targets.ts"},"cdk4-6":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/targets.ts"},"parp":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"atr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"wee1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"idh":{"commit":"eddf60116c","date":"2026-09-11","author":"Jude Gomila","message":"Onboard the ClinicalTrials.gov wave: pipeline drugs into cancer pipelines, target and sponsor product lists; phase 3 tri","file":"src/data/targets.ts"},"menin":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ezh2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"bcl2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"vegf":{"commit":"c14cf76e3e","date":"2026-09-13","author":"Jude Gomila","message":"Targets: glucocorticoid receptor, gamma-secretase, FGFR1 and HER4 added with UniProt sources and cross-references; VEGFR","file":"src/data/targets.ts"},"hif2a":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"estrogen-receptor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"androgen-receptor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tp53":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"brca":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/targets.ts"},"cd47":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cyp17a1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"aromatase":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"proteasome":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cereblon":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"top1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"top2a":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tyms":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"dhfr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gnrhr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"xpo1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"slamf7":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tubulin":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"dnmt1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"rrm1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pik3cd":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"rara":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"fgfr3-receptor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pdgfrb":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"src":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ifnar1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"csf3r":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"htr3a":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tacr1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"epor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"axl":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"glucocorticoid-receptor":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gamma-secretase":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"fgfr1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"erbb4":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ada":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pgr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"eef2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"fkbp12":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"dnmt3a":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gart":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tlr7":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pap":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ron":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ddr2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"epha2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"raf1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pkc":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cox2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tshr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"igf1r":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tie2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"il11ra":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"csf2ra":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"lyn":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"hck":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ptk6":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"frk":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"xdh":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"txnrd1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"gsr":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"pola1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cyp11a1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"srd5a2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"drd2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"oprm1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"cnr1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"tph1":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"impdh2":{"commit":"4b8ae9d467","date":"2026-09-18","author":"Jude Gomila","message":"Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets","file":"src/data/targets.ts"},"ct":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"mri":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/technologies.ts"},"ultrasound":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"mammography":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"pet":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"pet-ct":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"pet-mri":{"commit":"238adc044e","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-ac93cfe141478a8fe (technology dependencies)","file":"src/data/technologies.ts"},"fdg-pet":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"psma-pet":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/technologies.ts"},"fapi-pet":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"trop2-pet":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/technologies.ts"},"her2-pet":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/technologies.ts"},"immuno-pet":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"parp-pet":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/technologies.ts"},"spect":{"commit":"238adc044e","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-ac93cfe141478a8fe (technology dependencies)","file":"src/data/technologies.ts"},"whole-body-mri":{"commit":"20af5171c1","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources (landmark papers, FDA, WHO, NICE, EAU pages) on 14 high-traffic technologies that","file":"src/data/technologies.ts"},"radiology-ai-screening":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"optical-imaging":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"histopathology-ihc":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"cgp":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"wes-wgs":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"rna-seq":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"single-cell-spatial":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"liquid-biopsy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"mrd-testing":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"mced":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"digital-pathology-ai":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"companion-diagnostic":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"hrd-testing":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"germline-testing":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"functional-drug-testing":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"organoids":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"pdx-models":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"proteomics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"methylation-profiling":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"robotic-surgery":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"fluorescence-guided-surgery":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"sentinel-node":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"thermal-ablation":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"hifu-histotripsy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"irreversible-electroporation":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"imrt-igrt":{"commit":"f9c9c72a63","date":"2026-09-18","author":"Jude Gomila","message":"Merge pull request #31 from mstorey20: radiation wave 5, LET, RBE and when protons beat IMRT","file":"src/data/technologies.ts"},"sbrt":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/technologies.ts"},"proton-therapy":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/technologies.ts"},"carbon-ion":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/technologies.ts"},"brachytherapy":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"mr-linac":{"commit":"238adc044e","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-ac93cfe141478a8fe (technology dependencies)","file":"src/data/technologies.ts"},"flash-rt":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"radioligand-therapy":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"targeted-alpha-therapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"radioimmunotherapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"bnct":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"cytotoxic-chemotherapy":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"platinum":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"topoisomerase-inhibitors":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/technologies.ts"},"hipec":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/technologies.ts"},"kinase-inhibitors":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"monoclonal-antibody":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/technologies.ts"},"bispecific-antibody":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"parp-inhibitor":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"cdk46-inhibitor":{"commit":"d6625dd92d","date":"2026-09-17","author":"Jude Gomila","message":"Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers","file":"src/data/technologies.ts"},"kras-inhibitors":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"protac-degrader":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"antisense-sirna":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"synthetic-lethality-approaches":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"antiangiogenic":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"adc":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"bispecific-adc":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"dual-payload-adc":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/technologies.ts"},"degrader-antibody-conjugate":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"immune-stimulating-adc":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/technologies.ts"},"masked-adc":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/technologies.ts"},"site-specific-conjugation":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"peptide-drug-conjugate":{"commit":"8d4a21fe25","date":"2026-09-12","author":"Jude Gomila","message":"Ideas and technologies: landmark papers as the primary source on 13 more records that had none","file":"src/data/technologies.ts"},"checkpoint-inhibitor":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"t-cell-engager":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"neoantigen-mrna-vaccine":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"shared-antigen-vaccine":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/technologies.ts"},"oncolytic-virus":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"cytokine-therapy":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"sting-agonist":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"car-t":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"in-vivo-car-t":{"commit":"4f9321d362","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 14 more technologies (landmark papers, FDA, eCFR and DOE pages)","file":"src/data/technologies.ts"},"til-therapy":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/technologies.ts"},"tcr-t":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"car-nk-macrophage":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"allogeneic-cell-therapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"armored-car":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"endocrine-therapy":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"androgen-deprivation":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"epigenetic-drugs":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"scalp-cooling":{"commit":"1f545daf9e","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, end","file":"src/data/technologies.ts"},"cardio-oncology":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"exercise-oncology":{"commit":"d81ab23654","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: key paper DOI or linked trial registry entry as the primary source on 22 technologies that had none","file":"src/data/technologies.ts"},"geriatric-assessment":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"pathology-foundation-model":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"ai-trial-matching":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"ai-drug-design":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"crispr-screens":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/technologies.ts"},"hpv-vaccine":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/technologies.ts"},"chemoprevention":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"ttfields":{"commit":"9784c2d0ea","date":"2026-09-17","author":"Jude Gomila","message":"Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres","file":"src/data/technologies.ts"},"photoimmunotherapy":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/technologies.ts"},"hyperthermia":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/technologies.ts"},"spatial-transcriptomics":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"imaging-mass-cytometry":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"multiplex-immunofluorescence":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"ai-pathology-scoring":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"radiomics":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"ctc-capture":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"cfdna-methylation-testing":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"gene-expression-prognostic-assays":{"commit":"cdc3bf1e9b","date":"2026-09-16","author":"Jude Gomila","message":"data: repoint four Wikipedia links whose articles do not exist (extragonadal germ cell tumour, imaging mass cytometry, O","file":"src/data/technologies.ts"},"oncology-pharmacogenomics":{"commit":"d1a1461270","date":"2026-09-17","author":"Jude Gomila","message":"Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)","file":"src/data/technologies.ts"},"ai-mammography-screening":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"ai-endoscopy-detection":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"cns-tumour-methylation-classifier":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"clonal-evolution-tracking":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"tigit-blockade":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"lag3-blockade":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"tim3-blockade":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"cd47-blockade":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"cd40-agonists":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"immunocytokines":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"nk-cell-engagers":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"trispecific-antibodies":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"dendritic-cell-vaccines":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"bacterial-vector-vaccines":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"gamma-delta-t-cell-therapy":{"commit":"f06aa2d396","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list","file":"src/data/technologies.ts"},"nk-cell-therapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"virus-specific-t-cells":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"lu177-radioligand-therapy":{"commit":"c5ca07f69b","date":"2026-09-18","author":"Jude Gomila","message":"Backlink fill: text-supported relations for 303 weakly connected records","file":"src/data/technologies.ts"},"astatine-211-alpha-therapy":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"radioligand-dosimetry":{"commit":"78e6df748b","date":"2026-09-17","author":"Jude Gomila","message":"Technology dependency DAG viewer (roadmap 134)","file":"src/data/technologies.ts"},"menin-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"bcl2-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"idh-inhibitors":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/technologies.ts"},"pi3k-akt-mtor-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"mdm2-inhibitors":{"commit":"337f82189f","date":"2026-09-18","author":"Jude Gomila","message":"Add sarcoma and bone tumour subtype pages with landmark trials","file":"src/data/technologies.ts"},"her2-tyrosine-kinase-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"oral-serds":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"hedgehog-inhibitors":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/technologies.ts"},"gamma-secretase-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"celmods":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"lsd1-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"atr-chk1-inhibitors":{"commit":"35cc707f52","date":"2026-09-17","author":"Jude Gomila","message":"Link 28 cancer subtype pages from the drugs and trials that treat them","file":"src/data/technologies.ts"},"kat6-inhibitors":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"genetically-engineered-mouse-models":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"humanised-mouse-models":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"cancer-cell-line-encyclopedias":{"commit":"cdc3bf1e9b","date":"2026-09-16","author":"Jude Gomila","message":"data: repoint four Wikipedia links whose articles do not exist (extragonadal germ cell tumour, imaging mass cytometry, O","file":"src/data/technologies.ts"},"tumour-on-chip":{"commit":"72b401323e","date":"2026-09-15","author":"Jude Gomila","message":"data: 46 technology areas the Prometheus technology map showed OnCo lacked (spatial biology, AI pathology and screening,","file":"src/data/technologies.ts"},"cell-term":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"cell-membrane":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"nucleus":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"dna-term":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"rna":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"gene":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"chromosome":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"protein":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"enzyme":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"gene-expression":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"mutation":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"driver-mutation":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/terms-basics.ts"},"amplification":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"overexpression":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"deletion":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"oncogene":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"tumour-suppressor-gene":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"receptor":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"ligand":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"growth-factor":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"growth-signal":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"signalling-pathway":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"downstream":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"kinase":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"phosphorylation":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"inhibitor":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"agonist-antagonist":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"antibody":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"antigen":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"epitope":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"monoclonal":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"cell-cycle":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"cell-division":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"proliferation":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"differentiation":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"stem-cell":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"apoptosis":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"necrosis":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"angiogenesis":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"benign-vs-malignant":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"primary-tumour":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"metastasis":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/terms-basics.ts"},"lesion":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"carcinoma":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"adenocarcinoma":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"squamous-cell-carcinoma":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-basics.ts"},"sarcoma-type":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"lymphoma-type":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"leukaemia-type":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"bone-marrow":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"tumour-grade":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"cancer-stage":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"in-situ":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"invasive-cancer":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"lymph-node":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"biopsy":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"histology":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-basics.ts"},"biomarker":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/terms-basics.ts"},"tumour-marker":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"genomic-profiling":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"immune-system":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"t-cell":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"b-cell":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"nk-cell":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"macrophage":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"cytokine":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"inflammation":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/terms-basics.ts"},"immune-checkpoint":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"immunotherapy-term":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"chemotherapy-term":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"targeted-therapy-term":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"hormone-therapy":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"radiotherapy":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"systemic-vs-local-therapy":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"maintenance-therapy":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-basics.ts"},"palliative-treatment":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"remission":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"complete-response":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"partial-response":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"stable-disease":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"progression":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"relapse-recurrence":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"refractory":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-basics.ts"},"duration-of-response":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"prognosis":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"clinical-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"trial-phases":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"randomised-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"placebo":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"blinding":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"endpoint":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"surrogate-endpoint":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"hazard-ratio-basics":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"median-survival":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"confidence-interval":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"p-value":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-basics.ts"},"dose":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"half-life":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"toxicity-grade":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"side-effect-vs-adverse-event":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"quality-of-life":{"commit":"d6625dd92d","date":"2026-09-17","author":"Jude Gomila","message":"Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers","file":"src/data/terms-basics.ts"},"prodrug":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"off-label":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"orphan-drug":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"incidence-vs-prevalence":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"mortality":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"risk-factor":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"screening":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"early-detection-term":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-basics.ts"},"in-vitro-in-vivo":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-basics.ts"},"preclinical":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"model-organism":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"cell-line":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"organoid":{"commit":"9dc851cddc","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: biology and clinic basics for newcomers","file":"src/data/terms-basics.ts"},"medulloblastoma-molecular-groups":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"pole-ultramutation":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"nsmp":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"ependymoma-molecular-groups":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"sclc-molecular-subtypes":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"uveal-melanoma-prognostic-markers":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"interferon-gamma-signature":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"ipss-m-ipss-r":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-biomarkers-wave.ts"},"sokal-elts-scores":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"mipi":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"dipss-mipss70":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"ipset-thrombosis":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"li-rads":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-biomarkers-wave.ts"},"pretext-chic":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"wilms-risk-markers":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"b-all-cytogenetic-risk":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"disease-volume-chaarted":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"graded-prognostic-assessment":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"ph-like-all":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"abl1-kinase-domain-mutations":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"mpn-driver-mutations":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"aml-myelodysplasia-related":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"sf3b1-mutation":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"del5q":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"myd88-l265p":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"cyclin-d1-t11-14":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"btki-bcl2i-resistance-mutations":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"brca-reversion-mutations":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"met-exon-14-skipping":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"mlh1-promoter-methylation":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"1p19q-codeletion":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"cdkn2a-homozygous-deletion":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"pten-loss":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"bap1-loss":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"sdh-deficiency":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"foxo1-fusion-status":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"ss18-ssx-fusion":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"mcpyv-status":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"hhv8-kshv":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"gist-risk-stratification":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"histological-response-induction":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"extranodal-extension":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"depth-of-invasion":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"segmental-chromosomal-aberrations":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"urinary-catecholamines":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"curie-siopen-score":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"psa-kinetics":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-biomarkers-wave.ts"},"m-protein-free-light-chains":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-biomarkers-wave.ts"},"oesophagectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"whipple":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/terms-jargon.ts"},"lobectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"segmentectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"pneumonectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"cystectomy":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"nephrectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"mastectomy":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"lumpectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"sentinel-lymph-node-biopsy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"lymphadenectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"gastrectomy":{"commit":"fbecb89e75","date":"2026-09-18","author":"Jude Gomila","message":"Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIS","file":"src/data/terms-jargon.ts"},"colectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"total-mesorectal-excision":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/terms-jargon.ts"},"abdominoperineal-resection":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"hepatectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"prostatectomy":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"orchiectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"hysterectomy":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"salpingo-oophorectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"debulking":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"thyroidectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"adrenalectomy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"turbt":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"limb-salvage-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"wide-local-excision":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"mohs-surgery":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"endoscopic-resection-term":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"colonoscopy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"endoscopy":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"bronchoscopy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"staging-laparoscopy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"minimally-invasive-surgery":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"radiofrequency-ablation":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"microwave-ablation":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"cryoablation":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"tace-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"tare":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"stereotactic-radiosurgery":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"wbrt":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"pci-term":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"biliary-stent":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"pleurodesis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"apheresis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"intrathecal-therapy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"central-venous-access":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"feeding-tube":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"stoma":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"core-needle-biopsy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"hipec-procedure":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"brachytherapy-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"sbrt-term":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"imrt-term":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"mediastinum":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"peritoneum":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"pleura":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"pleural-effusion":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"retroperitoneum":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"lymph-node-status":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"gej":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"head-neck-subsites":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"leptomeningeal-disease":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"brain-metastases":{"commit":"19835bf58e","date":"2026-09-18","author":"Jude Gomila","message":"Add brain and spinal tumour subtype pages","file":"src/data/terms-jargon.ts"},"bone-metastases":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"portal-vein-tumour-thrombus":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"lymphovascular-invasion":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"perineural-invasion":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"resection-margins":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"tumour-differentiation":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"dysplasia":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"carcinoma-in-situ":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"dcis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"pd-l1-testing":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"hormone-receptor-status":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"her2-positive":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"fish":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"tumour-markers":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-jargon.ts"},"cirrhosis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"hpv-status":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"ebv-term":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"mss-pmmr":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"gbrca-mutation":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"wild-type":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"gene-amplification":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"egfr-mutation-subtypes":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"kras-mutation-subtypes":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"braf-v600-mutation":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"gatekeeper-mutation":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-jargon.ts"},"stk11-keap1":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"tp53-mutated":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"cytogenetics":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"flow-cytometry":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"blasts":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"cfdna":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"umrd":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"deauville":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/terms-jargon.ts"},"molecular-response":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"philadelphia-chromosome":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-jargon.ts"},"staging-systems":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"performance-status":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms-jargon.ts"},"chemoradiation":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"induction-therapy":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"consolidation-therapy":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"salvage-therapy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"relapsed-refractory":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"platinum-sensitivity":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"mcrpc-mhspc":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"adt":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"arpi":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"aromatase-inhibitor":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"serd":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"hypofractionation":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"gray-unit":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"re-irradiation":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"dose-dense-chemotherapy":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"doublet-triplet":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"chemotherapy-regimen":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"anthracycline":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"taxane":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"alkylating-agent":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"folfox-family":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"flot-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"abvd-beacopp":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"seven-plus-three":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"proteasome-inhibitor":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"imid":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"hma":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"tki-term":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"immuno-oncology":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"backbone-add-on":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"cross-resistance":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"rechallenge":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"fixed-duration":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"step-up-dosing":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"de-escalation":{"commit":"2b3e3b7cb4","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: primary sources on 13 terms that had none (cited trial registry entries; FDA page for ODAC)","file":"src/data/terms-jargon.ts"},"organ-preservation":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms-jargon.ts"},"active-surveillance-term":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"curative-intent":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"locally-advanced":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"resectability":{"commit":"8db7431b25","date":"2026-09-18","author":"Jude Gomila","message":"Add 11 pancreatic cancer subtype pages: stage, driver and histology","file":"src/data/terms-jargon.ts"},"limited-extensive-stage":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"intravesical-therapy":{"commit":"8da184f376","date":"2026-09-11","author":"Jude Gomila","message":"Merge remaining same-kind duplicates found by the name scan","file":"src/data/terms-jargon.ts"},"intraperitoneal-chemotherapy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"liver-directed-therapy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"total-neoadjuvant-therapy":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/terms-jargon.ts"},"downstaging":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"autologous-transplant":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"allogeneic-transplant":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"conditioning-regimen":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"gvhd":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"lymphodepletion":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"bridging-therapy":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"vein-to-vein-time":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"antigen-escape":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"t-cell-exhaustion-term":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"prrt-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"radioiodine-term":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"cns-penetration":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"pharmacokinetics":{"commit":"9cbac1b065","date":"2026-09-11","author":"Jude Gomila","message":"Link orphan journals, startups, investors, collections and roadmaps; add Wikipedia links to sourceless terms","file":"src/data/terms-jargon.ts"},"therapeutic-index":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"centralisation":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/terms-jargon.ts"},"surgical-morbidity":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"confirmatory-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"complete-response-letter":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"label-indication":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"bla-nda":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"orphan-designation":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"fast-track-rmat":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"conditional-approval":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"full-approval":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"approval-withdrawal":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"odac":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/terms-jargon.ts"},"regulatory-agencies":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"hta":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms-jargon.ts"},"crossover":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"non-inferiority":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"futility":{"commit":"00696513f1","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-a704410598866f2e6","file":"src/data/terms-jargon.ts"},"interim-analysis":{"commit":"00696513f1","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-a704410598866f2e6","file":"src/data/terms-jargon.ts"},"primary-endpoint":{"commit":"e43475c0ae","date":"2026-09-11","author":"Jude Gomila","message":"Merge -term glossary twins into the basics records","file":"src/data/terms-jargon.ts"},"intention-to-treat":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"prespecified-vs-post-hoc":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"subgroup-analysis":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"statistical-significance":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"double-blind":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"single-arm":{"commit":"f7cea1cb62","date":"2026-09-17","author":"Jude Gomila","message":"Add Wikipedia links to six terms lacking one","file":"src/data/terms-jargon.ts"},"external-control-arm":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"control-arm":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"dose-limiting-toxicity":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/terms-jargon.ts"},"mtd":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"rp2d":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"dose-escalation-design":{"commit":"23aaa93122","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-aa00478b61a4a9d25 (trial design)","file":"src/data/terms-jargon.ts"},"first-in-human":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"window-of-opportunity-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"pivotal-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"seamless-adaptive":{"commit":"23aaa93122","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-aa00478b61a4a9d25 (trial design)","file":"src/data/terms-jargon.ts"},"accrual":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"complete-response-term":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"progressive-disease":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"duration-of-response-term":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"ttp":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"landmark-survival":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"data-maturity":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"qol-pro":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms-jargon.ts"},"ctcae-grading":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"febrile-neutropenia":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"neutropenia":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"thrombocytopenia":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"anaemia":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"cytopenias":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"mucositis":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"hand-foot-syndrome":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"peripheral-neuropathy":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"cardiotoxicity":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"hepatotoxicity":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"immune-colitis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"immune-endocrinopathy":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms-jargon.ts"},"myocarditis":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"ocular-toxicity":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"qt-prolongation":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"hyperglycaemia":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"rash-skin-toxicity":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"extravasation-infusion-reaction":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"vte":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"antiangiogenic-toxicities":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"secondary-malignancy":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-jargon.ts"},"late-effects":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms-jargon.ts"},"hypogammaglobulinaemia":{"commit":"43fe1bd451","date":"2026-09-10","author":"Jude Gomila","message":"Community batch: review queue and roster, issue forms for every change type, record scaffolder, discussions, idea votes,","file":"src/data/terms-jargon.ts"},"dose-modification":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms-jargon.ts"},"obstructive-jaundice":{"commit":"10c0426b0b","date":"2026-09-09","author":"Jude Gomila","message":"Glossary: specialist jargon found across the site","file":"src/data/terms-jargon.ts"},"dysphagia":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms-jargon.ts"},"small-molecule":{"commit":"cd9a5e4490","date":"2026-09-17","author":"Jude Gomila","message":"Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-lon","file":"src/data/terms-modalities.ts"},"vaccines-and-oncolytic-viruses":{"commit":"cd9a5e4490","date":"2026-09-17","author":"Jude Gomila","message":"Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-lon","file":"src/data/terms-modalities.ts"},"payload":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/terms.ts"},"linker":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/terms.ts"},"dar":{"commit":"8a68b0a5ff","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 23 more terms (516 of 594)","file":"src/data/terms.ts"},"bystander-effect":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms.ts"},"ild":{"commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/terms.ts"},"efflux-pump":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"resistance":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms.ts"},"orr":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"recist":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"pfs":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"os":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"efs":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"hazard-ratio":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"pcr":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"rcb":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms.ts"},"ppv":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms.ts"},"stage-shift":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/terms.ts"},"suv":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"ihc":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"her2-low":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms.ts"},"cps":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/terms.ts"},"tils":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"tmb":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"msi":{"commit":"dd2d7b78d3","date":"2026-09-18","author":"Jude Gomila","message":"Add 50 biomarker terms named by the cancer subtype pages","file":"src/data/terms.ts"},"hrd":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"ctdna":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"mrd":{"commit":"d59a4e09c1","date":"2026-09-11","author":"Jude Gomila","message":"Expand 83 short summaries: mechanisms, pairings and journals","file":"src/data/terms.ts"},"vaf":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms.ts"},"vus":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"ngs":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"gene-fusion":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"mutational-signature":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"pam50":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/terms.ts"},"neoantigen":{"commit":"c05d91dcb7","date":"2026-09-10","author":"Jude Gomila","message":"Glossary: Wikipedia links verified for remaining terms; aliases for hover-linking","file":"src/data/terms.ts"},"oncogene-addiction":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"synthetic-lethality":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"crs":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"icans":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms.ts"},"irae":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/terms.ts"},"abscopal-effect":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"immunogenic-cell-death":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"adcc":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"fc-effector":{"commit":"792918ebe9","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 26 more terms (542 of 594)","file":"src/data/terms.ts"},"oligometastatic":{"commit":"aef83185b2","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified primary sources (NCI dictionary, ESMO, ESPEN, ESTRO, FDA guidance, landmark papers) on 21 terms that ","file":"src/data/terms.ts"},"neoadjuvant-adjuvant":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/terms.ts"},"first-line":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms.ts"},"standard-of-care":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"accelerated-approval":{"commit":"4ac5c3e4a7","date":"2026-09-17","author":"Jude Gomila","message":"Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)","file":"src/data/terms.ts"},"breakthrough-designation":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"companion-diagnostic-term":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"tumour-agnostic":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"basket-umbrella-platform":{"commit":"23aaa93122","date":"2026-09-17","author":"Jude Gomila","message":"Merge worktree-agent-aa00478b61a4a9d25 (trial design)","file":"src/data/terms.ts"},"real-world-evidence":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/terms.ts"},"theranostics":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"alpha-vs-beta":{"commit":"7ecdf918e0","date":"2026-09-17","author":"mstorey20","message":"Radiation wave 5: LET, RBE and when protons beat IMRT","file":"src/data/terms.ts"},"dosimetry":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"germline-vs-somatic":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"tnm-staging":{"commit":"bd1dc0b828","date":"2026-09-11","author":"Jude Gomila","message":"Expand 80 short term summaries: glossary, supporting, ADC chemistry, models","file":"src/data/terms.ts"},"cold-vs-hot":{"commit":"b805550edc","date":"2026-09-13","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 16 more terms (558 of 594)","file":"src/data/terms.ts"},"adc-sequencing":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/terms.ts"},"seminoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/testis-oesophagus-subtypes.ts"},"non-seminoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/testis-oesophagus-subtypes.ts"},"oesophageal-squamous-cell-carcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/testis-oesophagus-subtypes.ts"},"oesophageal-adenocarcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/testis-oesophagus-subtypes.ts"},"oncomine-dx-target-test":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"cobas-egfr-mutation-test":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"therascreen-cdx":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/tests.ts"},"ventana-pd-l1-sp142":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"ventana-pd-l1-sp263":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/tests.ts"},"dako-pd-l1-22c3-pharmdx":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/tests.ts"},"her2-testing-assays":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"ventana-mmr-rxdx":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"trusight-oncology-comprehensive":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"tempus-xt-cdx":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"caris-mi-cancer-seek":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"cologuard":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"cologuard-plus":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"simplescreen-crc":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"cancerguard":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"clonoseq":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"guardant-reveal":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"radar-mrd":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"oncodetect":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"prosigna":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"endopredict":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"breast-cancer-index":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"prolaris":{"commit":"618fac98e4","date":"2026-09-17","author":"Jude Gomila","message":"Link 51 new technologies back from their drugs, targets and base drawings","file":"src/data/tests.ts"},"oncotype-dx-gps":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"afirma":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"cxbladder":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"urovysion":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"illuccix":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"locametz":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"fludeoxyglucose-f18":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"paige-prostate":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"transpara":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"lunit-insight-mmg":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"optellum-virtual-nodule-clinic":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"icad-profound-ai":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"kheiron-mia":{"commit":"a96eda0ee8","date":"2026-09-13","author":"Jude Gomila","message":"Companies: duplicate Kheiron records merged into one with a redirect from the old page; Ultima Genomics preprint cited f","file":"src/data/tests.ts"},"msi-mmr-testing":{"commit":"50643d7ced","date":"2026-09-12","author":"Jude Gomila","message":"Link check across 9,206 cited URLs: dead links repaired, report regenerated","file":"src/data/tests.ts"},"tmb-testing":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"nhs-targeted-lung-health-check":{"commit":"cb0c44e8d8","date":"2026-09-12","author":"Jude Gomila","message":"Technologies: verified primary sources on 12 more technologies (landmark papers, FDA, NCI and UK NSC pages)","file":"src/data/tests.ts"},"prostate-screening-psa-mri":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"skin-cancer-screening":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"oral-visual-screening":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/tests.ts"},"gastric-endoscopic-screening":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/tests.ts"},"polygenic-risk-scores":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"mindact":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/tests.ts"},"nordicc":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/tests.ts"},"tmist":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"masai":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"blue-c":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/tests.ts"},"deep-c":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"eclipse-shield":{"commit":"5a7e60ee81","date":"2026-09-13","author":"Jude Gomila","message":"Trials: primary publication cited on 34 more numeric outcome rows across 29 trials (EMERALD to FIGHT-202), each DOI chec","file":"src/data/tests.ts"},"goteborg-2":{"commit":"fa022c7b0a","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 48 technologies, 51 drugs, targets and pathways, and 81 trials, cancers, collections, bottlenecks, p","file":"src/data/tests.ts"},"myriad-genetics":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/tests.ts"},"agendia":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"hologic":{"commit":"a34bf3702d","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 80 more companies","file":"src/data/tests.ts"},"screenpoint-medical":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/tests.ts"},"optellum":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/tests.ts"},"icad":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/tests.ts"},"advanced-accelerator-applications":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/tests.ts"},"abbott":{"commit":"2443adef87","date":"2026-09-18","author":"Jude Gomila","message":"Add Wikidata ids and Wikipedia links for 48 companies","file":"src/data/tests.ts"},"pacific-edge":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/tests.ts"},"mdxhealth":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/tests.ts"},"on-target-laboratories":{"commit":"2689ae36bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: remaining companies (all 305 done)","file":"src/data/tests.ts"},"lumicell":{"commit":"f70f6bde8a","date":"2026-09-17","author":"Jude Gomila","message":"Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them","file":"src/data/tests.ts"},"fda-ldt-rule":{"commit":"8a68b0a5ff","date":"2026-09-12","author":"Jude Gomila","message":"Glossary: verified Wikipedia links on 23 more terms (516 of 594)","file":"src/data/tests.ts"},"ivdr":{"commit":"3776441b2e","date":"2026-09-11","author":"Jude Gomila","message":"TL;DR clarity pass: 56 glossary terms and 58 companies rewritten with concrete mechanism, use and caveat; 63 summary ope","file":"src/data/tests.ts"},"sensitivity-specificity":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"overdiagnosis":{"commit":"a6be7dc3d0","date":"2026-09-10","author":"Jude Gomila","message":"Screening and diagnostic tests: companion diagnostics, MCED and MRD tests, genomic classifiers, PSMA kits, AI readers, s","file":"src/data/tests.ts"},"somatic-mutation-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"driver-passenger-model":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"clonal-evolution-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"hallmarks-synthesis":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"cancer-stem-cell-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"epigenetic-progenitor-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"aneuploidy-theory-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"metabolic-theory-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"tissue-organisation-field-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"microenvironment-inflammation-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"seed-and-soil-hypothesis":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"immune-surveillance-immunoediting":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"ageing-tissue-field-theory":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"atavistic-theory-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"mechanical-theory-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"bioelectric-theory-of-cancer":{"commit":"0660b50b07","date":"2026-09-17","author":"Jude Gomila","message":"Theories of cancer: hub map and sixteen theory records in the mechanics section","file":"src/data/theories-wave.ts"},"papillary-thyroid-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/thyroid-subtypes.ts"},"follicular-thyroid-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/thyroid-subtypes.ts"},"medullary-thyroid-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/thyroid-subtypes.ts"},"anaplastic-thyroid-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/thyroid-subtypes.ts"},"non-inferiority-margin":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"stratified-randomisation":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"clinical-equipoise":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"basket-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"umbrella-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"sample-size-re-estimation":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"response-adaptive-randomisation":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"bayesian-trial-design":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"smart-design":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"biomarker-stratified-design":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"pragmatic-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"registry-based-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"decentralised-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"n-of-1-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"cluster-randomised-trial":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"stepped-wedge-design":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"kaplan-meier-curve":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"group-sequential-design":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"absolute-benefit":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"estimand":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"surrogate-validation":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"quality-adjusted-survival":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"data-monitoring-committee":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"ethics-review":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"informed-consent":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"trial-registration":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"trial-protocol":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"trial-lifecycle":{"commit":"791f94b65d","date":"2026-09-17","author":"Jude Gomila","message":"Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)","file":"src/data/trial-design-wave.ts"},"trial-failure-modes":{"commit":"ee286f5497","date":"2026-09-18","author":"Jude Gomila","message":"Six more glossary terms gain Wikipedia links; 74 recorded as having no article","file":"src/data/trial-design-wave.ts"},"checkmate-227":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"destiny-lung01":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"pacific-2":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"chrysalis":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"destiny-gastric01":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"destiny-gastric02":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"keynote-811":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"keynote-062":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"flot4":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"esopec":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"abc-06":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"fight-302":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"reach-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"heracles":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"spinet":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"ifm-2009":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"cassiopeia":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"cartitude-6":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/trials-subtypes-wave.ts"},"apl0406":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"commands":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"medalist":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"imerge":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"verona":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"momentum":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"manifest-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"dasision":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"murano":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"augment":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"zuma-5":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"zuma-1":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"zuma-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aspen-wm":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"echelon-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"alcanza":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aall0434":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aren0532":{"commit":"9b99e342e1","date":"2026-09-18","author":"Jude Gomila","message":"Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)","file":"src/data/trials-subtypes-wave.ts"},"acns0332":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"cabone":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"sarc028":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"regobone":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"tappas":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"navigator":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"tam-01":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"comet-dcis":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"penelope-b":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"bolero-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"nala":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"patina":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"atempt":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"tuxedo-1":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"geparsixto":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"checkmate-915":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"stamp-merkel":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"keynote-412":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"tpextreme":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"orator":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"exam":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"prosper":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aramis":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"enzamet":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aranote":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"checkmate-025":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"carmena":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"papmet":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"keynote-057":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"calla":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"shape":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"garnet":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"soraya":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"portec-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"intellance-1":{"commit":"d62120881c","date":"2026-09-18","author":"Jude Gomila","message":"Add 111 trial investigators and lead authors named by the subtype trials and key papers","file":"src/data/trials-subtypes-wave.ts"},"attraction-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"gatsby":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"klass-01":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aza-001":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"maia":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"determination":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"aquila":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"resonate-2":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"mavoric":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"herby":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"avaglio":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"codel":{"commit":"a8b6eecb20","date":"2026-09-18","author":"Jude Gomila","message":"Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled","file":"src/data/trials-subtypes-wave.ts"},"neosphere":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"brightness":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"imspire150":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"checkmate-358":{"commit":"dbb02d72ae","date":"2026-09-18","author":"Jude Gomila","message":"Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts","file":"src/data/trials-subtypes-wave.ts"},"zeta":{"commit":"15a0727e9e","date":"2026-09-18","author":"Jude Gomila","message":"Chinese quality pass 4 over 243 folded TL;DRs","file":"src/data/trials-subtypes-wave.ts"},"netter-1":{"commit":"59ca4f86a7","date":"2026-09-18","author":"Jude Gomila","message":"Add neuroendocrine subtypes by site and grade","file":"src/data/trials.ts"},"luminosity":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"navigate":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"keynote-355":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"impassion130":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"ascent":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"ascent-03":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"ascent-04":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"tropion-breast01":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/trials.ts"},"tropion-breast02":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"tropion-breast05":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"bl-b01d1-307":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/trials.ts"},"izabright-breast01":{"commit":"74fac200e0","date":"2026-09-11","author":"Jude Gomila","message":"Fact-check and audit corrections across the corpus","file":"src/data/trials.ts"},"optimice-pcr":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"scarlet-s2212":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/trials.ts"},"olympia":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"destiny-breast03":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/trials.ts"},"destiny-breast04":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"destiny-breast06":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"destiny-breast09":{"commit":"aef7c0508d","date":"2026-09-11","author":"Jude Gomila","message":"Link wave 4 leaders and trialists from their institutions and trials; add KEGG pathways to cancers and targets","file":"src/data/trials.ts"},"destiny-breast11":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"natalee":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"monarche":{"commit":"0671dcea08","date":"2026-09-18","author":"Jude Gomila","message":"Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive bra","file":"src/data/trials.ts"},"veritac-2":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"adaura":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"flaura2":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"mariposa":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"tropion-lung01":{"commit":"8effc34ed5","date":"2026-09-18","author":"Jude Gomila","message":"Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials","file":"src/data/trials.ts"},"codebreak-300":{"commit":"ab09e524c5","date":"2026-09-18","author":"Jude Gomila","message":"Add colorectal subtype pages and primary mediastinal B-cell lymphoma","file":"src/data/trials.ts"},"dellphi-304":{"commit":"4a8562bb6f","date":"2026-09-18","author":"Jude Gomila","message":"Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;","file":"src/data/trials.ts"},"checkmate-067":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/trials.ts"},"interpath-001":{"commit":"6e06422547","date":"2026-09-18","author":"Jude Gomila","message":"Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP","file":"src/data/trials.ts"},"ev-302":{"commit":"031b515c3b","date":"2026-09-18","author":"Jude Gomila","message":"Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics","file":"src/data/trials.ts"},"imvigor011":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"vision":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/trials.ts"},"psmafore":{"commit":"a1e2a3b5fc","date":"2026-09-17","author":"Jude Gomila","message":"Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge","file":"src/data/trials.ts"},"nhs-galleri":{"commit":"e7dc799681","date":"2026-09-10","author":"Jude Gomila","message":"Graph health: link 2,100 orphan records and add primary sources to 2,560 records","file":"src/data/trials.ts"},"pathfinder-2":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"dynamic":{"commit":"d9460370bb","date":"2026-09-10","author":"Jude Gomila","message":"Expand short summaries: 306 trials","file":"src/data/trials.ts"},"bostongene-tumor-portrait":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"tempus-xt":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"tempus-xe":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"foundationone-heme":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"caris-mi-profile":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"guardant-shield":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"stratangs":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"strataexp":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"neotype-profiles":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"next-personal":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"trusight-oncology-500":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"altera":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"oncotype-dx-breast":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"oncoextra":{"commit":"b35fe212ab","date":"2026-09-17","author":"Jude Gomila","message":"Free in oncology and tumour sequencing test pages (roadmap 117, 118)","file":"src/data/tumour-tests.ts"},"omniseq-insight":{"commit":"07af851d20","date":"2026-09-17","author":"Jude Gomila","message":"Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys","file":"src/data/tumour-tests.ts"},"drugs-nci-az":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"cancers-nci-az":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"cancers-globocan":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"targets-chembl":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"trials-ctgov-interventional":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"trials-ctgov-phase3":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"trials-ctgov-recruiting":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"companies-ctgov-industry-p3":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"companies-fda-oce":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"institutions-nci":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"institutions-oeci":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/universe.ts"},"companies-evenone":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/universe.ts"},"institutions-nhs-alliances":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"institutions-uicc":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"people-oeci-leaders":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"people-nci-directors":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"pathways-kegg-cancer":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"pathways-hallmarks":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"pathways-reactome":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"journals-nlm":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"papers-openalex-top100":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"terms-nci-dictionary":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"technologies":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"sections":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"pairings":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"roadmaps":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"ideas":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"bottlenecks":{"commit":"898a8a0e9d","date":"2026-09-10","author":"Jude Gomila","message":"Completeness: sourced denominators per kind, coverage and missing items","file":"src/data/universe.ts"},"collections":{"commit":"df6ff18aa8","date":"2026-09-16","author":"Jude Gomila","message":"owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton ","file":"src/data/universe.ts"},"gastric-her2-positive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gastric-cldn18-2-positive":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gastric-pdl1-high":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gastric-msi-high":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"early-gastric-cancer":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"hcc-early":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"hcc-intermediate":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"hcc-advanced":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"intrahepatic-cholangiocarcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"extrahepatic-cholangiocarcinoma":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gist-kit-exon-11":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gist-pdgfra-d842v":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"},"gist-imatinib-resistant":{"commit":"5323aeec94","date":"2026-09-18","author":"Jude Gomila","message":"Link cancer subtypes to their siblings and name parents in tldrs","file":"src/data/upper-gi-liver-subtypes.ts"}}